0001079973-23-000655.txt : 20230510 0001079973-23-000655.hdr.sgml : 20230510 20230510173028 ACCESSION NUMBER: 0001079973-23-000655 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230510 DATE AS OF CHANGE: 20230510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BION ENVIRONMENTAL TECHNOLOGIES INC CENTRAL INDEX KEY: 0000875729 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE CHEMICALS [2870] IRS NUMBER: 841176672 STATE OF INCORPORATION: CO FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19333 FILM NUMBER: 23907894 BUSINESS ADDRESS: STREET 1: PO BOX 323 CITY: OLD BETHPAGE STATE: NY ZIP: 11804 BUSINESS PHONE: (212) 758-6622 MAIL ADDRESS: STREET 1: PO BOX 323 CITY: OLD BETHPAGE STATE: NY ZIP: 11804 FORMER COMPANY: FORMER CONFORMED NAME: RSTS CORP DATE OF NAME CHANGE: 19930328 10-Q 1 bion_10q-q3.htm FORM 10-Q
0000875729 false --06-30 2023 Q3 0000875729 2022-07-01 2023-03-31 0000875729 2021-07-01 2023-03-31 0000875729 2023-04-30 0000875729 2023-03-31 0000875729 2022-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2023-03-31 0000875729 us-gaap:SeriesAPreferredStockMember 2022-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2023-03-31 0000875729 us-gaap:SeriesCPreferredStockMember 2022-06-30 0000875729 2023-01-01 2023-03-31 0000875729 2022-01-01 2022-03-31 0000875729 2021-07-01 2022-03-31 0000875729 us-gaap:SeriesAPreferredStockMember 2021-12-31 0000875729 us-gaap:SeriesCPreferredStockMember 2021-12-31 0000875729 us-gaap:CommonStockMember 2021-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000875729 bnet:SubscriptionsReceivableMember 2021-12-31 0000875729 us-gaap:RetainedEarningsMember 2021-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2021-12-31 0000875729 2021-12-31 0000875729 us-gaap:SeriesAPreferredStockMember 2022-12-31 0000875729 us-gaap:SeriesCPreferredStockMember 2022-12-31 0000875729 us-gaap:CommonStockMember 2022-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000875729 bnet:SubscriptionsReceivableMember 2022-12-31 0000875729 us-gaap:RetainedEarningsMember 2022-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2022-12-31 0000875729 2022-12-31 0000875729 us-gaap:SeriesAPreferredStockMember 2021-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2021-06-30 0000875729 us-gaap:CommonStockMember 2021-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000875729 bnet:SubscriptionsReceivableMember 2021-06-30 0000875729 us-gaap:RetainedEarningsMember 2021-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2021-06-30 0000875729 2021-06-30 0000875729 us-gaap:CommonStockMember 2022-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000875729 bnet:SubscriptionsReceivableMember 2022-06-30 0000875729 us-gaap:RetainedEarningsMember 2022-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2022-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-03-31 0000875729 us-gaap:SeriesCPreferredStockMember 2022-01-01 2022-03-31 0000875729 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000875729 bnet:SubscriptionsReceivableMember 2022-01-01 2022-03-31 0000875729 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000875729 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0000875729 us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-03-31 0000875729 us-gaap:SeriesCPreferredStockMember 2023-01-01 2023-03-31 0000875729 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000875729 bnet:SubscriptionsReceivableMember 2023-01-01 2023-03-31 0000875729 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000875729 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0000875729 us-gaap:SeriesAPreferredStockMember 2021-07-01 2022-03-31 0000875729 us-gaap:SeriesCPreferredStockMember 2021-07-01 2022-03-31 0000875729 us-gaap:CommonStockMember 2021-07-01 2022-03-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2022-03-31 0000875729 bnet:SubscriptionsReceivableMember 2021-07-01 2022-03-31 0000875729 us-gaap:RetainedEarningsMember 2021-07-01 2022-03-31 0000875729 us-gaap:NoncontrollingInterestMember 2021-07-01 2022-03-31 0000875729 us-gaap:SeriesAPreferredStockMember 2022-07-01 2023-03-31 0000875729 us-gaap:SeriesCPreferredStockMember 2022-07-01 2023-03-31 0000875729 us-gaap:CommonStockMember 2022-07-01 2023-03-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2023-03-31 0000875729 bnet:SubscriptionsReceivableMember 2022-07-01 2023-03-31 0000875729 us-gaap:RetainedEarningsMember 2022-07-01 2023-03-31 0000875729 us-gaap:NoncontrollingInterestMember 2022-07-01 2023-03-31 0000875729 us-gaap:SeriesAPreferredStockMember 2022-03-31 0000875729 us-gaap:SeriesCPreferredStockMember 2022-03-31 0000875729 us-gaap:CommonStockMember 2022-03-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000875729 bnet:SubscriptionsReceivableMember 2022-03-31 0000875729 us-gaap:RetainedEarningsMember 2022-03-31 0000875729 us-gaap:NoncontrollingInterestMember 2022-03-31 0000875729 2022-03-31 0000875729 us-gaap:CommonStockMember 2023-03-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000875729 bnet:SubscriptionsReceivableMember 2023-03-31 0000875729 us-gaap:RetainedEarningsMember 2023-03-31 0000875729 us-gaap:NoncontrollingInterestMember 2023-03-31 0000875729 bnet:RibbonwireMember 2022-07-01 2023-03-31 0000875729 2020-07-01 2021-06-30 0000875729 2021-07-01 2022-06-30 0000875729 2017-07-01 2018-06-30 0000875729 srt:MinimumMember 2023-03-31 0000875729 srt:MaximumMember 2023-03-31 0000875729 bnet:CenterpointMember 2023-03-31 0000875729 us-gaap:WarrantMember 2022-07-01 2023-03-31 0000875729 us-gaap:WarrantMember 2021-07-01 2022-03-31 0000875729 us-gaap:EmployeeStockOptionMember 2022-07-01 2023-03-31 0000875729 us-gaap:EmployeeStockOptionMember 2021-07-01 2022-03-31 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2022-07-01 2023-03-31 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2021-07-01 2022-03-31 0000875729 bnet:ConvertiblePreferredStockAntidilutiveSecuritiesMember 2022-07-01 2023-03-31 0000875729 bnet:ConvertiblePreferredStockAntidilutiveSecuritiesMember 2021-07-01 2022-03-31 0000875729 bnet:PropertyPlantAndEquipmentOfPA1Member 2022-07-01 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember 2022-03-31 0000875729 bnet:BassaniMember 2022-03-31 0000875729 bnet:SmithMember 2022-03-31 0000875729 bnet:ConsultantsMember 2023-03-31 0000875729 bnet:ConsultantsMember 2022-03-31 0000875729 srt:ChiefExecutiveOfficerMember 2022-07-01 2023-03-31 0000875729 bnet:SmithMember 2023-01-01 2023-03-31 0000875729 bnet:SmithMember 2022-07-01 2023-03-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2023-01-01 2023-03-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2022-01-01 2022-03-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2022-07-01 2023-03-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2021-07-01 2022-03-31 0000875729 bnet:PennvestLoanMember 2023-03-31 0000875729 2021-09-30 0000875729 2021-12-29 0000875729 bnet:YearsOneThroughFiveMember bnet:PennvestLoanMember 2022-07-01 2023-03-31 0000875729 bnet:YearsSixThroughMaturityMember bnet:PennvestLoanMember 2022-07-01 2023-03-31 0000875729 bnet:PennvestLoanMember 2021-07-01 2022-06-30 0000875729 bnet:PennvestLoanMember 2020-07-01 2021-06-30 0000875729 bnet:PA1Member 2014-09-25 0000875729 bnet:PA1Member 2022-06-01 2022-06-15 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-01-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-03-31 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-03-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-03-31 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-03-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-03-31 0000875729 bnet:The2020ConvertibleObligationsMember 2022-07-01 2023-03-31 0000875729 bnet:PrincipalMember bnet:ConvertibleObligations2020Member 2022-07-01 2023-03-31 0000875729 bnet:PrincipalMember bnet:ConvertibleObligations2020Member bnet:CommonSharesMember 2022-07-01 2023-03-31 0000875729 bnet:PrincipalMember bnet:ConvertibleObligations2020Member bnet:WarrantsMember 2022-07-01 2023-03-31 0000875729 bnet:AccruedInterestMember bnet:ConvertibleObligations2020Member 2022-07-01 2023-03-31 0000875729 bnet:AccruedInterestMember bnet:ConvertibleObligations2020Member bnet:CommonSharesMember 2022-07-01 2023-03-31 0000875729 bnet:WarrantsMember bnet:AccruedInterestMember bnet:ConvertibleObligations2020Member 2022-07-01 2023-03-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-01-01 2023-03-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-01-01 2022-03-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-07-01 2023-03-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-07-01 2022-03-31 0000875729 bnet:MarkASmithMember 2023-03-31 0000875729 bnet:DominicBassaniMember 2023-03-31 0000875729 bnet:EdSchaferMember 2023-03-31 0000875729 srt:PresidentMember bnet:SecuredPromissoryNoteMember 2023-03-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniFamilyTrustsMember 2023-03-31 0000875729 bnet:ConsultantsMember bnet:September2015ConvertibleNotesMember bnet:SchaferMember 2023-03-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember bnet:ShareholderMember 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniFamilyTrustsMember 2022-03-31 0000875729 bnet:ConsultantsMember bnet:September2015ConvertibleNotesMember bnet:SchaferMember 2022-03-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember bnet:ShareholderMember 2022-03-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2023-01-01 2023-03-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2022-01-01 2022-03-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2022-07-01 2023-03-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2021-07-01 2022-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember bnet:SmithMember 2023-02-02 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember bnet:BassaniFamilyTrustsMember 2023-02-02 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember bnet:SchaferMember 2023-02-02 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniMember 2023-02-02 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:EdSchaferMember 2023-02-02 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-03-07 2023-03-08 0000875729 bnet:AdjustedConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-03-02 2023-03-31 0000875729 bnet:ConvertibleObligations2020Member bnet:CommonSharesMember 2023-03-07 2023-03-08 0000875729 bnet:ConvertibleObligations2020Member bnet:WarrantsMember 2023-03-07 2023-03-08 0000875729 bnet:CommonSharesMember bnet:DirectOwnershipMember 2023-03-08 0000875729 bnet:WarrantsMember bnet:DirectOwnershipMember 2023-03-08 0000875729 bnet:CommonSharesMember bnet:IndirectOwnershipMember 2023-03-08 0000875729 bnet:WarrantsMember bnet:IndirectOwnershipMember 2023-03-08 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember 2023-03-31 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember 2023-03-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:The2020ConvertibleObligationsMember 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember 2023-03-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember 2023-03-31 0000875729 bnet:September2015ConvertibleNotesMember bnet:RestrictedCommonSharesMember 2023-03-31 0000875729 us-gaap:SeriesBPreferredStockMember 2014-07-02 0000875729 us-gaap:SeriesBPreferredStockMember 2014-07-03 0000875729 us-gaap:SeriesBPreferredStockMember 2014-06-25 2014-07-01 0000875729 us-gaap:SeriesBPreferredStockMember 2023-03-31 0000875729 us-gaap:SeriesBPreferredStockMember 2022-07-01 2023-03-31 0000875729 us-gaap:SeriesBPreferredStockMember 2021-07-01 2022-03-31 0000875729 us-gaap:RestrictedStockMember 2022-07-01 2023-03-31 0000875729 us-gaap:CommonStockMember 2023-01-02 2023-01-10 0000875729 us-gaap:CommonStockMember 2022-12-02 2022-12-31 0000875729 us-gaap:CommonStockMember 2022-07-01 2023-03-31 0000875729 bnet:RestrictedCommonStockMember 2023-01-01 2023-03-31 0000875729 bnet:RestrictedCommonStockMember 2023-03-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember bnet:PrincipalMember 2022-07-01 2023-03-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000875729 us-gaap:ConvertibleDebtMember bnet:The2020ConvertibleObligationsMember 2023-03-31 0000875729 srt:PresidentMember 2023-03-31 0000875729 bnet:RestrictedCommonStockMember 2022-07-01 2023-03-31 0000875729 bnet:ConsultantServiceMember 2022-07-01 2023-03-31 0000875729 bnet:ConsultantServiceMember 2023-03-31 0000875729 bnet:The2020ConvertibleObligationsMember bnet:PrincipalMember us-gaap:WarrantMember 2022-07-01 2023-03-31 0000875729 bnet:AccruedInterestMember us-gaap:WarrantMember bnet:The2020ConvertibleObligationsMember 2022-07-01 2023-03-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2022-07-01 2023-03-31 0000875729 us-gaap:ConvertibleDebtMember bnet:The2020ConvertibleObligationsMember us-gaap:WarrantMember 2023-03-31 0000875729 us-gaap:WarrantMember 2023-03-31 0000875729 bnet:WarrantsMember 2023-03-31 0000875729 bnet:WarrantsMember 2022-07-01 2023-03-31 0000875729 bnet:AdjustedConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-07-01 2023-03-31 0000875729 bnet:ConvertibleObligations2020Member bnet:CommonSharesMember 2022-07-01 2023-03-31 0000875729 bnet:ConvertibleObligations2020Member bnet:WarrantsMember 2022-07-01 2023-03-31 0000875729 bnet:CommonSharesMember bnet:DirectOwnershipMember 2023-03-31 0000875729 bnet:WarrantsMember bnet:DirectOwnershipMember 2023-03-31 0000875729 bnet:CommonSharesMember bnet:IndirectOwnershipMember 2023-03-31 0000875729 bnet:WarrantsMember bnet:IndirectOwnershipMember 2023-03-31 0000875729 bnet:ThreeConsultantsMember us-gaap:WarrantMember 2022-07-01 2023-03-31 0000875729 us-gaap:WarrantMember 2022-07-01 2023-03-31 0000875729 bnet:ThreeConsultantsMember us-gaap:WarrantMember srt:MinimumMember 2023-03-31 0000875729 bnet:ThreeConsultantsMember us-gaap:WarrantMember srt:MaximumMember 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember 2022-05-01 0000875729 bnet:ConsultantsMember us-gaap:WarrantMember 2023-03-31 0000875729 bnet:ConsultantsMember us-gaap:WarrantMember 2022-07-01 2023-03-31 0000875729 bnet:ConsultantsMember us-gaap:WarrantMember 2023-01-01 2023-03-31 0000875729 us-gaap:EmployeeStockOptionMember bnet:EquityIncentivePlanMember 2023-03-31 0000875729 us-gaap:EmployeeStockOptionMember 2023-03-31 0000875729 bnet:Plan2006Member 2022-02-01 2022-02-11 0000875729 2022-04-01 2022-04-29 0000875729 bnet:NorthropMember 2022-04-01 2022-04-29 0000875729 bnet:BassaniMember 2022-04-01 2022-04-29 0000875729 bnet:SmithMember 2022-04-01 2022-04-29 0000875729 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0000875729 us-gaap:EmployeeStockOptionMember 2022-07-01 2023-03-31 0000875729 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0000875729 us-gaap:EmployeeStockOptionMember 2021-07-01 2022-03-31 0000875729 us-gaap:OptionMember 2023-01-01 2023-03-31 0000875729 us-gaap:OptionMember 2022-07-01 2023-03-31 0000875729 us-gaap:OptionMember 2022-01-01 2022-03-31 0000875729 us-gaap:OptionMember 2021-07-01 2022-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteMember 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:WarrantsIssusedSubscriptionReceivableMember 2023-03-31 0000875729 bnet:FormerEmployeeMember bnet:WarrantsIssusedSubscriptionReceivableMember 2023-03-31 0000875729 srt:PresidentMember bnet:WarrantsIssusedSubscriptionReceivableMember 2022-03-31 0000875729 srt:PresidentMember bnet:WarrantsIssusedSubscriptionReceivableMember 2023-03-31 0000875729 bnet:SmithsMember bnet:SecuredPromissoryNoteMember 2023-03-31 0000875729 bnet:FormerEmployeeMember bnet:SecuredPromissoryNoteMember 2023-03-31 0000875729 srt:PresidentMember 2016-10-01 2016-10-10 0000875729 srt:PresidentMember bnet:WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember 2023-03-31 0000875729 2022-04-27 2022-05-02 0000875729 bnet:SmithMember 2022-01-01 2022-03-31 0000875729 bnet:SmithMember 2021-07-01 2022-03-31 0000875729 srt:ChiefExecutiveOfficerMember 2015-02-03 2015-02-10 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2016-10-31 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2017-04-27 0000875729 bnet:BassaniMember 2018-02-28 0000875729 bnet:BassaniMember 2018-07-28 2018-08-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:WarrantsExpiringOnDecember312025Member 2018-08-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2023-01-01 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2022-01-01 2022-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2022-07-01 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2021-07-01 2022-03-31 0000875729 bnet:WilliamONeillMember 2022-04-25 2022-05-02 0000875729 srt:ChiefExecutiveOfficerMember 2023-01-01 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember 2022-01-01 2022-03-31 0000875729 srt:ChiefExecutiveOfficerMember 2021-07-01 2022-03-31 0000875729 2022-01-01 2022-01-28 0000875729 2022-03-02 2022-03-31 0000875729 2022-06-01 2022-06-30 0000875729 2023-01-02 2023-01-17 0000875729 2023-02-09 2023-03-01 0000875729 2022-04-01 2022-04-30 0000875729 2022-03-02 2022-03-23 0000875729 us-gaap:SubsequentEventMember 2023-04-01 2023-05-09 0000875729 us-gaap:SubsequentEventMember 2023-01-01 2023-05-10 0000875729 us-gaap:SubsequentEventMember 2023-04-29 2023-05-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure bnet:Decimal

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2023

 

   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______ to _________

 

Commission File No. 000-19333

 

Bion Environmental Technologies, Inc.

(Name of registrant in its charter)

 

Colorado   84-1176672
(State or other jurisdiction of incorporation or formation)   (I.R.S. employer identification number)

 

9 East Park Court

Old Bethpage, New York 11804

(Address of principal executive offices)

 

516-586-5643

(Registrant’s telephone number, including area code) 

 

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Securities Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock BNET OTCQB

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

    Large accelerated filer     Accelerated filer    
    Non-accelerated filer     Smaller reporting company    
    Emerging growth company         

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). o Yes x No

 

 
 

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS: Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Not applicable.

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

On April 30, 2023, there were 48,046,370 Common Shares issued and 47,342,061 Common Shares outstanding.

 

 

 

 
 

 

BION ENVIRONMENTAL TECHNOLOGIES, INC.

 

FORM 10-Q

 

TABLE OF CONTENTS

 

PART I.  FINANCIAL INFORMATION   Page
       
Item 1.

Condensed Consolidated Financial Statements 

  4
  Condensed consolidated financial statements (unaudited):    
    Balance sheets   4
    Statements of operations   5
    Statement of changes in equity (deficit)   6
    Statements of cash flows   7
    Notes to unaudited condensed consolidated financial statements   8-38
       
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations   39
       
Item 3. Quantitative and Qualitative Disclosures about Market Risk   50
       
Item 4. Controls and Procedures   50
       
PART II.  OTHER INFORMATION    
       
Item 1. Legal Proceedings   51
       
Item 1A. Risk Factors   53
       
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   53
       
Item 3. Defaults Upon Senior Securities   53
       
Item 4. Mine Safety Disclosures   53
       
Item 5. Other Information   53
       
Item 6. Exhibits   54
       
  Signatures   55

 

 

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements, within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that involve substantial risks and uncertainties. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expect," "intend," "estimate," "anticipate," "project," "predict," "plan," "believe" or "continue" or the negative thereof or variations thereon or similar terminology. The expectations reflected in forward-looking statements may prove to be incorrect.

3 
 

 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

         
   March 31,   June 30, 
   2023   2022 
   (unaudited)     
         
ASSETS
         
 Current assets:          
 Cash  $1,612,977   $3,160,442 
 Prepaid expenses   113,101    157,550 
 Deposits and other assets   6,000    1,000 
           
 Total current assets   1,732,078    3,318,992 
           
 Operating lease right-of-use asset   107,162    145,787 
 Property and equipment, net (Note 3)   5,788,203    2,895,558 
           
 Total assets  $7,627,443   $6,360,337 
           
 LIABILITIES AND EQUITY (DEFICIT)          
           
 Current liabilities:          
 Accounts payable and accrued expenses  $800,901   $1,360,644 
 Deferred compensation (Note 4)   784,255    594,798 
           
 Total current liabilities   1,585,156    1,955,442 
           
 Operating lease liability   119,951    128,864 
 Convertible notes payable - affiliates (Note 6)   1,735,507    5,170,610 
           
 Total liabilities   3,440,614    7,254,916 
           
           
 Equity (deficit):          
Bion's stockholders' equity (deficit):          
Series A Preferred stock, $0.01 par value, 50,000 shares authorized, no shares issued and outstanding            
           
Series C Convertible Preferred stock, $0.01 par value, 60,000 shares authorized; no shares issued and outstanding            
          
Common stock, no par value, 250,000,000 shares authorized, 48,044,790 and 43,758,820 shares issued, respectively; 47,340,480 and 43,054,511 shares outstanding, respectively            
Additional paid-in capital   131,208,759    123,620,046 
Subscription receivable - affiliates (Note 8)   (504,650)   (504,650 
Accumulated deficit   (126,554,853)   (124,047,548)
           
Total Bion's stockholders’ equity (deficit)   4,149,256    (932,152)
           
Noncontrolling interest   37,573    37,573 
           
Total equity (deficit)   4,186,829    (894,579)
           
Total liabilities and deficit  $7,627,443   $6,360,337 

 

See notes to condensed consolidated financial statements

4 
 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
NINE MONTHS ENDED MARCH 31, 2023 AND 2022
(UNAUDITED)

 

 

                
   Three months ended   Nine months ended 
   March 31,   March 31, 
   2023   2022   2023   2022 
                 
Revenue  $     $     $     $   
                     
Operating expenses:                    
General and administrative (including stock-based compensation)   859,011    397,743    2,356,047    1,506,839 
Depreciation   461    252    1,185    832 
Research and development (including stock-based compensation)   24,242    29,411    67,833    145,624 
                     
Total operating expenses   883,714    427,406    2,425,065    1,653,295 
                     
Loss from operations   (883,714)   (427,406)   (2,425,065)   (1,653,295)
                     
Other (income) expense:                    
Interest income   (1,342)   (1,338)   (4,652)   (4,101)
Interest expense   (24,488)   51,361    86,892    281,906 
Gain on sale of domain         (902,490)         (902,490)
Gain on debt extinguishment                     (10,234,501)
                     
Total other expense   (25,830)   (852,467)   82,240    (10,859,186)
                     
Net income (loss)   (857,884)   425,061    (2,507,305)   9,205,891 
                     
Net loss attributable to the noncontrolling interest         549          1,544 
                     
Net income (loss) applicable to Bion's common stockholders  $(857,884)  $425,610   $(2,507,305)  $9,207,435 
                     
Net income (loss) applicable to Bion's common stockholders per basic and diluted common share  $(0.02)  $0.01   $(0.06)  $0.22 
                     
Weighted-average number of common shares outstanding:                    
Basic and diluted   45,456,417    43,029,511    44,165,309    41,602,390 

  

See notes to condensed consolidated financial statements

5 
 

 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES
                                                               
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) 
                                                               
FOR THE THREE AND NINE MONTHS ENDED MARCH 31, 2023 AND 2022
                                                               
(UNAUDITED)

 

                                  
Three months ended March 31, 2023 and 2022            
   Bion's Stockholders'      
   Series A Preferred Stock  Series C Preferred Stock  Common Stock  Additional paid-in  Subscription Receivables for  Accumulated  Noncontrolling  Total
   Shares  Amount  Shares  Amount  Shares  Amount  capital  Shares  deficit  interest  equity/(deficit)
Balances, December 31, 2021        $           $      43,733,820   $     $123,150,676   $(504,650)  $(123,558,048)  $38,122   $(873,900)
Vesting of options for services   —            —            —            4,650                      4,650 
Net income (loss)   —            —            —                        425,610    (549)   425,061 
Balances, March 31, 2022        $           $      43,733,820   $     $123,155,326   $(504,650)  $(123,132,438)  $37,573   $(444,189)
                                                        
Balances, December 31, 2022        $           $      44,529,884   $     $124,627,172   $(504,650)  $(125,696,969)  $37,573   $(1,536,874)
Sale of units   —            —            2,375,000          2,720,000                      2,720,000 
Warrants exercised for common shares   —            —            84,000          63,000                      63,000 
Issuance of warrants for services   —            —            —            9,844                      9,844 
Conversion of debt and liabilities   —            —            1,055,906          99,889                      99,889 
Vesting of options for employees and services   —            —            —            220,510                      220,510 
Commissions on sale of units   —            —            —            (48,000)                     (48,000)
Debt modification                                 3,516,345                   3,516,345 
Net loss   —            —            —                        (857,884)         (857,884)
Balances, March 31, 2023        $           $      48,044,790   $     $131,208,759   $(504,650)  $(126,554,853)  $37,573   $4,186,829 

 

 

  

          
Nine months ended March 31, 2023 and 2022
  Bion's Stockholders'      
   Series A Preferred Stock  Series C Preferred Stock  Common Stock  Additional paid-in  Subscription Receivables for  Accumulated  Noncontrolling  Total
   Shares  Amount  Shares  Amount  Shares  Amount  capital  Shares  deficit  interest  equity/(deficit)
                                  
Balances, July 1, 2021        $           $      41,315,986   $      121,399,067   $(504,650)  $(132,339,873)  $39,117   $(11,406,339)
Warrants exercised for common shares   —            —            2,315,550          1,736,662                      1,736,662 
Commissions on warrant exercises   —            —            66,860          (18,601)                     (18,601)
Issuance of warrants for services   —            —            —            7,500                      7,500 
Conversion of debt and liabilities   —            —            35,424          17,711                      17,711 
Vesting of options for employees and services   —            —            —            4,650                      4,650 
Modification of warrants   —            —            —            8,337                      8,337 
Net loss   —            —            —                        9,207,435    (1,544)   9,205,891 
Balances, March 31, 2022        $           $      43,733,820   $     $123,155,326   $(504,650)  $(123,132,438)  $37,573   $(444,189)
                                                        
Balances, July 1, 2022        $           $      43,758,820   $      123,620,046   $(504,650)  $(124,047,548)  $37,573   $(894,579)
Sale of units   —            —            2,921,230          3,266,230                      3,266,230 
Warrants exercised for common shares   —            —            158,834          119,125                      119,125 
Issuance of units for services   —            —            50,000          80,000                      80,000 
Issuance of warrants for services   —            —            —            57,094                      57,094 
Conversion of debt and liabilities   —            —            1,155,906          149,889                      149,889 
Vesting of options for employees and services   —            —                       220,510                      220,510 
Commissions on sale of units   —            —            —            (48,000)                     (48,000)
Modification of warrants - non-cash comp   —            —            —            159,433                      159,433 
Modification of warrants - interest   —            —            —            68,088                      68,088 
Debt modification   —            —            —            3,516,345                      3,516,345 
Net loss   —            —            —                        (2,507,305)         (2,507,305)
Balances, March 31, 2023        $           $      48,044,790   $     $131,208,759   $(504,650)  $(126,554,853)  $37,573   $4,186,829 

 

 

 

 

See notes to condensed consolidated financial statements

6 
 

 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES
                     
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                     
NINE MONTHS ENDED MARCH 31, 2023 AND 2022
                     
(UNAUDITED)

 

           
   2023   2022 
CASH FLOWS FROM OPERATING ACTIVITIES          
Net income (loss)  $(2,507,305)  $9,205,891 
Adjustments to reconcile net loss to net cash used in operating activities:          
Gain on legal dissolution of subsidiary         (10,234,501)
Depreciation expense   1,185    832 
Accrued interest on loans payable, deferred compensation and other   86,891    299,770 
Stock- based compensation   220,510    17,774 
Stock-based compensation for services   80,000       
Modification of warrants   154,932      
Warrants issued for compensation for services   57,094      
Decrease in prepaid expenses   44,449    118,778 
Increase (decrease) in deposits in other assets   (5,000)   (45,000)
(Increase) in other receivable from the sale of doman name         (902,490)
Increase (decrease) in accounts payable and accrued expenses   (908,644)   223,822 
Decrease (increase) in operating lease assets and liabilities   29,712    (33,073)
Increase in deferred compensation   265,000    224,367 
           
Net cash used in operating activities   (2,481,176)   (1,123,830)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Purchase of property and equipment   (2,403,644)   (1,167,463)
           
Net cash used in investing activities   (2,403,644)   (1,167,463)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Proceeds from sale of units   3,266,230       
Proceeds from exercise of warrants   119,125    1,736,662 
Commissions on exercise of warrants         (18,601)
Commissions on sale of units   (48,000)      
Redemption of Preferred Series B shares and interest         (41,000)
           
Net cash provided by financing activities   3,337,355    1,677,061 
           
Net increase (decrease) in cash   (1,547,465)   (614,232)
           
Cash at beginning of year   3,160,442    4,216,321 
           
Cash at end of year  $1,612,977   $3,602,089 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest  $     $   
           
Non-cash investing and financing transactions:          
Conversion of debt and liabilities into common units  $149,888   $17,711 
Conversion of debt and liabilities into notes payable  $23,943   $   
Conversion of deferred compensation to notes payable  $90,000   $190,000 
Capitalized interest in property and equipment  $117,342   $   
Shares issued for warrant exercise commissions  $     $50,145 
Purchase of property and equipment for accounts payable  $372,844   $666,375 

 

 

See notes to condensed consolidated financial statements

7 
 

 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NINE MONTHS ENDED MARCH 31, 2023 AND 2022

 

1.ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS:

 

Organization and nature of business:

 

Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Bion’s mission is to make livestock production more sustainable, transparent and profitable. We intend to accomplish this by deploying our Gen3Tech platform/business model (discussed below) in ventures focused on the ‘feeder’ space of the livestock production/value chain to provide the consumer with verifiably sustainable premium products. Bion believes this approach can create extraordinary value for our shareholders and employees (all of whom own securities in the Company).

 

Our patented and proprietary technology provides advanced waste treatment and resource recovery for large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs"). Livestock production and its waste, particularly from CAFOs, has been identified as one of the greatest soil, air, and water quality problems in the U.S. today.  Application of our third-generation technology and business/technology platform (“Gen3Tech”) can largely mitigate these environmental problems, while simultaneously improving operational/ resource efficiencies by recovering high-value co-products from the CAFOs’ waste stream. These waste ‘assets’ – nutrients and methane – have traditionally been wasted or underutilized and are the same ‘pollutants’ that today fuel harmful algae blooms, contaminate surface groundwater, and exacerbate climate change.

 

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms) (“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long-term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

Bion’s Gen3Tech was designed to capture and stabilize these assets and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the animal raising and waste treatment process will be third-party verified, providing the basis for additional revenues, including carbon and/or renewable energy-related credits and, eventually, payment for a range of ecosystem services, including nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.

 

During the first half of 2022 Bion began pre-marketing our sustainable beef to retailers, food service distributors and the meat industry in the U.S.  In general, the response has been favorable. During July 2022, Bion announced a letter of intent (“Ribbonwire LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Ribbonwire Ranch, in Dalhart, Texas (with a provision to expand to 60,000 head) (“Dalhart Project”). During January 2023 Bion announced a letter of intent (“Olson LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Olson Feeders and TD Angus, near North Platte, Nebraska (with a provision to expand to 45,000 head or more) (“Olson Project”). During April 2023 Bion announced a letter of intent (“DVG LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with Dakota Valley Growers near Bathgate, North Dakota. The Olson, Dalhart and DVG Projects (and subsequent Projects) will be developed to produce verified, sustainable beef in customized covered barns (resulting in reduced stress on cattle caused by extreme weather and temperatures and resulting higher feed/weight gain efficiency) with ongoing manure transfer (through slatted floors) to anaerobic digesters (AD) to capture nitrogen from the manure stream before loss to the atmosphere and generate renewable natural gas (RNG) for sale while remediating the environmental/carbon impacts usually associated with cattle feedlots and CAFOs. Bion’s patented technology will refine the waste stream into valuable coproducts that include clean water, RNG, photovoltaic solar electricity and fertilizer (‘climate smart’ and organic) products. We anticipate converting these LOI into definitive JV agreements and creating distribution agreements with key retailers and food service distributors during the next six-nine months.

 

8 
 

 

Our business plan is focused on executing multiple agreements and letters of intent related to additional sustainable beef JV projects over the next twelve months while moving forward with the Initial Project (see below) and one or more of the Dalhart/Olson/DVG Projects (“LOI Projects”)(and/or other Gen3Tech beef JV projects) and pursuing other opportunities in the livestock industry enabled by our Gen3Tech business model.  The Ribbonwire and Olson LOI announcements have generated significant interest within the livestock industry (among ranchers, feedlot operators, farmers and other AG industry parties). We believe that this interest, combined with consumer interest in ‘sustainable products’ and growing enthusiasm among some livestock industry parties for environmental/sustainable/regenerative practices, may provide Bion (and its partners/venturers) with an opportunity to move forward with a truly sustainable solution in this industry segment at a rapid pace.

During the next three months, the Company intends to complete construction and begin operations of phase 1 of our Initial Project located near Fair Oaks, Indiana. Bion expects the Initial Project to provide data that illustrates the effectiveness of our Gen3Tech in a commercial-scale setting by the end of the 2nd quarter in 2023 and supports development of the LOI Projects (and/or other Gen3Tech beef JV projects) commencing later during 2023.  We do not presently know the order in which these JV Projects will be developed as that decision will be made based on many factors not yet in place. We believe the Initial Project data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, food distributors and retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below). 

 

Bion is now focused primarily on: i) development/construction/operation of the Initial Project, our initial commercial-scale Gen3Tech installation, ii) pre-development planning of the Dalhart, Olson and DVG Projects (and/or other Gen3Tech beef JV projects), iii) developing applications and markets for its low carbon ‘ClimateSmart’ and organic fertilizer products (including listings/certifications of multiple liquid and solid products) and its sustainable (conventional and organic) animal protein products, and iv) discussions regarding initiation and development of agreements and joint ventures (“JVs” as discussed below) (and related Projects) based on the augmented capabilities of our Gen3Tech business platform (in the sustainable beef and other livestock segments), while (v) continuing to pursue business opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and vi) ongoing R&D activities.

 

HISTORY, BACKGROUND AND CURRENT ACTIVITIES

Since the Company’s inception, Bion has designed and developed advanced waste treatment systems for livestock. The first and second generations of Bion’s technology platform were biological systems, primarily focused on nutrient control. Over 30 of these systems were deployed at New York dairies, Florida food processing facilities and dairies, North Carolina hog farms, a Texas dairy and a Pennsylvania dairy (“Kreider 1 Project”). The systems were highly effective at their intended purpose: capturing nitrogen and phosphorus. They produced BionSoil as a byproduct, which was a remarkably effective soil amendment/ fertilizer product, but whose value was not enough to support a viable business model. As such, these early technology iterations were largely dependent on either implementation of new regulations requiring waste treatment, or subsidy/incentive programs that would provide ‘payment for ecosystem services’. By the mid-2010’s, it became apparent that neither of these options were imminent or even assured, so the Company initiated the steps to reimagine and redesign its technology.

 

9 
 

 

From 2016 to 2021 fiscal years, the Company focused most of its activities and resources on developing, testing and demonstrating the third generation of its technology and technology platform (“Gen3Tech”). Our Gen3Tech was developed with an emphasis producing more valuable co-products from the waste treatment process, including renewable natural gas and ammonium bicarbonate, a low-carbon and organic ‘pure’ nitrogen fertilizer product while raising livestock in a verifiably sustainable manner to produce premium sustainable meat products.

 

The $175 billion U.S. livestock industry is under intense scrutiny for its environmental and public health impacts – its ‘environmental sustainability’-- at the same time it is struggling with declining revenues and margins (derived in part from clinging to its historic practices and resulting limitations and impacts) which threaten its ‘economic sustainability’. Its failure to adequately respond to consumer concerns including food safety, environmental impacts, and inhumane treatment of animals have provided impetus for plant-based alternatives such as Beyond Meat and Impossible Burger (and many others) being marketed as “sustainable” alternatives for this growing consumer segment of the market.

 

The Company believes that its Gen3Tech, in addition to providing superior environmental remediation, creates opportunities for large scale production of i) verifiably sustainable, branded livestock products and ii) verifiably sustainable organic-branded livestock products, both of which will command premium pricing (in part due to ongoing monitoring and third-party verification of environmental performance which will provide meaningful assurances to both consumers and regulatory agencies). Each of these two distinct market segments (which the Company intends to pursue in parallel) presents a large production/marketing opportunity for Bion. Our Gen3Tech will also produce (as co-products) biogas, solar photovoltaic electricity in appropriate locations, and valuable fertilizer products --low carbon and/or organic (which can be utilized in the production of organic grains for use as feed for raising organic livestock (some of which may be utilized in the Company’s JV projects)) and/or marketed to the growing markets for ‘ClimateSmart’ and/or organic fertilizer.

 

During July 2022, January 2023 and April 2023 the Company entered into letters of intent with Ribbonwire Ranch (Dalhart, Texas), Olson Feeders (North Platte, Nebraska) and Dakota Valley Growers (North Bathgate, Dakota), respectively, setting forth the parties’ intentions to negotiate joint venture agreements and enter into JVs to develop and operate initial 15,000 head integrated, sustainable beef facility for each Project including:

 

  a) innovative cattle barns (with slatted floors to facilitate movement of manure to the anaerobic digester and potentially solar PV generation on the rooftops which barns will improve the living conditions of the animals while increasing feeding/weight gain efficiency,

 

  b) ‘customized’ anaerobic digestion systems -- including pretreatment to increase renewable natural gas (‘RNG’) production and an RNG cleaning system (which will include capture/recycling of the CO2) to allow pipeline sales and monetization of related environmental credits,

 

  c) a Bion Gen3Tech module (which will utilize the recycled CO2 from the RNG production to increase fertilizer yield) for the production of pure nitogen fertilizer ‘ClimateSmart’ and/or organic (for use in organic crop production) plus residual organic solids and clean water, and

 

  d) which will produce verifiably sustainable beef products with USDA certified branding.

 

The Dalhart Project and the Olson Project, respectively, will include expansion capability up to 60,000 and 45,000 (or more) head of cattle, in aggregate, located at/around/contiguous to the initial Project facilities.

The opportunity presented by the Ribbonwire LOI and Olson LOI to commercialize the Company’s Gen3Tech and business model matured more quickly than anticipated (reflecting strong industry and public momentum in favor of verifiably sustainable food ventures). As a result, we have shifted our plans to focus resources and make our initial 15,000 head modules a reality as soon as possible.

 

To place the LOI Projects in the context of Company’s business plan (and our prior public disclosure), if one or more of the contemplated JVs move forward on anticipated timelines, active development of the first LOI Project will commence during the second half of calendar year 2023.

 

 

10 
 

 

Prior to such activity, the Company intends to construct and operate the initial phase of the previously announced Gen3Tech demonstration project near Fair Oaks, Indiana (“Initial Project”): i) to validate our existing data and modeling at commercial scale and ii) to optimize the Bion Gen3Tech module for finalization of design parameters and fabrication details of our planned 15,000 head commercial facilities (including the 3 sets of LOI Projects). For the purposes of this initial phase, the Company, in order to accelerate the data acquisition phase, intends to utilize anaerobic digester effluent from the nearby/contiguous Fair Oaks dairy. Construction and related activities of this demonstration project have commenced with main module assembly on site in process since February 2023 (somewhat delayed due to supply chain constraints) followed by operations through the first half of 2023 (and thereafter) to generate the required information. Thereafter, the Company will evaluate what, if any, additional facilities and testing will take place at that location.

 

The Company anticipates that it will negotiate additional letters of intent and enter into additional joint ventures related to the development of further commercial-scale sustainable beef projects over the next 6-18 months in addition to the Dalhart, Olson and DVG Projects.

 

As previously disclosed, during late September 2021, Bion entered into a lease for the development site of the Initial Project, our initial commercial scale Gen3Tech project, which Initial Project will be located on approximately four (4) acres of leased land near Fair Oaks, Indiana, and a related agreement regarding disposal of certain manure effluent with the Curtis Creek Dairy unit of Fair Oaks Farms (“FOF”). Design and pre-development work commenced during August 2021 and surveying, site engineering and other site-specific engineering and design work is largely completed. Fabrication of the primary Gen3Tech equipment modules for the Initial Project commenced during January 2022. Construction work has been largely completed to prepare for the arrival in mid-February of the main modules of the Gen3Tech system. The Initial Project was initially planned to be an environmentally sustainable beef cattle feeding facility, equipped with state-of-the-art housing and Bion’s 3G-Tech platform to provide waste treatment and resource recovery. Bion designed the project to house and feed approximately 300 head of beef cattle. If all phases of the Initial Project are constructed, the facility will include Bion’s Gen3Tech platform including: i) covered barns ( including roof top solar photovoltaic generation in appropriate locations), ii) anaerobic digestion for renewable energy recovery, iii) livestock waste treatment and resource recovery technology, iv) Bion’s ammonium bicarbonate recovery (and crystallization) technology and iv) data collection software to document system efficiencies and environmental benefits (with the Bion Gen3Tech facilities capable of treating the waste from approximately 1,500 head). The facility will be large enough to demonstrate engineering capabilities of Bion’s Gen3Tech at commercial scale, but small enough that it can be constructed and commissioned relatively quickly. Originally, construction and onsite assembly operations were targeted to commence sometime late in 2022, however, supply chain backlogs have delayed likely delivery dates for core modules of the Bion system to the site until February 2023. 3G1 has been moving forward with the development and construction process of the Initial Project which we expect to become operational during the current quarter ending June 2023. See Note 3 “Property and Equipment” and Note 10 “Subsequent Events” (for activities since the start of the fourth quarter of the 2023 fiscal year).

 

The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing larger commercial projects with JV partners.

 

Specifically, the Initial Project (if all phases are constructed) is being developed to provide and/or accomplish (if all phases are constructed) the following:

 

  i. Proof of Gen3Tech platform scalability

 

  - Document system efficiency and environmental benefits and enable final engineering modifications to optimize each unit process within the Bion Gen3Tech platform.

 

  - Environmental benefits will include (without limitation) renewable energy production (natural gas recovery from AD and solar electric from integrated roof top photovoltaic generation); nutrient recovery and conversion to stable ‘ClimateSmart’ (low carbon) and/or organic fertilizer; pathogen destruction; water recovery and reuse; air emission reductions.

 

  ii. Use Bion’s data collection system to support 3rd party verified system efficiency requirement to qualify for USDA Process-Verified-Program (PVP): certification of sustainable branded beef (and potentially pork) product metrics.

 

  iii. Produce sufficient ammonium bicarbonate nitrogen fertilizer for certification/listing applications and commercial testing by potential joint venture partners and/or purchasers and for university growth trials.

 

 

11 
 

 

The Initial Project will be carried out in stages with phase one focused on portions of items i. and iii. set forth above.

 

Upon completing the primary goals of phase 1 of the Initial Project, (coupled with progress regarding certifications(s) and markets for our fertilizer product lines (liquid and/or solid)), Bion expects to be ready to move forward with its plans for development (and related project financing) of much larger facilities including the LOI Projects. The Company anticipates that discussions and negotiations it has begun (together with additional opportunities that will be generated over the next 6-18 months) regarding potential JVs with strategic partners in the financial, livestock and food distribution industries to develop large scale projects will continue during the development/construction of the Initial Project with a 2023-24 goal of establishing multiple JV’s for large scale projects that will produce sustainable and/or sustainable-organic corn-fed beef. These products will be supported by a USDA PVP-certified sustainable brand that will, initially, highlight reductions in carbon and nutrient footprint, as well as pathogen reductions associated with foodborne illness and antibiotic resistance, along with the organic designation where appropriate. Bion’s RNG, nutrient, and water recovery will be transparent, third-party verified, and supported by blockchain --- that data, coupled with cattle production history, will underpin the sustainable brand. Sustainability will be measured by improvements in resource efficiencies, animal health and welfare, and reduced impacts to air, water, and soil, and will be communicated to the consumer at the point of sale. Bion has successfully navigated the USDA PVP application process previously, having received conditional approval of its 2G Tech platform (pending resubmission and final site audits), and is confident it will be successful in qualifying its Gen3Tech platform.

 

After the basic technology start-up milestones of the Initial Project (primarily optimization and steady-state operations of the core modules of our Gen3Tech platform to generate data to support design/development of larger 15,000 head commercial modules) have been met, the core modules may be re-located to a subsequent more permanent location to be determined at a later date. The Company is in discussion with the University of Nebraska-Lincoln to jointly develop an integrated beef facility based on Bion’s Gen3Tech and business model at its Klosterman Feedyard Innovation Center (“KFIC”) (or elsewhere) including innovative barns, an anaerobic digester and a Bion Gen3Tech system to conduct ongoing research and development related thereto and the KFIC is a possible site for the long term re-location of the core modules. This venture, if it moves forward, is anticipated to include joint preparation of applications for grants and other funding from the USDA (‘climate smart’ program, rural development, etc.) and other sources. The Company is also considering re-locating the core modules of the Initial Project to Dalhart, Texas, where they may be integrated into the first phases of the Dalhart Project or a separate smaller organic beef project. 

 

The Company’s initial ammonium bicarbonate liquid fertilizer product completed its Organic Materials Review Institute (“OMRI”) application and review process with listing approval during May 2020. Applications for our first solid ammonium bicarbonate product line with OMRI and the California Department of Food & Agriculture (“CDFA”) have been unsuccessful to date. Later this calendar year (Summer/Fall 2023) the Company intends to pursue further applications for liquid and solid products (of varying nitrogen concentrations) utilizing material produced at the Initial Project. See ‘Fertilizer: Organic and ClimateSmart’ below.

 

Additionally, the Company believes there will also be opportunities to proceed with selected ‘retrofit projects’ of existing facilities (see ‘Gen3Tech Kreider 2 Poultry Project’ below as an example) in the swine, dairy and poultry industries utilizing our Gen3Tech.

 

Bion believes that substantial unmet demand currently exists– potentially very large – for ‘real’ meat/dairy/egg products that offer the verifiable/believable sustainability consumers seek, but with the taste and texture they have come to expect from American beef and pork, dairy and poultry. Numerous studies demonstrate the U.S. consumers’ preferences for sustainability. For example, 2019 NYU Stern’s Center for Sustainable Business study found that ‘products marketed as sustainable grew 5.6 times faster than those that were not…’ and that ‘…in more than 90 percent of consumer-packaged-goods (CPG) categories, sustainability-marketed products grew faster than their conventional counterparts.’ Sales growth of plant-based alternatives, including both dairy and more recently ground meat (Beyond Meat, Impossible Foods, etc.) have shown that a large and growing segment of consumers is choosing seemingly sustainable offering, and are also willing to pay a premium for it. Tyson Foods recently said, “consumers would be willing to pay at least 24 percent more for environmentally friendly, sustainable options at retail.” Numerous studies also support the consumers’ ‘willingness-to-pay’ (WTP) for sustainable choices, including a recent meta-analysis of 80 worldwide studies with results that calculate the overall WTP premium for sustainability is 29.5 percent on average.

 

12 
 

 

As one of the largest contributors to some of the greatest air and water quality problems in America, it is clear that livestock waste cleanup, at scale, represents one of the greatest opportunities we have to reduce negative environmental impacts of the food supply chain on air and water quality. Bion’s Gen3Tech platform, along with its business model, will enable the cleanup of one of the ‘dirtiest’ parts of the food supply chain: animal protein production and creates the opportunity to produce and market verifiably sustainable organic and conventional ‘real meat’ products that can participate in the growth and premium pricing that appears to be readily available for the ‘right’ products.

 

Bion believes that at least a premium segment of the U.S. beef industry (and potentially other livestock industry groups) is at the doorstep of a transformative opportunity to address the growing demand for sustainable food product offerings, while pushing back against today’s anti-meat messaging. At $66 billion/year (2021 wholesale/farmgate value), the beef industry is a fragmented, commodity industry whose practices date back decades. In 1935 inflation-adjusted terms, beef was 63% more expensive in 2021, while pork and chicken, which are now primarily raised in covered barns at CAFOs with highly integrated supply chains, were 12% and 62% cheaper, respectively. In recent years, the beef industry has come under increasing fire from advocacy groups, regulatory agencies, institutional investors, and ultimately, their own consumers, over concerns that include climate change, water pollution, food safety, and the treatment of animals and workers.

 

Advocacy groups targeting livestock and the beef industry have recently been joined by competitors that produce animal protein alternatives in seeking to exploit the industry’s environmental and economic weaknesses. Their global anti-meat messaging has had a substantial chilling effect on the relationships the beef industry has with its institutional investors; retail distributors, such as fast-food restaurants; and mostly, its consumers. Led by the United Nations Food and Agriculture Organization, a coordinated anti-meat messaging campaign has targeted consumers worldwide, primarily focused on the industry’s impacts on climate change. Meat alternatives, especially plant-based protein producers like Beyond Meat and Impossible Foods, are being heavily promoted by themselves and the media, and have enjoyed steady sales growth. A 2018 NielsenIQ Homescan survey last year found that 39% of Americans are actively trying to eat more plant-based foods. Some of the recent growth in plant-based proteins results from increasing lactose intolerance and other health concerns; however, most of that growth is attributed to consumers’ growing concerns for the environmental impacts of real meat and dairy. Several large US companies that have traditionally focused on livestock production, including Cargill, ADM, Perdue Foods, and Tyson, have also recently entered the plant protein space. In terms of changing customer preferences, ‘saving the planet’ has proven to be a more compelling argument than the traditional animal activism/ welfare pitch. To date, the primary ‘industry response’ to this has been grass-fed beef, which is regarded as a generally more sustainable offering than grain-fed (largely without empirical evidence). However grass-fed beef has had only limited acceptance in U.S. markets, because it is less flavorful and tougher than the traditional corn-fed beef consumers have grown to enjoy. Sustainability initiatives have been launched by large US livestock producers (including Tyson’s very recent ‘Brazen’ program), but it is not yet possible to determine whether any will be substantive and verifiable rather than completely ‘modeled’ and largely public relations ‘greenwashing’.

 

It should be noted that these plant-based protein producers are primarily expected to be able to serve the ground/ processed meat market, which represents only about 10 percent of the overall animal protein market. Further, there has recently been pushback to these plant-based products, focusing on their highly processed nature and unproven health benefits, scalability/ pricing, and their uncertain carbon footprint---and market growth rates have substantially slowed and may have already plateaued and/or peaked. There have also been several companies recently enter the cellular and 3D-printed meat arena. While facing myriad challenges and further out on the development timeline, some people believe cellular agriculture (aka cultured, clean, lab-grown, cultivated) meat may have the potential to service a much larger percentage of the market than plant-based protein, including cuts like steaks, chops and roasts, but the likely cost remains very uncertain at this point.

 

13 
 

 

Each of these items supports Bion’s belief that there is a potentially very large opportunity to supply premium sustainable beef products that satisfy consumer concerns. We believe that the real meat/beef products that can be cost-effectively produced today using our Gen3Tech platform, both sustainable and/or organic, can provide an affordable product that satisfies the consumer’s desire for sustainability, but with the superior taste and texture those consumers have grown to prefer.

 

Sustainable Beef

 

Bion’s goal is to be first to market with meaningfully verified sustainable beef products that can be produced at sufficient scale to service national market demand. The cattle produced at a Bion facility will have a substantially lower carbon footprint, dramatically reduced nutrient impacts to water, and an almost total pathogen kill in the waste stream. Further, the economics of producing these cattle (including the cost of the facility/technology upgrade) will be greatly enhanced by the revenue realized from the recovery of valuable resources, including renewable energy, high-value fertilizer products, and clean water.

 

A Bion sustainable beef facility will be comprised of covered barns with slotted floors (allowing the waste to pass through) which will reduce ammonia and greenhouse gas volatilization and loss, as well as odors, thereby improving animal health and human working conditions while preventing air/soil pollution. The manure will be collected and moved directly to anaerobic digestion facilities which will produce renewable natural gas (and re-cycle CO2 from the gas cleaning process). Covered barns will reduce weather impacts on the livestock and have been demonstrated to promote improved general health and weight gain in the cattle housed in them. The barns’ very large roof surface area will be utilized (in geographical locations with adequate sunshine and appropriate ‘tariffs’) for the installation of photovoltaic solar generation systems to produce electricity for the facility, as well as export to the grid. The barn roofs will also be configured to capture rainwater, which, coupled with the water recovered from the treatment process, will reduce the projects’ reliance on current water supplies.

 

Waste treatment and resource recovery will be provided by Bion’s advanced Gen3Tech platform, which Bion believes offers the most comprehensive solution for livestock waste available today. In addition to direct environmental benefits, every pound of nitrogen that is captured, upcycled, and returned to the agricultural nitrogen cycle as high-quality fertilizer (vs lost to contaminate downstream waters), is also a pound of nitrogen that will not have to be produced as synthetic urea or anhydrous ammonia, with their tremendous carbon cost. System performance and environmental benefits will be monitored and verified through third parties, with USDA PVP certification of the sustainable brand that Bion also believes will be the most comprehensive available in the market.

 

Recently there have been efforts to establish sustainable brands (including USDA PVP certification) for a number of small-scale livestock producers (largely in the grass-fed beef category). To date, the reach and extent of such efforts is limited and it is difficult to determine their effectiveness. Additionally, there have been public announcements of initiatives related to beef sustainability (largely focused on the ‘cow-calf’ segment of the livestock chain) in procurement by major beef processing companies (including Tyson’s very recent ‘Brazen’ program), but a closer look finds that many have consisted largely of ‘green washing’ public proclamations in the wake of environmental and social criticism that re-package prior initiatives and lack any significant new substance.

 

Sustainable Organic Beef

 

Bion also believes it has a unique opportunity to produce, at scale, affordable corn-fed organic beef that is also certified as sustainable. In addition to the sustainable practices described above, organic-sourced beef cows would be finished on organic corn, which would be produced using the ammonium bicarbonate fertilizer captured by the Gen3Tech platform. Bion believes its meat products will meet consumer demands with respect to sustainability and safety (organic) and provide the tenderness and taste American consumers have come to expect from premium conventional American beef. Such products are largely unavailable in the market today. We believe Bion’s unique ability to produce the fertilizer needed to grow a supply of relatively low-cost organic corn, and the resulting opportunity to produce organic beef, will dramatically differentiate us from potential competitors. This organic opportunity is dependent on successfully establishing Bion’s fertilizer products as acceptable for use in organic grain production.

 

14 
 

 

Today, organic beef demand is limited and mostly supplied with grass-fed cattle. While organic ground/ chopped meat has enjoyed success in U.S. markets, grass-fed steaks have seen limited acceptance, mostly resulting from consumer issues with taste and texture. In other words, it’s tough. Regardless, such steaks sell for a significant premium over conventional beef. A grain-finished organic beef product is largely unavailable in the marketplace today due to the higher costs of producing organic corn and grain. The exception is offerings that are very expensive from small ‘boutique’ beef producers. Like all plants, corn requires nitrogen to grow. Corn is especially sensitive to a late-season application of readily available nitrogen – the key to maximizing yields. With non-organic field corn, this nitrogen is supplied by an application of a low-cost synthetic fertilizer, such as urea or anhydrous ammonia. However, the cost for suitable nitrogen fertilizer that can be applied late-season in organic corn production is so high that the late-season application becomes uneconomical, resulting in substantially lower yields – a widely recognized phenomena known as the ‘yield gap’ in organic production. The yield gap results in higher costs for organic corn that, in turn, make it uneconomical to feed that corn to livestock. As is the case for sustainable but not organic beef, Bion believes there is a potentially large unmet demand for affordable beef products that are both sustainable AND organic, but with the taste and texture consumers have come to expect from American beef. Bion’s ability to produce the low-cost nitrogen fertilizer that can close the organic yield (and affordability) gap puts the Company in a unique, if not exclusive at this time, position to participate in JV’s that will benefit from this opportunity starting next year.

 

The demonstrated willingness of consumers to purchase sustainable products (along with numerous research and marketing studies confirming consumers are seeking, and are willing to pay a premium for, sustainable products)---in combination with the threat to the livestock industry market (primarily beef and pork) posed by plant-based alternatives (heightened by pandemic conditions)--- has succeeded in focusing the large scale livestock industry on how to meet the plant-based market challenge by addressing the consumer sustainability issues. The consumer demand for sustainability appears to be a real and lasting trend, but consumers remain skeptical of generalized claims of ‘sustainability’. To date, a large portion of the industry responses to this trend have been at a superficial level or consist of ‘green washing’, a deceptive marketing practice where companies promote non-substantive initiatives. Real sustainability for the livestock industry will require implementation of advanced waste treatment technology at or near the CAFOs – where most of the negative environmental impacts take place.

 

Fertilizer: Organic and ‘Climate Smart’

 

The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“Gen3Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of low carbon and/or organically certified soluble nitrogen fertilizer products. The Company’s low concentration ammonium bicarbonate liquid product successfully completed its Organic Materials Review Institute (“OMRI”) application and review process with listing approval during May 2020. During the next 3-6 months the Company intends to file applications for a line of higher concentration (up to 7-10%) liquid ammonium bicarbonate products during the current year based on production during operation of the Initial Project during the next 3-6 months. The Company anticipates applying for and obtaining one or more listings/certifications for higher concentration products in our liquid ammonium nitrogen fertilizer line well prior to operational dates for the Company’s initial large scale JV Gen3Tech Sustainable Beef Projects.

 

Additionally, the Company is exploring the market potential for its fertilizer to be a verifiably ‘ClimateSmart’ product (potentially a much larger market than the organic market). This may require working with industry and academic entities to develop appropriate metrics and producing a ‘life cycle assessment’ (LCA) for Bion’s ammonium nitrogen fertilizer product which can be compared to conventional nitrogen fertilizer products. Bion’s processes will capture and utilize CO2 in the waste stream (including CO2 produced with the renewable natural gas (RNG) by anaerobic digestion) as stabilizing agent thereby potentially creating carbon offsets compared to natural gas utilized as feedstock in chemical ammonia production which reduction will be reflected in the LCA. This LCA will assess environmental impacts associated with fertilizer production in support of the beef cattle supply chain for both the existing conventional approach (primarily fossil fuel-based Haber-Bosch production methods) and the largely decarbonized Bion production approach. We believe a series of coincident yet significant LCA benefits accrue from Bion’s patented fertilizer production approach including the reduced loss of ammonia to the environment via air (volatilized) and water (nitrate in groundwater) pathways, recycled/reused water, elimination of pathogens, the production of renewable natural gas, the production solar energy from photovoltaic panels on barn roofs, enhanced animal welfare practices and reduced animal husbandry risks from extreme weather events. Bion believes that current evaluations of the carbon impact from feedlot operations materially underestimate the negative impacts because existing models do not properly include significant ‘downstream’ carbon impacts of required energy intensive waste water treatment for re-deposited ammonia nitrogen. If the Company determines there is a significant ‘ClimateSmart’ opportunity for our fertilizer products, such an LCA can be completed (based in part on data from the Initial Project) and support marketing efforts well prior to operational dates for the Company’s initial large scale JV Gen3Tech projects.

 

15 
 

 

Ammonium bicarbonate, manufactured using thermal and mechanical processes, has a long history of use as a fertilizer. In addition to liquid ammonium nitrogen fertilizer, Bion’s Gen3Tech is capable of recovering nitrogen in the form of solid ammonium bicarbonate products containing up to 18-22 (or higher) percent nitrogen in a crystalline form that is easily transported (while producing liquids with various percentages of ammonium bicarbonate nitrogen during interim stages of the process). This solid product is water soluble and provides a readily available nitrogen source for crops. It will contain virtually none of the other salt, iron and mineral constituents of the livestock waste stream that often accompany other organic fertilizers. This product is being developed to fertilizer industry standards so that it that can be precision-applied to crops using existing equipment. Bion believes that this product will potentially have broad applications in the production of organic and/or ClimateSmart grains for livestock feed, row crops, horticulture, greenhouse and hydroponic production, and potentially retail lawn and garden products.

 

The ammonium bicarbonate products (liquid and solid) produced by Bion’s Gen3Tech platform will enjoy a dramatically lower carbon footprint than synthetic nitrogen fertilizers. The reactive nitrogen captured and upcycled into our fertilizer products was going to be lost through volatilization and runoff, and that loss would generally need to be offset with a synthetic nitrogen fertilizer, such as anhydrous ammonia or urea. These synthetic nitrogen products are produced through the Haber-Bosch (and other) synthetic processes, which converts hydrogen and atmospheric nitrogen to ammonia, with methane from fossil fuels as the energy source. It is an extremely energy-intensive process with a carbon footprint that, while not yet fully understood, is widely accepted to by very large. While a complete Life Cycle Assessment (LCA) of carbon impacts from synthetic fertilizer production is not yet available, according to the Institute for Industrial Productivity, its production alone is responsible for approximately 1 percent of total global CO2 emissions. To the extent that Bion can capture and repurpose the nitrogen traditionally lost from livestock waste, that carbon cost will no longer need to be paid by the environment/climate.

 

Applications for our first solid form of concentrated ammonia, soluble nitrogen fertilizer product line have been filed with OMRI (filed during May 2021) and the California Department of Food & Agriculture (“CDFA”)(filed during May 2022) without success to date. After an extended review processes (which was largely opaque), the OMRI application proceeded through multiple stages without receiving a positive result. The Company believes that OMRI failed to properly follow its own procedures and reached a result without scientific support. The Company has elected to proceed with “Judicial Dispute Resolution” as set forth in the OMRI Policy Manual and has initiated litigation contesting the determination. OMRI filed its Answer to Bion’s Complaint during the first week of May 2023 and the discovery process has now commenced. Recently the Company has also received a negative determination from CDFA. We have initiated an informal dialogue with CDFA regarding the basis for and re-consideration of its initial determination. The Company’s solid product line is novel in part due to the fact that there is not a formal listing category in the organic space for a solid form of concentrated ammonia, soluble nitrogen fertilizers and there is no clear guidance at present from internal policy manuals on how to categorize this product and the process that produces it. There is also no clear guidance at present from either the NOP or the National Organic Standards Board (“NOSB”) (which is currently involved in a related review and recommendations process regarding ‘high nitrogen liquid fertilizers’ derived from ammonia from manure). The Company and its representatives, along with a number of other stakeholders, are involved in discussions regarding resolution of these matters at all three levels. The Company intends to continue efforts to obtain listing/certification for its solid nitrogen fertilizer line over the course of this calendar year.

 

 

16 
 

 

Gen3Tech Kreider 2 Poultry Project

 

Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) (‘Kreider Renewable Energy Facility’ or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). Now that development of the Company’s Gen3Tech is being deployed, the Company has commenced discussions with KF regarding updating and amending the JV agreement and anticipates executing an amended joint venture agreement during 2023. During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA). Note that this Project may also be expanded in the future to treat wastes from other local and regional CAFOs (poultry and/or dairy---including the Kreider Dairy) and/or additional Kreider poultry expansion (some of which may not qualify for nutrient reduction credits). The Company anticipates if and when PA2 re-commences work on the Kreider 2 Project, it will submit a new application based on our Gen3Tech. Site specific design and engineering work for this facility have not commenced, and the Company does not yet have financing in place for the Kreider 2 Project. This opportunity is being pursued through PA2. If there are positive developments related to the market for nutrient reductions in Pennsylvania, of which there is no assurance, the Company intends to pursue development, design and construction of the Kreider 2 Project with a goal of achieving operational status for its initial modules during the following calendar year. The economics (potential revenues and profitability) of the Kreider 2 Project, despite its proposed use of Bion’s Gen3Tech for increased recovery of marketable by-products and sustainable branding, are based in material part the long-term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. However, liquidity in the Pennsylvania nutrient credit market has not yet developed significant breadth and depth, which lack of liquidity has negatively impacted Bion’s business plans and will most likely delay PA2’s Kreider 2 Project and other proposed projects in Pennsylvania.

 

Note that while Bion believes that the Kreider 2 Project and/or subsequent Bion Projects in PA and the Chesapeake Bay Watershed will eventually generate revenue from the sale of: a) nutrient reductions (credits or in other form), b) renewable energy (and related credits), c) sales of fertilizer products, and/or d) potentially, in time, credits for the reduction of greenhouse gas emissions, plus e) license fees/premiums related to a ‘sustainable brand’, the Covid-19 pandemic has delayed legislative efforts needed to commence its development. However, the Company is currently engaged in dialogue with the regional EPA office and the Chesapeake Bay Program Office regarding the potential of the Company’s Gen3Tech Kreider2 Project (and other potential projects) to enable Pennsylvania to move forward toward meeting its Chesapeake Bay clean-up goals. We believe that the potential market is very large, but it is not possible to predict the exact timing and/or magnitude of these potential markets at this time.

 

Technology Deployment: Bion Gen3Tech

 

Widespread deployment of waste treatment technology, and the sustainability it enables, is largely dependent upon generating sufficient additional revenues to offset the capital and operating costs associated with technology adoption. Bion’s Gen3Tech business platform has been developed to create opportunities for such augmented revenue streams, while providing third party verification of sustainability claims. The Gen3Tech platform has been designed to maximize the value of co-products produced during the waste treatment/recovery processes, including pipeline-quality renewable natural gas (biogas) and commercial fertilizer products approved for organic production. All processes will be verifiable by third parties (including regulatory authorities and certifying boards) to comply with environmental regulations and trading programs and meet the requirements for: a) renewable energy and carbon credits, b) organic certification of the fertilizer coproducts and c) USDA PVP certification of an ‘Environmentally Sustainable’ brand (see discussion above and below), and d) payment for verified ecosystem services. The Company’s first patent on its Gen3Tech was issued during 2018. In August 2020, the Company received a Notice of Allowance on its third patent which significantly expands the breadth and depth of the Company’s Gen3Tech coverage. The Company has additional applications pending and/or planned.

 

17 
 

 

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

In parallel with technology development, Bion has worked (which work continues) to implement market-driven strategies designed to stimulate private-sector participation in the overall U.S. nutrient and carbon reduction strategy. These market-driven strategies can generate “payment for ecosystem services”, in which farmers or landowners are rewarded for managing their land and operations to provide environmental benefits that will generate additional revenues. Existing renewable energy credits for the production and use of biogas are an example of payment for ecosystem services. Another such strategy is nutrient trading (or water quality trading), which will potentially create markets (in Pennsylvania and other states) that will utilize taxpayer funding for the purchase of verified pollution reductions from agriculture (“nutrient credits”) by the state (or others) through competitively-bid procurement programs. Such credits can then be used as a ‘qualified offset’ by an individual state (or municipality) to meet its federal clean water mandates at significantly lower cost to the taxpayer. Market-driven strategies, including competitive procurement of verified credits, is supported by U.S. EPA, the Chesapeake Bay Commission, national livestock interests, and other key stakeholders. Legislation in Pennsylvania to establish the first such state competitive procurement program passed the Pennsylvania Senate by a bi-partisan majority during March 2019 but has not yet crossed the hurdles required for actual adoption. The Covid-19 pandemic and related financial/budgetary crises have slowed progress for this and other policy initiatives and, as a result, it is not currently possible to project the timeline for completion (or meaningful progress) of this and other similar initiatives (see discussion below).

 

The livestock industry and its markets are already changing. With our commercial-ready technology and business model, Bion believes it has a ‘first-mover advantage’ over others that will seek to exploit the opportunities that will arise from the industry’s inevitable transformation. Bion anticipates moving forward with the development process of its initial commercial installations utilizing its Gen3Tech, during the current 2023 fiscal year. We believe that Bion’s Gen3Tech platform and business model can provide a pathway to true economic and environmental sustainability with ‘win-win’ benefits for at least a premium sector of the livestock industry, the environment, and the consumer, an opportunity which the Company intends to pursue.

 

The Livestock Problem

 

The livestock industry is under tremendous pressure from regulatory agencies, a wide range of advocacy groups, institutional investors and the industry’s own consumers, to adopt sustainable practices. Environmental cleanup is inevitable and has already begun — and policies have already begun to change, as well. Bion’s Gen3Tech was developed for implementation on large scale livestock production facilities, where scale drives both lower treatment costs and efficient co-products production, as well as dramatic environmental improvements. We believe that scale, coupled with Bion’s verifiable treatment technology platform, will create a transformational opportunity to integrate clean production practices at (or close to) the point of production—the primary source of the industry’s environmental impacts. Bion intends to assist the forward-looking segment of the livestock industry to bring animal protein production in line with 21st Century consumer demands for meaningful sustainability.

 

In the U.S. (according to the USDA’s 2017 agricultural census) there are over 9 million dairy cows, 90 million beef cattle, 60 million swine and more than 2 billion poultry which provides an indication of both the scope of the problem addressed by Bion’s technology, as well as the size of Bion’s opportunity. Environmental impacts from livestock production include surface and groundwater pollution, greenhouse gas emissions, ammonia, and other air pollution, excess water use, and pathogens related to foodborne illnesses and antibiotic resistance. While the most visible and immediate problems are related to nutrient runoff and its effects on water quality, the industry has recently been targeted by various stakeholder groups for its impacts on climate change.

 

Estimates of total annual U.S. livestock manure waste vary widely, but start around a billion tons, between 100 and 130 times greater than human waste. However, while human waste is generally treated by septic or municipal wastewater plants, livestock waste – raw manure – is spread on our nation’s croplands for its fertilizer value. Large portions of U.S. feed crop production (and most organic crop production) are fertilized, in part, in this manner. Under current manure management practices, 80% or more of total nitrogen from manure, much of it in the form of ammonia, escapes during storage, transportation, and during and after soil application, representing both substantial lost value and environmental costs.

 

18 
 

 

More than half of the nitrogen impacts from livestock waste come from airborne ammonia emissions, which are extremely volatile, reactive and mobile. Airborne ammonia nitrogen eventually settles back to the ground through atmospheric deposition — it ‘rains’ everywhere. While some of this nitrogen is captured and used by plants, most of it runs off and enters surface waters or percolates down to groundwater. It is now well-established that most of the voluntary conservation practices, such as vegetated buffers that ‘filter’ runoff (often referred to as “BMPs” or “Best Management Practices” that have traditionally been implemented to attempt to mitigate nutrient runoff), are considerably less effective than was previously believed to be the case. This is especially true with regard to addressing the volatile and mobile nitrogen from ammonia emissions, because BMPs are primarily focused on surface water runoff, directly from farm fields in current production, versus the re-deposition that takes place everywhere or groundwater flow.

 

Runoff from livestock waste has been identified in most of our major watersheds as a primary source of excess nutrients that fuel algae blooms in both fresh and saltwater. Over the last several years, algae blooms have become increasingly toxic to both humans and animals, such as the Red Tides on the Florida and California coasts, and the Lake Erie algae bloom that cut off the water supply to Toledo, Ohio, residents in 2014. When the nutrient runoff subsides, it leaves the algae blooms with no more ‘food’ and the blooms die. The algae’s decomposition takes oxygen from the water, leading to ‘dead zones’ in local ponds, lakes, and ultimately, the Great Lakes, as well as the Chesapeake Bay, Gulf of Mexico, and other estuary waters. Both the toxic algae blooms and the low/no-oxygen dead zones devastate marine life, from shrimp and fish to higher mammals, including dolphins and manatees. U.S. EPA already considers excess nutrients “one of America’s most widespread, costly and challenging environmental problems”. Nutrient runoff is expected to worsen dramatically in the coming decades due to rising temperatures and increasing rainstorm intensity as a result of climate change.

 

Nitrate-contaminated groundwater is of growing concern in agricultural regions nationwide, where it has been directly correlated with nutrient runoff from upstream agricultural operations using raw manure as fertilizer. Pennsylvania, Wisconsin, California and Washington, and others, now have regions where groundwater nitrate levels exceed EPA standards for safe drinking water. High levels of nitrate can cause blue baby syndrome (methemoglobinemia) in infants and affect women who are or may become pregnant, and it has been linked to thyroid disease and colon cancer. EPA has set an enforceable standard called a maximum contaminant level (MCL) in water for nitrates at 10 parts per million (ppm) (10 mg/L) and for nitrites at 1 ppm (1 mg/L). Federal regulations require expensive pretreatment for community water sources that exceed the MCL; however, private drinking water wells are not regulated, and it is the owners’ responsibility to test and treat their wells. Additionally, groundwater flows also transport this volatile nitrogen downstream where, along its way, it intermixes with surface water, further exacerbating the runoff problem. Like atmospheric deposition, the current conservation practices we rely on to reduce agricultural runoff are largely bypassed by this subsurface flow.

 

Additionally, in arid climates, such as California, airborne ammonia emissions from livestock manure contribute to air pollution as a precursor to PM2.5 formation, small inhalable particulate matter that is a regulated air pollutant with significant public health risks. Whether airborne or dissolved in water, ammonia can only be cost-effectively controlled and treated at the source—before it has a chance to escape into the environment where it becomes extremely expensive to ‘chase’, capture, and treat.

 

High phosphorus concentrations in soils fertilized with raw manure are another growing problem. The ratio of nitrogen to phosphorus in livestock waste is fixed, and because manure application rates are calculated based on nitrogen requirements, often phosphorus is overapplied as an unintended consequence. Phosphorus accumulation in agricultural soils reduces its productivity, increases the risk of phosphorus runoff, and represents a waste of a finite resource. Decoupling the nitrogen from the phosphorus would allow them to be precision-applied, independently of each other, when and where needed.

 

The livestock industry has recently come under heavy fire for its impacts on climate change, which has become a rallying cry for the anti-meat campaign discussed above. Estimates of the magnitude of those impacts vary widely, but the general consensus is that globally, livestock account for 14.5 percent of greenhouse emissions. In the U.S. however, that number drops to 4.2 percent, due to the increased efficiencies of American beef production. The greatest impacts come from direct emissions of methane from enteric fermentation (belches), methane and nitrous oxide emissions from the manure, with arguably the largest being the massive carbon footprint of the synthetic nitrogen fertilizers used to grow the grains to feed the livestock.

 

For decades the livestock industry has overlooked and/or socialized its environmental problems and costs. Today, the impacts of livestock production on public health and the environment can no longer be ignored and are coming under increasing scrutiny from environmental groups and health organizations, regulatory agencies and the courts, the media, consumers, and activist institutional investors. The result has been a significant and alarming loss of market share to plant-based protein and other alternative products. Bion’s Gen3Tech platform was designed to resolve these environmental issues and bring the industry in line with twenty-first century consumer expectations.

 

19 
 

 

Going concern and management’s plans:

 

The condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has not generated significant revenues and has incurred net losses of approximately $3,451,000 during the year ended June 30, 2021 and a net income of $8,291,000 for the year ended June 30, 2022. The net income for the year ended June 30, 2022 was largely due to a one-time, non-cash event of the dissolution of PA-1 resulting in a gain of approximately $10,235,000 as well as a one-time gain of $902,000 from the sale of the Company’s ‘biontech.com’ domain pursuant to a purchase agreement during the period. For the nine months ended March 31, 2023, the Company had a net loss of $2,507,305 At March 31, 2023, the Company has a working deficit and a stockholders’ equity of approximately $147,000 and $4,149,000, respectively. During the three months ended March 31, 2023 the Company had debt modifications that resulted in a reduction of debt of $3,516,000 and an increase in equity. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. The following paragraphs describe management’s plans with regard to these conditions.

 

The Company continues to explore sources of additional financing (including potential agreements with strategic partners – both financial and ag-industry) to satisfy its current and future operating and capital expenditure requirements as it is not currently generating any significant revenues.

 

During the years ended June 30, 2022 and 2021, the Company received gross proceeds of approximately $1,737,000 and $5,209,000, respectively, from the sale of its debt and equity securities.

 

During the nine months ended March 31, 2023, the Company received total proceeds of approximately $3,385,000 from the sale of its equity securities. There were $48,000 in cash commissions paid.

 

During fiscal years 2022 and 2021, the Company faced less difficulty in raising equity funding (but was subject to substantial equity dilution from the larger amounts of equity financing during the periods) than was experienced in the prior 3 years. During the first nine months of the current fiscal year, the Company has raised limited equity funds to meet its some of its immediate needs but will need to raise additional funds in the coming periods. The Company anticipates substantial increases in demands for capital and operating expenditures during the second half of the current fiscal year and thereafter as it moves toward commercial implementation of its 3G Tech and development of JVs (including costs associated with additions of personnel to carry out the business activities of the Company) and, therefore, is likely to continue to face significant cash flow management challenges due to limited capital resources and working capital constraints which have only recently begun to be alleviated. To partially mitigate these working capital constraints, the Company’s core senior management and several key employees and consultants have been deferring (and continue to defer) portions of their cash compensation and/or are accepting compensation in part in the form of securities of the Company and/or converting portions of their compensation and deferred compensation to securities of the Company (Notes 5 and 7) and members of the Company’s senior management have made loans to the Company from time to time. During the year ended June 30, 2018, senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $2,404,000. Additionally, the Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again during the year ended June 30, 2018. The constraint on available resources has had, and continues to have, negative effects on the pace and scope of the Company’s efforts to develop its business. At times, the Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company is able to continue its recent relative success in its efforts to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and curtailment of ongoing activities including research and development activities.

 

20 
 

 

The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Projects (including the Initial Project, JV Projects (including the Dalhart and Olson Projects),and the Kreider 2 facility) and CAFO Retrofit waste remediation systems. The Company anticipates that it will seek to raise from $20,000,000 to $80,000,000 or more debt and/or equity through joint ventures, strategic partnerships and/or sale of its equity securities (common, preferred and/or hybrid) and/or debt (including convertible) securities, and/or through use of ‘rights’ and/or warrants (new and/or existing) and/or through other means during the next twelve months. However, as discussed above, there is no assurance, especially in light of the difficulties the Company has experienced in many recent years and the extremely unsettled capital markets that presently exist for small companies like us, that the Company will be able to obtain the funds that it needs to stay in business, complete its technology development or to successfully develop its business and Projects.

 

There is no realistic likelihood that funds required during the next twelve months (or in the periods immediately thereafter) for the Company’s basic operations, the Initial Project and/or proposed JVs and/or Projects will be generated from operations. Therefore, the Company will need to raise sufficient funds from external sources such as debt or equity financings or other potential sources. The lack of sufficient additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company’s existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for small companies like Bion.

 

Covid-19 pandemic related matters:

 

The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.

 

2.       SIGNIFICANT ACCOUNTING POLICIES

 

Principles of consolidation:

 

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its 58.9% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.

 

The accompanying condensed consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements reflect all adjustments (consisting of only normal recurring entries) that, in the opinion of management, are necessary to present fairly the financial position at March 31, 2023, the results of operations of the Company for the three and nine months ended March 31, 2023 and 2022 and the cash flows of the Company for the nine months ended March 31, 2023 and 2022. Operating results for the three and nine months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending June 30, 2023.

 

21 
 

 

Cash and cash equivalents:

 

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of March 31, 2023 and June 30, 2022 there are no cash equivalents.

 

Property and equipment:

 

Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects such as consulting fees, internal salaries and benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.

 

Patents:

 

The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s condensed consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.

 

Stock-based compensation:

 

The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.

 

Derivative Financial Instruments:

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.

 

Options:

 

The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.

 

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

22 
 

 

Concentrations of credit risk:

 

The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.

 

Noncontrolling interests:

 

In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the condensed consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the condensed consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.

 

Fair value measurements:

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.

 

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;

 

Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

 

Level 3 – assets and liabilities whose significant value drivers are unobservable.

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.

 

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the condensed consolidated statements of operations over the lease term.

23 
 

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s condensed consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.

 

Revenue Recognition:

 

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.

 

Income (Loss) per share:

 

Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the three and nine months ended March 31, 2023 and 2022, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.

 

The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:

 

          
   March 31,
2023
   March 31,
2022
 
Warrants   21,944,437    19,078,635 
Options   11,506,600    10,481,600 
Convertible debt   10,052,765    10,847,026 
Convertible preferred stock            

 

The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the three and nine months ended March 31, 2023 and 2022:

 

                    
   Three months
ended
March 31,
2023
   Three months
ended
March 31,
2022
   Nine months
ended
March 31,
2023
   Nine months
ended
March 31,
2022
 
Shares issued – beginning of period   44,529,884    43,733,850    43,758,820    41,315,986 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)   (704,309)   (704,309)
Shares outstanding – beginning of period   43,825,575    43,029,511    43,054,511    40,611,677 
Weighted average shares issued
    during the period
   1,630,842          1,110,798    990,713 
Diluted weighted average shares –
    end of period
   45,456,417    43,029,511    44,165,309    40,904,342 

 

 

24 
 

 

Use of estimates:

 

In preparing the Company’s condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements:

 

The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its condensed consolidated financial statements and assures that there are proper controls in place to ascertain that the Company’s condensed consolidated financial statements properly reflect the change.

 

 

3.  PROPERTY AND EQUIPMENT:

 

Property and equipment consist of the following:

 

          
   March 31,
2023
   June 30,
2022
 
Computers and office equipment   15,156    13,598 
Initial Project: construction in process   5,784,494    2,892,222 
Property and equipment, gross   5,799,650    2,905,820 
Less accumulated depreciation   (11,447)   (10,262)
 Property and equipment, net  $5,788,203   $2,895,558 

 

The 3G1 project (“Initial Project”) began in July of 2021, with a lease signed on land October 1, 2021 (Note 9). Once the lease commenced the Company moved into construction phase. The balance for the Initial Project construction in process includes $149,342 for capitalized interest and $135,648 in non-cash compensation as of March 31, 2023.

 

Management has reviewed the remaining property and equipment for impairment as of March 31, 2023 and believes that no impairment exists.

 

Depreciation expense was $461 and $252 for the three months ended March 31, 2023 and 2022, respectively and $1,185 and $832 for the nine months ended March 31, 2023 and 2022, respectively.

 

4.       DEFERRED COMPENSATION:

The Company owes deferred compensation to various employees, former employees and consultants totaling $784,255 and $525,699 as of March 31, 2023 and 2022, respectively. Included in the deferred compensation balances as of March 31, 2023, are $504,401 and $5,000 owed Dominic Bassani (“Bassani”), the Company’s Chief Operating Officer (who was Chief Executive Officer until through April 30, 2022), and Mark A. Smith (“Smith”), the Company’s President, respectively, pursuant to extension agreements effective January 1, 2015, whereby unpaid compensation earned after January 1, 2015, accrues interest at 4% per annum and can be converted into shares of the Company’s common stock at the election of the employee during the first five calendar days of any month. The conversion price shall be the average closing price of the Company’s common stock for the last 10 trading days of the immediately preceding month. The deferred compensation owed Bassani and Smith as of March 31, 2022 was $410,585 and nil, respectively. The Company also owes various consultants and an employee, pursuant to various agreements, for deferred compensation of $92,355 and $42,614 as of March 31, 2023 and 2022, respectively, with similar conversion terms as those described above for Bassani and Smith, with the exception that the interest accrues at 0% to 3% per annum. The Company also owes a former employee $72,500, which is not convertible and is non-interest bearing. Bassani and Smith have each been granted the right to convert up to $300,000 of deferred compensation balances at a price of $0.75 per share until June 30, 2024 into common shares (to be issued pursuant to the 2006 Plan). Smith also has the right to convert all or part of his deferred compensation balance into the Company’s securities (to be issued pursuant to the 2006 Plan) “at market” and/or on the same terms as the Company is selling or has sold its securities in its then current (or most recent if there is no current) private placement. Smith also received the right to transfer future deferred compensation to his 2020 Convertible Obligation at his election but such right is no longer in force.

25 
 

 

Bill O’Neill has a balance of $110,000 and nil at March 31, 2023 and 2022, respectively. There is no interest or conversions on the deferred balance. During the three and nine months ended March 31, 2023, Smith elected to convert $30,000 and $90,000, respectively, of deferred compensation into the 2020 Convertible Note.

The Company recorded interest expense of $5,034 ($4,428 with related parties) and $3,824 ($3,570 with related parties) for the three months ended March 31, 2023 and 2022, respectively, and $14,458 ($12,893 with related parties) and $12,124 ($11,615 with related parties) for the nine months ended March 31, 2023 and 2022, respectively.

  

5.       LOANS PAYABLE:

 

Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s condensed consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s condensed consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer condensed consolidated and included in the Company’s balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436). The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s condensed consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

26 
 

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest described above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

6.       CONVERTIBLE NOTES PAYABLE - AFFILIATES:

 

2020 Convertible Obligations

 

The 2020 Convertible Obligations, which accrue interest at either 4% per annum or 4% compounded quarterly and effective January 1, 2020 are due and payable on July 1, 2024. The 2020 Convertible Obligations (including accrued interest, plus all future deferred compensation added subsequently), are convertible, at the sole election of the holder, into Units consisting of one share of the Company’s common stock and one half to one warrant to purchase a share of the Company’s common stock, at a price of $0.50 per Unit until July 1, 2024. The original conversion price of $0.50 per Unit approximated the fair value of the Units at the date of the agreements; therefore, no beneficial conversion feature exists. Management evaluated the terms and conditions of the embedded conversion features based on the guidance of ASC 815-15 “Embedded Derivatives” to determine if there was an embedded derivative requiring bifurcation. An embedded derivative instrument (such as a conversion option embedded in the deferred compensation) must be bifurcated from its host instruments and accounted for separately as a derivative instrument only if the “risks and rewards” of the embedded derivative instrument are not “clearly and closely related” to the risks and rewards of the host instrument in which it is embedded. Management concluded that the embedded conversion feature of the deferred compensation was not required to be bifurcated because the conversion feature is clearly and closely related to the host instrument, and because of the Company’s limited trading volume that indicates the feature is not readily convertible to cash in accordance with ASC 815-10, “Derivatives and Hedging”. Effective February 1, 2023, a large portion of the 2020 Convertible Obligations were adjusted as set forth below.

 

27 
 

 

As of March 31, 2023, the remaining unadjusted portion of the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts (and his donees), Smith and Edward Schafer (“Schafer”), a director of the Company, were $358,151, $36,072 and nil, respectively. As of March 31, 2022, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts, Smith and Schafer were $2,573,716, $1,315,069 and $494,736, respectively.

 

During the nine months ended March 31, 2023 (on dates prior to the adjustment on February 1, 2023), Smith elected to add $90,000 of his salary and $23,943 in accounts payable for reimbursable expenses to his 2020 Convertible Obligations.

 

During the nine months ended March 31, 2023 (on dates prior to the adjustment on February 1, 2023), Smith elected to convert $30,000 in principal of the 2020 Convertible Obligation to 60,000 units (60,000 common shares and 60,000 warrants), and $20,000 of accrued interest of the 2020 Convertible Obligation to 40,000 units (40,000 common shares and 40,000 warrants). The warrants are exercisable for three years from conversion date.

 

 

The Company recorded interest expense of $16,208 and $6,366 for the three months ended March 31, 2023 and 2022, respectively. The Company recorded interest expense of $98,948 and $17,430 for the nine months ended March 31, 2023 and 2022, respectively. The Company capitalized $51,238 and nil related to the Initial Project for the three months ended March 31, 2023 and 2022, respectively. The Company capitalized $117,342 and nil related to the Initial Project for the nine months ended March 31, 2023 and 2022, respectively.

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long-term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes) owed to them by the Company in a manner which reduces the indebtedness of the Company by 80% (approximately $3.47 million, in aggregate) while equitably maintaining existing conversion rights.  Mark A. Smith (the Company’s President) (“Smith”), Dominic Bassani (the Company’s Chief Operating Officer) (“Bassani”) and Ed Schafer (Director) (“Schafer”), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations (see below).

 

September 2015 Convertible Notes

 

During the year ended June 30, 2016, the Company entered into September 2015 Convertible Notes with Bassani, Schafer and a Shareholder which replaced previously issued promissory notes. The September 2015 Convertible Notes bear interest at 4% per annum, have maturity dates of July 1, 2024, and may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.60 per share. As the conversion price of $0.60 approximated the fair value of the common shares at the date of the September 2015 Convertible Notes, no beneficial conversion feature exists.

 

The balances of the September 2015 Convertible Notes as of March 31, 2023, including accrued interest owed Bassani, Schafer and Shareholder, are $157,682, nil and $457,094, respectively. The balances of the September 2015 Convertible Notes as of March 31, 2022, including accrued interest, were $276,944, $20,681 and $441,977, respectively.

 

The Company recorded interest expense of $5,507 and $5,366 for the three months ended March 31, 2023 and 2022, respectively. The Company recorded interest expense of $18,239 and $17,430 for the nine months ended March 31, 2023 and 2022, respectively.

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including the September 2015 Convertible Notes owned by Bassani and Schafer) owed to them by the Company in a manner which reduces the indebtedness of the Company by 80% (approximately $3.47 million, in aggregate) while equitably maintaining existing conversion rights.  Mark A. Smith (the Company’s President), Dominic Bassani (the Company’s Chief Operating Officer)(and a family Trust) and Ed Schafer (Director), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively.

 

28 
 

 

Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes) owed to them by the Company in a manner which reduces the indebtedness of the Company by 80% (approximately $3.47 million, in aggregate) while equitably maintaining existing conversion rights.  Mark A. Smith (the Company’s President)(“Smith”), Dominic Bassani (the Company’s Chief Operating Officer)(“Bassani”) and Ed Schafer (Director)(“Schafer”), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes. The Adjusted 2020 Convertible Obligations of Smith, Bassani and Schafer are convertible into Units at prices of $.0946, $0953, and $.0953, respectively, and the Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.115 per share. The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (July 1, 2024). Effective February 1, 2023 the Company owed Smith, Bassani (and trust) and Schafer $262,154, $434,016 and $96,364 of Adjusted 2020 Convertible Obligations and Bassani and Schafer $24,230 and $4,012 of Adjusted September 2015 Convertible Notes.

 

Effective March 8, 2023, Smith converted $70,000 of his Adjusted 2020 Convertible Obligation into 739,958 Units (each Unit consisting one share and one warrant). Effective March 31, 2023, Smith converted $29,888.64 of his Adjusted Convertible Obligation into 315,948 Units (each Unit consisting one share of common stock and one warrant). Smith donated to charitable organizations and/or gifted to family members and others a large portion of these securities (450,000 common shares and 705,000 warrants, in aggregate) while retaining direct ownership of 255,906 common shares and 79,958 warrants and indirect ownership of 350,000 common shares and 270,948 warrants (owned by his wife). The warrants are exercisable for three years from conversion date.

 

As of March 31, 2023, the Adjusted 2020 Convertible Obligation balances, including accrued interest, owed Bassani (and his donees), Smith and Edward Schafer were $436,988, $164,060 and $97,024, respectively.

 

As of March 31, 2023 the Adjusted September 2015 Convertible Notes balances, including accrued interest, owed Bassani Family Trusts and Schafer were $24,396 and $4,039, respectively.

 

7.       STOCKHOLDERS' EQUITY:

 

Debt Modification to Additional Paid in Capital

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes) owed to them by the Company in a manner which reduces the indebtedness of the Company by 80% (approximately $3.47 million, in aggregate) while equitably maintaining existing conversion rights.  Mark A. Smith (the Company’s President)(“Smith”), Dominic Bassani (the Company’s Chief Operating Officer)(“Bassani”) and Ed Schafer (Director)(“Schafer”), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes. The Adjusted 2020 Convertible Obligations of Smith, Bassani and Schafer are convertible into units at prices of $.0946, $0953, and $.0953, respectively, and the Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.115 per share. The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (July 1, 2024). The Company treated this as an equity transaction and recorded the reduction of debt through addiotnal paid in capital at the net present value of the modified debt agreements. This resulted in an increase to Additional Paid in Capital of $3,521,000 at the modification date and a reduction of additional paid in capital of $5,620 for the three months ended March 31, 2023 for the adjustment to the net present value of the modified debt agreements.

 

29 
 

 

 

Series B Preferred stock:

 

Since July 1, 2014, the Company had 200 shares of Series B redeemable convertible Preferred stock outstanding with a par value of $0.01 per share, convertible at the option of the holder at $2.00 per share, with dividends accrued and payable at 2.5% per quarter. The Series B Preferred stock is mandatorily redeemable at $100 per share by the Company three years after issuance and accordingly was classified as a liability. The 200 shares had reached their redemption date and the Company approved the redemption of the Series B preferred stock during the year ended June 30, 2022. The 200 shares of Series B redeemable convertible Preferred stock were redeemed for $41,000, which included the $21,000 in accrued dividend payable.

 

During the years ended June 30, 2022, and 2021, the Company declared dividends of $1,000 and $2,000 respectively. The dividends are classified as a component of operations as the Series B Preferred stock is presented as a liability in these financial statements. There is no liability at March 31, 2023.

 

Common stock:

 

Holders of common stock are entitled to one vote per share on all matters to be voted on by common stockholders. In the event of liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to share in all assets remaining after liabilities have been paid in full or set aside and the rights of any outstanding preferred stock have been satisfied. Common stock has no preemptive, redemption or conversion rights. The rights of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of any outstanding series of preferred stock or any series of preferred stock the Company may designate in the future.

 

Centerpoint holds 704,309 shares of the Company’s common stock. These shares of the Company’s common stock held by Centerpoint are for the benefit of its shareholders without any beneficial interest.

 

During the three months ended December 31, 2022, the Company entered into a subscription agreement to sell 2,000,000 shares of restricted and legended common stock of which 1,800,000 shares were purchased on January 10, 2023 (the other 200,000 shares were purchased on December 31, 2022) for total proceeds during the nine month period ending March 31, 2023 of $2,000,000.

 

During the three months ended March 31, 2023, the Company entered into subscription agreements to sell 575,000 units at a price of $1.60, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $2.40 per share with an expiry date of June 30, 2024, and pursuant thereto, the Company issued 575,000 units for total proceeds of $920,000, in aggregate. The Company paid commissions of $48,000 on the sale of units.

During the three months ended March 31, 2023, 84,000 warrants were exercised to purchase 84,000 shares of the Company’s common stock at $0.75 per share for total proceeds of $63,000.

During the three months ended March 31, 2023, Smith elected to convert $99,889 in principal of his Adjusted 2020 Convertible Obligation into 1,055,906 units at $0.0946 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until March 2026.

 

During the nine months ended March 31, 2023, the Company entered into subscription agreements to sell units for $1.00 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share with an expiry date of December 31, 2024, and pursuant thereto, the Company issued 346,230 units for total proceeds of $346,230.

 

During the nine months ended March 31, 2023, the Company entered into a subscription agreement to sell 2,000,000 shares of restricted and legended common stock of which 1,800,000 shares were purchased on January 10, 2023 (the other 200,000 shares were purchased on December 31, 2022) for total proceeds during the nine-month period ending March 31, 2023 of $2,000,000.

 

30 
 

 

During the nine months ended March 31, 2023, the Company entered into subscription agreements to sell 575,000 units at a price of $1.60, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $2.40 per share with an expiry date of June 30, 2024, and pursuant thereto, the Company issued 575,000 units for total proceeds of $920,000, in aggregate. The Company paid commissions of $48,000 on the sale of units.

During the nine months ended March 31, 2023, 158,834 warrants were exercised to purchase 158,834 shares of the Company’s common stock at $0.75 per share for total proceeds of $119,125.

During the nine months ended March 31, 2023, the Company issued 50,000 shares of the Company’s common stock to a consultant for services. The shares were issued at $1.60 per share for a total value of $80,000.

During the nine months ended March 31, 2023, Smith elected to convert $30,000 in principal and $20,000 in accrued interest from the 2020 Convertible Obligation to 100,000 units at $.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until December 31, 2024.

 

 Warrants:

 

As of March 31, 2023, the Company had approximately 21.9 million warrants outstanding, with exercise prices from $0.60 to $2.40 and expiring on various dates through November 9, 2026.

 

The weighted-average exercise price for the outstanding warrants is $0.78, and the weighted-average remaining contractual life as of March 31, 2023 is 1.8 years.

 

During the nine months ended March 31, 2023, Smith elected to convert $30,000 in principal and $20,000 in accrued interest from the 2020 Convertible Obligation to 100,000 units at $.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until three years after the date of conversion.

 

During the nine months ended March 31, 2023, Smith converted $70,000 of his Adjusted 2020 Convertible Obligation into 739,958 Units (each Unit consisting one share and one warrant) and converted $29,889 of his Adjusted Convertible Obligation into 315,948 Units (each Unit consisting one share of common stock and one warrant). Smith donated to charitable organizations and/or gifted to family members and others a large portion of these securities (450,000 common shares and 705,000 warrants, in aggregate) while retaining direct ownership of 255,906 common shares and 79,958 warrants and indirect ownership of 350,000 common shares and 270,948 warrants (owned by his wife). The warrants are exercisable for three years from conversion date.

 

During the nine months ended March 31, 2023, the Company approved the issuance of 210,000 warrants, in aggregate, to three new members of its Advisory Group for advisory and/or consulting services of $21,000, in aggregate. The warrants are exercisable at $1.50 to $1.60 and expire in August 2025.

During the nine months ended March 31, 2023, the Company approved the modification of existing warrants held by one former consultant and investors, which extended certain expiration dates. The modifications resulted in incremental non-cash compensation of $154,932 and interest expenses of $72,589.

During the nine months ended March 31, 2023, 158,834 warrants were exercised to purchase 158,834 shares of the Company’s common stock at $0.75 per share for total proceeds of $119,125.

 

Effective May 1, 2022, an entity affiliated with William O’Neill (“O’Neill”) was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise bonus if the terms set forth therein are met.

 

31 
 

 

The 700,000 of the warrants are vesting through May 1, 2023 and 2024. The vesting resulted in non-cash compensation of $9,844 and $36,094 during the three and nine months ended March 31, 2023.

 

Stock options:

 

On April 7, 2022 the Company’s shareholders approved the Bion Environmental Technologies, Inc. 2021 Equity Incentive Award Plan (the “Equity Plan”). The Equity Plan provides for the issuance of options (and/or other securities) to purchase up to 30,000,000 shares of the Company’s common stock. The Equity Plan was adopted and ratified by Board of Directors on April 8, 2022. Terms of exercise and expiration of options/securities granted under the Equity Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. No grants have been made pursuant to the Equity Plan as of the date of this report.

 

The Company’s 2006 Consolidated Incentive Plan, as amended during the year ended June 30, 2021 (the “2006 Plan”), provides for the issuance of options (and/or other securities) to purchase up to 36,000,000 shares of the Company’s common stock. Terms of exercise and expiration of options/securities granted under the 2006 Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. The 2006 Plan will be maintained to service grants already made thereunder (together with new grants, if any, to employees and consultants who already has received grants pursuant to its terms,

 

On February 11, 2022, the Company granted 10,000 options under the 2006 Plan to one consultant.

 

On April 29, 2022, the Company granted an aggregate of 720,000 options under the 2006 Plan to seven employees/consultants/directors including: i) 50,000 options each to Schafer and Northrop for service as directors, ii) 200,000 options to Bassani (now COO of the Company and formerly CEO) and iii) 200,000 options to Smith, the Company’s President, which new option grants are included in the presentation below.

 

The Company recorded compensation expense related to employee stock options of $220,510 and $4,650 for both the three and nine months ended March 31, 2023 and 2022, respectively. The Company granted 305,000 and 10,000 options for both the three and nine months ended March 31, 2023 and 2022, respectively.

 

A summary of option activity under the 2006 Plan for nine months ended March 31, 2023 is as follows:

                      
    Options   Weighted-
Average
Exercise
Price
   Weighted-
Average
Remaining
Contractual
Life
   Aggregate
Intrinsic
Value
 
 Outstanding at July 1, 2022    11,201,600   $0.80    2.7   $4,429,263 
   Granted    305,000                 
   Exercised                       
   Forfeited                       
   Expired                       
 Outstanding at March 31, 2023    11,506,600   $0.82    2.02   $10,238,395 

 

The total fair value of stock options that vested during both the three and nine months ended March 31, 2023 and 2022 was $220,510 and $4,650, respectively. As of March 31, 2023, the Company had no unrecognized compensation cost related to stock options.

 

 

32 
 

8.       SUBSCRIPTION RECEIVABLE - AFFILIATES:

 

As of March 31, 2023, the Company has three interest bearing, secured promissory notes with an aggregate principal amount of $428,250 ($513,282, including interest) from Bassani which were received as consideration for purchases of warrants to purchase 5,565,000 shares, in aggregate, of the Company’s restricted common stock, which warrants have an exercise price of $0.75 and have expiry dates ranging from December 31, 2024 to December 31, 2025. The promissory notes bear interest at 4% per annum and are secured by portions of Bassani Family Trust’s 2020 Convertible Obligation and Bassani Family Trust’s September 2015 Convertible Notes. The secured promissory notes are payable July 1, 2024.

 

As of March 31, 2023, the Company has an interest bearing, secured promissory note for $30,000 ($35,586 including interest) from Smith as consideration to purchase warrants to purchase 300,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of December 31, 2024. The warrants have a 75% exercise bonus and the promissory note bears interest at 4% per annum, and is secured by $30,000 ($35,714, including interest) of Smith’s 2020 Convertible Obligations. The secured promissory note is payable on July 1, 2024.

As of March 31, 2023 the Company has two interest bearing, secured promissory notes with an aggregate principal amount of $46,400 ($56,396 including interest) from two former employees as consideration to purchase warrants to purchase 928,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.75 and have expiry dates of December 31, 2024. These warrants have a 90% exercise bonus. The promissory notes bear interest at 4% per annum, are secured by a perfected security interest in the warrants, and are payable on July 1, 2024.

These secured promissory notes are recorded as “Subscription receivable—affiliates” on the Company’s balance sheet pending payment.

9.       COMMITMENTS AND CONTINGENCIES:

 

Employment and consulting agreements:

 

Smith has held the positions of Director, Executive Chairman, President and General Counsel of Company and its subsidiaries under various agreements (and extensions) and terms since March 2003. On October 10, 2016, the Company approved a month to month contract extension with Smith which includes provisions for i) a monthly salary of $18,000 until the Board of Directors re-instates cash payments to all employees and consultants who are deferring compensation, ii) the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, until December 31, 2024, and iii) the right to convert his deferred compensation in whole or in part, at his sole election, at any time in any amount at “market” or into securities sold in the Company’s current/most recent private offering at the price of such offering to third parties. Smith agreed effective July 29, 2018 to continue to serve the Company under the same basic terms on a month-to-month basis. On May 1, 2022 Smith’s compensation was increased to $25,000 per month of which $5,000 per month is deferred. For the three months ended March 31, 2023 and 2022, Smith was paid $40,000 and $18,000, respectively, of cash compensation. For the nine months ended March 31, 2023 and 2022, Smith was paid $140,000 and $72,000, respectively, of cash compensation.

 

Since March 31, 2005, the Company has had various agreements with Bassani (and/or Brightcap which provided his services during some of the initial years), now the Company’s Chief Operating Officer (‘COO’) and formerly the Company’s Chief Executive Officer (‘CEO’), (any reference to Brightcap or Bassani for all purposes are the same individual). The Board appointed Bassani as the Company's CEO effective May 13, 2011. On February 10, 2015, the Company executed an Extension Agreement with Bassani pursuant to which Bassani extended the term of his service to the Company to December 31, 2017, (with the Company having an option to extend the term an additional six months.) Pursuant to the Extension Agreement, Bassani continued to defer his cash compensation ($31,000 per month) until the Board of Directors re-instates cash payments to all employees and consultants who are deferring their compensation. During October 2016 Bassani was granted the right to convert up to $125,000 of his deferred compensation, at his sole election, at $0.75 per share, until March 15, 2018 (which was expanded on April 27, 2017 to the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, until June 30, 2024 (including extensions). During February 2018, the Company agreed to the material terms for a binding two-year extension agreement for Bassani’s services as CEO. Bassani’s salary remained $31,000 per month, which will continue to be accrued in part until there is adequate cash available. Additionally, the Company has agreed to pay him $2,000 per month to be applied to life insurance premiums (which sums have been accrued as liabilities). On August 1, 2018, in the context of extending his agreement to provide services to the Company on a full-time basis through December 31, 2022) plus 2 years after that on a part-time basis, the Company received an interest bearing secured promissory note for $300,000 from Bassani as consideration to purchase warrants to purchase 3,000,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of June 30, 2025. The promissory note is secured by a portion of Bassani’s 2020 Convertible Obligations and as of March 31, 2023, the principal and accrued interest was $358,151. For the three months ended March 31, 2023 and 2022, Brightcap was paid $75,000 and $60,000, respectively, of cash compensation. For the nine months ended March 31, 2023 and 2022, Brightcap was paid $225,000 and $184,764, respectively, of cash compensation.

 

 

33 
 

William O’Neill (“O’Neill”) was hired as the Company’s Chief Executive Officer (“CEO”) effective May 1, 2022.  O’Neill had previously been working with the Company as a consultant and had been employed by the Company as its CEO during 2010-2011. Bassani, CEO of the Company since 2011, has assumed the position of COO while retaining existing operational management responsibilities and working with O’Neill on ‘commercialization’ of the Company’s technology and work related to JVs (and other transactions) based on the Company’s Gen3 Technology and related matters. Bassani’s compensation arrangements with the Company have not been altered in the context of the change of positions. The Company and O’Neill have entered into a thirty-seven (37) month employment agreement (subject to Board renewal for the final two (2) years during the 13th month ) with compensation of $25,000 cash and $10,000 deferred compensation per month. The cash payment is paid $12,500 to O’Neill and $12,500 to an entity affiliated with O’Neill. An entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise bonus if the terms set forth therein are met.  For the three months ended March 31, 2023 and 2022, O’Neill and the entity affiliated with O’Neill was paid $75,500 and nil , respectively, of cash compensation. For the nine months ended March 31, 2023 and 2022, O’Neill was paid $150,000 and nil , respectively, of cash compensation.

 

Execution/exercise bonuses:

 

As part of agreements the Company entered into with Bassani and Smith effective May 15, 2013, they were each granted the following: a) a 50% execution/exercise bonus which shall be applied upon the effective date of the notice of intent to exercise (for options and warrants) or issuance event, as applicable, of any currently outstanding and/or subsequently acquired options, warrants and/or contingent stock bonuses owned by each (and/or their donees) as follows: i) in the case of exercise by payment of cash, the bonus shall take the form of reduction of the exercise price; ii) in the case of cashless exercise, the bonus shall be applied to reduce the exercise price prior to the cashless exercise calculations; and iii) with regard to contingent stock bonuses, issuance shall be triggered upon the Company’s common stock reaching a closing price equal to 50% of currently specified price; and b) the right to extend the exercise period of all or part of the applicable options and warrants for up to five years (one year at a time) by annual payments of $.05 per option or warrant to the Company on or before a date during the three months prior to expiration of the exercise period at least three business days before the end of the expiration period. Effective January 1, 2016 such annual payments to extend warrant exercise periods have been reduced to $.01 per option or warrant. These exercise bonuses were subsequently increased to 75%.

 

During the year ended June 30, 2021, the Company added a 75% execution/exercise bonus to the terms of 3,000,000 warrants held by a trust owned by Bassani.

 

As of March 31, 2023, the execution/exercise bonuses ranging from 50-90% were applicable to 11,114,600 of the Company’s outstanding options and 18,438,339 of the Company’s outstanding warrants.

 

Effective May 1, 2022, an entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise bonus if the terms set forth therein are met.

 

Purchase Order Agreement and Initial Project:

 

On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $2,665,500 (and made the initial 25% payment ($666,375) for the core of the ‘Bion System’ portion (without the crystallization  modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. The Company received progress billing in March 2022 and June 2022 for the second and third 25% installments, both of which have been paid as of the filing date. On January 17, 2023 the Company received an invoice from Buflovak for $533,100 which was paid on March 1, 2023 bringing the aggregate payments to $2,532,225 as of the date of this filing. There remains $133,275 open on the Purchase Order of which $86,275 has been billed in April and the remaining $50,000 will be invoiced at the completion of the project.

 

 

34 
 

Buflovak has worked with the Company on design and testing of its 3G Tech over several years. The basic design for the Initial Project’s Bion System is complete, fabrication and delivery of equipment from Bufflovak from the Purchase Order Agreement has been largely completed and assembly/construction is in process.  3G1 is working in concert with Integrated Engineering Services, the primary site engineering firm for the facility, on the integration of all project components/modules at the Initial Project site. Additional agreements have been entered into various professional services providers (engineers, surveyors, utilities, etc.) for work related to the Initial Project. The Company has incurred costs of $5,164,256 on the Initial Project, not including capitalized labor and interest.

 

Litigation:

 

A: Website: Domain Sale/Resolved Litigation/Hacking/Theft

 

 On March 23, 2022 the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490. The Company has been using www.bionenviro.com as its primary website (and domain) since July 2021 due to the events described below. The Company has not been using biontech.com as its primary website since July 2021 so domain name <biontech.com> no longer represented a core asset of the Company.

 

As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the <biontech.com> domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.

 

On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name <biontech.com> ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name <biontech.com> to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).

 

No shareholder, sensitive or confidential information was available to be breached which has limited damages from the hack/theft to date. However, the Company’s email operations were subjected to disruption and expenses were incurred related to the matter including legal fees.

 

The Company created ‘work-arounds’ as a result. These issues have been resolved and the Company has moved our website (and email) to a new domain: bionenviro.com. Website access is now www.bionenviro.com. To send emails to Bion personnel, one uses the same name identifier previously used, but in the address, substitute ‘bionenviro.com’ for “biontech.com’: For example cscott@biontech.com (no longer functional) is cscott@bionenviro.com and mas@biontech.com (no longer functional) is now mas@bionenviro.com.

 

35 
 

 

B: Pennvest Loan and Dissolution of Bion PA1, LLC (“PA1”)

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s condensed consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s condensed consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s condensed consolidated balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s condensed consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

 

36 
 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest set forth above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception, and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

C: OMRI Litigation

 

On February 23, 2023 the Company filed ‘Complaint for Declaratory Judgment and Injunctive Relief’ against the Organic Materials Review Institute (“OMRI”) in the Circuit Court for the State of Oregon for the County of Lane to contest OMRI’s negative determination with regard to the Company’s application for listing of its solid ammonium bicarbonate product. The Company alleges that OMRI failed to properly follow its own procedures and reached a result without scientific support. The Company has elected to proceed with “Judicial Dispute Resolution” as set forth in the OMRI Policy Manual and has initiated litigation contesting the determination. The Company has requested declaratory relief from the court. OMRI filed its Answer to the Complaint during the first week of May 2023 and the discovery process has now commenced. See Note 1 “Fertilizer: Organic and ‘Climate Smart’” above.

 

The Company currently is not involved in any other material litigation or similar events.

 

Lease:

 

The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.

 

The requirement for payment of Lease obligations commenced January 1, 2023 and the Company is awaiting a rent invoice. The sum of $18,750 has been accrued as a current liability for the period for the quarter ended March 31, 2023.

 

The future minimum lease payment under noncancelable operating lease with terms greater than one year as of March 31, 2023:

 

     
From April 2023 to December 2023   56,250 
From January 2024 to December 2024    75,000 
Undiscounted cash flow   131,250 
Less imputed interest   (11,299)
Total   119,951 

  

The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of March 31, 2023 were 1.83 years and 10%, respectively. The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.

 

 

37 
 

 

10.        SUBSEQUENT EVENTS:

 

The Company has evaluated events that occurred subsequent to March 31, 2023 for recognition and disclosure in the financial statements and notes to the financial statements.

From April 1, 2023 through May 9, 2023, the Company has paid $395,000 and accrued $65,000 for an aggregate of $6,245,000 for the Initial Project. 

 

The requirement for payment of Lease obligations commenced January 1, 2023 and the Company was awaiting rent invoices as of March 31, 2023.  The sum of $18,750 has been accrued as a current liability for the quarter ended March 31, 2023.  On May 10, 2023 the invoices were received and $31,250 was paid for rent covering January through May 2023. 

 

From April 1, 2023, through May 9, 2023, 1,280 warrants have been exercised at $0.75 for a total of $ 960.

 

On May 1, 2023, a contract for consulting services was signed and 32,259 shares with a valuation of $50,000 were issued.  Additional shares valued at $50,000 will vest in 3 months.   

 

On May 9, 2023, the Board of Directors confirmed the final two years of the Personal Services Agreement of O’Neill, the Company’s CEO, and granted O’Neill 500,000 Incentive Options (“Options”), which Options: i) are exercisable at a price of $1.60 per share, ii) expire June 30, 2026, iii) vest one-half on June 1, 2024 and one-half on June 1, 2025, and iv) include a 50% exercise bonus.

 

 

 

 

38 
 

 

 

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

Statements made in this Form 10-Q that are not historical or current facts, which represent the Company's expectations or beliefs including, but not limited to, statements concerning the Company's operations, performance, financial condition, business strategies, and other information, involve substantial risks and uncertainties. The Company's actual results of operations, most of which are beyond the Company's control, could differ materially. These statements often can be identified by the use of terms such as "may," "will," "expect," "believe," anticipate," "estimate," or "continue" or the negative thereof. We wish to caution readers not to place undue reliance on any such forward looking statements, which speak only as of the date made. Any forward-looking statements represent management's best judgment as to what may occur in the future. However, forward looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected.

 

THESE FACTORS INCLUDE ADVERSE ECONOMIC CONDITIONS, ENTRY OF NEW AND STRONGER COMPETITORS, INADEQUATE CAPITAL AND LIMITED ABILITY TO OBTAIN FINANCING, UNEXPECTED COSTS, FAILURE (OR DELAY) TO GAIN PRODUCT CERTIFICATIONS AND/OR REGULATORY APPROVALS IN THE UNITED STATES (OR PARTICULAR STATES) OR FOREIGN COUNTRIES FOR THE COMPANY’S PLANNED MEAT AND/OR FERTILIZER PRODUCTS, LOSS (PERMANENTLY OR FOR ANY EXTENDED PERIOD OF TIME) OF THE SERVICES OF MEMBERS OF THE COMPANY’S SMALL CORE MANAGEMENT TEAM (MANY OF WHOM ARE AGE 70 OR OLDER), THE COMPANY’S ABILITY TO HANDLE EXTREME GROWTH WITH ITS REQUIREMENTS FOR ADDITIONAL PERSONNEL, SYSTEMS AND CAPITAL, AND FAILURE TO CAPITALIZE UPON ACCESS TO NEW MARKETS. ADDITIONAL RISKS AND UNCERTAINTIES THAT MAY AFFECT FORWARD LOOKING STATEMENTS ABOUT BION'S BUSINESS AND PROSPECTS INCLUDE: I) DELAYS AND/OR COSTS EXCEEDING EXPECTATIONS RELATING TO BION'S DEVELOPMENT OF THE INITIAL PROJECT, JVs AND/OR PROJECTS, II) THE POSSIBILITY THAT MARKETS FOR CARBON AND/OR NUTRIENT REDUCTION CREDITS AND/OR OTHER WAYS TO MONETIZE ENVIRONMENTAL BENEFITS (INCLUDING CARBON REDUCTIONS, NUTRIENT REDUCTIONS, ETC.) WILL BE SLOW TO DEVELOP (OR NOT DEVELOP AT ALL), III) PA1’S DISSOLUTION AND ITS EFFECT ON HOW THE COMPANY IS VIEWED, (IF ANY), IV) THE POSSIBILITY THAT COMPETITORS WILL DEVELOP MORE COMPREHENSIVE AND/OR LESS EXPENSIVE ENVIRONMENTAL SOLUTIONS, V) DELAYS IN MARKET AWARENESS OF BION AND OUR SYSTEMS, VI) UNCERTAINTIES AND COSTS INCREASES RELATED TO RESEARCH AND DEVELOPMENT EFFORTS TO UPDATE AND IMPROVE BION’S TECHNOLOGIES AND APPLICATIONS THEREOF, AND/OR VII) FAILURE OF MARKETING STRATEGIES, EACH OF WHICH COULD HAVE BOTH IMMEDIATE AND LONG TERM MATERIAL ADVERSE EFFECTS BY PLACING US BEHIND OUR COMPETITORS AND REQUIRING EXPENDITURES OF OUR LIMITED RESOURCES.

 

THESE RISKS, UNCERTAINTIES AND FACTORS BEYOND OUR CONTROL ARE MAGNIFIED DURING THE CURRENT UNCERTAIN PERIOD RELATED TO THE COVID-19 PANDEMIC AND THE UNIQUE ECONOMIC, FINANCIAL, GOVERNMENTAL AND HEALTH-RELATED CONDITIONS IN WHICH THE COMPANY, THE ENTIRE COUNTRY AND THE ENTIRE WORLD NOW RESIDE.  TO DATE THE COMPANY HAS EXPERIENCED DIRECT IMPACTS  IN VARIOUS AREAS INCLUDING WITHOUT LIMITATION: I) GOVERNMENT-ORDERED  SHUTDOWNS WHICH HAVE SLOWED THE COMPANY’S RESEARCH AND DEVELOPMENT PROJECTS AND OTHER INITIATIVES, II) SHIFTED FOCUS OF STATE AND FEDERAL GOVERNMENT WHICH IS LIKELY TO NEGATIVELY IMPACT THE COMPANY’S LEGISLATIVE INITIATIVES IN PENNSYLVANIA AND WASHINGTON DC, III) STRAINS AND UNCERTAINTIES IN BOTH THE EQUITY AND DEBT MARKETS HAVE MADE DISCUSSION AND PLANNING OF FUNDING OF THE COMPANY AND ITS INITIATIVES AND PROJECTS WITH INVESTMENT BANKERS, BANKS AND POTENTIAL STRATEGIC PARTNERS MORE TENUOUS, IV) STRAINS AND UNCERTAINTIES IN THE AGRICULTURAL SECTOR AND MARKETS HAVE MADE DISCUSSION AND PLANNING OF FUNDING OF THE COMPANY AND ITS INITIATIVES AND PROJECTS MORE DIFFICULT AS FUTURE INDUSTRY CONDITIONS ARE NOW MORE DIFFICULT TO ASSESS/PREDICT, V) CONSTRAINTS DUE TO PROBLEMS EXPERIENCED IN THE GLOBAL INDUSTRIAL SUPPLY CHAIN WHICH HAVE INCREASED ANTICIPATED PROJECT DEVELOPMENT COSTS, VI) DUE TO THE AGE AND HEALTH OF OUR CORE MANAGEMENT TEAM, MOST OF WHOM ARE AGE 70 OR OLDER AND HAVE HAD ONE OR MORE EXISTING HEALTH ISSUES, THE COVID-19 PANDEMIC PLACES THE COMPANY AT GREATER RISK THAN WAS PREVIOUSLY THE CASE (TO A HIGHER DEGREE THAN WOULD BE THE CASE IF THE COMPANY HAD A LARGER, DEEPER AND/OR YOUNGER CORE MANAGEMENT TEAM), AND VII) THERE ALMOST CERTAINLY WILL BE OTHER UNANTICIPATED CONSEQUENCES FOR THE COMPANY AS A RESULT OF THE CURRENT PANDEMIC EMERGENCY AND ITS AFTERMATH.

 

39 
 

Bion disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

 

The following discussion and analysis should be read in conjunction with the Condensed Consolidated Financial Statements and Notes to Condensed Consolidated Financial Statements filed with this Report.

 

BUSINESS OVERVIEW AND PLAN

 

Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Bion’s mission is to make livestock production more sustainable, transparent and profitable. We intend to accomplish this by deploying our Gen3Tech platform/business model (discussed below) in ventures focused on the ‘feeder’ space of the livestock production/value chain to provide the consumer with verifiably sustainable premium products.  Bion believes this approach can create extraordinary value for our shareholders and employees (all of whom own securities in the Company).

 

Our patented and proprietary technology provides advanced waste treatment and resource recovery for large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs"). Livestock production and its waste, particularly from CAFOs, has been identified as one of the greatest soil, air, and water quality problems in the U.S. today.  Application of our third-generation technology and business/technology platform (“Gen3Tech”) can largely mitigate these environmental problems, while simultaneously improving operational/ resource efficiencies by recovering high-value co-products from the CAFOs’ waste stream. These wastes ‘assets’ – nutrients and methane – have traditionally been wasted or underutilized and are the same ‘pollutants’ that today fuel harmful algae blooms, contaminate surface groundwater, and exacerbate climate change.

 

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms) (“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long-term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

Bion’s Gen3Tech was designed to capture and stabilize these assets and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the animal raising and waste treatment process will be third-party verified, providing the basis for additional revenues, including carbon and/or renewable energy-related credits and, eventually, payment for a range of ecosystem services, including nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.

 

During the first half of 2022 Bion began pre-marketing our sustainable beef to retailers, food service distributors and the meat industry in the U.S.  In general, the response has been favorable. During July 2022, Bion announced a letter of intent (“Ribbonwire LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Ribbonwire Ranch, in Dalhart, Texas (with a provision to expand to 60,000 head) (“Dalhart Project”). During January 2023 Bion announced a letter of intent (“Olson LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Olson Feeders and TD Angus, near North Platte, Nebraska (with a provision to expand to 45,000 head or more) (“Olson Project”). During April 2023 Bion announced a letter of intent (“DVG LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with Dakota Valley Growers near Bathgate, North Dakota. The Olson, Dalhart and DVG Projects (through slatted floors) (and subsequent Projects) will be developed to produce verified, sustainable beef in customized covered barns (resulting in reduced stress on cattle caused by extreme weather and temperatures and resulting higher feed/weight gain efficiency) with ongoing manure transfer (through slatted floors) to anaerobic digesters (AD) to capture nitrogen from the manure stream before loss to the atmosphere and generate renewable natural gas (RNG) for sale while remediating the environmental/carbon impacts usually associated with cattle feedlots and CAFOs. Bion’s patented technology will refine the waste stream into valuable coproducts that include clean water, RNG, photovoltaic solar electricity and fertilizer (‘climate smart’ and organic) products. We anticipate converting these LOIs into definitive JV agreements and creating distribution agreements with key retailers and food service distributors during the next six-nine months.

 

 

40 
 

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long-term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and, in some cases, Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

Bion’s Gen3Tech was designed to capture and stabilize the assets contained in the livestock waste stream and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the treatment process will be third-party verified, providing the basis for additional revenues, including renewable energy-related credits and, eventually, payment for ecosystem services, such as nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.

 

Our business plan is focused on executing multiple agreements and letters of intent related to additional sustainable beef JV projects over the next twelve months while moving forward with the Initial Project (see below) and one or more of the Dalhart/Olson/DVG Projects (“LOI Projects”)(and/or other Gen3Tech beef JV projects) and pursuing other opportunities in the livestock industry enabled by our Gen3Tech business model.  The Ribbonwire and Olson LOI announcements generated significant interest within the livestock industry (among ranchers, feedlot operators, farmers and other AG industry parties). We believe that this interest, combined with consumer interest in ‘sustainable products’ and growing enthusiasm among some livestock industry parties for environmental/sustainable/regenerative practices, may provide Bion (and its partners/venturers) with an opportunity to move forward with a truly sustainable solution in this industry segment at a rapid pace.

 

At present, there is essentially no traceable and verifiable ‘sustainable beef’ nationally marketed and available to the US market except for niche products. In response to consumer demand for transparency and sustainability, Bion expects the meat industry in general, and beef specifically, to evolve towards using new technologies to deliver these attributes in their products. While we anticipate a faster adoption of tracking, verification and sustainability technologies in other perishable food categories like produce and dairy due to their harvest and production techniques, meat industry leaders have also announced their willingness to move forward with initiatives in this area. Bion predicts that within approximately five years, consumers will be able to track and verify claims including sustainability on 25% (or more) of the products merchandised in the meat department. Bion believes that the retail market share of verifiably sustainable beef in the US will approach 7-10 % within three (3) years (end of 2026) and 25% in five (5) years (end of 2028) (approximately 2,000,000 cattle annually) (and more thereafter). If Bion can successfully execute on its sustainable beef business plan, facilities utilizing Bion’s Gen3Tech platform will provide one-third (1/3) or more of that of the premium market segment (and a higher portion of meat that is actually traceable and verifiably sustainable). Our goal is to have multiple sustainable beef projects under development (within 3-5 distinct JVs) by the end of 2024. Our first commercial project (commencing development work late in 2023) is likely to be one of the LOI Projects and we anticipate commencing multiple additional sustainable beef projects during 2024 as well. Our current target is to have at least three (3) facility modules (15,000 head per module)(“Modules”) in development/under construction during the next twelve (12) months in three (3)(or more) distinct JVs with the initial barns being populated with livestock by winter 2024-25. Further expansion in the number of distinct JVs is projected through 2025 aiming at 5-10 JVs in process --- each of which JVs will be pursuing development of multiple Modules with targets of 12-15 populated Modules by the end of 2025 (approximately 2%-3% of the US beef market) and 30-45 Modules under construction and/or being populated with cattle by late 20228 (approximately 6%-8% of the US beef market) with further expansion thereafter. Bion’s current goal is that its Gen3Tech platform will be utilized to produce 33% of the verifiable “sustainable beef” category at the end of the period (which will equal approximately 2 million cattle annually)(45 Modules).

 

 

41 
 

During this five (5) year period, the Company also anticipates having additional Gen3Tech projects underway in the pork/dairy/egg sectors of the US animal protein market.

 

During the next three months, the Company intends to complete construction and begin operations of phase 1 of our Initial Project located near Fair Oaks, Indiana. Bion expects the Initial Project to provide data that illustrates the effectiveness of our Gen3Tech in a commercial-scale setting by the end of the 2nd quarter in 2023 and supports development of the LOI Projects (and/or other Gen3Tech beef JV projects) commencing later during 2023.  We do not presently know the order in which these JV Projects will be developed as that decision will be made based on many factors not yet in place. We believe the Initial Project data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, food distributors and retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below). 

 

Bion is now focused primarily on: i) development/construction/operation of the Initial Project, our initial commercial-scale Gen3Tech installation, ii) pre-development planning of the Dalhart, Olson and DVG Projects (and/or other Gen3Tech beef JV projects), iii) developing applications and markets for its low carbon ‘ClimateSmart’ and organic fertilizer products (including listings/certifications of multiple liquid and solid products) and its sustainable (conventional and organic) animal protein products, and iv) discussions regarding initiation and development of agreements and joint ventures (“JVs” as discussed below) (and related Projects) based on the augmented capabilities of our Gen3Tech business platform (in the sustainable beef and other livestock segments), while (v) continuing to pursue business opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and vi) ongoing R&D activities.

 

There is no assurance that the Company will reach or approach the goals/targets set forth above. Reaching such goals/targets will require access to very large amounts of capital (equity and debt) as each module is projected to cost in excess of $50 million (debt/equity/grants) to construct and require mobilization of substantial personnel, technical resources and management skills. The Company does not possess either the financial or personnel resources required internally and will need to source such resources from outside itself.

 

For additional information regarding our ‘HISTORY, BACKGROUND AND CURRENT ACTIVITIES’,  see discussion in Notes to the Financial Statements (particularly Notes 1, 3, 5 and 9) included in this report and Item 1 in our annual report on Form 10-K.

 

COVID-19 PANDEMIC RELATED MATTERS:

 

The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.

 

 

42 
 

CRITICAL ACCOUNTING POLICIES

 

Revenue Recognition

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of Accounting Standards Codification (“ASC”) 606 “Revenue from Contracts with Customers”.

Stock-based compensation

 

The Company follows the provisions of ASC 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of income based upon their grant date fair values.

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. As of March 31, 2023 and 2022, there are no derivative financial instruments.

 

Options:

 

The Company has issued options to employees and consultants under its 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.

 

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the condensed consolidated statements of operations over the lease term.

 

43 
 

 

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s condensed consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.

THREE MONTHS ENDED MARCH 31, 2023 COMPARED TO THE THREE MONTHS ENDED MARCH 31, 2022

Revenue

Total revenues were nil for both the three months ended March 31, 2023 and 2022.

General and Administrative

Total general and administrative expenses were $859,000 and $398,000 for the three months ended March 31, 2023 and 2022, respectively.

Salaries and related payroll tax expenses were $194,000 and $23,000 for the three months ended March 31, 2023 and 2022, respectively, representing a $171,000 increase. The increase is a due to less salaries capitalized to the Initial Project. Consulting costs were $107,000 and $48,000 for the three months ended March 31, 2023 and 2022, respectively. The $59,000 decrease in consulting costs is due to the capitalization of Brightcap’s consulting expense to the Initial Project. Investor relations expenses were $172,000 and $128,000 for the three months ended March 31, 2023 and 2022, respectively, and the $44,000 increase is due to a new contract with an investor relations firm and increased activity during the three months ended March 31, 2023 due to the resumption of investor conferences and other matters. Legal costs were $21,000 and $98,000 for the three months ended March 31, 2023 and 2022, respectively, and the $77,000 decrease is due to less outside legal activities in the quarter.

Stock-based compensation for the three months ended March 31, 2023 and 2022 were $407,000 and $5,000, respectively.

Depreciation

Total depreciation expense was $461 and $252 for the three months ended March 31, 2023 and 2022, respectively.

Research and Development

Total research and development expenses were $24,000 and $29,000 for the three months ended March 31, 2023 and 2022, respectively, representing a $5,000 decrease due to less legal and salary expense allocated to research and development.

Salaries and related payroll tax expenses were $2,000 and $7,000 for the three months ended March 31, 2023 and 2022, respectively, as more salary expense was allocated to administrative expense for the three months ended March 31, 2023. Consulting costs were $9,000 and $5,000 for the three months ended March 31, 2023 and 2022, respectively. The Company also incurred $5,000 and $11,000 for the three months ended March 31, 2023 and 2022, respectively in legal costs related to patent applications and renewals.

Stock-based compensation for the three months ended March 31, 2023 and 2022 were $4,100 and nil, respectively.

Income/(Loss) from Operations

As a result of the factors described above, the income/(loss) from operations was $(884,000) and $(427,000) for the three months ended March 31, 2023 and 2022 respectively.

 

44 
 

Other (Income)/ Expense

Other (income) expense was $(26,000) and $(852,000) for the three months ended March 31, 2023 and 2022, respectively and the difference was attributed to the gain on the adjustment of the 2015 and 2020 convertible notes.

 

Interest expense related to deferred compensation, loan payable and convertible notes prior to capitalization was $27,000 and $51,000 for the three months ended March 31, 2023 and 2022, respectively.

Net Loss Attributable to the Noncontrolling Interest

The net loss attributable to the noncontrolling interest was nil and $500 for the three months ended March 31, 2023 and 2022, respectively.

Net Income/(Loss) Attributable to Bion’s Common Stockholders

As a result of the factors described above, the net income attributable to Bion’s stockholders was $(858,000) and $(426,000) for the three months ended March 31, 2023 and 2022, respectively, and the net income/(loss) per basic common share was $.02 and $(.01) for the three months ended March 31, 2023 and 2022, respectively

NINE MONTHS ENDED MARCH 31, 2023 COMPARED TO THE NINE MONTHS ENDED MARCH 31, 2022

Revenue

Total revenues were nil for both the nine months ended March 31, 2023 and 2022, respectively.

General and Administrative

Total general and administrative expenses were $2,356,000 and $1,507,000 for the nine months ended March 31, 2023 and 2022, respectively.

General and administrative expenses, excluding stock-based compensation charges of $407,000 and $10,000, were $1,949,000 and $1,497,000 for the nine months ended March 31, 2023 and 2022, respectively, representing a $452,000 increase. Salaries and related payroll tax expenses were $541,000 and $230,000 for the nine months ended March 31, 2023 and 2022, respectively, representing a $311,000 increase due to compensation increases and addition of Bill O’Neill as a new employee. Consulting costs were $326,000 and $388,000 for the nine months ended March 31, 2023 and 2022, respectively. The decrease in consulting costs is due to the capitalization of costs related to the Initial Project. Investor relations expenses were $594,000 and $303,000 for the nine months ended March 31, 2023 and 2022, respectively, and the increase is due to a new contract with an investor relations firm and increased activity during the nine months ended March 31, 2023 due to the resumption of investor conferences. Legal costs were $52,000 and $245,000 for the nine months ended March 31, 2023 and 2022, respectively. The nine months ended March 31, 2022 incurred greater legal costs as a result of the hiring of a law firm to represent the Company in a lawsuit for the hack and attempt to steal the Company’s domain, engaging a law firm on the dissolution of PA-1, legal work in relation to corporate structure matters and preparation for the 2022 shareholder meeting and other matters.

General and administrative stock-based employee compensation for the nine months ended March 31, 2023 and 2022 consists of the following:

 

   Nine months
ended
March 31,
2023
   Nine months
ended
March 31,
2022
 
General and administrative:          
  Change in fair value from modification of warrant terms   155.000    6,000 
  Fair value of warrants expensed under ASC 718   36,000    —   
  Fair value of stock options expensed under ASC 718   216,000    5,000 
      Total   407,000   $11,000 

 

The company granted 305,000 and 10,000 fully vested options during the nine months ended March 31, 2023 and 2022, respectively.

 

45 
 

Depreciation

Total depreciation expense was $1,185 and $832 for the nine months ended March 31, 2023 and 2022, respectively.

Research and Development

Total research and development expenses were $68,000 and $146,000 for the nine months ended March 31, 2023 and 2022, respectively.

 

Salaries and related payroll tax expenses were $8,000 and $14,000 for the nine months ended March 31, 2023 and 2022, respectively. Consulting costs were $35,000 and $70,000 for the nine months ended March 31, 2023 and 2022, respectively. 

 

Legal expenses were $10,000 and $51,000 for the nine months ended March 31, 2023 and 2022, respectively. The difference of $41,000 was due to greater costs incurred in 2021 related to patent work and OMRI certification.

Loss from Operations

As a result of the factors described above, the loss from operations was $2,425,000 and $1,653,000 for the nine months ended March 31, 2023 and 2022, respectively.

Other (Income)/Expense

Other (income) expense was $82,000 and $(10,859,000) for the nine months ended March 31, 2023 and 2022, respectively. The company recognized a gain on the legal dissolution of PA-1 of $10,235,000 in the nine months ended March 31, 2022. Interest expense of $73,000 and $3,000 was recorded during the nine months ended March 31, 2023 and 2022, respectively, due to the modification of expiring warrants held by investors. Interest expense related to convertible notes was $132,000 and $276,000 for the nine months ended March 31, 2023 and 2022.

Net Loss Attributable to the Noncontrolling Interest

The net loss attributable to the noncontrolling interest was nil and $2,000 for the nine months ended March 31, 2023 and 2022, respectively.

Net Income/(Loss) Attributable to Bion’s Common Stockholders

As a result of the factors described above, the net (income) loss attributable to Bion’s stockholders was $(2,507,000) and $9,207,000 for the nine months ended March 31, 2023 and 2022, respectively, and the net (income) loss per basic common share was ($.06) and $.22 for both the nine months ended March 31, 2023 and 2022, respectively.

 

LIQUIDITY AND CAPITAL RESOURCES

 

The Company's condensed consolidated financial statements for the nine months ended March 31, 2023 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Report of our Independent Registered Public Accounting Firm on the Company's condensed consolidated financial statements as of and for the year ended June 30, 2022 includes a "going concern" explanatory paragraph which means that the auditors stated that conditions exist that raise substantial doubt about the Company's ability to continue as a going concern.

 

46 
 

 

Operating Activities

 

As of March 31, 2023, the Company had cash of approximately $1,613,000. During the nine months ended March 31, 2023, net cash used in operating activities was $2,481,000, primarily consisting of cash operating expenses related to salaries and benefits, and other general and administrative costs such as insurance, legal, accounting, consulting and investor relations expenses as well as the purchase of property and equipment. Cash expenditures were offset by proceeds from financing activities, primarily the exercise of warrants and sale of common shares. As previously noted, the Company is currently not generating significant revenue and accordingly has not generated cash flows from operations. The Company does not anticipate generating sufficient revenues to offset operating and capital costs for a minimum of two to five years. While there are no assurances that the Company will be successful in its efforts to develop and construct its Projects and market its Systems, it is certain that the Company will require substantial funding from external sources. Given the unsettled state of the current credit and capital markets for companies such as Bion, there is no assurance the Company will be able to raise the funds it needs on reasonable terms.

 

Investing Activities

 

During the nine months ended March 31, 2023, the Company invested $2,404,000 in the purchase of property and equipment, primarily related to the Initial Project construction in process.

 

Financing Activities

During the nine months ended March 31, 2023, the Company received gross cash proceeds of $119,000 from the exercise of 158,834 warrants into shares of the Company’s common stock.

During the nine months ended March 31, 2023, the Company entered into subscription agreements to sell units for $1.00 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share with an expiry date of December 31, 2024, and pursuant thereto, the Company issued 346,230 units for total proceeds of $346,230.

 

During the nine months ended March 31, 2023, the Company entered into a subscription agreement to sell 2,000,000 shares of restricted and legended common stock of which 1,800,000 shares were purchased on January 10, 2023 (the other 200,000 shares were purchased on December 31, 2022) for total proceeds during the nine-month period ending March 31, 2023 of $2,000,000.

 

During the nine months ended March 31, 2023, the Company entered into subscription agreements to sell 575,000 units at a price of $1.60 , with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $2.40 per share with an expiry date of June 30, 2024, and pursuant thereto, the Company issued 575,000 units for total proceeds of $920,000, in aggregate. The Company paid commissions of $48,000 on the sale of units.

 

As of March 31, 2023, the Company has debt obligations consisting of: a) deferred compensation of $784,000 and b) convertible notes payable – affiliates of $1,736,000.

 

 

47 
 

Plan of Operations and Outlook

 

As of March 31, 2023, the Company had cash of approximately $1,613,000.

 

The Company continues to explore sources of additional financing to satisfy its current operating requirements as it is not currently generating any significant revenues. During fiscal years 2022 and 2021, the Company has faced progressively less difficulty in raising equity funding (but substantial equity dilution has resulted from the larger amounts of equity financing during the periods). Less funds were raised during the nine months ended March 31, 2023 and the Company anticipates substantial increases in demands for capital and operating expenditures during the second half of fiscal year 2023 (and periods thereafter) as it moves toward commercial implementation of its 3G Tech and development of JVs and, therefore, is likely to continue to face, significant cash flow management challenges due to limited capital resources and working capital constraints which have only recently begun to be alleviated. As a result, the Company has faced, and continues to face, significant cash flow management challenges due to material working capital constraints. To partially mitigate these working capital constraints, the Company's core senior management and some key employees and consultants have been deferring part of their cash compensation and/or are accepting compensation in the form of securities of the Company (Notes 5 and 7 to Financial Statements) and members of the Company's senior management have from time to time made loans to the Company. During the year ended June 30, 2018 senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $2,404,000. As of June 30 2022, such deferrals/loans totaled approximately $5,765,000 (including accrued interest and deferred compensation converted into convertible obligations and convertible promissory notes but excluding conversions of deferred compensation into the Company's common stock by officers, employees and consultants that have already been completed) and not reflecting the ‘note adjustment’ which reduced amounts owed by the Company by approximately $3.5 million which took place during the recently completed quarter. The extended constraints on available resources have had, and continue to have, negative effects on the pace and scope of the Company's effort to develop its business. The Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again in 2018. The constraint on available resources has had, and continues to have, negative effects on the pace and scope of the Company’s efforts to develop its business. The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company is able to continue its recent increased success in its efforts to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and curtailment of ongoing activities including research and development activities.

 

The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop the Initial Project, JVs, Projects and CAFO Retrofit waste remediation systems (potentially including the Kreider 2 facility. The Company anticipates that it will seek to raise from $20,000,000 to $80,000,000 or more (debt and equity) during the next twelve months. However, as discussed above, there is no guarantee that we will be able to raise sufficient funds or further capital for the operations planned in the near future.

 

The Company is not currently generating any significant revenues. Further, the Company’s anticipated revenues, if any, from existing projects, JVs and proposed projects will not be sufficient to meet the Company’s anticipated operational and capital expenditure needs for many years. During the nine months ended March 31, 2023 the Company raised gross proceeds of approximately $3,385,000 through the sale of its securities and paid commissions of approximately $48,000. During the year ended June 30, 2021 the Company raised gross proceeds of approximately $5,209,000 through the sale of its securities and paid commissions of approximately $165,000, and anticipates raising additional funds from such sales and transactions. During the year ended June 30, 2022 the Company raised gross proceeds for approximately $1,737,000 and paid commissions of approximately $18,600. The Company anticipates raising additional funds from such sales and transactions in the coming periods. However, there is no guarantee that we will be able to raise sufficient funds or further capital for the operations planned in the near future.

 

Because the Company is not currently generating significant revenues, the Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop the Initial Project and subsequent Projects.

 

 

48 
 

As indicated above, the Company anticipates that it will seek to raise from $20,000,000 to $80,000,000 or more (from debt, equity, joint venture, strategic partnering, etc.) during the next twelve months, some of which may be in the context of joint ventures for the development of one or more large scale projects. We reiterate that there is no assurance, especially in the extremely unsettled capital markets that presently exist for companies such as Bion, that the Company will be able to obtain the funds that it needs to stay in business, finance its Projects and other activities, continue its technology development and/or to successfully develop its business.

 

See Item 2 below and Note 5 (“Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution”) to the Financial Statements included in this report and the Company’s Forms 10-K for the year ended June 30, 2022 (and the years 2009-2021) for discussion and more details related to the dissolution of PA1, the Pennvest Loan and the

Kreider 1 project.

 

There is extremely limited likelihood that funds required during the next twelve months or in the periods immediately thereafter will be generated from operations and there is no assurance that those funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company's existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for companies such as Bion.

 

Covid-19 pandemic related matters:

 

The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.

 

CONTRACTUAL OBLIGATIONS

 

We have the following material contractual obligations (in addition to employment and consulting agreements with management and employees):

 

The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.

 

The future minimum lease payment under noncancelable operating lease with terms greater than one year as of March 31, 2023:

 

From April 2023 to December 2023   56,250 
From January 2024 to December 2024    75,000 
Undiscounted cash flow   131,250 
Less imputed interest   (11,299)
Total   119,951 

 

 

49 
 

  

The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of March 31, 2023 were 1.83 years and 10%, respectively. The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.

 

Through 3G1 the Company is in the process of developing the Initial Project. See discussion above and in the Notes to our Financial Statements. 

 

OFF-BALANCE SHEET ARRANGEMENTS

 

The Company does not have any off-balance sheet arrangements (as that term is defined in Item 303 of Regulation S-K) that are reasonably likely to have a current or future material effect on our financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable.

 

Item 4. Controls and Procedures.

 

(a) Evaluation of Disclosure Controls and Procedures.

 

The term "disclosure controls and procedures" is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). This term refers to the controls and procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files under the Exchange Act is recorded, processed, summarized, and reported within the required time periods. Our Chief Executive Officer and Principal Financial Officer has evaluated the effectiveness of the design and operations of our disclosure controls and procedures as of the end of the period covered by this quarterly report, and has concluded that, as of that date, our disclosure controls and procedures were not effective at ensuring that required information will be disclosed on a timely basis in our reports filed under the Exchange Act, as a result of the material weakness in internal control over financial reporting discussed in Item 9(A) of our Form 10-K for the year ended June 30, 2022.

 

(b) Changes in Internal Control over Financial Reporting.

 

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

 

50 
 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

The Company is currently involved in no litigation matters except:

 

A:Website: Domain Sale/Resolved Litigation/Hacking/Theft

 

On March 23, 2022 the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490. The Company has been using www.bionenviro.com as its primary website (and domain) since July 2021 due to the events described below. The Company has not been using biontech.com as its primary website since July 2021 so domain name <biontech.com> no longer represented a core asset of the Company.

 

As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the <biontech.com> domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.

 

On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name <biontech.com> ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name <biontech.com> to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).

 

No shareholder, sensitive or confidential information was available to be breached which has limited damages from the hack/theft to date. However, the Company’s email operations were subject to short term disruption and expenses were incurred related to the matter including legal fees.

 

The Company created ‘work-arounds’ as a result. These issues have been resolved and the Company has moved our website (and email) to a new domain: bionenviro.com. Website access is now www.bionenviro.com. To send emails to Bion personnel, one uses the same name identifier previously used, but in the address, substitute ‘bionenviro.com’ for “biontech.com’: For example cscott@biontech.com (no longer functional) is cscott@bionenviro.com and mas@biontech.com (no longer functional) is now mas@bionenviro.com.

 

 

51 
 

 

B: Dissolution of Bion PA1, LLC (“PA1”)

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s condensed consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s condensed consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s condensed consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

 

52 
 

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who  arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest described above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1, since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

C: OMRI litigation

 

On February 23, 2023 the Company filed ‘Complaint for Declaratory Judgment and Injunctive Relief’ against the Organic Materials Review Institute (“OMRI”) in the Circuit Court for the State of Oregon for the County of Lane to contest OMRI’s negative determination with regard to the Company’s application for listing of its solid ammonium bicarbonate product. The Company alleges that OMRI failed to properly follow its own procedures and reached a result without scientific support. The Company has elected to proceed with “Judicial Dispute Resolution” as set forth in the OMRI Policy Manual and has initiated litigation contesting the determination. The Company has requested declaratory relief from the court. OMRI filed its Answer to the Complaint during the first week of May 2023 and the discovery process has now commenced. See Note 1 “Fertilizer: Organic and ‘Climate Smart’” above.

 

The Company currently is not involved in any other material litigation or similar events.

 

Item 1A.  Risk Factors.

Not applicable.

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds.

During the quarter ended March 31, 2023, the Company sold the following restricted securities: a) 575,000 units at $1.60 per unit consisting of one share of the Company’s restricted common stock and ½ warrant to purchase one share of the Company’s restricted common stock at $2.40 until June 30, 2024 and received gross proceeds of $920,000 and net proceeds of$872,000 and b) the Company sold 1,800,000 shares of restricted common stock at $1.00 per share and received proceeds of $1,800,000 and c)1,055,906 shares were issued pursuant to our 2006 Consolidated Incentive Plan (“Plan”) upon the conversion of debt and d) 84,000 shares were issued when 84,000 warrants were exercised @$0.75/warrant and the Company received gross proceeds of $63,000. 

For the nine months ended March 31, 2023, the Company sold the following restricted securities: a) 346,230 units at $1.00 per unit consisting of one share of the Company’s restricted common stock and 1 warrant to purchase one share of the Company’s restricted common stock at $1.25 until December 31, 2023 and received gross proceeds of $346,230,  b) the Company sold 575,000 units at $1.60 per unit consisting of one share of the Company’s restricted common stock and ½ warrant to purchase ½ share of the Company’s restricted common stock at $2.40 until June 30, 2024 and received gross proceeds of $920,000 and net proceeds of $872,000 and  c) 2,000,000 shares of restricted common stock at $1.00  per share and received  proceeds of $2,000,000 and c) 1,155,906 shares issued pursuant to our 2006 Consolidated Incentive Plan (“Plan”) upon the conversion of debt and d) 162,834 warrants were exercised @$0.75/warrant and the Company received gross proceeds of $119,126.  In addition, the Company issued 25,000 Commission Warrants @ $2.40 until June 30, 2024 and issued 50,000 shares of restricted common stock for services valued at $80,000.   All of these transactions the Company relied on the exemptions in Section 4(2) of the Securities Act of 1933, as amended, and/or under Rule 506 of Regulation D under the Securities Act of 1933, as amended. See Notes to Financial Statements (included herein) for additional details.

The proceeds were utilized for general corporate purposes.

Item 3.  Defaults Upon Senior Securities.

Not applicable.

Item 4.  Mine Safety Disclosures.

Not applicable.

Item 5.  Other Information.

Not applicable.

53 
 

Item 6.  Exhibits.

  (a) Exhibits required by Item 601 of Regulation S-K.

 

Exhibit       Incorporated by Reference   Filed/Furnished
No.   Description   Form     Exhibit   Filing Date   Herewith
31.1*   Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act                 X
31.2*   Certification of Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act                 X
32.1**   Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act                 X
32.2**   Certification of Principal Accounting Officer Pursuant to Section 906 of the Sarbanes-Oxley Act                 X
101.INS*   Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.                 X
101.SCH*   Inline XBRL Taxonomy Extension Schema Document                 X
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document                 X
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document                 X
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document                 X
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document                 X
104*   Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.                 X

 

* Filed herewith.
   
** Furnished herewith.

 

 

54 
 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

    BION ENVIRONMENTAL TECHNOLOGIES, INC.
     
     
Date: May 10, 2023 By: /s/ Mark A. Smith
    Mark A. Smith, President and Chief Financial Officer (Principal Financial and Accounting Officer)
     
     
     
Date:  May 10, 2023 By: /s/ William O’Neill
    William O’Neill, Chief Executive Officer
     
     

 

55 
 

 

 

 

 

EX-31.1 2 ex31x1.htm EXHIBIT 31.1

Exhibit 31.1

 

 

SECTION 302 CERTIFICATION

 

I, William O’Neill, certify that:

 

1.   I have reviewed this quarterly report on Form 10-Q of Bion Environmental Technologies, Inc.;

 

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.   Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the of the registrant as of, and for, the periods presented in this report;

 

4.   The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)  Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.   The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

 

Date: May 10, 2023

 

 

 

/s/ William O’Neill

William O’Neill

Chief Executive Officer

EX-31.2 3 ex31x2.htm EXHIBIT 31.2

Exhibit 31.2

 

SECTION 302 CERTIFICATION

 

I, Mark A. Smith, certify that:

 

1.   I have reviewed this quarterly report on Form 10-Q of Bion Environmental Technologies, Inc.;

 

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.   Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the of the registrant as of, and for, the periods presented in this report;

 

4.   The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)  Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.   The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date:  May 10, 2023

 

 

/s/ Mark A. Smith

Mark A. Smith

Executive Chairman, President and Chief Financial Officer

EX-32.1 4 ex32x1.htm EXHIBIT 32.1

Exhibit 32.1

 

 

CERTIFICATION OF CEO PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Form 10-Q of Bion Environmental Technologies, Inc., a company duly formed under the laws of Colorado (the "Company"), for the quarter ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), William O’Neill, Chief Executive Officer of the Company, hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

May 10, 2023 /s/ William O’Neill  
 

William O’Neill

Chief Executive Officer

 

 

 

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 

 

A signed original of this written statement required by Section 906 has been provided to Bion Environmental Technologies, Inc. and will be retained by Bion Environmental Technologies, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

EX-32.2 5 ex32x2.htm EXHIBIT 32.2

Exhibit 32.2

 

 

CERTIFICATION OF CFO PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the Form 10-Q of Bion Environmental Technologies, Inc., a company duly formed under the laws of Colorado (the "Company"), for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Mark A. Smith, President (Executive Chairman) and Interim Chief Financial Officer (Principal Financial and  Accounting Officer) of the Company, hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

       
Date: May 10, 2023   /s/ Mark A. Smith  
   

Mark A. Smith

Executive Chairman, President and

Interim Chief Financial Officer

 
       

 

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 

A signed original of this written statement required by Section 906 has been provided to Bion Environmental Technologies, Inc. and will be retained by Bion Environmental Technologies, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

 

EX-101.SCH 6 bnet-20230331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS: link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - PROPERTY AND EQUIPMENT: link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - DEFERRED COMPENSATION: link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - LOANS PAYABLE: link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES: link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - STOCKHOLDERS' EQUITY: link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES: link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES: link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SUBSEQUENT EVENTS: link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - PROPERTY AND EQUIPMENT: (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - STOCKHOLDERS' EQUITY: (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - COMMITMENTS AND CONTINGENCIES: (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS: (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - PROPERTY AND EQUIPMENT: (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - DEFERRED COMPENSATION: (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - LOANS PAYABLE: (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES: (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - STOCKHOLDERS' EQUITY - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - STOCKHOLDERS' EQUITY: (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES: (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES: (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - SUBSEQUENT EVENTS: (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 bnet-20230331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 bnet-20230331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 bnet-20230331_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A Preferred Stock [Member] Series C Preferred Stock [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Subscriptions Receivable [Member] Retained Earnings [Member] Noncontrolling Interest [Member] Counterparty Name [Axis] Ribbonwire [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Ownership [Axis] Centerpoint [Member] Antidilutive Securities [Axis] Warrant [Member] Share-Based Payment Arrangement, Option [Member] Convertible Debt Securities [Member] Convertible Preferred Stock Antidilutive Securities [Member] Long-Lived Tangible Asset [Axis] Property Plant And Equipment Of P A 1 [Member] Title of Individual [Axis] Chief Executive Officer [Member] Bassani [Member] Smith [Member] Consultants [Member] Nature of Expense [Axis] Interest Expense On Deferred Compensation Obligation [Member] Debt Instrument [Axis] Pennvest Loan [Member] Scenario [Axis] Years One Through Five [Member] Years Six Through Maturity [Member] Legal Entity [Axis] P A 1 [Member] The 2020 Convertible Obligations [Member] Long-Term Debt, Type [Axis] Convertible Debt [Member] President [Member] Executive Vice Chairman [Member] Principal [Member] Convertible Obligations 2020 [Member] Award Type [Axis] Common Shares [Member] Warrants [Member] Accrued Interest [Member] Mark A Smith [Member] Dominic Bassani [Member] Ed Schafer [Member] Receivable Type [Axis] Secured Promissory Note [Member] September 2015 Convertible Notes [Member] Related Party Transaction [Axis] Bassani Family Trusts [Member] Schafer [Member] Shareholder [Member] Adjusted Convertible Obligations [Member] Direct Ownership [Member] Indirect Ownership [Member] Restricted Common Shares [Member] Series B Preferred Stock [Member] Restricted Stock [Member] Restricted Common Stock [Member] Consultant Service [Member] Three Consultants [Member] Plan Name [Axis] Equity Incentive Plan [Member] Plan 2006 [Member] Northrop [Member] Financial Instrument [Axis] Options Held [Member] Class of Warrant or Right [Axis] Warrants Issused Subscription Receivable [Member] Former Employee [Member] Smiths [Member] Warrants Issued In Connection With Sale Of Units In Exchange For Salary [Member] Extension Bonus [Member] Fy 2016 Extension Agreement [Member] Warrants Expiring On December 312025 [Member] Secured Promissory Note Consideration For Warrants Expiring On December 312025 [Member] William O Neill [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] ASSETS  Current assets:  Cash  Prepaid expenses  Deposits and other assets  Total current assets  Operating lease right-of-use asset  Property and equipment, net (Note 3)  Total assets  LIABILITIES AND EQUITY (DEFICIT)  Current liabilities:  Accounts payable and accrued expenses  Deferred compensation (Note 4)  Total current liabilities  Operating lease liability  Convertible notes payable - affiliates (Note 6)  Total liabilities  Equity (deficit): Bion's stockholders' equity (deficit): Preferred stock Common stock, no par value, 250,000,000 shares authorized, 48,044,790 and 43,758,820 shares issued, respectively; 47,340,480 and 43,054,511 shares outstanding, respectively Additional paid-in capital Subscription receivable - affiliates (Note 8) Accumulated deficit Total Bion's stockholders’ equity (deficit) Noncontrolling interest Total equity (deficit) Total liabilities and deficit Preferred stock, par value (in dollars per share) Preferred stock, authorized (in shares) Preferred stock, issued (in shares) Preferred stock, outstanding (in shares) Common stock, par value Common stock, authorized (in shares) Common Stock, Shares Issued Common Stock, Shares Outstanding Income Statement [Abstract] Revenue Operating expenses: General and administrative (including stock-based compensation) Depreciation Research and development (including stock-based compensation) Total operating expenses Loss from operations Other (income) expense: Interest income Interest expense Gain on sale of domain Gain on debt extinguishment Total other expense Net income (loss) Net loss attributable to the noncontrolling interest Net income (loss) applicable to Bion's common stockholders Net income (loss) applicable to Bion's common stockholders per basic and diluted common share Weighted-average number of common shares outstanding: Basic and diluted Beginning balance, value Beginning balance, shares Sale of units Sale of units, shares Warrants exercised for common shares Warrants exercised for common shares , shares Issuance of units for services Issuance of units for services, shares Commissions on warrant exercises Commissions on warrant exercises , shares Issuance of warrants for services Conversion of debt and liabilities Conversion of debt and liabilities, shares Vesting of options for employees and services Modification of warrants Commissions on sale of units Modification of warrants - non-cash comp Modification of warrants - interest Debt modification Vesting of options for services Net loss Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net income (loss) Adjustments to reconcile net loss to net cash used in operating activities: Gain on legal dissolution of subsidiary Depreciation expense Accrued interest on loans payable, deferred compensation and other Stock- based compensation Stock-based compensation for services Modification of warrants Warrants issued for compensation for services Decrease in prepaid expenses Increase (decrease) in deposits in other assets (Increase) in other receivable from the sale of doman name Increase (decrease) in accounts payable and accrued expenses Decrease (increase) in operating lease assets and liabilities Increase in deferred compensation Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from sale of units Proceeds from exercise of warrants Commissions on exercise of warrants Commissions on sale of units Redemption of Preferred Series B shares and interest Net cash provided by financing activities Net increase (decrease) in cash Cash at beginning of year Cash at end of year Supplemental disclosure of cash flow information: Cash paid for interest Non-cash investing and financing transactions: Conversion of debt and liabilities into common units Conversion of debt and liabilities into notes payable Conversion of deferred compensation to notes payable Capitalized interest in property and equipment Shares issued for warrant exercise commissions Purchase of property and equipment for accounts payable Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS: Accounting Policies [Abstract] SIGNIFICANT ACCOUNTING POLICIES Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT: Share-Based Payment Arrangement [Abstract] DEFERRED COMPENSATION: Debt Disclosure [Abstract] LOANS PAYABLE: Convertible Notes Payable - Affiliates CONVERTIBLE NOTES PAYABLE - AFFILIATES: Equity [Abstract] STOCKHOLDERS' EQUITY: Subscription Receivable - Affiliates SUBSCRIPTION RECEIVABLE - AFFILIATES: Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES: Subsequent Events [Abstract] SUBSEQUENT EVENTS: Principles of consolidation Cash and cash equivalents Property and equipment Patents Stock-based compensation Derivative Financial Instruments Options Warrants Concentrations of credit risk Noncontrolling interests Fair value measurements Lease Accounting Revenue Recognition Income (Loss) per share Use of estimates Recent Accounting Pronouncements Schedule of warrants and options and convertible securities Schedule of earnings per share, basic and diluted Schedule of property and equipment Schedule of option activity Schedule of future minimum lease payments Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Tech wastage Cattle per head Percentage of sustainable Description of kreider 2 poultry project Net Income (loss) Net income Gain on sale of domain Working Capital Reduction of debt Proceeds from Issuance or Sale of Equity Commissions paid Deferred Compensation Liability, Amount Cancelled Capital Required for Capital Adequacy Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities Shares issued – beginning of period Shares held by subsidiaries (Note 7) Shares outstanding – beginning of period Weighted average shares issued     during the period Diluted weighted average shares –     end of period Noncontrolling interest, ownership percentage by parent Cash equivalents Computers and office equipment Initial Project: construction in process Property and equipment, gross Less accumulated depreciation  Property and equipment, net Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Capitalized interest Non cash compensation Impairment of Long-Lived Assets Held-for-use Depreciation expense Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Deferred compensation liability Interest Rate on Deferred Compensation Deferred Compensation Consecutive Trading Days (Day) Deferred Compensation, Convertible to Common Stock Deferred Compensation, Convertible to Common Stock, Price Per Share (in dollars per share) Deferred compensation Interest Expense Interest Expense, Related Party Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Construction Loan Accrued Interest and Late Charges Payable Total assets Total liabilities Accounts payable and accrued liabilities Accounts payable Accrued Liabilities, Current Gain on legal dissolution of subsidiary Line of Credit Facility, Maximum Borrowing Capacity Debt Instrument, Interest Rate During Period Debt Instrument, Annual Principal Payment Long-Term Debt, Maturity, Year Two Long-Term Debt, Maturity, Year Three Long-Term Debt, Maturity, Year Four Interest Expense, Debt Loans as a liability Debt Instrument, Debt Default, Amount Realized from the asset sale Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage, Quarterly Conversion price per unit Original conversion price Convertible Notes Payable, Noncurrent Salary paid Accounts payable for reimbursable expenses Debt conversion value Debt conversion shares, warrants Capitalized amount Convertible note Principal amount Financing receivable interest rate stated percentage Convertible Notes Payable Conversion of shares, value Conversion of shares, shares Convertible stock shares issued, warrants Shares issued, warrants Options outstanding, beginning (in shares) Options outstanding, beginning weighted-average exercise price Outstanding, weighted-average remaining contractual life (Year) Outstanding, aggregate intrinsic value beginning Granted, options (in shares) Granted, weighted-average exercise price Exercised, options (in shares) Exercised, weighted-average exercise price Forfeited, options (in shares) Forfeited, weighted-average exercise price Expired, options (in shares) Expired, weighted-average exercise price Options outstanding, ending (in shares) Options outstanding, ending weighted-average exercise price Outstanding, aggregate intrinsic value ending Schedule of Stock by Class [Table] Class of Stock [Line Items] Convertible debt maturity date Increase to additional paid in capital Reduction of additional paid in capital Preferred Stock, Shares Outstanding, Ending Balance (in shares) Par value Preferred Stock, Convertible Option Per Share Preferred stock dividend rate percentage Preferred Stock, Redemption Price Per Share Redemption of convertible Preferred stock Dividends Payable Dividends, Preferred Stock Liability Shares Held by Subsidiaries Sale of stock, shares Shares purchased, shares Shares purchased, value Sale of units Sell units Vesting period Number of shares issued Number of shares issued, value Class of Warrant or Right, Exercised During Period Common Stock Shares Issued upon Exercise of Warrants Warrants exercisable per share Warrant Exercised for Common Stock Debt conversion shares Conversion price per share Shares issued for consultant services Share price Total value of consultant services Warrant outstanding Weighted average exercise price Remaining contractual life Number of shares issued Issuance of warrants Share-based Payment Arrangement, Plan Modification, Incremental Cost Interest expenses Cancellation of warrants Exercise bonus Non cash compensation Stock options, authorized (in shares) Number of shares granted Share-based Compensation, Granted Share-based Compensation, Granted Share-based Payment Arrangement, Expense Fair value of stock options Financing Receivable, after Allowance for Credit Loss, Total Notes receivable interest Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Financing Receivable, Principal Amount Financing Receivable, Interest Rate, Stated Percentage From April 2023 to December 2023 From January 2024 to December 2024 Undiscounted cash flow Less imputed interest Total Loss Contingencies [Table] Loss Contingencies [Line Items] Monthly Officers Cash Compensation Compensation increased Cash compensation paid Deferred Compensation, Maximum Convertible Amount Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share) Salaries and wages Additional paid amount Interest bearing secured promissory note Repayments of Long-term Debt, Total Payment for cash Warrants held by trust owned Warrants and Rights Outstanding Debt instrument paid amount Principal, interest Aggregate payment Purchase order Purchase order billed Purchase order Invoiced Capitalized labor and interest costs Sale of domain, description Loan related to construction Accrued interest Gain on legal dissolution of subsidiary Accrued current liability Weighted average remaining lease term Discounted rate Subsequent Event [Table] Subsequent Event [Line Items] Cash paid Accrued paid Aggregate amount Rent Warrants Warrants exercised Consulting services description Options granted Assets, Current Common Stock, Share Subscribed but Unissued, Subscriptions Receivable Stockholders' Equity Attributable to Parent Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Income, Operating Gain (Loss) on Extinguishment of Debt Other Nonoperating Income (Expense) Net Income (Loss) Attributable to Noncontrolling Interest Net Income (Loss) Available to Common Stockholders, Basic Shares, Outstanding GainOnLegalDissolutionsOfSubsidiary ModificationOfWarrants Increase (Decrease) in Prepaid Expense Increase (Decrease) in Other Operating Assets Increase (Decrease) in Accounts and Other Receivables Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Payments for Repurchase of Warrants CommissionsOnSaleOfUnits Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Gain on sale of domain [Default Label] Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, Plant and Equipment, Other, Net Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value SaleOfUnitPricePerUnit Share-Based Payment Arrangement, Expense Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Extinguishment of Debt, Gain (Loss), Net of Tax Warrants [Default Label] EX-101.PRE 10 bnet-20230331_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - shares
9 Months Ended 21 Months Ended
Mar. 31, 2023
Mar. 31, 2023
Apr. 30, 2023
Cover [Abstract]      
Document Type 10-Q    
Amendment Flag false    
Document Quarterly Report true    
Document Transition Report false    
Document Period End Date Mar. 31, 2023    
Document Fiscal Period Focus Q3    
Document Fiscal Year Focus 2023    
Current Fiscal Year End Date --06-30    
Entity File Number 000-19333    
Entity Registrant Name Bion Environmental Technologies, Inc    
Entity Central Index Key 0000875729    
Entity Tax Identification Number 84-1176672    
Entity Incorporation, State or Country Code CO    
Entity Address, Address Line One 9 East Park Court    
Entity Address, City or Town Old Bethpage    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 11804    
City Area Code 516    
Local Phone Number 586-5643    
Title of 12(b) Security Common Stock    
Trading Symbol BNET    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company   false  
Entity Common Stock, Shares Outstanding     47,342,061
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2023
Jun. 30, 2022
 Current assets:    
 Cash $ 1,612,977 $ 3,160,442
 Prepaid expenses 113,101 157,550
 Deposits and other assets 6,000 1,000
 Total current assets 1,732,078 3,318,992
 Operating lease right-of-use asset 107,162 145,787
 Property and equipment, net (Note 3) 5,788,203 2,895,558
 Total assets 7,627,443 6,360,337
 Current liabilities:    
 Accounts payable and accrued expenses 800,901 1,360,644
 Deferred compensation (Note 4) 784,255 594,798
 Total current liabilities 1,585,156 1,955,442
 Operating lease liability 119,951 128,864
 Convertible notes payable - affiliates (Note 6) 1,735,507 5,170,610
 Total liabilities 3,440,614 7,254,916
Bion's stockholders' equity (deficit):    
Common stock, no par value, 250,000,000 shares authorized, 48,044,790 and 43,758,820 shares issued, respectively; 47,340,480 and 43,054,511 shares outstanding, respectively
Additional paid-in capital 131,208,759 123,620,046
Subscription receivable - affiliates (Note 8) (504,650) (504,650)
Accumulated deficit (126,554,853) (124,047,548)
Total Bion's stockholders’ equity (deficit) 4,149,256 (932,152)
Noncontrolling interest 37,573 37,573
Total equity (deficit) 4,186,829 (894,579)
Total liabilities and deficit 7,627,443 6,360,337
Series A Preferred Stock [Member]    
Bion's stockholders' equity (deficit):    
Preferred stock
Total equity (deficit)
Series C Preferred Stock [Member]    
Bion's stockholders' equity (deficit):    
Preferred stock
Total equity (deficit)
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Mar. 31, 2023
Jun. 30, 2022
Common stock, par value $ 0 $ 0
Common stock, authorized (in shares) 250,000,000 250,000,000
Common Stock, Shares Issued 48,044,790 43,758,820
Common Stock, Shares Outstanding 47,340,480 43,054,511
Series A Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized (in shares) 50,000 50,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Series C Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized (in shares) 60,000 60,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]        
Revenue
Operating expenses:        
General and administrative (including stock-based compensation) 859,011 397,743 2,356,047 1,506,839
Depreciation 461 252 1,185 832
Research and development (including stock-based compensation) 24,242 29,411 67,833 145,624
Total operating expenses 883,714 427,406 2,425,065 1,653,295
Loss from operations (883,714) (427,406) (2,425,065) (1,653,295)
Other (income) expense:        
Interest income (1,342) (1,338) (4,652) (4,101)
Interest expense (24,488) 51,361 86,892 281,906
Gain on sale of domain (902,490) (902,490)
Gain on debt extinguishment (10,234,501)
Total other expense (25,830) (852,467) 82,240 (10,859,186)
Net income (loss) (857,884) 425,061 (2,507,305) 9,205,891
Net loss attributable to the noncontrolling interest 549 1,544
Net income (loss) applicable to Bion's common stockholders $ (857,884) $ 425,610 $ (2,507,305) $ 9,207,435
Net income (loss) applicable to Bion's common stockholders per basic and diluted common share $ (0.02) $ 0.01 $ (0.06) $ 0.22
Weighted-average number of common shares outstanding:        
Basic and diluted 45,456,417 43,029,511 44,165,309 41,602,390
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) - USD ($)
Series A Preferred Stock [Member]
Series C Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Subscriptions Receivable [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Total
Beginning balance, value at Jun. 30, 2021 $ 121,399,067 $ (504,650) $ (132,339,873) $ 39,117 $ (11,406,339)
Beginning balance, shares at Jun. 30, 2021 41,315,986          
Warrants exercised for common shares 1,736,662 1,736,662
Warrants exercised for common shares , shares     2,315,550          
Commissions on warrant exercises (18,601) (18,601)
Commissions on warrant exercises , shares     66,860          
Issuance of warrants for services 7,500 7,500
Conversion of debt and liabilities 17,711 17,711
Conversion of debt and liabilities, shares     35,424          
Vesting of options for employees and services 4,650 4,650
Modification of warrants 8,337 8,337
Net loss 9,207,435 (1,544) 9,205,891
Ending balance, value at Mar. 31, 2022 123,155,326 (504,650) (123,132,438) 37,573 (444,189)
Ending balance, shares at Mar. 31, 2022 43,733,820          
Beginning balance, value at Dec. 31, 2021 123,150,676 (504,650) (123,558,048) 38,122 (873,900)
Beginning balance, shares at Dec. 31, 2021 43,733,820          
Vesting of options for services 4,650 4,650
Net loss 425,610 (549) 425,061
Ending balance, value at Mar. 31, 2022 123,155,326 (504,650) (123,132,438) 37,573 (444,189)
Ending balance, shares at Mar. 31, 2022 43,733,820          
Beginning balance, value at Jun. 30, 2022 123,620,046 (504,650) (124,047,548) 37,573 (894,579)
Beginning balance, shares at Jun. 30, 2022 43,758,820          
Sale of units 3,266,230 3,266,230
Sale of units, shares     2,921,230          
Warrants exercised for common shares 119,125 119,125
Warrants exercised for common shares , shares     158,834          
Issuance of units for services 80,000 80,000
Issuance of units for services, shares     50,000          
Issuance of warrants for services 57,094 57,094
Conversion of debt and liabilities 149,889 149,889
Conversion of debt and liabilities, shares     1,155,906          
Vesting of options for employees and services 220,510 220,510
Commissions on sale of units (48,000) (48,000)
Modification of warrants - non-cash comp 159,433 159,433
Modification of warrants - interest 68,088 68,088
Debt modification 3,516,345 3,516,345
Net loss (2,507,305) (2,507,305)
Ending balance, value at Mar. 31, 2023 131,208,759 (504,650) (126,554,853) 37,573 4,186,829
Ending balance, shares at Mar. 31, 2023 48,044,790          
Beginning balance, value at Dec. 31, 2022 124,627,172 (504,650) (125,696,969) 37,573 (1,536,874)
Beginning balance, shares at Dec. 31, 2022 44,529,884          
Sale of units 2,720,000 2,720,000
Sale of units, shares     2,375,000          
Warrants exercised for common shares 63,000 63,000
Warrants exercised for common shares , shares     84,000          
Issuance of warrants for services 9,844 9,844
Conversion of debt and liabilities 99,889 99,889
Conversion of debt and liabilities, shares     1,055,906          
Vesting of options for employees and services 220,510 220,510
Commissions on sale of units (48,000) (48,000)
Debt modification       3,516,345       3,516,345
Net loss (857,884) (857,884)
Ending balance, value at Mar. 31, 2023 $ 131,208,759 $ (504,650) $ (126,554,853) $ 37,573 $ 4,186,829
Ending balance, shares at Mar. 31, 2023 48,044,790          
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
9 Months Ended
Mar. 31, 2023
Mar. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES    
Net income (loss) $ (2,507,305) $ 9,205,891
Adjustments to reconcile net loss to net cash used in operating activities:    
Gain on legal dissolution of subsidiary (10,234,501)
Depreciation expense 1,185 832
Accrued interest on loans payable, deferred compensation and other 86,891 299,770
Stock- based compensation 220,510 17,774
Stock-based compensation for services 80,000
Modification of warrants 154,932  
Warrants issued for compensation for services 57,094  
Decrease in prepaid expenses 44,449 118,778
Increase (decrease) in deposits in other assets (5,000) (45,000)
(Increase) in other receivable from the sale of doman name (902,490)
Increase (decrease) in accounts payable and accrued expenses (908,644) 223,822
Decrease (increase) in operating lease assets and liabilities 29,712 (33,073)
Increase in deferred compensation 265,000 224,367
Net cash used in operating activities (2,481,176) (1,123,830)
CASH FLOWS FROM INVESTING ACTIVITIES    
Purchase of property and equipment (2,403,644) (1,167,463)
Net cash used in investing activities (2,403,644) (1,167,463)
CASH FLOWS FROM FINANCING ACTIVITIES    
Proceeds from sale of units 3,266,230
Proceeds from exercise of warrants 119,125 1,736,662
Commissions on exercise of warrants (18,601)
Commissions on sale of units (48,000)
Redemption of Preferred Series B shares and interest (41,000)
Net cash provided by financing activities 3,337,355 1,677,061
Net increase (decrease) in cash (1,547,465) (614,232)
Cash at beginning of year 3,160,442 4,216,321
Cash at end of year 1,612,977 3,602,089
Supplemental disclosure of cash flow information:    
Cash paid for interest
Non-cash investing and financing transactions:    
Conversion of debt and liabilities into common units 149,888 17,711
Conversion of debt and liabilities into notes payable 23,943
Conversion of deferred compensation to notes payable 90,000 190,000
Capitalized interest in property and equipment 117,342
Shares issued for warrant exercise commissions 50,145
Purchase of property and equipment for accounts payable $ 372,844 $ 666,375
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS:
9 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS:

 

1.ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS:

 

Organization and nature of business:

 

Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Bion’s mission is to make livestock production more sustainable, transparent and profitable. We intend to accomplish this by deploying our Gen3Tech platform/business model (discussed below) in ventures focused on the ‘feeder’ space of the livestock production/value chain to provide the consumer with verifiably sustainable premium products. Bion believes this approach can create extraordinary value for our shareholders and employees (all of whom own securities in the Company).

 

Our patented and proprietary technology provides advanced waste treatment and resource recovery for large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs"). Livestock production and its waste, particularly from CAFOs, has been identified as one of the greatest soil, air, and water quality problems in the U.S. today.  Application of our third-generation technology and business/technology platform (“Gen3Tech”) can largely mitigate these environmental problems, while simultaneously improving operational/ resource efficiencies by recovering high-value co-products from the CAFOs’ waste stream. These waste ‘assets’ – nutrients and methane – have traditionally been wasted or underutilized and are the same ‘pollutants’ that today fuel harmful algae blooms, contaminate surface groundwater, and exacerbate climate change.

 

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms) (“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long-term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

Bion’s Gen3Tech was designed to capture and stabilize these assets and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the animal raising and waste treatment process will be third-party verified, providing the basis for additional revenues, including carbon and/or renewable energy-related credits and, eventually, payment for a range of ecosystem services, including nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.

 

During the first half of 2022 Bion began pre-marketing our sustainable beef to retailers, food service distributors and the meat industry in the U.S.  In general, the response has been favorable. During July 2022, Bion announced a letter of intent (“Ribbonwire LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Ribbonwire Ranch, in Dalhart, Texas (with a provision to expand to 60,000 head) (“Dalhart Project”). During January 2023 Bion announced a letter of intent (“Olson LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Olson Feeders and TD Angus, near North Platte, Nebraska (with a provision to expand to 45,000 head or more) (“Olson Project”). During April 2023 Bion announced a letter of intent (“DVG LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with Dakota Valley Growers near Bathgate, North Dakota. The Olson, Dalhart and DVG Projects (and subsequent Projects) will be developed to produce verified, sustainable beef in customized covered barns (resulting in reduced stress on cattle caused by extreme weather and temperatures and resulting higher feed/weight gain efficiency) with ongoing manure transfer (through slatted floors) to anaerobic digesters (AD) to capture nitrogen from the manure stream before loss to the atmosphere and generate renewable natural gas (RNG) for sale while remediating the environmental/carbon impacts usually associated with cattle feedlots and CAFOs. Bion’s patented technology will refine the waste stream into valuable coproducts that include clean water, RNG, photovoltaic solar electricity and fertilizer (‘climate smart’ and organic) products. We anticipate converting these LOI into definitive JV agreements and creating distribution agreements with key retailers and food service distributors during the next six-nine months.

Our business plan is focused on executing multiple agreements and letters of intent related to additional sustainable beef JV projects over the next twelve months while moving forward with the Initial Project (see below) and one or more of the Dalhart/Olson/DVG Projects (“LOI Projects”)(and/or other Gen3Tech beef JV projects) and pursuing other opportunities in the livestock industry enabled by our Gen3Tech business model.  The Ribbonwire and Olson LOI announcements have generated significant interest within the livestock industry (among ranchers, feedlot operators, farmers and other AG industry parties). We believe that this interest, combined with consumer interest in ‘sustainable products’ and growing enthusiasm among some livestock industry parties for environmental/sustainable/regenerative practices, may provide Bion (and its partners/venturers) with an opportunity to move forward with a truly sustainable solution in this industry segment at a rapid pace.

During the next three months, the Company intends to complete construction and begin operations of phase 1 of our Initial Project located near Fair Oaks, Indiana. Bion expects the Initial Project to provide data that illustrates the effectiveness of our Gen3Tech in a commercial-scale setting by the end of the 2nd quarter in 2023 and supports development of the LOI Projects (and/or other Gen3Tech beef JV projects) commencing later during 2023.  We do not presently know the order in which these JV Projects will be developed as that decision will be made based on many factors not yet in place. We believe the Initial Project data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, food distributors and retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below). 

 

Bion is now focused primarily on: i) development/construction/operation of the Initial Project, our initial commercial-scale Gen3Tech installation, ii) pre-development planning of the Dalhart, Olson and DVG Projects (and/or other Gen3Tech beef JV projects), iii) developing applications and markets for its low carbon ‘ClimateSmart’ and organic fertilizer products (including listings/certifications of multiple liquid and solid products) and its sustainable (conventional and organic) animal protein products, and iv) discussions regarding initiation and development of agreements and joint ventures (“JVs” as discussed below) (and related Projects) based on the augmented capabilities of our Gen3Tech business platform (in the sustainable beef and other livestock segments), while (v) continuing to pursue business opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and vi) ongoing R&D activities.

 

HISTORY, BACKGROUND AND CURRENT ACTIVITIES

Since the Company’s inception, Bion has designed and developed advanced waste treatment systems for livestock. The first and second generations of Bion’s technology platform were biological systems, primarily focused on nutrient control. Over 30 of these systems were deployed at New York dairies, Florida food processing facilities and dairies, North Carolina hog farms, a Texas dairy and a Pennsylvania dairy (“Kreider 1 Project”). The systems were highly effective at their intended purpose: capturing nitrogen and phosphorus. They produced BionSoil as a byproduct, which was a remarkably effective soil amendment/ fertilizer product, but whose value was not enough to support a viable business model. As such, these early technology iterations were largely dependent on either implementation of new regulations requiring waste treatment, or subsidy/incentive programs that would provide ‘payment for ecosystem services’. By the mid-2010’s, it became apparent that neither of these options were imminent or even assured, so the Company initiated the steps to reimagine and redesign its technology.

 

From 2016 to 2021 fiscal years, the Company focused most of its activities and resources on developing, testing and demonstrating the third generation of its technology and technology platform (“Gen3Tech”). Our Gen3Tech was developed with an emphasis producing more valuable co-products from the waste treatment process, including renewable natural gas and ammonium bicarbonate, a low-carbon and organic ‘pure’ nitrogen fertilizer product while raising livestock in a verifiably sustainable manner to produce premium sustainable meat products.

 

The $175 billion U.S. livestock industry is under intense scrutiny for its environmental and public health impacts – its ‘environmental sustainability’-- at the same time it is struggling with declining revenues and margins (derived in part from clinging to its historic practices and resulting limitations and impacts) which threaten its ‘economic sustainability’. Its failure to adequately respond to consumer concerns including food safety, environmental impacts, and inhumane treatment of animals have provided impetus for plant-based alternatives such as Beyond Meat and Impossible Burger (and many others) being marketed as “sustainable” alternatives for this growing consumer segment of the market.

 

The Company believes that its Gen3Tech, in addition to providing superior environmental remediation, creates opportunities for large scale production of i) verifiably sustainable, branded livestock products and ii) verifiably sustainable organic-branded livestock products, both of which will command premium pricing (in part due to ongoing monitoring and third-party verification of environmental performance which will provide meaningful assurances to both consumers and regulatory agencies). Each of these two distinct market segments (which the Company intends to pursue in parallel) presents a large production/marketing opportunity for Bion. Our Gen3Tech will also produce (as co-products) biogas, solar photovoltaic electricity in appropriate locations, and valuable fertilizer products --low carbon and/or organic (which can be utilized in the production of organic grains for use as feed for raising organic livestock (some of which may be utilized in the Company’s JV projects)) and/or marketed to the growing markets for ‘ClimateSmart’ and/or organic fertilizer.

 

During July 2022, January 2023 and April 2023 the Company entered into letters of intent with Ribbonwire Ranch (Dalhart, Texas), Olson Feeders (North Platte, Nebraska) and Dakota Valley Growers (North Bathgate, Dakota), respectively, setting forth the parties’ intentions to negotiate joint venture agreements and enter into JVs to develop and operate initial 15,000 head integrated, sustainable beef facility for each Project including:

 

  a) innovative cattle barns (with slatted floors to facilitate movement of manure to the anaerobic digester and potentially solar PV generation on the rooftops which barns will improve the living conditions of the animals while increasing feeding/weight gain efficiency,

 

  b) ‘customized’ anaerobic digestion systems -- including pretreatment to increase renewable natural gas (‘RNG’) production and an RNG cleaning system (which will include capture/recycling of the CO2) to allow pipeline sales and monetization of related environmental credits,

 

  c) a Bion Gen3Tech module (which will utilize the recycled CO2 from the RNG production to increase fertilizer yield) for the production of pure nitogen fertilizer ‘ClimateSmart’ and/or organic (for use in organic crop production) plus residual organic solids and clean water, and

 

  d) which will produce verifiably sustainable beef products with USDA certified branding.

 

The Dalhart Project and the Olson Project, respectively, will include expansion capability up to 60,000 and 45,000 (or more) head of cattle, in aggregate, located at/around/contiguous to the initial Project facilities.

The opportunity presented by the Ribbonwire LOI and Olson LOI to commercialize the Company’s Gen3Tech and business model matured more quickly than anticipated (reflecting strong industry and public momentum in favor of verifiably sustainable food ventures). As a result, we have shifted our plans to focus resources and make our initial 15,000 head modules a reality as soon as possible.

 

To place the LOI Projects in the context of Company’s business plan (and our prior public disclosure), if one or more of the contemplated JVs move forward on anticipated timelines, active development of the first LOI Project will commence during the second half of calendar year 2023.

 

Prior to such activity, the Company intends to construct and operate the initial phase of the previously announced Gen3Tech demonstration project near Fair Oaks, Indiana (“Initial Project”): i) to validate our existing data and modeling at commercial scale and ii) to optimize the Bion Gen3Tech module for finalization of design parameters and fabrication details of our planned 15,000 head commercial facilities (including the 3 sets of LOI Projects). For the purposes of this initial phase, the Company, in order to accelerate the data acquisition phase, intends to utilize anaerobic digester effluent from the nearby/contiguous Fair Oaks dairy. Construction and related activities of this demonstration project have commenced with main module assembly on site in process since February 2023 (somewhat delayed due to supply chain constraints) followed by operations through the first half of 2023 (and thereafter) to generate the required information. Thereafter, the Company will evaluate what, if any, additional facilities and testing will take place at that location.

 

The Company anticipates that it will negotiate additional letters of intent and enter into additional joint ventures related to the development of further commercial-scale sustainable beef projects over the next 6-18 months in addition to the Dalhart, Olson and DVG Projects.

 

As previously disclosed, during late September 2021, Bion entered into a lease for the development site of the Initial Project, our initial commercial scale Gen3Tech project, which Initial Project will be located on approximately four (4) acres of leased land near Fair Oaks, Indiana, and a related agreement regarding disposal of certain manure effluent with the Curtis Creek Dairy unit of Fair Oaks Farms (“FOF”). Design and pre-development work commenced during August 2021 and surveying, site engineering and other site-specific engineering and design work is largely completed. Fabrication of the primary Gen3Tech equipment modules for the Initial Project commenced during January 2022. Construction work has been largely completed to prepare for the arrival in mid-February of the main modules of the Gen3Tech system. The Initial Project was initially planned to be an environmentally sustainable beef cattle feeding facility, equipped with state-of-the-art housing and Bion’s 3G-Tech platform to provide waste treatment and resource recovery. Bion designed the project to house and feed approximately 300 head of beef cattle. If all phases of the Initial Project are constructed, the facility will include Bion’s Gen3Tech platform including: i) covered barns ( including roof top solar photovoltaic generation in appropriate locations), ii) anaerobic digestion for renewable energy recovery, iii) livestock waste treatment and resource recovery technology, iv) Bion’s ammonium bicarbonate recovery (and crystallization) technology and iv) data collection software to document system efficiencies and environmental benefits (with the Bion Gen3Tech facilities capable of treating the waste from approximately 1,500 head). The facility will be large enough to demonstrate engineering capabilities of Bion’s Gen3Tech at commercial scale, but small enough that it can be constructed and commissioned relatively quickly. Originally, construction and onsite assembly operations were targeted to commence sometime late in 2022, however, supply chain backlogs have delayed likely delivery dates for core modules of the Bion system to the site until February 2023. 3G1 has been moving forward with the development and construction process of the Initial Project which we expect to become operational during the current quarter ending June 2023. See Note 3 “Property and Equipment” and Note 10 “Subsequent Events” (for activities since the start of the fourth quarter of the 2023 fiscal year).

 

The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing larger commercial projects with JV partners.

 

Specifically, the Initial Project (if all phases are constructed) is being developed to provide and/or accomplish (if all phases are constructed) the following:

 

  i. Proof of Gen3Tech platform scalability

 

  - Document system efficiency and environmental benefits and enable final engineering modifications to optimize each unit process within the Bion Gen3Tech platform.

 

  - Environmental benefits will include (without limitation) renewable energy production (natural gas recovery from AD and solar electric from integrated roof top photovoltaic generation); nutrient recovery and conversion to stable ‘ClimateSmart’ (low carbon) and/or organic fertilizer; pathogen destruction; water recovery and reuse; air emission reductions.

 

  ii. Use Bion’s data collection system to support 3rd party verified system efficiency requirement to qualify for USDA Process-Verified-Program (PVP): certification of sustainable branded beef (and potentially pork) product metrics.

 

  iii. Produce sufficient ammonium bicarbonate nitrogen fertilizer for certification/listing applications and commercial testing by potential joint venture partners and/or purchasers and for university growth trials.

 

The Initial Project will be carried out in stages with phase one focused on portions of items i. and iii. set forth above.

 

Upon completing the primary goals of phase 1 of the Initial Project, (coupled with progress regarding certifications(s) and markets for our fertilizer product lines (liquid and/or solid)), Bion expects to be ready to move forward with its plans for development (and related project financing) of much larger facilities including the LOI Projects. The Company anticipates that discussions and negotiations it has begun (together with additional opportunities that will be generated over the next 6-18 months) regarding potential JVs with strategic partners in the financial, livestock and food distribution industries to develop large scale projects will continue during the development/construction of the Initial Project with a 2023-24 goal of establishing multiple JV’s for large scale projects that will produce sustainable and/or sustainable-organic corn-fed beef. These products will be supported by a USDA PVP-certified sustainable brand that will, initially, highlight reductions in carbon and nutrient footprint, as well as pathogen reductions associated with foodborne illness and antibiotic resistance, along with the organic designation where appropriate. Bion’s RNG, nutrient, and water recovery will be transparent, third-party verified, and supported by blockchain --- that data, coupled with cattle production history, will underpin the sustainable brand. Sustainability will be measured by improvements in resource efficiencies, animal health and welfare, and reduced impacts to air, water, and soil, and will be communicated to the consumer at the point of sale. Bion has successfully navigated the USDA PVP application process previously, having received conditional approval of its 2G Tech platform (pending resubmission and final site audits), and is confident it will be successful in qualifying its Gen3Tech platform.

 

After the basic technology start-up milestones of the Initial Project (primarily optimization and steady-state operations of the core modules of our Gen3Tech platform to generate data to support design/development of larger 15,000 head commercial modules) have been met, the core modules may be re-located to a subsequent more permanent location to be determined at a later date. The Company is in discussion with the University of Nebraska-Lincoln to jointly develop an integrated beef facility based on Bion’s Gen3Tech and business model at its Klosterman Feedyard Innovation Center (“KFIC”) (or elsewhere) including innovative barns, an anaerobic digester and a Bion Gen3Tech system to conduct ongoing research and development related thereto and the KFIC is a possible site for the long term re-location of the core modules. This venture, if it moves forward, is anticipated to include joint preparation of applications for grants and other funding from the USDA (‘climate smart’ program, rural development, etc.) and other sources. The Company is also considering re-locating the core modules of the Initial Project to Dalhart, Texas, where they may be integrated into the first phases of the Dalhart Project or a separate smaller organic beef project. 

 

The Company’s initial ammonium bicarbonate liquid fertilizer product completed its Organic Materials Review Institute (“OMRI”) application and review process with listing approval during May 2020. Applications for our first solid ammonium bicarbonate product line with OMRI and the California Department of Food & Agriculture (“CDFA”) have been unsuccessful to date. Later this calendar year (Summer/Fall 2023) the Company intends to pursue further applications for liquid and solid products (of varying nitrogen concentrations) utilizing material produced at the Initial Project. See ‘Fertilizer: Organic and ClimateSmart’ below.

 

Additionally, the Company believes there will also be opportunities to proceed with selected ‘retrofit projects’ of existing facilities (see ‘Gen3Tech Kreider 2 Poultry Project’ below as an example) in the swine, dairy and poultry industries utilizing our Gen3Tech.

 

Bion believes that substantial unmet demand currently exists– potentially very large – for ‘real’ meat/dairy/egg products that offer the verifiable/believable sustainability consumers seek, but with the taste and texture they have come to expect from American beef and pork, dairy and poultry. Numerous studies demonstrate the U.S. consumers’ preferences for sustainability. For example, 2019 NYU Stern’s Center for Sustainable Business study found that ‘products marketed as sustainable grew 5.6 times faster than those that were not…’ and that ‘…in more than 90 percent of consumer-packaged-goods (CPG) categories, sustainability-marketed products grew faster than their conventional counterparts.’ Sales growth of plant-based alternatives, including both dairy and more recently ground meat (Beyond Meat, Impossible Foods, etc.) have shown that a large and growing segment of consumers is choosing seemingly sustainable offering, and are also willing to pay a premium for it. Tyson Foods recently said, “consumers would be willing to pay at least 24 percent more for environmentally friendly, sustainable options at retail.” Numerous studies also support the consumers’ ‘willingness-to-pay’ (WTP) for sustainable choices, including a recent meta-analysis of 80 worldwide studies with results that calculate the overall WTP premium for sustainability is 29.5 percent on average.

 

As one of the largest contributors to some of the greatest air and water quality problems in America, it is clear that livestock waste cleanup, at scale, represents one of the greatest opportunities we have to reduce negative environmental impacts of the food supply chain on air and water quality. Bion’s Gen3Tech platform, along with its business model, will enable the cleanup of one of the ‘dirtiest’ parts of the food supply chain: animal protein production and creates the opportunity to produce and market verifiably sustainable organic and conventional ‘real meat’ products that can participate in the growth and premium pricing that appears to be readily available for the ‘right’ products.

 

Bion believes that at least a premium segment of the U.S. beef industry (and potentially other livestock industry groups) is at the doorstep of a transformative opportunity to address the growing demand for sustainable food product offerings, while pushing back against today’s anti-meat messaging. At $66 billion/year (2021 wholesale/farmgate value), the beef industry is a fragmented, commodity industry whose practices date back decades. In 1935 inflation-adjusted terms, beef was 63% more expensive in 2021, while pork and chicken, which are now primarily raised in covered barns at CAFOs with highly integrated supply chains, were 12% and 62% cheaper, respectively. In recent years, the beef industry has come under increasing fire from advocacy groups, regulatory agencies, institutional investors, and ultimately, their own consumers, over concerns that include climate change, water pollution, food safety, and the treatment of animals and workers.

 

Advocacy groups targeting livestock and the beef industry have recently been joined by competitors that produce animal protein alternatives in seeking to exploit the industry’s environmental and economic weaknesses. Their global anti-meat messaging has had a substantial chilling effect on the relationships the beef industry has with its institutional investors; retail distributors, such as fast-food restaurants; and mostly, its consumers. Led by the United Nations Food and Agriculture Organization, a coordinated anti-meat messaging campaign has targeted consumers worldwide, primarily focused on the industry’s impacts on climate change. Meat alternatives, especially plant-based protein producers like Beyond Meat and Impossible Foods, are being heavily promoted by themselves and the media, and have enjoyed steady sales growth. A 2018 NielsenIQ Homescan survey last year found that 39% of Americans are actively trying to eat more plant-based foods. Some of the recent growth in plant-based proteins results from increasing lactose intolerance and other health concerns; however, most of that growth is attributed to consumers’ growing concerns for the environmental impacts of real meat and dairy. Several large US companies that have traditionally focused on livestock production, including Cargill, ADM, Perdue Foods, and Tyson, have also recently entered the plant protein space. In terms of changing customer preferences, ‘saving the planet’ has proven to be a more compelling argument than the traditional animal activism/ welfare pitch. To date, the primary ‘industry response’ to this has been grass-fed beef, which is regarded as a generally more sustainable offering than grain-fed (largely without empirical evidence). However grass-fed beef has had only limited acceptance in U.S. markets, because it is less flavorful and tougher than the traditional corn-fed beef consumers have grown to enjoy. Sustainability initiatives have been launched by large US livestock producers (including Tyson’s very recent ‘Brazen’ program), but it is not yet possible to determine whether any will be substantive and verifiable rather than completely ‘modeled’ and largely public relations ‘greenwashing’.

 

It should be noted that these plant-based protein producers are primarily expected to be able to serve the ground/ processed meat market, which represents only about 10 percent of the overall animal protein market. Further, there has recently been pushback to these plant-based products, focusing on their highly processed nature and unproven health benefits, scalability/ pricing, and their uncertain carbon footprint---and market growth rates have substantially slowed and may have already plateaued and/or peaked. There have also been several companies recently enter the cellular and 3D-printed meat arena. While facing myriad challenges and further out on the development timeline, some people believe cellular agriculture (aka cultured, clean, lab-grown, cultivated) meat may have the potential to service a much larger percentage of the market than plant-based protein, including cuts like steaks, chops and roasts, but the likely cost remains very uncertain at this point.

 

Each of these items supports Bion’s belief that there is a potentially very large opportunity to supply premium sustainable beef products that satisfy consumer concerns. We believe that the real meat/beef products that can be cost-effectively produced today using our Gen3Tech platform, both sustainable and/or organic, can provide an affordable product that satisfies the consumer’s desire for sustainability, but with the superior taste and texture those consumers have grown to prefer.

 

Sustainable Beef

 

Bion’s goal is to be first to market with meaningfully verified sustainable beef products that can be produced at sufficient scale to service national market demand. The cattle produced at a Bion facility will have a substantially lower carbon footprint, dramatically reduced nutrient impacts to water, and an almost total pathogen kill in the waste stream. Further, the economics of producing these cattle (including the cost of the facility/technology upgrade) will be greatly enhanced by the revenue realized from the recovery of valuable resources, including renewable energy, high-value fertilizer products, and clean water.

 

A Bion sustainable beef facility will be comprised of covered barns with slotted floors (allowing the waste to pass through) which will reduce ammonia and greenhouse gas volatilization and loss, as well as odors, thereby improving animal health and human working conditions while preventing air/soil pollution. The manure will be collected and moved directly to anaerobic digestion facilities which will produce renewable natural gas (and re-cycle CO2 from the gas cleaning process). Covered barns will reduce weather impacts on the livestock and have been demonstrated to promote improved general health and weight gain in the cattle housed in them. The barns’ very large roof surface area will be utilized (in geographical locations with adequate sunshine and appropriate ‘tariffs’) for the installation of photovoltaic solar generation systems to produce electricity for the facility, as well as export to the grid. The barn roofs will also be configured to capture rainwater, which, coupled with the water recovered from the treatment process, will reduce the projects’ reliance on current water supplies.

 

Waste treatment and resource recovery will be provided by Bion’s advanced Gen3Tech platform, which Bion believes offers the most comprehensive solution for livestock waste available today. In addition to direct environmental benefits, every pound of nitrogen that is captured, upcycled, and returned to the agricultural nitrogen cycle as high-quality fertilizer (vs lost to contaminate downstream waters), is also a pound of nitrogen that will not have to be produced as synthetic urea or anhydrous ammonia, with their tremendous carbon cost. System performance and environmental benefits will be monitored and verified through third parties, with USDA PVP certification of the sustainable brand that Bion also believes will be the most comprehensive available in the market.

 

Recently there have been efforts to establish sustainable brands (including USDA PVP certification) for a number of small-scale livestock producers (largely in the grass-fed beef category). To date, the reach and extent of such efforts is limited and it is difficult to determine their effectiveness. Additionally, there have been public announcements of initiatives related to beef sustainability (largely focused on the ‘cow-calf’ segment of the livestock chain) in procurement by major beef processing companies (including Tyson’s very recent ‘Brazen’ program), but a closer look finds that many have consisted largely of ‘green washing’ public proclamations in the wake of environmental and social criticism that re-package prior initiatives and lack any significant new substance.

 

Sustainable Organic Beef

 

Bion also believes it has a unique opportunity to produce, at scale, affordable corn-fed organic beef that is also certified as sustainable. In addition to the sustainable practices described above, organic-sourced beef cows would be finished on organic corn, which would be produced using the ammonium bicarbonate fertilizer captured by the Gen3Tech platform. Bion believes its meat products will meet consumer demands with respect to sustainability and safety (organic) and provide the tenderness and taste American consumers have come to expect from premium conventional American beef. Such products are largely unavailable in the market today. We believe Bion’s unique ability to produce the fertilizer needed to grow a supply of relatively low-cost organic corn, and the resulting opportunity to produce organic beef, will dramatically differentiate us from potential competitors. This organic opportunity is dependent on successfully establishing Bion’s fertilizer products as acceptable for use in organic grain production.

 

Today, organic beef demand is limited and mostly supplied with grass-fed cattle. While organic ground/ chopped meat has enjoyed success in U.S. markets, grass-fed steaks have seen limited acceptance, mostly resulting from consumer issues with taste and texture. In other words, it’s tough. Regardless, such steaks sell for a significant premium over conventional beef. A grain-finished organic beef product is largely unavailable in the marketplace today due to the higher costs of producing organic corn and grain. The exception is offerings that are very expensive from small ‘boutique’ beef producers. Like all plants, corn requires nitrogen to grow. Corn is especially sensitive to a late-season application of readily available nitrogen – the key to maximizing yields. With non-organic field corn, this nitrogen is supplied by an application of a low-cost synthetic fertilizer, such as urea or anhydrous ammonia. However, the cost for suitable nitrogen fertilizer that can be applied late-season in organic corn production is so high that the late-season application becomes uneconomical, resulting in substantially lower yields – a widely recognized phenomena known as the ‘yield gap’ in organic production. The yield gap results in higher costs for organic corn that, in turn, make it uneconomical to feed that corn to livestock. As is the case for sustainable but not organic beef, Bion believes there is a potentially large unmet demand for affordable beef products that are both sustainable AND organic, but with the taste and texture consumers have come to expect from American beef. Bion’s ability to produce the low-cost nitrogen fertilizer that can close the organic yield (and affordability) gap puts the Company in a unique, if not exclusive at this time, position to participate in JV’s that will benefit from this opportunity starting next year.

 

The demonstrated willingness of consumers to purchase sustainable products (along with numerous research and marketing studies confirming consumers are seeking, and are willing to pay a premium for, sustainable products)---in combination with the threat to the livestock industry market (primarily beef and pork) posed by plant-based alternatives (heightened by pandemic conditions)--- has succeeded in focusing the large scale livestock industry on how to meet the plant-based market challenge by addressing the consumer sustainability issues. The consumer demand for sustainability appears to be a real and lasting trend, but consumers remain skeptical of generalized claims of ‘sustainability’. To date, a large portion of the industry responses to this trend have been at a superficial level or consist of ‘green washing’, a deceptive marketing practice where companies promote non-substantive initiatives. Real sustainability for the livestock industry will require implementation of advanced waste treatment technology at or near the CAFOs – where most of the negative environmental impacts take place.

 

Fertilizer: Organic and ‘Climate Smart’

 

The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“Gen3Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of low carbon and/or organically certified soluble nitrogen fertilizer products. The Company’s low concentration ammonium bicarbonate liquid product successfully completed its Organic Materials Review Institute (“OMRI”) application and review process with listing approval during May 2020. During the next 3-6 months the Company intends to file applications for a line of higher concentration (up to 7-10%) liquid ammonium bicarbonate products during the current year based on production during operation of the Initial Project during the next 3-6 months. The Company anticipates applying for and obtaining one or more listings/certifications for higher concentration products in our liquid ammonium nitrogen fertilizer line well prior to operational dates for the Company’s initial large scale JV Gen3Tech Sustainable Beef Projects.

 

Additionally, the Company is exploring the market potential for its fertilizer to be a verifiably ‘ClimateSmart’ product (potentially a much larger market than the organic market). This may require working with industry and academic entities to develop appropriate metrics and producing a ‘life cycle assessment’ (LCA) for Bion’s ammonium nitrogen fertilizer product which can be compared to conventional nitrogen fertilizer products. Bion’s processes will capture and utilize CO2 in the waste stream (including CO2 produced with the renewable natural gas (RNG) by anaerobic digestion) as stabilizing agent thereby potentially creating carbon offsets compared to natural gas utilized as feedstock in chemical ammonia production which reduction will be reflected in the LCA. This LCA will assess environmental impacts associated with fertilizer production in support of the beef cattle supply chain for both the existing conventional approach (primarily fossil fuel-based Haber-Bosch production methods) and the largely decarbonized Bion production approach. We believe a series of coincident yet significant LCA benefits accrue from Bion’s patented fertilizer production approach including the reduced loss of ammonia to the environment via air (volatilized) and water (nitrate in groundwater) pathways, recycled/reused water, elimination of pathogens, the production of renewable natural gas, the production solar energy from photovoltaic panels on barn roofs, enhanced animal welfare practices and reduced animal husbandry risks from extreme weather events. Bion believes that current evaluations of the carbon impact from feedlot operations materially underestimate the negative impacts because existing models do not properly include significant ‘downstream’ carbon impacts of required energy intensive waste water treatment for re-deposited ammonia nitrogen. If the Company determines there is a significant ‘ClimateSmart’ opportunity for our fertilizer products, such an LCA can be completed (based in part on data from the Initial Project) and support marketing efforts well prior to operational dates for the Company’s initial large scale JV Gen3Tech projects.

 

Ammonium bicarbonate, manufactured using thermal and mechanical processes, has a long history of use as a fertilizer. In addition to liquid ammonium nitrogen fertilizer, Bion’s Gen3Tech is capable of recovering nitrogen in the form of solid ammonium bicarbonate products containing up to 18-22 (or higher) percent nitrogen in a crystalline form that is easily transported (while producing liquids with various percentages of ammonium bicarbonate nitrogen during interim stages of the process). This solid product is water soluble and provides a readily available nitrogen source for crops. It will contain virtually none of the other salt, iron and mineral constituents of the livestock waste stream that often accompany other organic fertilizers. This product is being developed to fertilizer industry standards so that it that can be precision-applied to crops using existing equipment. Bion believes that this product will potentially have broad applications in the production of organic and/or ClimateSmart grains for livestock feed, row crops, horticulture, greenhouse and hydroponic production, and potentially retail lawn and garden products.

 

The ammonium bicarbonate products (liquid and solid) produced by Bion’s Gen3Tech platform will enjoy a dramatically lower carbon footprint than synthetic nitrogen fertilizers. The reactive nitrogen captured and upcycled into our fertilizer products was going to be lost through volatilization and runoff, and that loss would generally need to be offset with a synthetic nitrogen fertilizer, such as anhydrous ammonia or urea. These synthetic nitrogen products are produced through the Haber-Bosch (and other) synthetic processes, which converts hydrogen and atmospheric nitrogen to ammonia, with methane from fossil fuels as the energy source. It is an extremely energy-intensive process with a carbon footprint that, while not yet fully understood, is widely accepted to by very large. While a complete Life Cycle Assessment (LCA) of carbon impacts from synthetic fertilizer production is not yet available, according to the Institute for Industrial Productivity, its production alone is responsible for approximately 1 percent of total global CO2 emissions. To the extent that Bion can capture and repurpose the nitrogen traditionally lost from livestock waste, that carbon cost will no longer need to be paid by the environment/climate.

 

Applications for our first solid form of concentrated ammonia, soluble nitrogen fertilizer product line have been filed with OMRI (filed during May 2021) and the California Department of Food & Agriculture (“CDFA”)(filed during May 2022) without success to date. After an extended review processes (which was largely opaque), the OMRI application proceeded through multiple stages without receiving a positive result. The Company believes that OMRI failed to properly follow its own procedures and reached a result without scientific support. The Company has elected to proceed with “Judicial Dispute Resolution” as set forth in the OMRI Policy Manual and has initiated litigation contesting the determination. OMRI filed its Answer to Bion’s Complaint during the first week of May 2023 and the discovery process has now commenced. Recently the Company has also received a negative determination from CDFA. We have initiated an informal dialogue with CDFA regarding the basis for and re-consideration of its initial determination. The Company’s solid product line is novel in part due to the fact that there is not a formal listing category in the organic space for a solid form of concentrated ammonia, soluble nitrogen fertilizers and there is no clear guidance at present from internal policy manuals on how to categorize this product and the process that produces it. There is also no clear guidance at present from either the NOP or the National Organic Standards Board (“NOSB”) (which is currently involved in a related review and recommendations process regarding ‘high nitrogen liquid fertilizers’ derived from ammonia from manure). The Company and its representatives, along with a number of other stakeholders, are involved in discussions regarding resolution of these matters at all three levels. The Company intends to continue efforts to obtain listing/certification for its solid nitrogen fertilizer line over the course of this calendar year.

 

Gen3Tech Kreider 2 Poultry Project

 

Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) (‘Kreider Renewable Energy Facility’ or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). Now that development of the Company’s Gen3Tech is being deployed, the Company has commenced discussions with KF regarding updating and amending the JV agreement and anticipates executing an amended joint venture agreement during 2023. During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA). Note that this Project may also be expanded in the future to treat wastes from other local and regional CAFOs (poultry and/or dairy---including the Kreider Dairy) and/or additional Kreider poultry expansion (some of which may not qualify for nutrient reduction credits). The Company anticipates if and when PA2 re-commences work on the Kreider 2 Project, it will submit a new application based on our Gen3Tech. Site specific design and engineering work for this facility have not commenced, and the Company does not yet have financing in place for the Kreider 2 Project. This opportunity is being pursued through PA2. If there are positive developments related to the market for nutrient reductions in Pennsylvania, of which there is no assurance, the Company intends to pursue development, design and construction of the Kreider 2 Project with a goal of achieving operational status for its initial modules during the following calendar year. The economics (potential revenues and profitability) of the Kreider 2 Project, despite its proposed use of Bion’s Gen3Tech for increased recovery of marketable by-products and sustainable branding, are based in material part the long-term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. However, liquidity in the Pennsylvania nutrient credit market has not yet developed significant breadth and depth, which lack of liquidity has negatively impacted Bion’s business plans and will most likely delay PA2’s Kreider 2 Project and other proposed projects in Pennsylvania.

 

Note that while Bion believes that the Kreider 2 Project and/or subsequent Bion Projects in PA and the Chesapeake Bay Watershed will eventually generate revenue from the sale of: a) nutrient reductions (credits or in other form), b) renewable energy (and related credits), c) sales of fertilizer products, and/or d) potentially, in time, credits for the reduction of greenhouse gas emissions, plus e) license fees/premiums related to a ‘sustainable brand’, the Covid-19 pandemic has delayed legislative efforts needed to commence its development. However, the Company is currently engaged in dialogue with the regional EPA office and the Chesapeake Bay Program Office regarding the potential of the Company’s Gen3Tech Kreider2 Project (and other potential projects) to enable Pennsylvania to move forward toward meeting its Chesapeake Bay clean-up goals. We believe that the potential market is very large, but it is not possible to predict the exact timing and/or magnitude of these potential markets at this time.

 

Technology Deployment: Bion Gen3Tech

 

Widespread deployment of waste treatment technology, and the sustainability it enables, is largely dependent upon generating sufficient additional revenues to offset the capital and operating costs associated with technology adoption. Bion’s Gen3Tech business platform has been developed to create opportunities for such augmented revenue streams, while providing third party verification of sustainability claims. The Gen3Tech platform has been designed to maximize the value of co-products produced during the waste treatment/recovery processes, including pipeline-quality renewable natural gas (biogas) and commercial fertilizer products approved for organic production. All processes will be verifiable by third parties (including regulatory authorities and certifying boards) to comply with environmental regulations and trading programs and meet the requirements for: a) renewable energy and carbon credits, b) organic certification of the fertilizer coproducts and c) USDA PVP certification of an ‘Environmentally Sustainable’ brand (see discussion above and below), and d) payment for verified ecosystem services. The Company’s first patent on its Gen3Tech was issued during 2018. In August 2020, the Company received a Notice of Allowance on its third patent which significantly expands the breadth and depth of the Company’s Gen3Tech coverage. The Company has additional applications pending and/or planned.

 

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

In parallel with technology development, Bion has worked (which work continues) to implement market-driven strategies designed to stimulate private-sector participation in the overall U.S. nutrient and carbon reduction strategy. These market-driven strategies can generate “payment for ecosystem services”, in which farmers or landowners are rewarded for managing their land and operations to provide environmental benefits that will generate additional revenues. Existing renewable energy credits for the production and use of biogas are an example of payment for ecosystem services. Another such strategy is nutrient trading (or water quality trading), which will potentially create markets (in Pennsylvania and other states) that will utilize taxpayer funding for the purchase of verified pollution reductions from agriculture (“nutrient credits”) by the state (or others) through competitively-bid procurement programs. Such credits can then be used as a ‘qualified offset’ by an individual state (or municipality) to meet its federal clean water mandates at significantly lower cost to the taxpayer. Market-driven strategies, including competitive procurement of verified credits, is supported by U.S. EPA, the Chesapeake Bay Commission, national livestock interests, and other key stakeholders. Legislation in Pennsylvania to establish the first such state competitive procurement program passed the Pennsylvania Senate by a bi-partisan majority during March 2019 but has not yet crossed the hurdles required for actual adoption. The Covid-19 pandemic and related financial/budgetary crises have slowed progress for this and other policy initiatives and, as a result, it is not currently possible to project the timeline for completion (or meaningful progress) of this and other similar initiatives (see discussion below).

 

The livestock industry and its markets are already changing. With our commercial-ready technology and business model, Bion believes it has a ‘first-mover advantage’ over others that will seek to exploit the opportunities that will arise from the industry’s inevitable transformation. Bion anticipates moving forward with the development process of its initial commercial installations utilizing its Gen3Tech, during the current 2023 fiscal year. We believe that Bion’s Gen3Tech platform and business model can provide a pathway to true economic and environmental sustainability with ‘win-win’ benefits for at least a premium sector of the livestock industry, the environment, and the consumer, an opportunity which the Company intends to pursue.

 

The Livestock Problem

 

The livestock industry is under tremendous pressure from regulatory agencies, a wide range of advocacy groups, institutional investors and the industry’s own consumers, to adopt sustainable practices. Environmental cleanup is inevitable and has already begun — and policies have already begun to change, as well. Bion’s Gen3Tech was developed for implementation on large scale livestock production facilities, where scale drives both lower treatment costs and efficient co-products production, as well as dramatic environmental improvements. We believe that scale, coupled with Bion’s verifiable treatment technology platform, will create a transformational opportunity to integrate clean production practices at (or close to) the point of production—the primary source of the industry’s environmental impacts. Bion intends to assist the forward-looking segment of the livestock industry to bring animal protein production in line with 21st Century consumer demands for meaningful sustainability.

 

In the U.S. (according to the USDA’s 2017 agricultural census) there are over 9 million dairy cows, 90 million beef cattle, 60 million swine and more than 2 billion poultry which provides an indication of both the scope of the problem addressed by Bion’s technology, as well as the size of Bion’s opportunity. Environmental impacts from livestock production include surface and groundwater pollution, greenhouse gas emissions, ammonia, and other air pollution, excess water use, and pathogens related to foodborne illnesses and antibiotic resistance. While the most visible and immediate problems are related to nutrient runoff and its effects on water quality, the industry has recently been targeted by various stakeholder groups for its impacts on climate change.

 

Estimates of total annual U.S. livestock manure waste vary widely, but start around a billion tons, between 100 and 130 times greater than human waste. However, while human waste is generally treated by septic or municipal wastewater plants, livestock waste – raw manure – is spread on our nation’s croplands for its fertilizer value. Large portions of U.S. feed crop production (and most organic crop production) are fertilized, in part, in this manner. Under current manure management practices, 80% or more of total nitrogen from manure, much of it in the form of ammonia, escapes during storage, transportation, and during and after soil application, representing both substantial lost value and environmental costs.

 

More than half of the nitrogen impacts from livestock waste come from airborne ammonia emissions, which are extremely volatile, reactive and mobile. Airborne ammonia nitrogen eventually settles back to the ground through atmospheric deposition — it ‘rains’ everywhere. While some of this nitrogen is captured and used by plants, most of it runs off and enters surface waters or percolates down to groundwater. It is now well-established that most of the voluntary conservation practices, such as vegetated buffers that ‘filter’ runoff (often referred to as “BMPs” or “Best Management Practices” that have traditionally been implemented to attempt to mitigate nutrient runoff), are considerably less effective than was previously believed to be the case. This is especially true with regard to addressing the volatile and mobile nitrogen from ammonia emissions, because BMPs are primarily focused on surface water runoff, directly from farm fields in current production, versus the re-deposition that takes place everywhere or groundwater flow.

 

Runoff from livestock waste has been identified in most of our major watersheds as a primary source of excess nutrients that fuel algae blooms in both fresh and saltwater. Over the last several years, algae blooms have become increasingly toxic to both humans and animals, such as the Red Tides on the Florida and California coasts, and the Lake Erie algae bloom that cut off the water supply to Toledo, Ohio, residents in 2014. When the nutrient runoff subsides, it leaves the algae blooms with no more ‘food’ and the blooms die. The algae’s decomposition takes oxygen from the water, leading to ‘dead zones’ in local ponds, lakes, and ultimately, the Great Lakes, as well as the Chesapeake Bay, Gulf of Mexico, and other estuary waters. Both the toxic algae blooms and the low/no-oxygen dead zones devastate marine life, from shrimp and fish to higher mammals, including dolphins and manatees. U.S. EPA already considers excess nutrients “one of America’s most widespread, costly and challenging environmental problems”. Nutrient runoff is expected to worsen dramatically in the coming decades due to rising temperatures and increasing rainstorm intensity as a result of climate change.

 

Nitrate-contaminated groundwater is of growing concern in agricultural regions nationwide, where it has been directly correlated with nutrient runoff from upstream agricultural operations using raw manure as fertilizer. Pennsylvania, Wisconsin, California and Washington, and others, now have regions where groundwater nitrate levels exceed EPA standards for safe drinking water. High levels of nitrate can cause blue baby syndrome (methemoglobinemia) in infants and affect women who are or may become pregnant, and it has been linked to thyroid disease and colon cancer. EPA has set an enforceable standard called a maximum contaminant level (MCL) in water for nitrates at 10 parts per million (ppm) (10 mg/L) and for nitrites at 1 ppm (1 mg/L). Federal regulations require expensive pretreatment for community water sources that exceed the MCL; however, private drinking water wells are not regulated, and it is the owners’ responsibility to test and treat their wells. Additionally, groundwater flows also transport this volatile nitrogen downstream where, along its way, it intermixes with surface water, further exacerbating the runoff problem. Like atmospheric deposition, the current conservation practices we rely on to reduce agricultural runoff are largely bypassed by this subsurface flow.

 

Additionally, in arid climates, such as California, airborne ammonia emissions from livestock manure contribute to air pollution as a precursor to PM2.5 formation, small inhalable particulate matter that is a regulated air pollutant with significant public health risks. Whether airborne or dissolved in water, ammonia can only be cost-effectively controlled and treated at the source—before it has a chance to escape into the environment where it becomes extremely expensive to ‘chase’, capture, and treat.

 

High phosphorus concentrations in soils fertilized with raw manure are another growing problem. The ratio of nitrogen to phosphorus in livestock waste is fixed, and because manure application rates are calculated based on nitrogen requirements, often phosphorus is overapplied as an unintended consequence. Phosphorus accumulation in agricultural soils reduces its productivity, increases the risk of phosphorus runoff, and represents a waste of a finite resource. Decoupling the nitrogen from the phosphorus would allow them to be precision-applied, independently of each other, when and where needed.

 

The livestock industry has recently come under heavy fire for its impacts on climate change, which has become a rallying cry for the anti-meat campaign discussed above. Estimates of the magnitude of those impacts vary widely, but the general consensus is that globally, livestock account for 14.5 percent of greenhouse emissions. In the U.S. however, that number drops to 4.2 percent, due to the increased efficiencies of American beef production. The greatest impacts come from direct emissions of methane from enteric fermentation (belches), methane and nitrous oxide emissions from the manure, with arguably the largest being the massive carbon footprint of the synthetic nitrogen fertilizers used to grow the grains to feed the livestock.

 

For decades the livestock industry has overlooked and/or socialized its environmental problems and costs. Today, the impacts of livestock production on public health and the environment can no longer be ignored and are coming under increasing scrutiny from environmental groups and health organizations, regulatory agencies and the courts, the media, consumers, and activist institutional investors. The result has been a significant and alarming loss of market share to plant-based protein and other alternative products. Bion’s Gen3Tech platform was designed to resolve these environmental issues and bring the industry in line with twenty-first century consumer expectations.

 

Going concern and management’s plans:

 

The condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has not generated significant revenues and has incurred net losses of approximately $3,451,000 during the year ended June 30, 2021 and a net income of $8,291,000 for the year ended June 30, 2022. The net income for the year ended June 30, 2022 was largely due to a one-time, non-cash event of the dissolution of PA-1 resulting in a gain of approximately $10,235,000 as well as a one-time gain of $902,000 from the sale of the Company’s ‘biontech.com’ domain pursuant to a purchase agreement during the period. For the nine months ended March 31, 2023, the Company had a net loss of $2,507,305 At March 31, 2023, the Company has a working deficit and a stockholders’ equity of approximately $147,000 and $4,149,000, respectively. During the three months ended March 31, 2023 the Company had debt modifications that resulted in a reduction of debt of $3,516,000 and an increase in equity. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. The following paragraphs describe management’s plans with regard to these conditions.

 

The Company continues to explore sources of additional financing (including potential agreements with strategic partners – both financial and ag-industry) to satisfy its current and future operating and capital expenditure requirements as it is not currently generating any significant revenues.

 

During the years ended June 30, 2022 and 2021, the Company received gross proceeds of approximately $1,737,000 and $5,209,000, respectively, from the sale of its debt and equity securities.

 

During the nine months ended March 31, 2023, the Company received total proceeds of approximately $3,385,000 from the sale of its equity securities. There were $48,000 in cash commissions paid.

 

During fiscal years 2022 and 2021, the Company faced less difficulty in raising equity funding (but was subject to substantial equity dilution from the larger amounts of equity financing during the periods) than was experienced in the prior 3 years. During the first nine months of the current fiscal year, the Company has raised limited equity funds to meet its some of its immediate needs but will need to raise additional funds in the coming periods. The Company anticipates substantial increases in demands for capital and operating expenditures during the second half of the current fiscal year and thereafter as it moves toward commercial implementation of its 3G Tech and development of JVs (including costs associated with additions of personnel to carry out the business activities of the Company) and, therefore, is likely to continue to face significant cash flow management challenges due to limited capital resources and working capital constraints which have only recently begun to be alleviated. To partially mitigate these working capital constraints, the Company’s core senior management and several key employees and consultants have been deferring (and continue to defer) portions of their cash compensation and/or are accepting compensation in part in the form of securities of the Company and/or converting portions of their compensation and deferred compensation to securities of the Company (Notes 5 and 7) and members of the Company’s senior management have made loans to the Company from time to time. During the year ended June 30, 2018, senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $2,404,000. Additionally, the Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again during the year ended June 30, 2018. The constraint on available resources has had, and continues to have, negative effects on the pace and scope of the Company’s efforts to develop its business. At times, the Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company is able to continue its recent relative success in its efforts to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and curtailment of ongoing activities including research and development activities.

 

The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Projects (including the Initial Project, JV Projects (including the Dalhart and Olson Projects),and the Kreider 2 facility) and CAFO Retrofit waste remediation systems. The Company anticipates that it will seek to raise from $20,000,000 to $80,000,000 or more debt and/or equity through joint ventures, strategic partnerships and/or sale of its equity securities (common, preferred and/or hybrid) and/or debt (including convertible) securities, and/or through use of ‘rights’ and/or warrants (new and/or existing) and/or through other means during the next twelve months. However, as discussed above, there is no assurance, especially in light of the difficulties the Company has experienced in many recent years and the extremely unsettled capital markets that presently exist for small companies like us, that the Company will be able to obtain the funds that it needs to stay in business, complete its technology development or to successfully develop its business and Projects.

 

There is no realistic likelihood that funds required during the next twelve months (or in the periods immediately thereafter) for the Company’s basic operations, the Initial Project and/or proposed JVs and/or Projects will be generated from operations. Therefore, the Company will need to raise sufficient funds from external sources such as debt or equity financings or other potential sources. The lack of sufficient additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company’s existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for small companies like Bion.

 

Covid-19 pandemic related matters:

 

The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.

 

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.1
SIGNIFICANT ACCOUNTING POLICIES
9 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES

2.       SIGNIFICANT ACCOUNTING POLICIES

 

Principles of consolidation:

 

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its 58.9% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.

 

The accompanying condensed consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements reflect all adjustments (consisting of only normal recurring entries) that, in the opinion of management, are necessary to present fairly the financial position at March 31, 2023, the results of operations of the Company for the three and nine months ended March 31, 2023 and 2022 and the cash flows of the Company for the nine months ended March 31, 2023 and 2022. Operating results for the three and nine months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending June 30, 2023.

 

Cash and cash equivalents:

 

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of March 31, 2023 and June 30, 2022 there are no cash equivalents.

 

Property and equipment:

 

Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects such as consulting fees, internal salaries and benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.

 

Patents:

 

The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s condensed consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.

 

Stock-based compensation:

 

The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.

 

Derivative Financial Instruments:

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.

 

Options:

 

The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.

 

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

Concentrations of credit risk:

 

The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.

 

Noncontrolling interests:

 

In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the condensed consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the condensed consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.

 

Fair value measurements:

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.

 

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;

 

Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

 

Level 3 – assets and liabilities whose significant value drivers are unobservable.

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.

 

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the condensed consolidated statements of operations over the lease term.

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s condensed consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.

 

Revenue Recognition:

 

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.

 

Income (Loss) per share:

 

Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the three and nine months ended March 31, 2023 and 2022, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.

 

The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:

 

          
   March 31,
2023
   March 31,
2022
 
Warrants   21,944,437    19,078,635 
Options   11,506,600    10,481,600 
Convertible debt   10,052,765    10,847,026 
Convertible preferred stock            

 

The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the three and nine months ended March 31, 2023 and 2022:

 

                    
   Three months
ended
March 31,
2023
   Three months
ended
March 31,
2022
   Nine months
ended
March 31,
2023
   Nine months
ended
March 31,
2022
 
Shares issued – beginning of period   44,529,884    43,733,850    43,758,820    41,315,986 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)   (704,309)   (704,309)
Shares outstanding – beginning of period   43,825,575    43,029,511    43,054,511    40,611,677 
Weighted average shares issued
    during the period
   1,630,842          1,110,798    990,713 
Diluted weighted average shares –
    end of period
   45,456,417    43,029,511    44,165,309    40,904,342 

 

Use of estimates:

 

In preparing the Company’s condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements:

 

The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its condensed consolidated financial statements and assures that there are proper controls in place to ascertain that the Company’s condensed consolidated financial statements properly reflect the change.

 

 

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.1
PROPERTY AND EQUIPMENT:
9 Months Ended
Mar. 31, 2023
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT:

3.  PROPERTY AND EQUIPMENT:

 

Property and equipment consist of the following:

 

          
   March 31,
2023
   June 30,
2022
 
Computers and office equipment   15,156    13,598 
Initial Project: construction in process   5,784,494    2,892,222 
Property and equipment, gross   5,799,650    2,905,820 
Less accumulated depreciation   (11,447)   (10,262)
 Property and equipment, net  $5,788,203   $2,895,558 

 

The 3G1 project (“Initial Project”) began in July of 2021, with a lease signed on land October 1, 2021 (Note 9). Once the lease commenced the Company moved into construction phase. The balance for the Initial Project construction in process includes $149,342 for capitalized interest and $135,648 in non-cash compensation as of March 31, 2023.

 

Management has reviewed the remaining property and equipment for impairment as of March 31, 2023 and believes that no impairment exists.

 

Depreciation expense was $461 and $252 for the three months ended March 31, 2023 and 2022, respectively and $1,185 and $832 for the nine months ended March 31, 2023 and 2022, respectively.

 

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.1
DEFERRED COMPENSATION:
9 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
DEFERRED COMPENSATION:

4.       DEFERRED COMPENSATION:

The Company owes deferred compensation to various employees, former employees and consultants totaling $784,255 and $525,699 as of March 31, 2023 and 2022, respectively. Included in the deferred compensation balances as of March 31, 2023, are $504,401 and $5,000 owed Dominic Bassani (“Bassani”), the Company’s Chief Operating Officer (who was Chief Executive Officer until through April 30, 2022), and Mark A. Smith (“Smith”), the Company’s President, respectively, pursuant to extension agreements effective January 1, 2015, whereby unpaid compensation earned after January 1, 2015, accrues interest at 4% per annum and can be converted into shares of the Company’s common stock at the election of the employee during the first five calendar days of any month. The conversion price shall be the average closing price of the Company’s common stock for the last 10 trading days of the immediately preceding month. The deferred compensation owed Bassani and Smith as of March 31, 2022 was $410,585 and nil, respectively. The Company also owes various consultants and an employee, pursuant to various agreements, for deferred compensation of $92,355 and $42,614 as of March 31, 2023 and 2022, respectively, with similar conversion terms as those described above for Bassani and Smith, with the exception that the interest accrues at 0% to 3% per annum. The Company also owes a former employee $72,500, which is not convertible and is non-interest bearing. Bassani and Smith have each been granted the right to convert up to $300,000 of deferred compensation balances at a price of $0.75 per share until June 30, 2024 into common shares (to be issued pursuant to the 2006 Plan). Smith also has the right to convert all or part of his deferred compensation balance into the Company’s securities (to be issued pursuant to the 2006 Plan) “at market” and/or on the same terms as the Company is selling or has sold its securities in its then current (or most recent if there is no current) private placement. Smith also received the right to transfer future deferred compensation to his 2020 Convertible Obligation at his election but such right is no longer in force.

Bill O’Neill has a balance of $110,000 and nil at March 31, 2023 and 2022, respectively. There is no interest or conversions on the deferred balance. During the three and nine months ended March 31, 2023, Smith elected to convert $30,000 and $90,000, respectively, of deferred compensation into the 2020 Convertible Note.

The Company recorded interest expense of $5,034 ($4,428 with related parties) and $3,824 ($3,570 with related parties) for the three months ended March 31, 2023 and 2022, respectively, and $14,458 ($12,893 with related parties) and $12,124 ($11,615 with related parties) for the nine months ended March 31, 2023 and 2022, respectively.

  

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.1
LOANS PAYABLE:
9 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
LOANS PAYABLE:

5.       LOANS PAYABLE:

 

Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s condensed consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s condensed consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer condensed consolidated and included in the Company’s balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436). The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s condensed consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest described above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE NOTES PAYABLE - AFFILIATES:
9 Months Ended
Mar. 31, 2023
Convertible Notes Payable - Affiliates  
CONVERTIBLE NOTES PAYABLE - AFFILIATES:

6.       CONVERTIBLE NOTES PAYABLE - AFFILIATES:

 

2020 Convertible Obligations

 

The 2020 Convertible Obligations, which accrue interest at either 4% per annum or 4% compounded quarterly and effective January 1, 2020 are due and payable on July 1, 2024. The 2020 Convertible Obligations (including accrued interest, plus all future deferred compensation added subsequently), are convertible, at the sole election of the holder, into Units consisting of one share of the Company’s common stock and one half to one warrant to purchase a share of the Company’s common stock, at a price of $0.50 per Unit until July 1, 2024. The original conversion price of $0.50 per Unit approximated the fair value of the Units at the date of the agreements; therefore, no beneficial conversion feature exists. Management evaluated the terms and conditions of the embedded conversion features based on the guidance of ASC 815-15 “Embedded Derivatives” to determine if there was an embedded derivative requiring bifurcation. An embedded derivative instrument (such as a conversion option embedded in the deferred compensation) must be bifurcated from its host instruments and accounted for separately as a derivative instrument only if the “risks and rewards” of the embedded derivative instrument are not “clearly and closely related” to the risks and rewards of the host instrument in which it is embedded. Management concluded that the embedded conversion feature of the deferred compensation was not required to be bifurcated because the conversion feature is clearly and closely related to the host instrument, and because of the Company’s limited trading volume that indicates the feature is not readily convertible to cash in accordance with ASC 815-10, “Derivatives and Hedging”. Effective February 1, 2023, a large portion of the 2020 Convertible Obligations were adjusted as set forth below.

 

As of March 31, 2023, the remaining unadjusted portion of the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts (and his donees), Smith and Edward Schafer (“Schafer”), a director of the Company, were $358,151, $36,072 and nil, respectively. As of March 31, 2022, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts, Smith and Schafer were $2,573,716, $1,315,069 and $494,736, respectively.

 

During the nine months ended March 31, 2023 (on dates prior to the adjustment on February 1, 2023), Smith elected to add $90,000 of his salary and $23,943 in accounts payable for reimbursable expenses to his 2020 Convertible Obligations.

 

During the nine months ended March 31, 2023 (on dates prior to the adjustment on February 1, 2023), Smith elected to convert $30,000 in principal of the 2020 Convertible Obligation to 60,000 units (60,000 common shares and 60,000 warrants), and $20,000 of accrued interest of the 2020 Convertible Obligation to 40,000 units (40,000 common shares and 40,000 warrants). The warrants are exercisable for three years from conversion date.

 

 

The Company recorded interest expense of $16,208 and $6,366 for the three months ended March 31, 2023 and 2022, respectively. The Company recorded interest expense of $98,948 and $17,430 for the nine months ended March 31, 2023 and 2022, respectively. The Company capitalized $51,238 and nil related to the Initial Project for the three months ended March 31, 2023 and 2022, respectively. The Company capitalized $117,342 and nil related to the Initial Project for the nine months ended March 31, 2023 and 2022, respectively.

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long-term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes) owed to them by the Company in a manner which reduces the indebtedness of the Company by 80% (approximately $3.47 million, in aggregate) while equitably maintaining existing conversion rights.  Mark A. Smith (the Company’s President) (“Smith”), Dominic Bassani (the Company’s Chief Operating Officer) (“Bassani”) and Ed Schafer (Director) (“Schafer”), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations (see below).

 

September 2015 Convertible Notes

 

During the year ended June 30, 2016, the Company entered into September 2015 Convertible Notes with Bassani, Schafer and a Shareholder which replaced previously issued promissory notes. The September 2015 Convertible Notes bear interest at 4% per annum, have maturity dates of July 1, 2024, and may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.60 per share. As the conversion price of $0.60 approximated the fair value of the common shares at the date of the September 2015 Convertible Notes, no beneficial conversion feature exists.

 

The balances of the September 2015 Convertible Notes as of March 31, 2023, including accrued interest owed Bassani, Schafer and Shareholder, are $157,682, nil and $457,094, respectively. The balances of the September 2015 Convertible Notes as of March 31, 2022, including accrued interest, were $276,944, $20,681 and $441,977, respectively.

 

The Company recorded interest expense of $5,507 and $5,366 for the three months ended March 31, 2023 and 2022, respectively. The Company recorded interest expense of $18,239 and $17,430 for the nine months ended March 31, 2023 and 2022, respectively.

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including the September 2015 Convertible Notes owned by Bassani and Schafer) owed to them by the Company in a manner which reduces the indebtedness of the Company by 80% (approximately $3.47 million, in aggregate) while equitably maintaining existing conversion rights.  Mark A. Smith (the Company’s President), Dominic Bassani (the Company’s Chief Operating Officer)(and a family Trust) and Ed Schafer (Director), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively.

 

Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes) owed to them by the Company in a manner which reduces the indebtedness of the Company by 80% (approximately $3.47 million, in aggregate) while equitably maintaining existing conversion rights.  Mark A. Smith (the Company’s President)(“Smith”), Dominic Bassani (the Company’s Chief Operating Officer)(“Bassani”) and Ed Schafer (Director)(“Schafer”), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes. The Adjusted 2020 Convertible Obligations of Smith, Bassani and Schafer are convertible into Units at prices of $.0946, $0953, and $.0953, respectively, and the Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.115 per share. The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (July 1, 2024). Effective February 1, 2023 the Company owed Smith, Bassani (and trust) and Schafer $262,154, $434,016 and $96,364 of Adjusted 2020 Convertible Obligations and Bassani and Schafer $24,230 and $4,012 of Adjusted September 2015 Convertible Notes.

 

Effective March 8, 2023, Smith converted $70,000 of his Adjusted 2020 Convertible Obligation into 739,958 Units (each Unit consisting one share and one warrant). Effective March 31, 2023, Smith converted $29,888.64 of his Adjusted Convertible Obligation into 315,948 Units (each Unit consisting one share of common stock and one warrant). Smith donated to charitable organizations and/or gifted to family members and others a large portion of these securities (450,000 common shares and 705,000 warrants, in aggregate) while retaining direct ownership of 255,906 common shares and 79,958 warrants and indirect ownership of 350,000 common shares and 270,948 warrants (owned by his wife). The warrants are exercisable for three years from conversion date.

 

As of March 31, 2023, the Adjusted 2020 Convertible Obligation balances, including accrued interest, owed Bassani (and his donees), Smith and Edward Schafer were $436,988, $164,060 and $97,024, respectively.

 

As of March 31, 2023 the Adjusted September 2015 Convertible Notes balances, including accrued interest, owed Bassani Family Trusts and Schafer were $24,396 and $4,039, respectively.

 

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS' EQUITY:
9 Months Ended
Mar. 31, 2023
Equity [Abstract]  
STOCKHOLDERS' EQUITY:

7.       STOCKHOLDERS' EQUITY:

 

Debt Modification to Additional Paid in Capital

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes) owed to them by the Company in a manner which reduces the indebtedness of the Company by 80% (approximately $3.47 million, in aggregate) while equitably maintaining existing conversion rights.  Mark A. Smith (the Company’s President)(“Smith”), Dominic Bassani (the Company’s Chief Operating Officer)(“Bassani”) and Ed Schafer (Director)(“Schafer”), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes. The Adjusted 2020 Convertible Obligations of Smith, Bassani and Schafer are convertible into units at prices of $.0946, $0953, and $.0953, respectively, and the Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.115 per share. The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (July 1, 2024). The Company treated this as an equity transaction and recorded the reduction of debt through addiotnal paid in capital at the net present value of the modified debt agreements. This resulted in an increase to Additional Paid in Capital of $3,521,000 at the modification date and a reduction of additional paid in capital of $5,620 for the three months ended March 31, 2023 for the adjustment to the net present value of the modified debt agreements.

 

 

Series B Preferred stock:

 

Since July 1, 2014, the Company had 200 shares of Series B redeemable convertible Preferred stock outstanding with a par value of $0.01 per share, convertible at the option of the holder at $2.00 per share, with dividends accrued and payable at 2.5% per quarter. The Series B Preferred stock is mandatorily redeemable at $100 per share by the Company three years after issuance and accordingly was classified as a liability. The 200 shares had reached their redemption date and the Company approved the redemption of the Series B preferred stock during the year ended June 30, 2022. The 200 shares of Series B redeemable convertible Preferred stock were redeemed for $41,000, which included the $21,000 in accrued dividend payable.

 

During the years ended June 30, 2022, and 2021, the Company declared dividends of $1,000 and $2,000 respectively. The dividends are classified as a component of operations as the Series B Preferred stock is presented as a liability in these financial statements. There is no liability at March 31, 2023.

 

Common stock:

 

Holders of common stock are entitled to one vote per share on all matters to be voted on by common stockholders. In the event of liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to share in all assets remaining after liabilities have been paid in full or set aside and the rights of any outstanding preferred stock have been satisfied. Common stock has no preemptive, redemption or conversion rights. The rights of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of any outstanding series of preferred stock or any series of preferred stock the Company may designate in the future.

 

Centerpoint holds 704,309 shares of the Company’s common stock. These shares of the Company’s common stock held by Centerpoint are for the benefit of its shareholders without any beneficial interest.

 

During the three months ended December 31, 2022, the Company entered into a subscription agreement to sell 2,000,000 shares of restricted and legended common stock of which 1,800,000 shares were purchased on January 10, 2023 (the other 200,000 shares were purchased on December 31, 2022) for total proceeds during the nine month period ending March 31, 2023 of $2,000,000.

 

During the three months ended March 31, 2023, the Company entered into subscription agreements to sell 575,000 units at a price of $1.60, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $2.40 per share with an expiry date of June 30, 2024, and pursuant thereto, the Company issued 575,000 units for total proceeds of $920,000, in aggregate. The Company paid commissions of $48,000 on the sale of units.

During the three months ended March 31, 2023, 84,000 warrants were exercised to purchase 84,000 shares of the Company’s common stock at $0.75 per share for total proceeds of $63,000.

During the three months ended March 31, 2023, Smith elected to convert $99,889 in principal of his Adjusted 2020 Convertible Obligation into 1,055,906 units at $0.0946 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until March 2026.

 

During the nine months ended March 31, 2023, the Company entered into subscription agreements to sell units for $1.00 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share with an expiry date of December 31, 2024, and pursuant thereto, the Company issued 346,230 units for total proceeds of $346,230.

 

During the nine months ended March 31, 2023, the Company entered into a subscription agreement to sell 2,000,000 shares of restricted and legended common stock of which 1,800,000 shares were purchased on January 10, 2023 (the other 200,000 shares were purchased on December 31, 2022) for total proceeds during the nine-month period ending March 31, 2023 of $2,000,000.

 

During the nine months ended March 31, 2023, the Company entered into subscription agreements to sell 575,000 units at a price of $1.60, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $2.40 per share with an expiry date of June 30, 2024, and pursuant thereto, the Company issued 575,000 units for total proceeds of $920,000, in aggregate. The Company paid commissions of $48,000 on the sale of units.

During the nine months ended March 31, 2023, 158,834 warrants were exercised to purchase 158,834 shares of the Company’s common stock at $0.75 per share for total proceeds of $119,125.

During the nine months ended March 31, 2023, the Company issued 50,000 shares of the Company’s common stock to a consultant for services. The shares were issued at $1.60 per share for a total value of $80,000.

During the nine months ended March 31, 2023, Smith elected to convert $30,000 in principal and $20,000 in accrued interest from the 2020 Convertible Obligation to 100,000 units at $.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until December 31, 2024.

 

 Warrants:

 

As of March 31, 2023, the Company had approximately 21.9 million warrants outstanding, with exercise prices from $0.60 to $2.40 and expiring on various dates through November 9, 2026.

 

The weighted-average exercise price for the outstanding warrants is $0.78, and the weighted-average remaining contractual life as of March 31, 2023 is 1.8 years.

 

During the nine months ended March 31, 2023, Smith elected to convert $30,000 in principal and $20,000 in accrued interest from the 2020 Convertible Obligation to 100,000 units at $.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until three years after the date of conversion.

 

During the nine months ended March 31, 2023, Smith converted $70,000 of his Adjusted 2020 Convertible Obligation into 739,958 Units (each Unit consisting one share and one warrant) and converted $29,889 of his Adjusted Convertible Obligation into 315,948 Units (each Unit consisting one share of common stock and one warrant). Smith donated to charitable organizations and/or gifted to family members and others a large portion of these securities (450,000 common shares and 705,000 warrants, in aggregate) while retaining direct ownership of 255,906 common shares and 79,958 warrants and indirect ownership of 350,000 common shares and 270,948 warrants (owned by his wife). The warrants are exercisable for three years from conversion date.

 

During the nine months ended March 31, 2023, the Company approved the issuance of 210,000 warrants, in aggregate, to three new members of its Advisory Group for advisory and/or consulting services of $21,000, in aggregate. The warrants are exercisable at $1.50 to $1.60 and expire in August 2025.

During the nine months ended March 31, 2023, the Company approved the modification of existing warrants held by one former consultant and investors, which extended certain expiration dates. The modifications resulted in incremental non-cash compensation of $154,932 and interest expenses of $72,589.

During the nine months ended March 31, 2023, 158,834 warrants were exercised to purchase 158,834 shares of the Company’s common stock at $0.75 per share for total proceeds of $119,125.

 

Effective May 1, 2022, an entity affiliated with William O’Neill (“O’Neill”) was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise bonus if the terms set forth therein are met.

 

The 700,000 of the warrants are vesting through May 1, 2023 and 2024. The vesting resulted in non-cash compensation of $9,844 and $36,094 during the three and nine months ended March 31, 2023.

 

Stock options:

 

On April 7, 2022 the Company’s shareholders approved the Bion Environmental Technologies, Inc. 2021 Equity Incentive Award Plan (the “Equity Plan”). The Equity Plan provides for the issuance of options (and/or other securities) to purchase up to 30,000,000 shares of the Company’s common stock. The Equity Plan was adopted and ratified by Board of Directors on April 8, 2022. Terms of exercise and expiration of options/securities granted under the Equity Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. No grants have been made pursuant to the Equity Plan as of the date of this report.

 

The Company’s 2006 Consolidated Incentive Plan, as amended during the year ended June 30, 2021 (the “2006 Plan”), provides for the issuance of options (and/or other securities) to purchase up to 36,000,000 shares of the Company’s common stock. Terms of exercise and expiration of options/securities granted under the 2006 Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. The 2006 Plan will be maintained to service grants already made thereunder (together with new grants, if any, to employees and consultants who already has received grants pursuant to its terms,

 

On February 11, 2022, the Company granted 10,000 options under the 2006 Plan to one consultant.

 

On April 29, 2022, the Company granted an aggregate of 720,000 options under the 2006 Plan to seven employees/consultants/directors including: i) 50,000 options each to Schafer and Northrop for service as directors, ii) 200,000 options to Bassani (now COO of the Company and formerly CEO) and iii) 200,000 options to Smith, the Company’s President, which new option grants are included in the presentation below.

 

The Company recorded compensation expense related to employee stock options of $220,510 and $4,650 for both the three and nine months ended March 31, 2023 and 2022, respectively. The Company granted 305,000 and 10,000 options for both the three and nine months ended March 31, 2023 and 2022, respectively.

 

A summary of option activity under the 2006 Plan for nine months ended March 31, 2023 is as follows:

                      
    Options   Weighted-
Average
Exercise
Price
   Weighted-
Average
Remaining
Contractual
Life
   Aggregate
Intrinsic
Value
 
 Outstanding at July 1, 2022    11,201,600   $0.80    2.7   $4,429,263 
   Granted    305,000                 
   Exercised                       
   Forfeited                       
   Expired                       
 Outstanding at March 31, 2023    11,506,600   $0.82    2.02   $10,238,395 

 

The total fair value of stock options that vested during both the three and nine months ended March 31, 2023 and 2022 was $220,510 and $4,650, respectively. As of March 31, 2023, the Company had no unrecognized compensation cost related to stock options.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSCRIPTION RECEIVABLE - AFFILIATES:
9 Months Ended
Mar. 31, 2023
Subscription Receivable - Affiliates  
SUBSCRIPTION RECEIVABLE - AFFILIATES:

8.       SUBSCRIPTION RECEIVABLE - AFFILIATES:

 

As of March 31, 2023, the Company has three interest bearing, secured promissory notes with an aggregate principal amount of $428,250 ($513,282, including interest) from Bassani which were received as consideration for purchases of warrants to purchase 5,565,000 shares, in aggregate, of the Company’s restricted common stock, which warrants have an exercise price of $0.75 and have expiry dates ranging from December 31, 2024 to December 31, 2025. The promissory notes bear interest at 4% per annum and are secured by portions of Bassani Family Trust’s 2020 Convertible Obligation and Bassani Family Trust’s September 2015 Convertible Notes. The secured promissory notes are payable July 1, 2024.

 

As of March 31, 2023, the Company has an interest bearing, secured promissory note for $30,000 ($35,586 including interest) from Smith as consideration to purchase warrants to purchase 300,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of December 31, 2024. The warrants have a 75% exercise bonus and the promissory note bears interest at 4% per annum, and is secured by $30,000 ($35,714, including interest) of Smith’s 2020 Convertible Obligations. The secured promissory note is payable on July 1, 2024.

As of March 31, 2023 the Company has two interest bearing, secured promissory notes with an aggregate principal amount of $46,400 ($56,396 including interest) from two former employees as consideration to purchase warrants to purchase 928,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.75 and have expiry dates of December 31, 2024. These warrants have a 90% exercise bonus. The promissory notes bear interest at 4% per annum, are secured by a perfected security interest in the warrants, and are payable on July 1, 2024.

These secured promissory notes are recorded as “Subscription receivable—affiliates” on the Company’s balance sheet pending payment.

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES:
9 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES:

9.       COMMITMENTS AND CONTINGENCIES:

 

Employment and consulting agreements:

 

Smith has held the positions of Director, Executive Chairman, President and General Counsel of Company and its subsidiaries under various agreements (and extensions) and terms since March 2003. On October 10, 2016, the Company approved a month to month contract extension with Smith which includes provisions for i) a monthly salary of $18,000 until the Board of Directors re-instates cash payments to all employees and consultants who are deferring compensation, ii) the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, until December 31, 2024, and iii) the right to convert his deferred compensation in whole or in part, at his sole election, at any time in any amount at “market” or into securities sold in the Company’s current/most recent private offering at the price of such offering to third parties. Smith agreed effective July 29, 2018 to continue to serve the Company under the same basic terms on a month-to-month basis. On May 1, 2022 Smith’s compensation was increased to $25,000 per month of which $5,000 per month is deferred. For the three months ended March 31, 2023 and 2022, Smith was paid $40,000 and $18,000, respectively, of cash compensation. For the nine months ended March 31, 2023 and 2022, Smith was paid $140,000 and $72,000, respectively, of cash compensation.

 

Since March 31, 2005, the Company has had various agreements with Bassani (and/or Brightcap which provided his services during some of the initial years), now the Company’s Chief Operating Officer (‘COO’) and formerly the Company’s Chief Executive Officer (‘CEO’), (any reference to Brightcap or Bassani for all purposes are the same individual). The Board appointed Bassani as the Company's CEO effective May 13, 2011. On February 10, 2015, the Company executed an Extension Agreement with Bassani pursuant to which Bassani extended the term of his service to the Company to December 31, 2017, (with the Company having an option to extend the term an additional six months.) Pursuant to the Extension Agreement, Bassani continued to defer his cash compensation ($31,000 per month) until the Board of Directors re-instates cash payments to all employees and consultants who are deferring their compensation. During October 2016 Bassani was granted the right to convert up to $125,000 of his deferred compensation, at his sole election, at $0.75 per share, until March 15, 2018 (which was expanded on April 27, 2017 to the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, until June 30, 2024 (including extensions). During February 2018, the Company agreed to the material terms for a binding two-year extension agreement for Bassani’s services as CEO. Bassani’s salary remained $31,000 per month, which will continue to be accrued in part until there is adequate cash available. Additionally, the Company has agreed to pay him $2,000 per month to be applied to life insurance premiums (which sums have been accrued as liabilities). On August 1, 2018, in the context of extending his agreement to provide services to the Company on a full-time basis through December 31, 2022) plus 2 years after that on a part-time basis, the Company received an interest bearing secured promissory note for $300,000 from Bassani as consideration to purchase warrants to purchase 3,000,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of June 30, 2025. The promissory note is secured by a portion of Bassani’s 2020 Convertible Obligations and as of March 31, 2023, the principal and accrued interest was $358,151. For the three months ended March 31, 2023 and 2022, Brightcap was paid $75,000 and $60,000, respectively, of cash compensation. For the nine months ended March 31, 2023 and 2022, Brightcap was paid $225,000 and $184,764, respectively, of cash compensation.

William O’Neill (“O’Neill”) was hired as the Company’s Chief Executive Officer (“CEO”) effective May 1, 2022.  O’Neill had previously been working with the Company as a consultant and had been employed by the Company as its CEO during 2010-2011. Bassani, CEO of the Company since 2011, has assumed the position of COO while retaining existing operational management responsibilities and working with O’Neill on ‘commercialization’ of the Company’s technology and work related to JVs (and other transactions) based on the Company’s Gen3 Technology and related matters. Bassani’s compensation arrangements with the Company have not been altered in the context of the change of positions. The Company and O’Neill have entered into a thirty-seven (37) month employment agreement (subject to Board renewal for the final two (2) years during the 13th month ) with compensation of $25,000 cash and $10,000 deferred compensation per month. The cash payment is paid $12,500 to O’Neill and $12,500 to an entity affiliated with O’Neill. An entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise bonus if the terms set forth therein are met.  For the three months ended March 31, 2023 and 2022, O’Neill and the entity affiliated with O’Neill was paid $75,500 and nil , respectively, of cash compensation. For the nine months ended March 31, 2023 and 2022, O’Neill was paid $150,000 and nil , respectively, of cash compensation.

 

Execution/exercise bonuses:

 

As part of agreements the Company entered into with Bassani and Smith effective May 15, 2013, they were each granted the following: a) a 50% execution/exercise bonus which shall be applied upon the effective date of the notice of intent to exercise (for options and warrants) or issuance event, as applicable, of any currently outstanding and/or subsequently acquired options, warrants and/or contingent stock bonuses owned by each (and/or their donees) as follows: i) in the case of exercise by payment of cash, the bonus shall take the form of reduction of the exercise price; ii) in the case of cashless exercise, the bonus shall be applied to reduce the exercise price prior to the cashless exercise calculations; and iii) with regard to contingent stock bonuses, issuance shall be triggered upon the Company’s common stock reaching a closing price equal to 50% of currently specified price; and b) the right to extend the exercise period of all or part of the applicable options and warrants for up to five years (one year at a time) by annual payments of $.05 per option or warrant to the Company on or before a date during the three months prior to expiration of the exercise period at least three business days before the end of the expiration period. Effective January 1, 2016 such annual payments to extend warrant exercise periods have been reduced to $.01 per option or warrant. These exercise bonuses were subsequently increased to 75%.

 

During the year ended June 30, 2021, the Company added a 75% execution/exercise bonus to the terms of 3,000,000 warrants held by a trust owned by Bassani.

 

As of March 31, 2023, the execution/exercise bonuses ranging from 50-90% were applicable to 11,114,600 of the Company’s outstanding options and 18,438,339 of the Company’s outstanding warrants.

 

Effective May 1, 2022, an entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise bonus if the terms set forth therein are met.

 

Purchase Order Agreement and Initial Project:

 

On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $2,665,500 (and made the initial 25% payment ($666,375) for the core of the ‘Bion System’ portion (without the crystallization  modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. The Company received progress billing in March 2022 and June 2022 for the second and third 25% installments, both of which have been paid as of the filing date. On January 17, 2023 the Company received an invoice from Buflovak for $533,100 which was paid on March 1, 2023 bringing the aggregate payments to $2,532,225 as of the date of this filing. There remains $133,275 open on the Purchase Order of which $86,275 has been billed in April and the remaining $50,000 will be invoiced at the completion of the project.

 

Buflovak has worked with the Company on design and testing of its 3G Tech over several years. The basic design for the Initial Project’s Bion System is complete, fabrication and delivery of equipment from Bufflovak from the Purchase Order Agreement has been largely completed and assembly/construction is in process.  3G1 is working in concert with Integrated Engineering Services, the primary site engineering firm for the facility, on the integration of all project components/modules at the Initial Project site. Additional agreements have been entered into various professional services providers (engineers, surveyors, utilities, etc.) for work related to the Initial Project. The Company has incurred costs of $5,164,256 on the Initial Project, not including capitalized labor and interest.

 

Litigation:

 

A: Website: Domain Sale/Resolved Litigation/Hacking/Theft

 

 On March 23, 2022 the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490. The Company has been using www.bionenviro.com as its primary website (and domain) since July 2021 due to the events described below. The Company has not been using biontech.com as its primary website since July 2021 so domain name <biontech.com> no longer represented a core asset of the Company.

 

As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the <biontech.com> domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.

 

On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name <biontech.com> ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name <biontech.com> to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).

 

No shareholder, sensitive or confidential information was available to be breached which has limited damages from the hack/theft to date. However, the Company’s email operations were subjected to disruption and expenses were incurred related to the matter including legal fees.

 

The Company created ‘work-arounds’ as a result. These issues have been resolved and the Company has moved our website (and email) to a new domain: bionenviro.com. Website access is now www.bionenviro.com. To send emails to Bion personnel, one uses the same name identifier previously used, but in the address, substitute ‘bionenviro.com’ for “biontech.com’: For example cscott@biontech.com (no longer functional) is cscott@bionenviro.com and mas@biontech.com (no longer functional) is now mas@bionenviro.com.

 

B: Pennvest Loan and Dissolution of Bion PA1, LLC (“PA1”)

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s condensed consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s condensed consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s condensed consolidated balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s condensed consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest set forth above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception, and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

C: OMRI Litigation

 

On February 23, 2023 the Company filed ‘Complaint for Declaratory Judgment and Injunctive Relief’ against the Organic Materials Review Institute (“OMRI”) in the Circuit Court for the State of Oregon for the County of Lane to contest OMRI’s negative determination with regard to the Company’s application for listing of its solid ammonium bicarbonate product. The Company alleges that OMRI failed to properly follow its own procedures and reached a result without scientific support. The Company has elected to proceed with “Judicial Dispute Resolution” as set forth in the OMRI Policy Manual and has initiated litigation contesting the determination. The Company has requested declaratory relief from the court. OMRI filed its Answer to the Complaint during the first week of May 2023 and the discovery process has now commenced. See Note 1 “Fertilizer: Organic and ‘Climate Smart’” above.

 

The Company currently is not involved in any other material litigation or similar events.

 

Lease:

 

The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.

 

The requirement for payment of Lease obligations commenced January 1, 2023 and the Company is awaiting a rent invoice. The sum of $18,750 has been accrued as a current liability for the period for the quarter ended March 31, 2023.

 

The future minimum lease payment under noncancelable operating lease with terms greater than one year as of March 31, 2023:

 

     
From April 2023 to December 2023   56,250 
From January 2024 to December 2024    75,000 
Undiscounted cash flow   131,250 
Less imputed interest   (11,299)
Total   119,951 

  

The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of March 31, 2023 were 1.83 years and 10%, respectively. The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.

 

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS:
9 Months Ended
Mar. 31, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS:

10.        SUBSEQUENT EVENTS:

 

The Company has evaluated events that occurred subsequent to March 31, 2023 for recognition and disclosure in the financial statements and notes to the financial statements.

From April 1, 2023 through May 9, 2023, the Company has paid $395,000 and accrued $65,000 for an aggregate of $6,245,000 for the Initial Project. 

 

The requirement for payment of Lease obligations commenced January 1, 2023 and the Company was awaiting rent invoices as of March 31, 2023.  The sum of $18,750 has been accrued as a current liability for the quarter ended March 31, 2023.  On May 10, 2023 the invoices were received and $31,250 was paid for rent covering January through May 2023. 

 

From April 1, 2023, through May 9, 2023, 1,280 warrants have been exercised at $0.75 for a total of $ 960.

 

On May 1, 2023, a contract for consulting services was signed and 32,259 shares with a valuation of $50,000 were issued.  Additional shares valued at $50,000 will vest in 3 months.   

 

On May 9, 2023, the Board of Directors confirmed the final two years of the Personal Services Agreement of O’Neill, the Company’s CEO, and granted O’Neill 500,000 Incentive Options (“Options”), which Options: i) are exercisable at a price of $1.60 per share, ii) expire June 30, 2026, iii) vest one-half on June 1, 2024 and one-half on June 1, 2025, and iv) include a 50% exercise bonus.

 

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.1
SIGNIFICANT ACCOUNTING POLICIES (Policies)
9 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Principles of consolidation

Principles of consolidation:

 

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its 58.9% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.

 

The accompanying condensed consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements reflect all adjustments (consisting of only normal recurring entries) that, in the opinion of management, are necessary to present fairly the financial position at March 31, 2023, the results of operations of the Company for the three and nine months ended March 31, 2023 and 2022 and the cash flows of the Company for the nine months ended March 31, 2023 and 2022. Operating results for the three and nine months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending June 30, 2023.

 

Cash and cash equivalents

Cash and cash equivalents:

 

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of March 31, 2023 and June 30, 2022 there are no cash equivalents.

 

Property and equipment

Property and equipment:

 

Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects such as consulting fees, internal salaries and benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.

 

Patents

Patents:

 

The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s condensed consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.

 

Stock-based compensation

Stock-based compensation:

 

The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.

 

Derivative Financial Instruments

Derivative Financial Instruments:

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.

 

Options

Options:

 

The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.

 

Warrants

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

Concentrations of credit risk

Concentrations of credit risk:

 

The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.

 

Noncontrolling interests

Noncontrolling interests:

 

In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the condensed consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the condensed consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.

 

Fair value measurements

Fair value measurements:

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.

 

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;

 

Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

 

Level 3 – assets and liabilities whose significant value drivers are unobservable.

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.

 

Lease Accounting

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the condensed consolidated statements of operations over the lease term.

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s condensed consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.

 

Revenue Recognition

Revenue Recognition:

 

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.

 

Income (Loss) per share

Income (Loss) per share:

 

Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the three and nine months ended March 31, 2023 and 2022, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.

 

The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:

 

          
   March 31,
2023
   March 31,
2022
 
Warrants   21,944,437    19,078,635 
Options   11,506,600    10,481,600 
Convertible debt   10,052,765    10,847,026 
Convertible preferred stock            

 

The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the three and nine months ended March 31, 2023 and 2022:

 

                    
   Three months
ended
March 31,
2023
   Three months
ended
March 31,
2022
   Nine months
ended
March 31,
2023
   Nine months
ended
March 31,
2022
 
Shares issued – beginning of period   44,529,884    43,733,850    43,758,820    41,315,986 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)   (704,309)   (704,309)
Shares outstanding – beginning of period   43,825,575    43,029,511    43,054,511    40,611,677 
Weighted average shares issued
    during the period
   1,630,842          1,110,798    990,713 
Diluted weighted average shares –
    end of period
   45,456,417    43,029,511    44,165,309    40,904,342 

 

Use of estimates

Use of estimates:

 

In preparing the Company’s condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements:

 

The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its condensed consolidated financial statements and assures that there are proper controls in place to ascertain that the Company’s condensed consolidated financial statements properly reflect the change.

 

 

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.1
SIGNIFICANT ACCOUNTING POLICIES (Tables)
9 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Schedule of warrants and options and convertible securities
          
   March 31,
2023
   March 31,
2022
 
Warrants   21,944,437    19,078,635 
Options   11,506,600    10,481,600 
Convertible debt   10,052,765    10,847,026 
Convertible preferred stock            
Schedule of earnings per share, basic and diluted
                    
   Three months
ended
March 31,
2023
   Three months
ended
March 31,
2022
   Nine months
ended
March 31,
2023
   Nine months
ended
March 31,
2022
 
Shares issued – beginning of period   44,529,884    43,733,850    43,758,820    41,315,986 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)   (704,309)   (704,309)
Shares outstanding – beginning of period   43,825,575    43,029,511    43,054,511    40,611,677 
Weighted average shares issued
    during the period
   1,630,842          1,110,798    990,713 
Diluted weighted average shares –
    end of period
   45,456,417    43,029,511    44,165,309    40,904,342 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.1
PROPERTY AND EQUIPMENT: (Tables)
9 Months Ended
Mar. 31, 2023
Property, Plant and Equipment [Abstract]  
Schedule of property and equipment
          
   March 31,
2023
   June 30,
2022
 
Computers and office equipment   15,156    13,598 
Initial Project: construction in process   5,784,494    2,892,222 
Property and equipment, gross   5,799,650    2,905,820 
Less accumulated depreciation   (11,447)   (10,262)
 Property and equipment, net  $5,788,203   $2,895,558 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS' EQUITY: (Tables)
9 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Schedule of option activity
                      
    Options   Weighted-
Average
Exercise
Price
   Weighted-
Average
Remaining
Contractual
Life
   Aggregate
Intrinsic
Value
 
 Outstanding at July 1, 2022    11,201,600   $0.80    2.7   $4,429,263 
   Granted    305,000                 
   Exercised                       
   Forfeited                       
   Expired                       
 Outstanding at March 31, 2023    11,506,600   $0.82    2.02   $10,238,395 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES: (Tables)
9 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Schedule of future minimum lease payments
     
From April 2023 to December 2023   56,250 
From January 2024 to December 2024    75,000 
Undiscounted cash flow   131,250 
Less imputed interest   (11,299)
Total   119,951 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS: (Details Narrative)
3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2023
USD ($)
Mar. 31, 2023
USD ($)
Decimal
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2018
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Tech wastage | Decimal   1,500      
Cattle per head | Decimal   300      
Percentage of sustainable   29.50%      
Description of kreider 2 poultry project   Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) (‘Kreider Renewable Energy Facility’ or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). Now that development of the Company’s Gen3Tech is being deployed, the Company has commenced discussions with KF regarding updating and amending the JV agreement and anticipates executing an amended joint venture agreement during 2023. During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA).      
Net Income (loss)   $ 2,507,305 $ 8,291,000 $ 3,451,000  
Net income     10,235,000    
Gain on sale of domain     902,000    
Working Capital $ 147,000 147,000      
Reduction of debt 3,516,000        
Proceeds from Issuance or Sale of Equity   3,385,000 $ 1,737,000 $ 5,209,000  
Commissions paid 48,000 48,000      
Deferred Compensation Liability, Amount Cancelled         $ 2,404,000
Minimum [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Capital Required for Capital Adequacy 20,000,000 20,000,000      
Maximum [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Capital Required for Capital Adequacy $ 80,000,000 $ 80,000,000      
Ribbonwire [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Tech wastage | Decimal   15,000      
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.1
SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) - shares
9 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities 21,944,437 19,078,635
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities 11,506,600 10,481,600
Convertible Debt Securities [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities 10,052,765 10,847,026
Convertible Preferred Stock Antidilutive Securities [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.1
SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) - shares
3 Months Ended 9 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Accounting Policies [Abstract]        
Shares issued – beginning of period 44,529,884 43,733,850 43,758,820 41,315,986
Shares held by subsidiaries (Note 7) (704,309) (704,309) (704,309) (704,309)
Shares outstanding – beginning of period 43,825,575 43,029,511 43,054,511 40,611,677
Weighted average shares issued     during the period 1,630,842 1,110,798 990,713
Diluted weighted average shares –     end of period 45,456,417 43,029,511 44,165,309 40,904,342
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.1
SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
Mar. 31, 2023
Jun. 30, 2022
Cash equivalents $ 0 $ 0
Centerpoint [Member]    
Noncontrolling interest, ownership percentage by parent 58.90%  
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.1
PROPERTY AND EQUIPMENT - Property and Equipment (Details) - USD ($)
Mar. 31, 2023
Jun. 30, 2022
Property, Plant and Equipment [Abstract]    
Computers and office equipment $ 15,156 $ 13,598
Initial Project: construction in process 5,784,494 2,892,222
Property and equipment, gross 5,799,650 2,905,820
Less accumulated depreciation (11,447) (10,262)
 Property and equipment, net $ 5,788,203 $ 2,895,558
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.1
PROPERTY AND EQUIPMENT: (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Property, Plant and Equipment [Line Items]        
Capitalized interest     $ 149,342  
Non cash compensation     135,648  
Depreciation expense $ 461 $ 252 1,185 $ 832
Property Plant And Equipment Of P A 1 [Member]        
Property, Plant and Equipment [Line Items]        
Impairment of Long-Lived Assets Held-for-use     $ 0  
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.1
DEFERRED COMPENSATION: (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Jun. 30, 2022
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Deferred compensation liability $ 784,255 $ 525,699 $ 784,255 $ 525,699 $ 594,798
Interest Rate on Deferred Compensation 4.00%   4.00%    
Deferred Compensation Consecutive Trading Days (Day)     10 days    
Deferred compensation $ 110,000 0 $ 110,000 0  
Interest Expense On Deferred Compensation Obligation [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Interest Expense 5,034 3,824 14,458 12,124  
Interest Expense, Related Party 4,428 3,570 12,893 11,615  
Bassani [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Deferred compensation liability   410,585   410,585  
Smith [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Deferred compensation liability   0   0  
Deferred Compensation, Convertible to Common Stock 30,000   90,000    
Chief Executive Officer [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Deferred compensation liability $ 504,401 5,000 504,401 5,000  
Deferred Compensation, Convertible to Common Stock     $ 300,000    
Deferred Compensation, Convertible to Common Stock, Price Per Share (in dollars per share) $ 0.75   $ 0.75    
Consultants [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Deferred compensation liability $ 92,355 $ 42,614 $ 92,355 $ 42,614  
Interest Rate on Deferred Compensation 0.00% 3.00% 0.00% 3.00%  
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.1
LOANS PAYABLE: (Details Narrative) - USD ($)
1 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2022
Jun. 15, 2022
Mar. 31, 2022
Jan. 28, 2022
Mar. 31, 2023
Jun. 30, 2022
Jun. 30, 2021
Dec. 29, 2021
Sep. 30, 2021
Sep. 25, 2014
Short-Term Debt [Line Items]                    
Total assets $ 6,360,337       $ 7,627,443 $ 6,360,337   $ 0 $ 297  
Total liabilities 7,254,916       3,440,614 7,254,916   10,234,501 10,154,334  
Accounts payable and accrued liabilities $ 1,360,644       800,901 1,360,644   10,009,802 9,939,148  
Accounts payable               212,263 214,235  
Accrued Liabilities, Current               $ 12,436 $ 950  
Gain on legal dissolution of subsidiary         10,234,501          
Debt Instrument, Interest Rate During Period 25.00%   25.00% 25.00%            
Loans as a liability             $ 9,868,495      
P A 1 [Member]                    
Short-Term Debt [Line Items]                    
Debt Instrument, Debt Default, Amount                   $ 8,137,117
Realized from the asset sale   $ 104,725                
Pennvest Loan [Member]                    
Short-Term Debt [Line Items]                    
Construction Loan         10,010,000          
Accrued Interest and Late Charges Payable         2,255,802          
Line of Credit Facility, Maximum Borrowing Capacity         7,754,000          
Debt Instrument, Annual Principal Payment         5,886,000          
Long-Term Debt, Maturity, Year Two         846,000          
Long-Term Debt, Maturity, Year Three         873,000          
Long-Term Debt, Maturity, Year Four         $ 149,000          
Interest Expense, Debt           $ 123,444 $ 246,887      
Pennvest Loan [Member] | Years One Through Five [Member]                    
Short-Term Debt [Line Items]                    
Debt Instrument, Interest Rate During Period         2.547%          
Pennvest Loan [Member] | Years Six Through Maturity [Member]                    
Short-Term Debt [Line Items]                    
Debt Instrument, Interest Rate During Period         3.184%          
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE NOTES PAYABLE - AFFILIATES: (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Mar. 08, 2023
Mar. 31, 2023
Jan. 28, 2022
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Feb. 02, 2023
Jun. 30, 2022
May 01, 2022
Jan. 01, 2020
Original conversion price   $ 0.50   $ 0.50   $ 0.50          
Convertible Notes Payable, Noncurrent   $ 1,735,507   $ 1,735,507   $ 1,735,507     $ 5,170,610    
Debt conversion value     $ 2,665,500                
Capitalized amount       51,238 $ 0 117,342 $ 0        
Convertible note   $ 3,470,000   $ 3,470,000   $ 3,470,000          
Mark A Smith [Member]                      
Conversion price per unit   $ 946   $ 946   $ 946          
Principal amount   $ 1,109,649   $ 1,109,649   $ 1,109,649          
Dominic Bassani [Member]                      
Conversion price per unit   $ 953   $ 953   $ 953          
Principal amount   $ 1,939,670   $ 1,939,670   $ 1,939,670          
Ed Schafer [Member]                      
Conversion price per unit   $ 953   $ 953   $ 953          
Principal amount   $ 424,873   $ 424,873   $ 424,873          
Common Shares [Member] | Direct Ownership [Member]                      
Shares issued, warrants 255,906 255,906   255,906   255,906          
Common Shares [Member] | Indirect Ownership [Member]                      
Shares issued, warrants 350,000 350,000   350,000   350,000          
Warrants [Member] | Direct Ownership [Member]                      
Shares issued, warrants 79,958 79,958   79,958   79,958          
Warrants [Member] | Indirect Ownership [Member]                      
Shares issued, warrants 270,948 270,948   270,948   270,948          
Chief Executive Officer [Member]                      
Shares issued, warrants                   1,000,000  
President [Member] | Secured Promissory Note [Member]                      
Financing receivable interest rate stated percentage   4.00%   4.00%   4.00%          
Convertible Obligations 2020 [Member] | Common Shares [Member]                      
Convertible stock shares issued, warrants 450,000         450,000          
Convertible Obligations 2020 [Member] | Warrants [Member]                      
Convertible stock shares issued, warrants 705,000         705,000          
The 2020 Convertible Obligations [Member]                      
Salary paid           $ 90,000          
Accounts payable for reimbursable expenses           23,943          
The 2020 Convertible Obligations [Member] | Chief Executive Officer [Member]                      
Convertible Notes Payable, Noncurrent   $ 436,988   $ 436,988   436,988          
The 2020 Convertible Obligations [Member] | Chief Executive Officer [Member] | Bassani Family Trusts [Member]                      
Convertible Notes Payable               $ 434,016      
The 2020 Convertible Obligations [Member] | Chief Executive Officer [Member] | Schafer [Member]                      
Convertible Notes Payable               96,364      
The 2020 Convertible Obligations [Member] | Chief Executive Officer [Member] | Smith [Member]                      
Convertible Notes Payable               262,154      
The 2020 Convertible Obligations [Member] | President [Member]                      
Convertible Notes Payable, Noncurrent   164,060   164,060   164,060          
The 2020 Convertible Obligations [Member] | Executive Vice Chairman [Member]                      
Convertible Notes Payable, Noncurrent   $ 97,024   $ 97,024   $ 97,024          
The 2020 Convertible Obligations [Member] | Convertible Debt [Member]                      
Debt Instrument, Interest Rate, Stated Percentage                     4.00%
Debt Instrument, Interest Rate, Stated Percentage, Quarterly                     4.00%
Conversion price per unit                     $ 0.50
Original conversion price   $ 0.0946   $ 0.0946   $ 0.0946          
Interest Expense       $ 16,208 6,366 $ 98,948 17,430        
Conversion of shares, value $ 70,000         $ 70,000          
Conversion of shares, shares 739,958         739,958          
The 2020 Convertible Obligations [Member] | Convertible Debt [Member] | Chief Executive Officer [Member]                      
Convertible Notes Payable, Noncurrent   $ 358,151   358,151 2,573,716 $ 358,151 2,573,716        
The 2020 Convertible Obligations [Member] | Convertible Debt [Member] | President [Member]                      
Convertible Notes Payable, Noncurrent   36,072   36,072 1,315,069 36,072 1,315,069        
The 2020 Convertible Obligations [Member] | Convertible Debt [Member] | Executive Vice Chairman [Member]                      
Convertible Notes Payable, Noncurrent   0   0 494,736 0 494,736        
Principal [Member] | Convertible Obligations 2020 [Member]                      
Debt conversion value           $ 30,000          
Debt conversion shares, warrants           60,000          
Principal [Member] | Convertible Obligations 2020 [Member] | Warrants [Member]                      
Debt conversion shares, warrants           60,000          
Principal [Member] | Convertible Obligations 2020 [Member] | Common Shares [Member]                      
Debt conversion shares, warrants           60,000          
Accrued Interest [Member] | Convertible Obligations 2020 [Member]                      
Debt conversion value           $ 20,000          
Debt conversion shares, warrants           40,000          
Accrued Interest [Member] | Convertible Obligations 2020 [Member] | Common Shares [Member]                      
Debt conversion shares, warrants           40,000          
Accrued Interest [Member] | Convertible Obligations 2020 [Member] | Warrants [Member]                      
Debt conversion shares, warrants           40,000          
September 2015 Convertible Notes [Member] | Chief Executive Officer [Member]                      
Convertible Notes Payable, Noncurrent   24,396   24,396   $ 24,396          
September 2015 Convertible Notes [Member] | Chief Executive Officer [Member] | Bassani Family Trusts [Member]                      
Convertible Notes Payable   157,682   157,682 276,944 157,682 276,944        
September 2015 Convertible Notes [Member] | Chief Executive Officer [Member] | Ed Schafer [Member]                      
Convertible Notes Payable               4,012      
September 2015 Convertible Notes [Member] | Chief Executive Officer [Member] | Bassani [Member]                      
Convertible Notes Payable               $ 24,230      
September 2015 Convertible Notes [Member] | Executive Vice Chairman [Member]                      
Convertible Notes Payable, Noncurrent   4,039   4,039   4,039          
September 2015 Convertible Notes [Member] | Executive Vice Chairman [Member] | Shareholder [Member]                      
Convertible Notes Payable   457,094   457,094 441,977 457,094 441,977        
September 2015 Convertible Notes [Member] | Consultants [Member] | Schafer [Member]                      
Convertible Notes Payable   $ 0   $ 0 20,681 $ 0 20,681        
September 2015 Convertible Notes [Member] | Convertible Debt [Member]                      
Conversion price per unit   $ 0.60   $ 0.60   $ 0.60          
Interest Expense       $ 5,507 $ 5,366 $ 18,239 $ 17,430        
Adjusted Convertible Obligations [Member] | Convertible Debt [Member]                      
Conversion of shares, value   $ 29,888       $ 29,889          
Conversion of shares, shares   315,948       315,948          
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS' EQUITY - Stock Option Activity (Details) - USD ($)
9 Months Ended 12 Months Ended
Mar. 31, 2023
Jun. 30, 2022
Equity [Abstract]    
Options outstanding, beginning (in shares) 11,201,600  
Options outstanding, beginning weighted-average exercise price $ 0.80  
Outstanding, weighted-average remaining contractual life (Year) 2 years 7 days 2 years 8 months 12 days
Outstanding, aggregate intrinsic value beginning $ 4,429,263  
Granted, options (in shares) 305,000  
Granted, weighted-average exercise price  
Exercised, options (in shares)  
Exercised, weighted-average exercise price  
Forfeited, options (in shares)  
Forfeited, weighted-average exercise price  
Expired, options (in shares)  
Expired, weighted-average exercise price  
Options outstanding, ending (in shares) 11,506,600 11,201,600
Options outstanding, ending weighted-average exercise price $ 0.82 $ 0.80
Outstanding, aggregate intrinsic value ending $ 10,238,395 $ 4,429,263
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS' EQUITY: (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Mar. 08, 2023
Jan. 10, 2023
Feb. 11, 2022
Jul. 01, 2014
Mar. 31, 2023
Dec. 31, 2022
Apr. 29, 2022
Jan. 28, 2022
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Jun. 30, 2022
May 01, 2022
Jan. 01, 2020
Jul. 03, 2014
Jul. 02, 2014
Class of Stock [Line Items]                                  
Convertible note         $ 3,470,000       $ 3,470,000   $ 3,470,000            
Increase to additional paid in capital                 3,521,000                
Reduction of additional paid in capital                 5,620                
Redemption of convertible Preferred stock                     41,000            
Liability         $ 1,585,156       $ 1,585,156   $ 1,585,156   $ 1,955,442        
Shares Held by Subsidiaries                 704,309 704,309 704,309 704,309          
Sale of units         $ 1.00       $ 1.00   $ 1.00            
Sell units         0.75       $ 0.75   $ 0.75            
Number of shares issued                     346,230            
Number of shares issued, value                     $ 346,230            
Commissions paid                 $ 48,000   $ 48,000            
Class of Warrant or Right, Exercised During Period                 84,000   158,834            
Common Stock Shares Issued upon Exercise of Warrants                 84,000   158,834            
Warrant Exercised for Common Stock                 $ 63,000   $ 119,125            
Debt conversion value               $ 2,665,500                  
Conversion price per share         $ 0.50       $ 0.50   $ 0.50            
Total value of consultant services                     $ 80,000            
Warrant outstanding         21,900,000       21,900,000   21,900,000            
Weighted average exercise price         $ 0.82       $ 0.82   $ 0.82   $ 0.80        
Exercise bonus                   75.00%   75.00%          
Number of shares granted                     305,000            
Share-based Compensation, Granted             720,000                    
Fair value of stock options                 $ 220,510 $ 4,650 $ 220,510 $ 4,650          
Options Held [Member]                                  
Class of Stock [Line Items]                                  
Share-based Compensation, Granted                 305,000 10,000 305,000 10,000          
Plan 2006 [Member]                                  
Class of Stock [Line Items]                                  
Number of shares granted     10,000                            
Minimum [Member]                                  
Class of Stock [Line Items]                                  
Warrants exercisable per share         $ 0.60       $ 0.60   $ 0.60            
Exercise bonus         50.00%       50.00%   50.00%            
Maximum [Member]                                  
Class of Stock [Line Items]                                  
Warrants exercisable per share         $ 2.40       $ 2.40   $ 2.40            
Exercise bonus         90.00%       90.00%   90.00%            
President [Member]                                  
Class of Stock [Line Items]                                  
Warrants exercisable per share         $ 0.75       $ 0.75   $ 0.75            
Consultant Service [Member]                                  
Class of Stock [Line Items]                                  
Shares issued for consultant services                     50,000            
Share price         1.60       1.60   $ 1.60            
Total value of consultant services                     $ 80,000            
Chief Executive Officer [Member]                                  
Class of Stock [Line Items]                                  
Warrants exercisable per share                           $ 1.00      
Number of shares issued                           1,000,000      
Cancellation of warrants                           700,000      
Exercise bonus                           75.00%      
Common Stock [Member]                                  
Class of Stock [Line Items]                                  
Warrants exercisable per share         0.75       0.75   $ 0.75            
Shares issued for consultant services                     50,000            
Total value of consultant services                                
Warrant [Member]                                  
Class of Stock [Line Items]                                  
Warrants exercisable per share         0.75       0.75   $ 0.75            
Issuance of warrants                     $ 21,000            
Share-based Payment Arrangement, Plan Modification, Incremental Cost                     154,932            
Interest expenses                     $ 72,589            
Warrant [Member] | Three Consultants [Member]                                  
Class of Stock [Line Items]                                  
Class of Warrant or Right, Exercised During Period                     210,000            
Warrant [Member] | Three Consultants [Member] | Minimum [Member]                                  
Class of Stock [Line Items]                                  
Warrants exercisable per share         1.50       1.50   $ 1.50            
Warrant [Member] | Three Consultants [Member] | Maximum [Member]                                  
Class of Stock [Line Items]                                  
Warrants exercisable per share         $ 1.60       $ 1.60   $ 1.60            
Warrant [Member] | Consultants [Member]                                  
Class of Stock [Line Items]                                  
Vesting period                     May 01, 2023            
Number of shares issued         700,000       700,000   700,000            
Non cash compensation                 $ 9,844   $ 36,094            
Series B Preferred Stock [Member]                                  
Class of Stock [Line Items]                                  
Preferred Stock, Shares Outstanding, Ending Balance (in shares)                                 200
Par value                                 $ 0.01
Preferred Stock, Convertible Option Per Share                               $ 2.00  
Preferred stock dividend rate percentage       2.50%                          
Preferred Stock, Redemption Price Per Share                                 $ 100
Dividends Payable         $ 21,000       21,000   21,000            
Dividends, Preferred Stock                     1,000 $ 2,000          
Liability         $ 0       $ 0   $ 0            
Restricted Stock [Member]                                  
Class of Stock [Line Items]                                  
Sale of stock, shares                     2,000,000            
Common Stock [Member]                                  
Class of Stock [Line Items]                                  
Shares purchased, shares   1,800,000       200,000                      
Shares purchased, value                     $ 2,000,000            
Restricted Common Stock [Member]                                  
Class of Stock [Line Items]                                  
Sale of stock, shares                 575,000   575,000            
Sale of units         $ 1.60       $ 1.60   $ 1.60            
Sell units         2.40       $ 2.40   $ 2.40            
Vesting period                 Jun. 30, 2024                
Number of shares issued                 575,000   575,000            
Number of shares issued, value                 $ 920,000   $ 920,000            
Warrants [Member]                                  
Class of Stock [Line Items]                                  
Weighted average exercise price         $ 0.78       $ 0.78   $ 0.78            
Remaining contractual life                     1 year 9 months 18 days            
Warrants [Member] | Direct Ownership [Member]                                  
Class of Stock [Line Items]                                  
Number of shares issued 79,958       79,958       79,958   79,958            
Warrants [Member] | Indirect Ownership [Member]                                  
Class of Stock [Line Items]                                  
Number of shares issued 270,948       270,948       270,948   270,948            
Warrants [Member] | Convertible Obligations 2020 [Member]                                  
Class of Stock [Line Items]                                  
Convertible stock shares issued, warrants 705,000                   705,000            
Common Shares [Member] | Direct Ownership [Member]                                  
Class of Stock [Line Items]                                  
Number of shares issued 255,906       255,906       255,906   255,906            
Common Shares [Member] | Indirect Ownership [Member]                                  
Class of Stock [Line Items]                                  
Number of shares issued 350,000       350,000       350,000   350,000            
Common Shares [Member] | Convertible Obligations 2020 [Member]                                  
Class of Stock [Line Items]                                  
Convertible stock shares issued, warrants 450,000                   450,000            
Share-Based Payment Arrangement, Option [Member]                                  
Class of Stock [Line Items]                                  
Stock options, authorized (in shares)         36,000,000       36,000,000   36,000,000            
Share-based Payment Arrangement, Expense                 $ 220,510 $ 4,650 $ 220,510 $ 4,650          
Share-Based Payment Arrangement, Option [Member] | Equity Incentive Plan [Member]                                  
Class of Stock [Line Items]                                  
Stock options, authorized (in shares)         30,000,000       30,000,000   30,000,000            
September 2015 Convertible Notes [Member] | Convertible Debt [Member]                                  
Class of Stock [Line Items]                                  
Conversion price per unit         $ 0.60       $ 0.60   $ 0.60            
Convertible debt maturity date                     Jul. 01, 2024            
September 2015 Convertible Notes [Member] | Restricted Common Shares [Member]                                  
Class of Stock [Line Items]                                  
Conversion price per unit         0.115       0.115   $ 0.115            
The 2020 Convertible Obligations [Member] | Warrant [Member] | Principal [Member]                                  
Class of Stock [Line Items]                                  
Debt conversion value                     $ 30,000            
The 2020 Convertible Obligations [Member] | Warrant [Member] | Accrued Interest [Member]                                  
Class of Stock [Line Items]                                  
Debt conversion value                     $ 20,000            
The 2020 Convertible Obligations [Member] | Convertible Debt [Member]                                  
Class of Stock [Line Items]                                  
Conversion price per unit                             $ 0.50    
Conversion price per share         0.0946       $ 0.0946   $ 0.0946            
Conversion of shares, value $ 70,000                   $ 70,000            
Conversion of shares, shares 739,958                   739,958            
The 2020 Convertible Obligations [Member] | Convertible Debt [Member] | Principal [Member]                                  
Class of Stock [Line Items]                                  
Debt conversion value                     $ 99,889            
The 2020 Convertible Obligations [Member] | Convertible Debt [Member] | Common Stock [Member]                                  
Class of Stock [Line Items]                                  
Debt conversion shares                 1,055,906                
The 2020 Convertible Obligations [Member] | Convertible Debt [Member] | Warrant [Member]                                  
Class of Stock [Line Items]                                  
Debt conversion shares                     100,000            
Conversion price per share         $ 0.50       $ 0.50   $ 0.50            
Adjusted Convertible Obligations [Member] | Convertible Debt [Member]                                  
Class of Stock [Line Items]                                  
Conversion of shares, value         $ 29,888           $ 29,889            
Conversion of shares, shares         315,948           315,948            
Mark A Smith [Member]                                  
Class of Stock [Line Items]                                  
Principal amount         $ 1,109,649       $ 1,109,649   $ 1,109,649            
Conversion price per unit         $ 946       $ 946   $ 946            
Dominic Bassani [Member]                                  
Class of Stock [Line Items]                                  
Principal amount         $ 1,939,670       $ 1,939,670   $ 1,939,670            
Conversion price per unit         $ 953       $ 953   $ 953            
Ed Schafer [Member]                                  
Class of Stock [Line Items]                                  
Principal amount         $ 424,873       $ 424,873   $ 424,873            
Conversion price per unit         $ 953       $ 953   $ 953            
Northrop [Member]                                  
Class of Stock [Line Items]                                  
Share-based Compensation, Granted             50,000                    
Bassani [Member]                                  
Class of Stock [Line Items]                                  
Share-based Compensation, Granted             200,000                    
Smith [Member]                                  
Class of Stock [Line Items]                                  
Share-based Compensation, Granted             200,000                    
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSCRIPTION RECEIVABLE - AFFILIATES: (Details Narrative) - USD ($)
Mar. 31, 2023
May 01, 2022
Mar. 31, 2022
Secured Promissory Note [Member] | Smiths [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Financing Receivable, after Allowance for Credit Loss, Total $ 35,714    
Financing Receivable, Principal Amount $ 30,000    
Chief Executive Officer [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)   $ 1.00  
Chief Executive Officer [Member] | Warrants Issused Subscription Receivable [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 5,565,000    
Chief Executive Officer [Member] | Secured Promissory Note [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Financing Receivable, after Allowance for Credit Loss, Total $ 428,250    
Notes receivable interest $ 513,282    
Former Employee [Member] | Warrants Issused Subscription Receivable [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 928,000    
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 0.75    
Former Employee [Member] | Secured Promissory Note [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Financing Receivable, after Allowance for Credit Loss, Total $ 56,396    
Financing Receivable, Principal Amount $ 46,400    
Financing Receivable, Interest Rate, Stated Percentage 4.00%    
President [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 0.75    
President [Member] | Warrants Issused Subscription Receivable [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 300,000   300,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 0.60    
President [Member] | Secured Promissory Note [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Financing Receivable, after Allowance for Credit Loss, Total $ 35,586    
Financing Receivable, Principal Amount $ 30,000    
Financing Receivable, Interest Rate, Stated Percentage 4.00%    
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES (Details)
Mar. 31, 2023
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
From April 2023 to December 2023 $ 56,250
From January 2024 to December 2024 75,000
Undiscounted cash flow 131,250
Less imputed interest (11,299)
Total $ 119,951
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES: (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
May 02, 2022
May 02, 2022
Aug. 01, 2018
Oct. 10, 2016
Feb. 10, 2015
Mar. 01, 2023
Jan. 17, 2023
Jun. 30, 2022
Jun. 15, 2022
Apr. 30, 2022
Mar. 31, 2022
Mar. 23, 2022
Jan. 28, 2022
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Jun. 30, 2022
Jun. 30, 2021
May 01, 2022
Dec. 29, 2021
Sep. 30, 2021
Feb. 28, 2018
Apr. 27, 2017
Oct. 31, 2016
Sep. 25, 2014
Loss Contingencies [Line Items]                                                    
Compensation increased $ 25,000                                                  
Cash compensation paid                               $ 220,510 $ 17,774                  
Exercise bonus                     75.00%       75.00%   75.00%                  
Warrants held by trust owned                               3,000,000                    
Warrants and Rights Outstanding                           $ 18,438,339   18,438,339                    
Debt instrument paid amount                         $ 2,665,500                          
Debt Instrument, Interest Rate During Period               25.00%     25.00%   25.00%                          
Principal, interest             $ 533,100           $ 666,375                          
Aggregate payment           $ 2,532,225                                        
Purchase order                   $ 133,275                                
Purchase order billed                   86,275                                
Purchase order Invoiced                   $ 50,000                                
Capitalized labor and interest costs                               5,164,256                    
Sale of domain, description                       the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490.                            
Loan related to construction                                         $ 10,010,000          
Accrued interest                                         2,255,802          
Total assets               $ 6,360,337           7,627,443   7,627,443   $ 6,360,337     0 $ 297        
Total liabilities               7,254,916           3,440,614   3,440,614   7,254,916     10,234,501 10,154,334        
Accounts payable and accrued liabilities               $ 1,360,644           800,901   800,901   1,360,644     10,009,802 9,939,148        
Accounts payable                                         212,263 214,235        
Accrued Liabilities, Current                                         $ 12,436 $ 950        
Gain on legal dissolution of subsidiary                               10,234,501                    
Loans as a liability                                     $ 9,868,495              
Accrued current liability                           $ 18,750   $ 18,750                    
Weighted average remaining lease term                           1 year 9 months 29 days   1 year 9 months 29 days                    
Discounted rate                           10.00%   10.00%                    
P A 1 [Member]                                                    
Loss Contingencies [Line Items]                                                    
Debt Instrument, Debt Default, Amount                                                   $ 8,137,117
Realized from the asset sale                 $ 104,725                                  
Pennvest Loan [Member]                                                    
Loss Contingencies [Line Items]                                                    
Line of Credit Facility, Maximum Borrowing Capacity                           $ 7,754,000   $ 7,754,000                    
Debt Instrument, Annual Principal Payment                           5,886,000   5,886,000                    
Long-Term Debt, Maturity, Year Two                           846,000   846,000                    
Long-Term Debt, Maturity, Year Three                           873,000   873,000                    
Long-Term Debt, Maturity, Year Four                           $ 149,000   $ 149,000                    
Interest Expense, Debt                                   $ 123,444 $ 246,887              
Pennvest Loan [Member] | Years One Through Five [Member]                                                    
Loss Contingencies [Line Items]                                                    
Debt Instrument, Interest Rate During Period                               2.547%                    
Pennvest Loan [Member] | Years Six Through Maturity [Member]                                                    
Loss Contingencies [Line Items]                                                    
Debt Instrument, Interest Rate During Period                               3.184%                    
Minimum [Member]                                                    
Loss Contingencies [Line Items]                                                    
Warrants exercisable per share                           $ 0.60   $ 0.60                    
Exercise bonus                           50.00%   50.00%                    
Maximum [Member]                                                    
Loss Contingencies [Line Items]                                                    
Warrants exercisable per share                           $ 2.40   $ 2.40                    
Exercise bonus                           90.00%   90.00%                    
Smith [Member]                                                    
Loss Contingencies [Line Items]                                                    
Cash compensation paid                           $ 40,000 $ 18,000 $ 140,000 $ 72,000                  
William O Neill [Member]                                                    
Loss Contingencies [Line Items]                                                    
Payment for cash   $ 12,500                                                
President [Member]                                                    
Loss Contingencies [Line Items]                                                    
Monthly Officers Cash Compensation       $ 18,000                                            
Warrants exercisable per share                           $ 0.75   $ 0.75                    
President [Member] | Extension Bonus [Member] | Fy 2016 Extension Agreement [Member]                                                    
Loss Contingencies [Line Items]                                                    
Deferred Compensation, Maximum Convertible Amount                                               $ 300,000 $ 125,000  
Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share)                                               $ 0.75 $ 0.75  
President [Member] | Warrants Issused Subscription Receivable [Member]                                                    
Loss Contingencies [Line Items]                                                    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)                     300,000     300,000 300,000 300,000 300,000                  
Warrants exercisable per share                           $ 0.60   $ 0.60                    
President [Member] | Warrants Issued In Connection With Sale Of Units In Exchange For Salary [Member]                                                    
Loss Contingencies [Line Items]                                                    
Warrants exercisable per share                           $ 0.75   $ 0.75                    
Chief Executive Officer [Member]                                                    
Loss Contingencies [Line Items]                                                    
Monthly Officers Cash Compensation         $ 31,000                     $ 25,000                    
Warrants exercisable per share                                       $ 1.00            
Cash compensation paid                           $ 75,500 $ 0 150,000 $ 0                  
Deferred Compensation, Maximum Convertible Amount                           10,000   10,000                    
Exercise bonus                                       75.00%            
Number of shares issued                                       1,000,000            
Cancellation of warrants                                       700,000            
Chief Executive Officer [Member] | Secured Promissory Note Consideration For Warrants Expiring On December 312025 [Member]                                                    
Loss Contingencies [Line Items]                                                    
Financing Receivable, after Allowance for Credit Loss, Total                           358,151   358,151                    
Repayments of Long-term Debt, Total                           $ 75,000 $ 60,000 $ 225,000 $ 184,764                  
Chief Executive Officer [Member] | Warrants Issused Subscription Receivable [Member]                                                    
Loss Contingencies [Line Items]                                                    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)                           5,565,000   5,565,000                    
Chief Executive Officer [Member] | Warrants Expiring On December 312025 [Member]                                                    
Loss Contingencies [Line Items]                                                    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)     3,000,000                                              
Bassani [Member]                                                    
Loss Contingencies [Line Items]                                                    
Salaries and wages                                             $ 31,000      
Additional paid amount                                             $ 2,000      
Interest bearing secured promissory note     $ 300,000                                              
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS: (Details Narrative) - USD ($)
1 Months Ended 4 Months Ended 9 Months Ended
May 01, 2023
May 09, 2023
May 10, 2023
Mar. 31, 2023
Subsequent Event [Line Items]        
Accrued current liability       $ 18,750
Options granted       305,000
Subsequent Event [Member]        
Subsequent Event [Line Items]        
Cash paid   $ 395,000    
Accrued paid   65,000    
Aggregate amount   $ 6,245,000    
Rent     $ 31,250  
Warrants   1,280    
Warrants exercised   $ 0.75    
Consulting services description a contract for consulting services was signed and 32,259 shares with a valuation of $50,000 were issued.  Additional shares valued at $50,000 will vest in 3 months.      
Options granted   500,000    
XML 47 bion_10q-q3_htm.xml IDEA: XBRL DOCUMENT 0000875729 2022-07-01 2023-03-31 0000875729 2021-07-01 2023-03-31 0000875729 2023-04-30 0000875729 2023-03-31 0000875729 2022-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2023-03-31 0000875729 us-gaap:SeriesAPreferredStockMember 2022-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2023-03-31 0000875729 us-gaap:SeriesCPreferredStockMember 2022-06-30 0000875729 2023-01-01 2023-03-31 0000875729 2022-01-01 2022-03-31 0000875729 2021-07-01 2022-03-31 0000875729 us-gaap:SeriesAPreferredStockMember 2021-12-31 0000875729 us-gaap:SeriesCPreferredStockMember 2021-12-31 0000875729 us-gaap:CommonStockMember 2021-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000875729 bnet:SubscriptionsReceivableMember 2021-12-31 0000875729 us-gaap:RetainedEarningsMember 2021-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2021-12-31 0000875729 2021-12-31 0000875729 us-gaap:SeriesAPreferredStockMember 2022-12-31 0000875729 us-gaap:SeriesCPreferredStockMember 2022-12-31 0000875729 us-gaap:CommonStockMember 2022-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000875729 bnet:SubscriptionsReceivableMember 2022-12-31 0000875729 us-gaap:RetainedEarningsMember 2022-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2022-12-31 0000875729 2022-12-31 0000875729 us-gaap:SeriesAPreferredStockMember 2021-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2021-06-30 0000875729 us-gaap:CommonStockMember 2021-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000875729 bnet:SubscriptionsReceivableMember 2021-06-30 0000875729 us-gaap:RetainedEarningsMember 2021-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2021-06-30 0000875729 2021-06-30 0000875729 us-gaap:CommonStockMember 2022-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000875729 bnet:SubscriptionsReceivableMember 2022-06-30 0000875729 us-gaap:RetainedEarningsMember 2022-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2022-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-03-31 0000875729 us-gaap:SeriesCPreferredStockMember 2022-01-01 2022-03-31 0000875729 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000875729 bnet:SubscriptionsReceivableMember 2022-01-01 2022-03-31 0000875729 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000875729 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0000875729 us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-03-31 0000875729 us-gaap:SeriesCPreferredStockMember 2023-01-01 2023-03-31 0000875729 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000875729 bnet:SubscriptionsReceivableMember 2023-01-01 2023-03-31 0000875729 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000875729 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0000875729 us-gaap:SeriesAPreferredStockMember 2021-07-01 2022-03-31 0000875729 us-gaap:SeriesCPreferredStockMember 2021-07-01 2022-03-31 0000875729 us-gaap:CommonStockMember 2021-07-01 2022-03-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2022-03-31 0000875729 bnet:SubscriptionsReceivableMember 2021-07-01 2022-03-31 0000875729 us-gaap:RetainedEarningsMember 2021-07-01 2022-03-31 0000875729 us-gaap:NoncontrollingInterestMember 2021-07-01 2022-03-31 0000875729 us-gaap:SeriesAPreferredStockMember 2022-07-01 2023-03-31 0000875729 us-gaap:SeriesCPreferredStockMember 2022-07-01 2023-03-31 0000875729 us-gaap:CommonStockMember 2022-07-01 2023-03-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2023-03-31 0000875729 bnet:SubscriptionsReceivableMember 2022-07-01 2023-03-31 0000875729 us-gaap:RetainedEarningsMember 2022-07-01 2023-03-31 0000875729 us-gaap:NoncontrollingInterestMember 2022-07-01 2023-03-31 0000875729 us-gaap:SeriesAPreferredStockMember 2022-03-31 0000875729 us-gaap:SeriesCPreferredStockMember 2022-03-31 0000875729 us-gaap:CommonStockMember 2022-03-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000875729 bnet:SubscriptionsReceivableMember 2022-03-31 0000875729 us-gaap:RetainedEarningsMember 2022-03-31 0000875729 us-gaap:NoncontrollingInterestMember 2022-03-31 0000875729 2022-03-31 0000875729 us-gaap:CommonStockMember 2023-03-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000875729 bnet:SubscriptionsReceivableMember 2023-03-31 0000875729 us-gaap:RetainedEarningsMember 2023-03-31 0000875729 us-gaap:NoncontrollingInterestMember 2023-03-31 0000875729 bnet:RibbonwireMember 2022-07-01 2023-03-31 0000875729 2020-07-01 2021-06-30 0000875729 2021-07-01 2022-06-30 0000875729 2017-07-01 2018-06-30 0000875729 srt:MinimumMember 2023-03-31 0000875729 srt:MaximumMember 2023-03-31 0000875729 bnet:CenterpointMember 2023-03-31 0000875729 us-gaap:WarrantMember 2022-07-01 2023-03-31 0000875729 us-gaap:WarrantMember 2021-07-01 2022-03-31 0000875729 us-gaap:EmployeeStockOptionMember 2022-07-01 2023-03-31 0000875729 us-gaap:EmployeeStockOptionMember 2021-07-01 2022-03-31 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2022-07-01 2023-03-31 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2021-07-01 2022-03-31 0000875729 bnet:ConvertiblePreferredStockAntidilutiveSecuritiesMember 2022-07-01 2023-03-31 0000875729 bnet:ConvertiblePreferredStockAntidilutiveSecuritiesMember 2021-07-01 2022-03-31 0000875729 bnet:PropertyPlantAndEquipmentOfPA1Member 2022-07-01 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember 2022-03-31 0000875729 bnet:BassaniMember 2022-03-31 0000875729 bnet:SmithMember 2022-03-31 0000875729 bnet:ConsultantsMember 2023-03-31 0000875729 bnet:ConsultantsMember 2022-03-31 0000875729 srt:ChiefExecutiveOfficerMember 2022-07-01 2023-03-31 0000875729 bnet:SmithMember 2023-01-01 2023-03-31 0000875729 bnet:SmithMember 2022-07-01 2023-03-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2023-01-01 2023-03-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2022-01-01 2022-03-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2022-07-01 2023-03-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2021-07-01 2022-03-31 0000875729 bnet:PennvestLoanMember 2023-03-31 0000875729 2021-09-30 0000875729 2021-12-29 0000875729 bnet:YearsOneThroughFiveMember bnet:PennvestLoanMember 2022-07-01 2023-03-31 0000875729 bnet:YearsSixThroughMaturityMember bnet:PennvestLoanMember 2022-07-01 2023-03-31 0000875729 bnet:PennvestLoanMember 2021-07-01 2022-06-30 0000875729 bnet:PennvestLoanMember 2020-07-01 2021-06-30 0000875729 bnet:PA1Member 2014-09-25 0000875729 bnet:PA1Member 2022-06-01 2022-06-15 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-01-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-03-31 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-03-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-03-31 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-03-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-03-31 0000875729 bnet:The2020ConvertibleObligationsMember 2022-07-01 2023-03-31 0000875729 bnet:PrincipalMember bnet:ConvertibleObligations2020Member 2022-07-01 2023-03-31 0000875729 bnet:CommonSharesMember bnet:PrincipalMember bnet:ConvertibleObligations2020Member 2022-07-01 2023-03-31 0000875729 bnet:PrincipalMember bnet:ConvertibleObligations2020Member bnet:WarrantsMember 2022-07-01 2023-03-31 0000875729 bnet:AccruedInterestMember bnet:ConvertibleObligations2020Member 2022-07-01 2023-03-31 0000875729 bnet:CommonSharesMember bnet:AccruedInterestMember bnet:ConvertibleObligations2020Member 2022-07-01 2023-03-31 0000875729 bnet:WarrantsMember bnet:AccruedInterestMember bnet:ConvertibleObligations2020Member 2022-07-01 2023-03-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-01-01 2023-03-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-01-01 2022-03-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-07-01 2023-03-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-07-01 2022-03-31 0000875729 bnet:MarkASmithMember 2023-03-31 0000875729 bnet:DominicBassaniMember 2023-03-31 0000875729 bnet:EdSchaferMember 2023-03-31 0000875729 srt:PresidentMember bnet:SecuredPromissoryNoteMember 2023-03-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniFamilyTrustsMember 2023-03-31 0000875729 bnet:ConsultantsMember bnet:September2015ConvertibleNotesMember bnet:SchaferMember 2023-03-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember bnet:ShareholderMember 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniFamilyTrustsMember 2022-03-31 0000875729 bnet:ConsultantsMember bnet:September2015ConvertibleNotesMember bnet:SchaferMember 2022-03-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember bnet:ShareholderMember 2022-03-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2023-01-01 2023-03-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2022-01-01 2022-03-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2022-07-01 2023-03-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2021-07-01 2022-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember bnet:SmithMember 2023-02-02 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember bnet:BassaniFamilyTrustsMember 2023-02-02 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember bnet:SchaferMember 2023-02-02 0000875729 bnet:BassaniMember srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember 2023-02-02 0000875729 bnet:EdSchaferMember srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember 2023-02-02 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-03-07 2023-03-08 0000875729 bnet:AdjustedConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-03-02 2023-03-31 0000875729 bnet:CommonSharesMember bnet:ConvertibleObligations2020Member 2023-03-07 2023-03-08 0000875729 bnet:WarrantsMember bnet:ConvertibleObligations2020Member 2023-03-07 2023-03-08 0000875729 bnet:DirectOwnershipMember bnet:CommonSharesMember 2023-03-08 0000875729 bnet:DirectOwnershipMember bnet:WarrantsMember 2023-03-08 0000875729 bnet:IndirectOwnershipMember bnet:CommonSharesMember 2023-03-08 0000875729 bnet:IndirectOwnershipMember bnet:WarrantsMember 2023-03-08 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember 2023-03-31 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember 2023-03-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:The2020ConvertibleObligationsMember 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember 2023-03-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember 2023-03-31 0000875729 bnet:RestrictedCommonSharesMember bnet:September2015ConvertibleNotesMember 2023-03-31 0000875729 us-gaap:SeriesBPreferredStockMember 2014-07-02 0000875729 us-gaap:SeriesBPreferredStockMember 2014-07-03 0000875729 us-gaap:SeriesBPreferredStockMember 2014-06-25 2014-07-01 0000875729 us-gaap:SeriesBPreferredStockMember 2023-03-31 0000875729 us-gaap:SeriesBPreferredStockMember 2022-07-01 2023-03-31 0000875729 us-gaap:SeriesBPreferredStockMember 2021-07-01 2022-03-31 0000875729 us-gaap:RestrictedStockMember 2022-07-01 2023-03-31 0000875729 us-gaap:CommonStockMember 2023-01-02 2023-01-10 0000875729 us-gaap:CommonStockMember 2022-12-02 2022-12-31 0000875729 us-gaap:CommonStockMember 2022-07-01 2023-03-31 0000875729 bnet:RestrictedCommonStockMember 2023-01-01 2023-03-31 0000875729 bnet:RestrictedCommonStockMember 2023-03-31 0000875729 bnet:PrincipalMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-07-01 2023-03-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-03-31 0000875729 srt:PresidentMember 2023-03-31 0000875729 bnet:RestrictedCommonStockMember 2022-07-01 2023-03-31 0000875729 bnet:ConsultantServiceMember 2022-07-01 2023-03-31 0000875729 bnet:ConsultantServiceMember 2023-03-31 0000875729 bnet:PrincipalMember bnet:The2020ConvertibleObligationsMember us-gaap:WarrantMember 2022-07-01 2023-03-31 0000875729 bnet:AccruedInterestMember bnet:The2020ConvertibleObligationsMember us-gaap:WarrantMember 2022-07-01 2023-03-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2022-07-01 2023-03-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2023-03-31 0000875729 us-gaap:WarrantMember 2023-03-31 0000875729 bnet:WarrantsMember 2023-03-31 0000875729 bnet:WarrantsMember 2022-07-01 2023-03-31 0000875729 bnet:AdjustedConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-07-01 2023-03-31 0000875729 bnet:CommonSharesMember bnet:ConvertibleObligations2020Member 2022-07-01 2023-03-31 0000875729 bnet:WarrantsMember bnet:ConvertibleObligations2020Member 2022-07-01 2023-03-31 0000875729 bnet:DirectOwnershipMember bnet:CommonSharesMember 2023-03-31 0000875729 bnet:DirectOwnershipMember bnet:WarrantsMember 2023-03-31 0000875729 bnet:IndirectOwnershipMember bnet:CommonSharesMember 2023-03-31 0000875729 bnet:IndirectOwnershipMember bnet:WarrantsMember 2023-03-31 0000875729 bnet:ThreeConsultantsMember us-gaap:WarrantMember 2022-07-01 2023-03-31 0000875729 us-gaap:WarrantMember 2022-07-01 2023-03-31 0000875729 srt:MinimumMember bnet:ThreeConsultantsMember us-gaap:WarrantMember 2023-03-31 0000875729 srt:MaximumMember bnet:ThreeConsultantsMember us-gaap:WarrantMember 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember 2022-05-01 0000875729 bnet:ConsultantsMember us-gaap:WarrantMember 2023-03-31 0000875729 bnet:ConsultantsMember us-gaap:WarrantMember 2022-07-01 2023-03-31 0000875729 bnet:ConsultantsMember us-gaap:WarrantMember 2023-01-01 2023-03-31 0000875729 us-gaap:EmployeeStockOptionMember bnet:EquityIncentivePlanMember 2023-03-31 0000875729 us-gaap:EmployeeStockOptionMember 2023-03-31 0000875729 bnet:Plan2006Member 2022-02-01 2022-02-11 0000875729 2022-04-01 2022-04-29 0000875729 bnet:NorthropMember 2022-04-01 2022-04-29 0000875729 bnet:BassaniMember 2022-04-01 2022-04-29 0000875729 bnet:SmithMember 2022-04-01 2022-04-29 0000875729 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0000875729 us-gaap:EmployeeStockOptionMember 2022-07-01 2023-03-31 0000875729 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0000875729 us-gaap:EmployeeStockOptionMember 2021-07-01 2022-03-31 0000875729 us-gaap:OptionMember 2023-01-01 2023-03-31 0000875729 us-gaap:OptionMember 2022-07-01 2023-03-31 0000875729 us-gaap:OptionMember 2022-01-01 2022-03-31 0000875729 us-gaap:OptionMember 2021-07-01 2022-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteMember 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:WarrantsIssusedSubscriptionReceivableMember 2023-03-31 0000875729 bnet:FormerEmployeeMember bnet:WarrantsIssusedSubscriptionReceivableMember 2023-03-31 0000875729 srt:PresidentMember bnet:WarrantsIssusedSubscriptionReceivableMember 2022-03-31 0000875729 srt:PresidentMember bnet:WarrantsIssusedSubscriptionReceivableMember 2023-03-31 0000875729 bnet:SmithsMember bnet:SecuredPromissoryNoteMember 2023-03-31 0000875729 bnet:FormerEmployeeMember bnet:SecuredPromissoryNoteMember 2023-03-31 0000875729 srt:PresidentMember 2016-10-01 2016-10-10 0000875729 srt:PresidentMember bnet:WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember 2023-03-31 0000875729 2022-04-27 2022-05-02 0000875729 bnet:SmithMember 2022-01-01 2022-03-31 0000875729 bnet:SmithMember 2021-07-01 2022-03-31 0000875729 srt:ChiefExecutiveOfficerMember 2015-02-03 2015-02-10 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2016-10-31 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2017-04-27 0000875729 bnet:BassaniMember 2018-02-28 0000875729 bnet:BassaniMember 2018-07-28 2018-08-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:WarrantsExpiringOnDecember312025Member 2018-08-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2023-01-01 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2022-01-01 2022-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2022-07-01 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2021-07-01 2022-03-31 0000875729 bnet:WilliamONeillMember 2022-04-25 2022-05-02 0000875729 srt:ChiefExecutiveOfficerMember 2023-01-01 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember 2022-01-01 2022-03-31 0000875729 srt:ChiefExecutiveOfficerMember 2021-07-01 2022-03-31 0000875729 2022-01-01 2022-01-28 0000875729 2022-03-02 2022-03-31 0000875729 2022-06-01 2022-06-30 0000875729 2023-01-02 2023-01-17 0000875729 2023-02-09 2023-03-01 0000875729 2022-04-01 2022-04-30 0000875729 2022-03-02 2022-03-23 0000875729 us-gaap:SubsequentEventMember 2023-04-01 2023-05-09 0000875729 us-gaap:SubsequentEventMember 2023-01-01 2023-05-10 0000875729 us-gaap:SubsequentEventMember 2023-04-29 2023-05-01 iso4217:USD shares iso4217:USD shares pure bnet:Decimal 0000875729 false --06-30 2023 Q3 10-Q true 2023-03-31 false 000-19333 Bion Environmental Technologies, Inc CO 84-1176672 9 East Park Court Old Bethpage NY 11804 516 586-5643 Common Stock BNET Yes Yes Non-accelerated Filer true false false 47342061 1612977 3160442 113101 157550 6000 1000 1732078 3318992 107162 145787 5788203 2895558 7627443 6360337 800901 1360644 784255 594798 1585156 1955442 119951 128864 1735507 5170610 3440614 7254916 0.01 0.01 50000 50000 0 0 0 0 0.01 0.01 60000 60000 0 0 0 0 0 0 250000000 250000000 48044790 43758820 47340480 43054511 131208759 123620046 504650 504650 -126554853 -124047548 4149256 -932152 37573 37573 4186829 -894579 7627443 6360337 859011 397743 2356047 1506839 461 252 1185 832 24242 29411 67833 145624 883714 427406 2425065 1653295 -883714 -427406 -2425065 -1653295 1342 1338 4652 4101 -24488 51361 86892 281906 -902490 -902490 10234501 25830 852467 -82240 10859186 -857884 425061 -2507305 9205891 -549 -1544 -857884 425610 -2507305 9207435 -0.02 0.01 -0.06 0.22 45456417 43029511 44165309 41602390 43733820 123150676 -504650 -123558048 38122 -873900 4650 4650 425610 -549 425061 43733820 123155326 -504650 -123132438 37573 -444189 44529884 124627172 -504650 -125696969 37573 -1536874 2375000 2720000 2720000 84000 63000 63000 9844 9844 1055906 99889 99889 220510 220510 -48000 -48000 3516345 3516345 -857884 -857884 48044790 131208759 -504650 -126554853 37573 4186829 41315986 121399067 -504650 -132339873 39117 -11406339 2315550 1736662 1736662 66860 -18601 -18601 7500 7500 35424 17711 17711 4650 4650 8337 8337 9207435 -1544 9205891 43733820 123155326 -504650 -123132438 37573 -444189 43758820 123620046 -504650 -124047548 37573 -894579 2921230 3266230 3266230 158834 119125 119125 50000 80000 80000 57094 57094 1155906 149889 149889 220510 220510 -48000 -48000 159433 159433 68088 68088 3516345 3516345 -2507305 -2507305 48044790 131208759 -504650 -126554853 37573 4186829 -2507305 9205891 10234501 1185 832 86891 299770 220510 17774 80000 154932 57094 -44449 -118778 5000 45000 902490 -908644 223822 29712 -33073 265000 224367 -2481176 -1123830 2403644 1167463 -2403644 -1167463 3266230 119125 1736662 18601 48000 -41000 3337355 1677061 -1547465 -614232 3160442 4216321 1612977 3602089 149888 17711 23943 90000 190000 117342 50145 372844 666375 <p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zpTZC2eo0MB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td><td style="width: 0.25in"/><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_820_zj9B081HhZyf">ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS:</span></b></span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Organization and nature of business: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b/></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Bion’s mission is to make livestock production more sustainable, transparent and profitable. We intend to accomplish this by deploying our Gen3Tech platform/business model (discussed below) in ventures focused on the ‘feeder’ space of the livestock production/value chain to provide the consumer with verifiably sustainable premium products. Bion believes this approach can create extraordinary value for our shareholders and employees (all of whom own securities in the Company). </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our patented and proprietary technology provides advanced waste treatment and resource recovery for large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs"). Livestock production and its waste, particularly from CAFOs, has been identified as one of the greatest soil, air, and water quality problems in the U.S. today.  Application of our third-generation technology and business/technology platform (“Gen3Tech”) can largely mitigate these environmental problems, while simultaneously improving operational/ resource efficiencies by recovering high-value co-products from the CAFOs’ waste stream. These waste ‘assets’ – nutrients and methane – have traditionally been wasted or underutilized and are the same ‘pollutants’ that today fuel harmful algae blooms, contaminate surface groundwater, and exacerbate climate change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms) (“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long-term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion’s Gen3Tech was designed to capture and stabilize these assets and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the animal raising and waste treatment process will be third-party verified, providing the basis for additional revenues, including carbon and/or renewable energy-related credits and, eventually, payment for a range of ecosystem services, including nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">During the first half of 2022 Bion began pre-marketing our sustainable beef to retailers, food service distributors and the meat industry in the U.S.  In general, the response has been favorable. During July 2022, Bion announced a letter of intent (“Ribbonwire LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Ribbonwire Ranch, in Dalhart, Texas (with a provision to expand to 60,000 head) (“Dalhart Project”). During January 2023 Bion announced a letter of intent (“Olson LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Olson Feeders and TD Angus, near North Platte, Nebraska (with a provision to expand to 45,000 head or more) (“Olson Project”). During April 2023 Bion announced a letter of intent (“DVG LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with Dakota Valley Growers near Bathgate, North Dakota. The Olson, Dalhart and DVG Projects (and subsequent Projects) will be developed to produce verified, sustainable beef in customized covered barns (resulting in reduced stress on cattle caused by extreme weather and temperatures and resulting higher feed/weight gain efficiency) with ongoing manure transfer (through slatted floors) to anaerobic digesters (AD) to capture nitrogen from the manure stream before loss to the atmosphere and generate renewable natural gas (RNG) for sale while remediating the environmental/carbon impacts usually associated with cattle feedlots and CAFOs. Bion’s patented technology will refine the waste stream into valuable coproducts that include clean water, RNG, photovoltaic solar electricity and fertilizer (‘climate smart’ and organic) products. We anticipate converting these LOI into definitive JV agreements and creating distribution agreements with key retailers and food service distributors during the next six-nine months.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Our business plan is focused on executing multiple agreements and letters of intent related to additional sustainable beef JV projects over the next twelve months while moving forward with the Initial Project (see below) and one or more of the Dalhart/Olson/DVG Projects (“LOI Projects”)(and/or other Gen3Tech beef JV projects) and pursuing other opportunities in the livestock industry enabled by our Gen3Tech business model.  The Ribbonwire and Olson LOI announcements have generated significant interest within the livestock industry (among ranchers, feedlot operators, farmers and other AG industry parties). We believe that this interest, combined with consumer interest in ‘sustainable products’ and growing enthusiasm among some livestock industry parties for environmental/sustainable/regenerative practices, may provide Bion (and its partners/venturers) with an opportunity to move forward with a truly sustainable solution in this industry segment at a rapid pace.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the next three months, the Company intends to complete construction and begin operations of phase 1 of our Initial Project located near Fair Oaks, Indiana. Bion expects the Initial Project to provide data that illustrates the effectiveness of our Gen3Tech in a commercial-scale setting by the end of the 2<sup>nd</sup> quarter in 2023 and supports development of the LOI Projects (and/or other Gen3Tech beef JV projects) commencing later during 2023.  We do not presently know the order in which these JV Projects will be developed as that decision will be made based on many factors not yet in place. We believe the Initial Project data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, food distributors and retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below). </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion is now focused primarily on: i) development/construction/operation of the Initial Project, our initial commercial-scale Gen3Tech installation, ii) pre-development planning of the Dalhart, Olson and DVG Projects (and/or other Gen3Tech beef JV projects), iii) developing applications and markets for its low carbon ‘ClimateSmart’ and organic fertilizer products (including listings/certifications of multiple liquid and solid products) and its sustainable (conventional and organic) animal protein products, and iv) discussions regarding initiation and development of agreements and joint ventures (“JVs” as discussed below) (and related Projects) based on the augmented capabilities of our Gen3Tech business platform (in the sustainable beef and other livestock segments), while (v) continuing to pursue business opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and vi) ongoing R&amp;D activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><b>HISTORY, BACKGROUND AND CURRENT ACTIVITIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Since the Company’s inception, Bion has designed and developed advanced waste treatment systems for livestock. The first and second generations of Bion’s technology platform were biological systems, primarily focused on nutrient control. Over 30 of these systems were deployed at New York dairies, Florida food processing facilities and dairies, North Carolina hog farms, a Texas dairy and a Pennsylvania dairy (“Kreider 1 Project”). The systems were highly effective at their intended purpose: capturing nitrogen and phosphorus. They produced BionSoil as a byproduct, which was a remarkably effective soil amendment/ fertilizer product, but whose value was not enough to support a viable business model. As such, these early technology iterations were largely dependent on either implementation of new regulations requiring waste treatment, or subsidy/incentive programs that would provide ‘payment for ecosystem services’. By the mid-2010’s, it became apparent that neither of these options were imminent or even assured, so the Company initiated the steps to reimagine and redesign its technology.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From 2016 to 2021 fiscal years, the Company focused most of its activities and resources on developing, testing and demonstrating the third generation of its technology and technology platform (“Gen3Tech”). Our Gen3Tech was developed with an emphasis producing more valuable co-products from the waste treatment process, including renewable natural gas and ammonium bicarbonate, a low-carbon and organic ‘pure’ nitrogen fertilizer product while raising livestock in a verifiably sustainable manner to produce premium sustainable meat products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The $175 billion U.S. livestock industry is under intense scrutiny for its environmental and public health impacts – its ‘environmental sustainability’-- at the same time it is struggling with declining revenues and margins (derived in part from clinging to its historic practices and resulting limitations and impacts) which threaten its ‘economic sustainability’. Its failure to adequately respond to consumer concerns including food safety, environmental impacts, and inhumane treatment of animals have provided impetus for plant-based alternatives such as Beyond Meat and Impossible Burger (and many others) being marketed as “sustainable” alternatives for this growing consumer segment of the market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company believes that its Gen3Tech, in addition to providing superior environmental remediation, creates opportunities for large scale production of i) verifiably sustainable, branded livestock products and ii) verifiably sustainable organic-branded livestock products, both of which will command premium pricing (in part due to ongoing monitoring and third-party verification of environmental performance which will provide meaningful assurances to both consumers and regulatory agencies). Each of these two distinct market segments (which the Company intends to pursue in parallel) presents a large production/marketing opportunity for Bion. Our Gen3Tech will also produce (as co-products) biogas, solar photovoltaic electricity in appropriate locations, and valuable fertilizer products --low carbon and/or organic (which can be utilized in the production of organic grains for use as feed for raising organic livestock (some of which may be utilized in the Company’s JV projects)) and/or marketed to the growing markets for ‘ClimateSmart’ and/or organic fertilizer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During July 2022, January 2023 and April 2023 the Company entered into letters of intent with Ribbonwire Ranch (Dalhart, Texas), Olson Feeders (North Platte, Nebraska) and Dakota Valley Growers (North Bathgate, Dakota), respectively, setting forth the parties’ intentions to negotiate joint venture agreements and enter into JVs to develop and operate initial <span id="xdx_90F_ecustom--Techwastage_uDecimal_c20220701__20230331__srt--CounterpartyNameAxis__custom--RibbonwireMember_zBV9Vn1vAZG" title="Tech wastage">15,000</span> head integrated, sustainable beef facility for each Project including:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 96px"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt; line-height: 106%">a)</span></td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 106%">innovative cattle barns (with slatted floors to facilitate movement of manure to the anaerobic digester and potentially solar PV generation on the rooftops which barns will improve the living conditions of the animals while increasing feeding/weight gain efficiency,</span></td></tr> </table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 96px"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt; line-height: 106%">b)</span></td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 106%">‘customized’ anaerobic digestion systems -- including pretreatment to increase renewable natural gas (‘RNG’) production and an RNG cleaning system (which will include capture/recycling of the CO2) to allow pipeline sales and monetization of related environmental credits, </span></td></tr> </table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 96px"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt; line-height: 106%">c)</span></td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 106%">a Bion Gen3Tech module (which will utilize the recycled CO2 from the RNG production to increase fertilizer yield) for the production of pure nitogen fertilizer ‘ClimateSmart’ and/or organic (for use in organic crop production) plus residual organic solids and clean water, and</span></td></tr> </table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 96px"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt; line-height: 106%">d)</span></td> <td style="font: 12pt Times New Roman, Times, Serif"><span style="font-size: 10pt; line-height: 106%">which will produce verifiably sustainable beef products with USDA certified branding.</span></td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Dalhart Project and the Olson Project, respectively, will include expansion capability up to 60,000 and 45,000 (or more) head of cattle, in aggregate, located at/around/contiguous to the initial Project facilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The opportunity presented by the Ribbonwire LOI and Olson LOI to commercialize the Company’s Gen3Tech and business model matured more quickly than anticipated (reflecting strong industry and public momentum in favor of verifiably sustainable food ventures). As a result, we have shifted our plans to focus resources and make our initial 15,000 head modules a reality as soon as possible.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To place the LOI Projects in the context of Company’s business plan (and our prior public disclosure), if one or more of the contemplated JVs move forward on anticipated timelines, active development of the first LOI Project will commence during the second half of calendar year 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to such activity, the Company intends to construct and operate the initial phase of the previously announced Gen3Tech demonstration project near Fair Oaks, Indiana (“Initial Project”): i) to validate our existing data and modeling at commercial scale and ii) to optimize the Bion Gen3Tech module for finalization of design parameters and fabrication details of our planned 15,000 head commercial facilities (including the 3 sets of LOI Projects). For the purposes of this initial phase, the Company, in order to accelerate the data acquisition phase, intends to utilize anaerobic digester effluent from the nearby/contiguous Fair Oaks dairy. Construction and related activities of this demonstration project have commenced with main module assembly on site in process since February 2023 (somewhat delayed due to supply chain constraints) followed by operations through the first half of 2023 (and thereafter) to generate the required information. Thereafter, the Company will evaluate what, if any, additional facilities and testing will take place at that location.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company anticipates that it will negotiate additional letters of intent and enter into additional joint ventures related to the development of further commercial-scale sustainable beef projects over the next 6-18 months in addition to the Dalhart, Olson and DVG Projects.</p> <p style="font: 14pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As previously disclosed, during late September 2021, Bion entered into a lease for the development site of the Initial Project, our initial commercial scale Gen3Tech project, which Initial Project will be located on approximately four (4) acres of leased land near Fair Oaks, Indiana, and a related agreement regarding disposal of certain manure effluent with the Curtis Creek Dairy unit of Fair Oaks Farms (“FOF”). Design and pre-development work commenced during August 2021 and surveying, site engineering and other site-specific engineering and design work is largely completed. Fabrication of the primary Gen3Tech equipment modules for the Initial Project commenced during January 2022. Construction work has been largely completed to prepare for the arrival in mid-February of the main modules of the Gen3Tech system. The Initial Project was initially planned to be an environmentally sustainable beef cattle feeding facility, equipped with state-of-the-art housing and Bion’s 3G-Tech platform to provide waste treatment and resource recovery. Bion designed the project to house and feed approximately <span id="xdx_90D_ecustom--CattlePerHead_uDecimal_c20220701__20230331_zVruEsGIzXh7" title="Cattle per head">300</span> head of beef cattle. If all phases of the Initial Project are constructed, the facility will include Bion’s Gen3Tech platform including: i) covered barns ( including roof top solar photovoltaic generation in appropriate locations), ii) anaerobic digestion for renewable energy recovery, iii) livestock waste treatment and resource recovery technology, iv) Bion’s ammonium bicarbonate recovery (and crystallization) technology and iv) data collection software to document system efficiencies and environmental benefits (with the Bion Gen3Tech facilities capable of treating the waste from approximately <span id="xdx_906_ecustom--Techwastage_uDecimal_c20220701__20230331_zbkSZ0Likti7" title="Tech wastage">1,500</span> head). The facility will be large enough to demonstrate engineering capabilities of Bion’s Gen3Tech at commercial scale, but small enough that it can be constructed and commissioned relatively quickly. Originally, construction and onsite assembly operations were targeted to commence sometime late in 2022, however, supply chain backlogs have delayed likely delivery dates for core modules of the Bion system to the site until February 2023. 3G1 has been moving forward with the development and construction process of the Initial Project which we expect to become operational during the current quarter ending June 2023. See Note 3 “Property and Equipment” and Note 10 “Subsequent Events” (for activities since the start of the fourth quarter of the 2023 fiscal year).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing larger commercial projects with JV partners.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Specifically, the Initial Project (if all phases are constructed) is being developed to provide and/or accomplish (if all phases are constructed) the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">i.</span></td> <td style="font: 12pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Proof of Gen3Tech platform scalability</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">-</span></td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Document system efficiency and environmental benefits and enable final engineering modifications to optimize each unit process within the Bion Gen3Tech platform.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">-</span></td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Environmental benefits will include (without limitation) renewable energy production (natural gas recovery from AD and solar electric from integrated roof top photovoltaic generation); nutrient recovery and conversion to stable ‘ClimateSmart’ (low carbon) and/or organic fertilizer; pathogen destruction; water recovery and reuse; air emission reductions.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">ii.</span></td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Use Bion’s data collection system to support 3rd party verified system efficiency requirement to qualify for USDA Process-Verified-Program (PVP): certification of sustainable branded beef (and potentially pork) product metrics.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">iii.</span></td> <td style="font: 12pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Produce sufficient ammonium bicarbonate nitrogen fertilizer for certification/listing applications and commercial testing by potential joint venture partners and/or purchasers and for university growth trials.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Initial Project will be carried out in stages with phase one focused on portions of items i. and iii. set forth above.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon completing the primary goals of phase 1 of the Initial Project, (coupled with progress regarding certifications(s) and markets for our fertilizer product lines (liquid and/or solid)), Bion expects to be ready to move forward with its plans for development (and related project financing) of much larger facilities including the LOI Projects. The Company anticipates that discussions and negotiations it has begun (together with additional opportunities that will be generated over the next 6-18 months) regarding potential JVs with strategic partners in the financial, livestock and food distribution industries to develop large scale projects will continue during the development/construction of the Initial Project with a 2023-24 goal of establishing multiple JV’s for large scale projects that will produce sustainable and/or sustainable-organic corn-fed beef. These products will be supported by a USDA PVP-certified sustainable brand that will, initially, highlight reductions in carbon and nutrient footprint, as well as pathogen reductions associated with foodborne illness and antibiotic resistance, along with the organic designation where appropriate. Bion’s RNG, nutrient, and water recovery will be transparent, third-party verified, and supported by blockchain --- that data, coupled with cattle production history, will underpin the sustainable brand. Sustainability will be measured by improvements in resource efficiencies, animal health and welfare, and reduced impacts to air, water, and soil, and will be communicated to the consumer at the point of sale. Bion has successfully navigated the USDA PVP application process previously, having received conditional approval of its 2G Tech platform (pending resubmission and final site audits), and is confident it will be successful in qualifying its Gen3Tech platform.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After the basic technology start-up milestones of the Initial Project (primarily optimization and steady-state operations of the core modules of our Gen3Tech platform to generate data to support design/development of larger 15,000 head commercial modules) have been met, the core modules may be re-located to a subsequent more permanent location to be determined at a later date. The Company is in discussion with the University of Nebraska-Lincoln to jointly develop an integrated beef facility based on Bion’s Gen3Tech and business model at its Klosterman Feedyard Innovation Center (“KFIC”) (or elsewhere) including innovative barns, an anaerobic digester and a Bion Gen3Tech system to conduct ongoing research and development related thereto and the KFIC is a possible site for the long term re-location of the core modules. This venture, if it moves forward, is anticipated to include joint preparation of applications for grants and other funding from the USDA (‘climate smart’ program, rural development, etc.) and other sources. The Company is also considering re-locating the core modules of the Initial Project to Dalhart, Texas, where they may be integrated into the first phases of the Dalhart Project or a separate smaller organic beef project. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s initial ammonium bicarbonate liquid fertilizer product completed its Organic Materials Review Institute (“OMRI”) application and review process with listing approval during May 2020. Applications for our first solid ammonium bicarbonate product line with OMRI and the California Department of Food &amp; Agriculture (“CDFA”) have been unsuccessful to date. Later this calendar year (Summer/Fall 2023) the Company intends to pursue further applications for liquid and solid products (of varying nitrogen concentrations) utilizing material produced at the Initial Project. See ‘<b>Fertilizer: Organic and ClimateSmart’</b> below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, the Company believes there will also be opportunities to proceed with selected ‘retrofit projects’ of existing facilities (see ‘<b><span style="text-decoration: underline">Gen3Tech Kreider 2 Poultry Project’</span></b> below as an example) in the swine, dairy and poultry industries utilizing our Gen3Tech.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Bion believes that substantial unmet demand currently exists– potentially very large – for ‘real’ meat/dairy/egg products that offer the verifiable/believable sustainability consumers seek, but with the taste and texture they have come to expect from American beef and pork, dairy and poultry. Numerous studies demonstrate the U.S. consumers’ preferences for sustainability. For example, 2019 NYU Stern’s Center for Sustainable Business study found that ‘products marketed as sustainable grew 5.6 times faster than those that were not…’ and that ‘…in more than 90 percent of consumer-packaged-goods (CPG) categories, sustainability-marketed products grew faster than their conventional counterparts.’ Sales growth of plant-based alternatives, including both dairy and more recently ground meat (Beyond Meat, Impossible Foods, etc.) have shown that a large and growing segment of consumers is choosing seemingly sustainable offering, and are also willing to pay a premium for it. Tyson Foods recently said, “consumers would be willing to pay at least 24 percent more for environmentally friendly, sustainable options at retail.” Numerous studies also support the consumers’ ‘willingness-to-pay’ (WTP) for sustainable choices, including a recent meta-analysis of 80 worldwide studies with results that calculate the overall WTP premium for sustainability is <span id="xdx_900_ecustom--PercentageOfSustainable_dp_c20220701__20230331_z9PN45MXpEgg" title="Percentage of sustainable">29.5</span> percent on average.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As one of the largest contributors to some of the greatest air and water quality problems in America, it is clear that livestock waste cleanup, at scale, represents one of the greatest opportunities we have to reduce negative environmental impacts of the food supply chain on air and water quality. Bion’s Gen3Tech platform, along with its business model, will enable the cleanup of one of the ‘dirtiest’ parts of the food supply chain: animal protein production and creates the opportunity to produce and market verifiably sustainable organic and conventional ‘real meat’ products that can participate in the growth and premium pricing that appears to be readily available for the ‘right’ products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion believes that at least a premium segment of the U.S. beef industry (and potentially other livestock industry groups) is at the doorstep of a transformative opportunity to address the growing demand for sustainable food product offerings, while pushing back against today’s anti-meat messaging. At $66 billion/year (2021 wholesale/farmgate value), the beef industry is a fragmented, commodity industry whose practices date back decades. In 1935 inflation-adjusted terms, beef was 63% more expensive in 2021, while pork and chicken, which are now primarily raised in covered barns at CAFOs with highly integrated supply chains, were 12% and 62% cheaper, respectively. In recent years, the beef industry has come under increasing fire from advocacy groups, regulatory agencies, institutional investors, and ultimately, their own consumers, over concerns that include climate change, water pollution, food safety, and the treatment of animals and workers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advocacy groups targeting livestock and the beef industry have recently been joined by competitors that produce animal protein alternatives in seeking to exploit the industry’s environmental and economic weaknesses. Their global anti-meat messaging has had a substantial chilling effect on the relationships the beef industry has with its institutional investors; retail distributors, such as fast-food restaurants; and mostly, its consumers. Led by the United Nations Food and Agriculture Organization, a coordinated anti-meat messaging campaign has targeted consumers worldwide, primarily focused on the industry’s impacts on climate change. Meat alternatives, especially plant-based protein producers like Beyond Meat and Impossible Foods, are being heavily promoted by themselves and the media, and have enjoyed steady sales growth. A 2018 NielsenIQ Homescan survey last year found that 39% of Americans are actively trying to eat more plant-based foods. Some of the recent growth in plant-based proteins results from increasing lactose intolerance and other health concerns; however, most of that growth is attributed to consumers’ growing concerns for the environmental impacts of real meat and dairy. Several large US companies that have traditionally focused on livestock production, including Cargill, ADM, Perdue Foods, and Tyson, have also recently entered the plant protein space. In terms of changing customer preferences, ‘saving the planet’ has proven to be a more compelling argument than the traditional animal activism/ welfare pitch. To date, the primary ‘industry response’ to this has been grass-fed beef, which is regarded as a generally more sustainable offering than grain-fed (largely without empirical evidence). However grass-fed beef has had only limited acceptance in U.S. markets, because it is less flavorful and tougher than the traditional corn-fed beef consumers have grown to enjoy. Sustainability initiatives have been launched by large US livestock producers (including Tyson’s very recent ‘Brazen’ program), but it is not yet possible to determine whether any will be substantive and verifiable rather than completely ‘modeled’ and largely public relations ‘greenwashing’.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">It should be noted that these plant-based protein producers are primarily expected to be able to serve the ground/ processed meat market, which represents only about 10 percent of the overall animal protein market. Further, there has recently been pushback to these plant-based products, focusing on their highly processed nature and unproven health benefits, scalability/ pricing, and their uncertain carbon footprint---and market growth rates have substantially slowed and may have already plateaued and/or peaked. There have also been several companies recently enter the cellular and 3D-printed meat arena. While facing myriad challenges and further out on the development timeline, some people believe cellular agriculture (aka cultured, clean, lab-grown, cultivated) meat may have the potential to service a much larger percentage of the market than plant-based protein, including cuts like steaks, chops and roasts, but the likely cost remains very uncertain at this point.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each of these items supports Bion’s belief that there is a potentially very large opportunity to supply premium sustainable beef products that satisfy consumer concerns. We believe that the real meat/beef products that can be cost-effectively produced today using our Gen3Tech platform, both sustainable and/or organic, can provide an affordable product that satisfies the consumer’s desire for sustainability, but with the superior taste and texture those consumers have grown to prefer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Sustainable Beef</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion’s goal is to be first to market with meaningfully verified sustainable beef products that can be produced at sufficient scale to service national market demand. The cattle produced at a Bion facility will have a substantially lower carbon footprint, dramatically reduced nutrient impacts to water, and an almost total pathogen kill in the waste stream. Further, the economics of producing these cattle (including the cost of the facility/technology upgrade) will be greatly enhanced by the revenue realized from the recovery of valuable resources, including renewable energy, high-value fertilizer products, and clean water.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A Bion sustainable beef facility will be comprised of covered barns with slotted floors (allowing the waste to pass through) which will reduce ammonia and greenhouse gas volatilization and loss, as well as odors, thereby improving animal health and human working conditions while preventing air/soil pollution. The manure will be collected and moved directly to anaerobic digestion facilities which will produce renewable natural gas (and re-cycle CO2 from the gas cleaning process). Covered barns will reduce weather impacts on the livestock and have been demonstrated to promote improved general health and weight gain in the cattle housed in them. The barns’ very large roof surface area will be utilized (in geographical locations with adequate sunshine and appropriate ‘tariffs’) for the installation of photovoltaic solar generation systems to produce electricity for the facility, as well as export to the grid. The barn roofs will also be configured to capture rainwater, which, coupled with the water recovered from the treatment process, will reduce the projects’ reliance on current water supplies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Waste treatment and resource recovery will be provided by Bion’s advanced Gen3Tech platform, which Bion believes offers the most comprehensive solution for livestock waste available today. In addition to direct environmental benefits, every pound of nitrogen that is captured, upcycled, and returned to the agricultural nitrogen cycle as high-quality fertilizer (vs lost to contaminate downstream waters), is also a pound of nitrogen that will not have to be produced as synthetic urea or anhydrous ammonia, with their tremendous carbon cost. System performance and environmental benefits will be monitored and verified through third parties, with USDA PVP certification of the sustainable brand that Bion also believes will be the most comprehensive available in the market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Recently there have been efforts to establish sustainable brands (including USDA PVP certification) for a number of small-scale livestock producers (largely in the grass-fed beef category). To date, the reach and extent of such efforts is limited and it is difficult to determine their effectiveness. Additionally, there have been public announcements of initiatives related to beef sustainability (largely focused on the ‘cow-calf’ segment of the livestock chain) in procurement by major beef processing companies (including Tyson’s very recent ‘Brazen’ program), but a closer look finds that many have consisted largely of ‘green washing’ public proclamations in the wake of environmental and social criticism that re-package prior initiatives and lack any significant new substance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Sustainable Organic Beef</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion also believes it has a unique opportunity to produce, at scale, affordable corn-fed organic beef that is also certified as sustainable. In addition to the sustainable practices described above, organic-sourced beef cows would be finished on organic corn, which would be produced using the ammonium bicarbonate fertilizer captured by the Gen3Tech platform. Bion believes its meat products will meet consumer demands with respect to sustainability and safety (organic) and provide the tenderness and taste American consumers have come to expect from premium conventional American beef. Such products are largely unavailable in the market today. We believe Bion’s unique ability to produce the fertilizer needed to grow a supply of relatively low-cost organic corn, and the resulting opportunity to produce organic beef, will dramatically differentiate us from potential competitors. This organic opportunity is dependent on successfully establishing Bion’s fertilizer products as acceptable for use in organic grain production.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Today, organic beef demand is limited and mostly supplied with grass-fed cattle. While organic ground/ chopped meat has enjoyed success in U.S. markets, grass-fed steaks have seen limited acceptance, mostly resulting from consumer issues with taste and texture. In other words, it’s tough. Regardless, such steaks sell for a significant premium over conventional beef. A grain-finished organic beef product is largely unavailable in the marketplace today due to the higher costs of producing organic corn and grain. The exception is offerings that are very expensive from small ‘boutique’ beef producers. Like all plants, corn requires nitrogen to grow. Corn is especially sensitive to a late-season application of readily available nitrogen – the key to maximizing yields. With non-organic field corn, this nitrogen is supplied by an application of a low-cost synthetic fertilizer, such as urea or anhydrous ammonia. However, the cost for suitable nitrogen fertilizer that can be applied late-season in organic corn production is so high that the late-season application becomes uneconomical, resulting in substantially lower yields – a widely recognized phenomena known as the ‘yield gap’ in organic production. The yield gap results in higher costs for organic corn that, in turn, make it uneconomical to feed that corn to livestock. As is the case for sustainable but not organic beef, Bion believes there is a potentially large unmet demand for affordable beef products that are both sustainable AND organic, but with the taste and texture consumers have come to expect from American beef. Bion’s ability to produce the low-cost nitrogen fertilizer that can close the organic yield (and affordability) gap puts the Company in a unique, if not exclusive at this time, position to participate in JV’s that will benefit from this opportunity starting next year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The demonstrated willingness of consumers to purchase sustainable products (along with numerous research and marketing studies confirming consumers are seeking, and are willing to pay a premium for, sustainable products)---in combination with the threat to the livestock industry market (primarily beef and pork) posed by plant-based alternatives (heightened by pandemic conditions)--- has succeeded in focusing the large scale livestock industry on how to meet the plant-based market challenge by addressing the consumer sustainability issues. The consumer demand for sustainability appears to be a real and lasting trend, but consumers remain skeptical of generalized claims of ‘sustainability’. To date, a large portion of the industry responses to this trend have been at a superficial level or consist of ‘green washing’, a deceptive marketing practice where companies promote non-substantive initiatives. Real sustainability for the livestock industry will require implementation of advanced waste treatment technology at or near the CAFOs – where most of the negative environmental impacts take place.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Fertilizer: Organic and ‘Climate Smart’</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“Gen3Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of low carbon and/or organically certified soluble nitrogen fertilizer products. The Company’s low concentration ammonium bicarbonate liquid product successfully completed its Organic Materials Review Institute (“OMRI”) application and review process with listing approval during May 2020. During the next 3-6 months the Company intends to file applications for a line of higher concentration (up to 7-10%) liquid ammonium bicarbonate products during the current year based on production during operation of the Initial Project during the next 3-6 months. The Company anticipates applying for and obtaining one or more listings/certifications for higher concentration products in our liquid ammonium nitrogen fertilizer line well prior to operational dates for the Company’s initial large scale JV Gen3Tech Sustainable Beef Projects.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, the Company is exploring the market potential for its fertilizer to be a verifiably ‘ClimateSmart’ product (potentially a much larger market than the organic market). This may require working with industry and academic entities to develop appropriate metrics and producing a ‘life cycle assessment’ (LCA) for Bion’s ammonium nitrogen fertilizer product which can be compared to conventional nitrogen fertilizer products. Bion’s processes will capture and utilize CO2 in the waste stream (including CO2 produced with the renewable natural gas (RNG) by anaerobic digestion) as stabilizing agent thereby potentially creating carbon offsets compared to natural gas utilized as feedstock in chemical ammonia production which reduction will be reflected in the LCA. This LCA will assess environmental impacts associated with fertilizer production in support of the beef cattle supply chain for both the existing conventional approach (primarily fossil fuel-based Haber-Bosch production methods) and the largely decarbonized Bion production approach. We believe a series of coincident yet significant LCA benefits accrue from Bion’s patented fertilizer production approach including the reduced loss of ammonia to the environment via air (volatilized) and water (nitrate in groundwater) pathways, recycled/reused water, elimination of pathogens, the production of renewable natural gas, the production solar energy from photovoltaic panels on barn roofs, enhanced animal welfare practices and reduced animal husbandry risks from extreme weather events. Bion believes that current evaluations of the carbon impact from feedlot operations materially underestimate the negative impacts because existing models do not properly include significant ‘downstream’ carbon impacts of required energy intensive waste water treatment for re-deposited ammonia nitrogen. If the Company determines there is a significant ‘ClimateSmart’ opportunity for our fertilizer products, such an LCA can be completed (based in part on data from the Initial Project) and support marketing efforts well prior to operational dates for the Company’s initial large scale JV Gen3Tech projects.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ammonium bicarbonate, manufactured using thermal and mechanical processes, has a long history of use as a fertilizer. In addition to liquid ammonium nitrogen fertilizer, Bion’s Gen3Tech is capable of recovering nitrogen in the form of solid ammonium bicarbonate products containing up to 18-22 (or higher) percent nitrogen in a crystalline form that is easily transported (while producing liquids with various percentages of ammonium bicarbonate nitrogen during interim stages of the process). This solid product is water soluble and provides a readily available nitrogen source for crops. It will contain virtually none of the other salt, iron and mineral constituents of the livestock waste stream that often accompany other organic fertilizers. This product is being developed to fertilizer industry standards so that it that can be precision-applied to crops using existing equipment. Bion believes that this product will potentially have broad applications in the production of organic and/or ClimateSmart grains for livestock feed, row crops, horticulture, greenhouse and hydroponic production, and potentially retail lawn and garden products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ammonium bicarbonate products (liquid and solid) produced by Bion’s Gen3Tech platform will enjoy a dramatically lower carbon footprint than synthetic nitrogen fertilizers. The reactive nitrogen captured and upcycled into our fertilizer products was going to be lost through volatilization and runoff, and that loss would generally need to be offset with a synthetic nitrogen fertilizer, such as anhydrous ammonia or urea. These synthetic nitrogen products are produced through the Haber-Bosch (and other) synthetic processes, which converts hydrogen and atmospheric nitrogen to ammonia, with methane from fossil fuels as the energy source. It is an extremely energy-intensive process with a carbon footprint that, while not yet fully understood, is widely accepted to by very large. While a complete Life Cycle Assessment (LCA) of carbon impacts from synthetic fertilizer production is not yet available, according to the Institute for Industrial Productivity, its production alone is responsible for approximately 1 percent of total global CO2 emissions. To the extent that Bion can capture and repurpose the nitrogen traditionally lost from livestock waste, that carbon cost will no longer need to be paid by the environment/climate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Applications for our first solid form of concentrated ammonia, soluble nitrogen fertilizer product line have been filed with OMRI (filed during May 2021) and the California Department of Food &amp; Agriculture (“CDFA”)(filed during May 2022) without success to date. After an extended review processes (which was largely opaque), the OMRI application proceeded through multiple stages without receiving a positive result. The Company believes that OMRI failed to properly follow its own procedures and reached a result without scientific support. The Company has elected to proceed with “Judicial Dispute Resolution” as set forth in the OMRI Policy Manual and has initiated litigation contesting the determination. OMRI filed its Answer to Bion’s Complaint during the first week of May 2023 and the discovery process has now commenced. Recently the Company has also received a negative determination from CDFA. We have initiated an informal dialogue with CDFA regarding the basis for and re-consideration of its initial determination. The Company’s solid product line is novel in part due to the fact that there is not a formal listing category in the organic space for a solid form of concentrated ammonia, soluble nitrogen fertilizers and there is no clear guidance at present from internal policy manuals on how to categorize this product and the process that produces it. There is also no clear guidance at present from either the NOP or the National Organic Standards Board (“NOSB”) (which is currently involved in a related review and recommendations process regarding ‘high nitrogen liquid fertilizers’ derived from ammonia from manure). The Company and its representatives, along with a number of other stakeholders, are involved in discussions regarding resolution of these matters at all three levels. The Company intends to continue efforts to obtain listing/certification for its solid nitrogen fertilizer line over the course of this calendar year.</p> <p style="font: 10pt/110% Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Gen3Tech Kreider 2 Poultry Project</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_906_ecustom--DescriptionOfKreider2PoultryProject_c20220701__20230331_zohycPnXrNij">Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) (‘Kreider Renewable Energy Facility’ or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). Now that development of the Company’s Gen3Tech is being deployed, the Company has commenced discussions with KF regarding updating and amending the JV agreement and anticipates executing an amended joint venture agreement during 2023. During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2<sup>nd</sup> generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA).</span> Note that this Project may also be expanded in the future to treat wastes from other local and regional CAFOs (poultry and/or dairy---including the Kreider Dairy) and/or additional Kreider poultry expansion (some of which may not qualify for nutrient reduction credits). The Company anticipates if and when PA2 re-commences work on the Kreider 2 Project, it will submit a new application based on our Gen3Tech. Site specific design and engineering work for this facility have not commenced, and the Company does not yet have financing in place for the Kreider 2 Project. This opportunity is being pursued through PA2. If there are positive developments related to the market for nutrient reductions in Pennsylvania, of which there is no assurance, the Company intends to pursue development, design and construction of the Kreider 2 Project with a goal of achieving operational status for its initial modules during the following calendar year. The economics (potential revenues and profitability) of the Kreider 2 Project, despite its proposed use of Bion’s Gen3Tech for increased recovery of marketable by-products and sustainable branding, are based in material part the long-term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. However, liquidity in the Pennsylvania nutrient credit market has not yet developed significant breadth and depth, which lack of liquidity has negatively impacted Bion’s business plans and will most likely delay PA2’s Kreider 2 Project and other proposed projects in Pennsylvania.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Note that while Bion believes that the Kreider 2 Project and/or subsequent Bion Projects in PA and the Chesapeake Bay Watershed will eventually generate revenue from the sale of: a) nutrient reductions (credits or in other form), b) renewable energy (and related credits), c) sales of fertilizer products, and/or d) potentially, in time, credits for the reduction of greenhouse gas emissions, plus e) license fees/premiums related to a ‘sustainable brand’, the Covid-19 pandemic has delayed legislative efforts needed to commence its development. However, the Company is currently engaged in dialogue with the regional EPA office and the Chesapeake Bay Program Office regarding the potential of the Company’s Gen3Tech Kreider2 Project (and other potential projects) to enable Pennsylvania to move forward toward meeting its Chesapeake Bay clean-up goals. We believe that the potential market is very large, but it is not possible to predict the exact timing and/or magnitude of these potential markets at this time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Technology Deployment: Bion Gen3Tech</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Widespread deployment of waste treatment technology, and the sustainability it enables, is largely dependent upon generating sufficient additional revenues to offset the capital and operating costs associated with technology adoption. Bion’s Gen3Tech business platform has been developed to create opportunities for such augmented revenue streams, while providing third party verification of sustainability claims. The Gen3Tech platform has been designed to maximize the value of co-products produced during the waste treatment/recovery processes, including pipeline-quality renewable natural gas (biogas) and commercial fertilizer products approved for organic production. All processes will be verifiable by third parties (including regulatory authorities and certifying boards) to comply with environmental regulations and trading programs and meet the requirements for: a) renewable energy and carbon credits, b) organic certification of the fertilizer coproducts and c) USDA PVP certification of an ‘Environmentally Sustainable’ brand (see discussion above and below), and d) payment for verified ecosystem services. The Company’s first patent on its Gen3Tech was issued during 2018. In August 2020, the Company received a Notice of Allowance on its third patent which significantly expands the breadth and depth of the Company’s Gen3Tech coverage. The Company has additional applications pending and/or planned.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In parallel with technology development, Bion has worked (which work continues) to implement market-driven strategies designed to stimulate private-sector participation in the overall U.S. nutrient and carbon reduction strategy. These market-driven strategies can generate “payment for ecosystem services”, in which farmers or landowners are rewarded for managing their land and operations to provide environmental benefits that will generate additional revenues. Existing renewable energy credits for the production and use of biogas are an example of payment for ecosystem services. Another such strategy is nutrient trading (or water quality trading), which will potentially create markets (in Pennsylvania and other states) that will utilize taxpayer funding for the purchase of verified pollution reductions from agriculture (“nutrient credits”) by the state (or others) through competitively-bid procurement programs. Such credits can then be used as a ‘qualified offset’ by an individual state (or municipality) to meet its federal clean water mandates at significantly lower cost to the taxpayer. Market-driven strategies, including competitive procurement of verified credits, is supported by U.S. EPA, the Chesapeake Bay Commission, national livestock interests, and other key stakeholders. Legislation in Pennsylvania to establish the first such state competitive procurement program passed the Pennsylvania Senate by a bi-partisan majority during March 2019 but has not yet crossed the hurdles required for actual adoption. The Covid-19 pandemic and related financial/budgetary crises have slowed progress for this and other policy initiatives and, as a result, it is not currently possible to project the timeline for completion (or meaningful progress) of this and other similar initiatives (see discussion below).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The livestock industry and its markets are already changing. With our commercial-ready technology and business model, Bion believes it has a ‘first-mover advantage’ over others that will seek to exploit the opportunities that will arise from the industry’s inevitable transformation. Bion anticipates moving forward with the development process of its initial commercial installations utilizing its Gen3Tech, during the current 2023 fiscal year. We believe that Bion’s Gen3Tech platform and business model can provide a pathway to true economic and environmental sustainability with ‘win-win’ benefits for at least a premium sector of the livestock industry, the environment, and the consumer, an opportunity which the Company intends to pursue.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">The Livestock Problem</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The livestock industry is under tremendous pressure from regulatory agencies, a wide range of advocacy groups, institutional investors and the industry’s own consumers, to adopt sustainable practices. Environmental cleanup is inevitable and has already begun — and policies have already begun to change, as well. Bion’s Gen3Tech was developed for implementation on large scale livestock production facilities, where scale drives both lower treatment costs and efficient co-products production, as well as dramatic environmental improvements. We believe that scale, coupled with Bion’s verifiable treatment technology platform, will create a transformational opportunity to integrate clean production practices at (or close to) the point of production—the primary source of the industry’s environmental impacts. Bion intends to assist the forward-looking segment of the livestock industry to bring animal protein production in line with 21<sup>st</sup> Century consumer demands for meaningful sustainability.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the U.S. (according to the USDA’s 2017 agricultural census) there are over 9 million dairy cows, 90 million beef cattle, 60 million swine and more than 2 billion poultry which provides an indication of both the scope of the problem addressed by Bion’s technology, as well as the size of Bion’s opportunity. Environmental impacts from livestock production include surface and groundwater pollution, greenhouse gas emissions, ammonia, and other air pollution, excess water use, and pathogens related to foodborne illnesses and antibiotic resistance. While the most visible and immediate problems are related to nutrient runoff and its effects on water quality, the industry has recently been targeted by various stakeholder groups for its impacts on climate change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Estimates of total annual U.S. livestock manure waste vary widely, but start around a billion tons, between 100 and 130 times greater than human waste. However, while human waste is generally treated by septic or municipal wastewater plants, livestock waste – raw manure – is spread on our nation’s croplands for its fertilizer value. Large portions of U.S. feed crop production (and most organic crop production) are fertilized, in part, in this manner. Under current manure management practices, 80% or more of total nitrogen from manure, much of it in the form of ammonia, escapes during storage, transportation, and during and after soil application, representing both substantial lost value and environmental costs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">More than half of the nitrogen impacts from livestock waste come from airborne ammonia emissions, which are extremely volatile, reactive and mobile. Airborne ammonia nitrogen eventually settles back to the ground through atmospheric deposition — it ‘rains’ everywhere. While some of this nitrogen is captured and used by plants, most of it runs off and enters surface waters or percolates down to groundwater. It is now well-established that most of the voluntary conservation practices, such as vegetated buffers that ‘filter’ runoff (often referred to as “BMPs” or “Best Management Practices” that have traditionally been implemented to attempt to mitigate nutrient runoff), are considerably less effective than was previously believed to be the case. This is especially true with regard to addressing the volatile and mobile nitrogen from ammonia emissions, because BMPs are primarily focused on surface water runoff, directly from farm fields in current production, versus the re-deposition that takes place everywhere or groundwater flow.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Runoff from livestock waste has been identified in most of our major watersheds as a primary source of excess nutrients that fuel algae blooms in both fresh and saltwater. Over the last several years, algae blooms have become increasingly toxic to both humans and animals, such as the Red Tides on the Florida and California coasts, and the Lake Erie algae bloom that cut off the water supply to Toledo, Ohio, residents in 2014. When the nutrient runoff subsides, it leaves the algae blooms with no more ‘food’ and the blooms die. The algae’s decomposition takes oxygen from the water, leading to ‘dead zones’ in local ponds, lakes, and ultimately, the Great Lakes, as well as the Chesapeake Bay, Gulf of Mexico, and other estuary waters. Both the toxic algae blooms and the low/no-oxygen dead zones devastate marine life, from shrimp and fish to higher mammals, including dolphins and manatees. U.S. EPA already considers excess nutrients “one of America’s most widespread, costly and challenging environmental problems”. Nutrient runoff is expected to worsen dramatically in the coming decades due to rising temperatures and increasing rainstorm intensity as a result of climate change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nitrate-contaminated groundwater is of growing concern in agricultural regions nationwide, where it has been directly correlated with nutrient runoff from upstream agricultural operations using raw manure as fertilizer. Pennsylvania, Wisconsin, California and Washington, and others, now have regions where groundwater nitrate levels exceed EPA standards for safe drinking water. High levels of nitrate can cause blue baby syndrome (methemoglobinemia) in infants and affect women who are or may become pregnant, and it has been linked to thyroid disease and colon cancer. EPA has set an enforceable standard called a maximum contaminant level (MCL) in water for nitrates at 10 parts per million (ppm) (10 mg/L) and for nitrites at 1 ppm (1 mg/L). Federal regulations require expensive pretreatment for community water sources that exceed the MCL; however, private drinking water wells are not regulated, and it is the owners’ responsibility to test and treat their wells. Additionally, groundwater flows also transport this volatile nitrogen downstream where, along its way, it intermixes with surface water, further exacerbating the runoff problem. Like atmospheric deposition, the current conservation practices we rely on to reduce agricultural runoff are largely bypassed by this subsurface flow.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, in arid climates, such as California, airborne ammonia emissions from livestock manure contribute to air pollution as a precursor to PM2.5 formation, small inhalable particulate matter that is a regulated air pollutant with significant public health risks. Whether airborne or dissolved in water, ammonia can only be cost-effectively controlled and treated at the source—before it has a chance to escape into the environment where it becomes extremely expensive to ‘chase’, capture, and treat.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">High phosphorus concentrations in soils fertilized with raw manure are another growing problem. The ratio of nitrogen to phosphorus in livestock waste is fixed, and because manure application rates are calculated based on nitrogen requirements, often phosphorus is overapplied as an unintended consequence. Phosphorus accumulation in agricultural soils reduces its productivity, increases the risk of phosphorus runoff, and represents a waste of a finite resource. Decoupling the nitrogen from the phosphorus would allow them to be precision-applied, independently of each other, when and where needed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The livestock industry has recently come under heavy fire for its impacts on climate change, which has become a rallying cry for the anti-meat campaign discussed above. Estimates of the magnitude of those impacts vary widely, but the general consensus is that globally, livestock account for 14.5 percent of greenhouse emissions. In the U.S. however, that number drops to 4.2 percent, due to the increased efficiencies of American beef production. The greatest impacts come from direct emissions of methane from enteric fermentation (belches), methane and nitrous oxide emissions from the manure, with arguably the largest being the massive carbon footprint of the synthetic nitrogen fertilizers used to grow the grains to feed the livestock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For decades the livestock industry has overlooked and/or socialized its environmental problems and costs. Today, the impacts of livestock production on public health and the environment can no longer be ignored and are coming under increasing scrutiny from environmental groups and health organizations, regulatory agencies and the courts, the media, consumers, and activist institutional investors. The result has been a significant and alarming loss of market share to plant-based protein and other alternative products. Bion’s Gen3Tech platform was designed to resolve these environmental issues and bring the industry in line with twenty-first century consumer expectations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Going concern and management’s plans:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has not generated significant revenues and has incurred net losses of approximately $<span id="xdx_904_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20200701__20210630_pp0p0" title="Net Income (loss)">3,451,000</span> during the year ended June 30, 2021 and a net income of $<span id="xdx_909_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20210701__20220630_pp0p0" title="Net Income (loss)">8,291,000</span> for the year ended June 30, 2022. The net income for the year ended June 30, 2022 was largely due to a one-time, non-cash event of the dissolution of PA-1 resulting in a gain of approximately $<span id="xdx_906_eus-gaap--IncomeLossFromContinuingOperations_c20210701__20220630_pp0p0" title="Net income">10,235,000</span> as well as a one-time gain of $<span id="xdx_903_ecustom--GainOnSaleOfDomainAmount_c20210701__20220630_pp0p0" title="Gain on sale of domain">902,000</span> from the sale of the Company’s ‘biontech.com’ domain pursuant to a purchase agreement during the period. For the nine months ended March 31, 2023, the Company had a net loss of $<span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pp0p0_c20220701__20230331_zGo14PL0KuH8" title="Net Income (loss)">2,507,305</span> At March 31, 2023, the Company has a working deficit and a stockholders’ equity of approximately $<span id="xdx_905_ecustom--WorkingCapital_c20230331_pp0p0" title="Working Capital">147,000</span> and $4,149,000, respectively. During the three months ended March 31, 2023 the Company had debt modifications that resulted in a reduction of debt of $<span id="xdx_907_ecustom--ReductionOfDebt_c20230101__20230331_zP9uVbavKoUi" title="Reduction of debt">3,516,000</span> and an increase in equity. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. The following paragraphs describe management’s plans with regard to these conditions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company continues to explore sources of additional financing (including potential agreements with strategic partners – both financial and ag-industry) to satisfy its current and future operating and capital expenditure requirements as it is not currently generating any significant revenues.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended June 30, 2022 and 2021, the Company received gross proceeds of approximately $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20210701__20220630_pp0p0" title="Proceeds from Issuance or Sale of Equity">1,737,000</span> and $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20200701__20210630_pp0p0" title="Proceeds from Issuance or Sale of Equity">5,209,000</span>, respectively, from the sale of its debt and equity securities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the nine months ended March 31, 2023, the Company received total proceeds of approximately $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20220701__20230331_pp0p0" title="Proceeds from Issuance or Sale of Equity">3,385,000</span> from the sale of its equity securities. There were $<span id="xdx_90C_eus-gaap--PaymentsForCommissions_pp0p0_c20220701__20230331_zarN415uScVl" title="Commissions paid">48,000</span> in cash commissions paid.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During fiscal years 2022 and 2021, the Company faced less difficulty in raising equity funding (but was subject to substantial equity dilution from the larger amounts of equity financing during the periods) than was experienced in the prior 3 years. During the first nine months of the current fiscal year, the Company has raised limited equity funds to meet its some of its immediate needs but will need to raise additional funds in the coming periods. The Company anticipates substantial increases in demands for capital and operating expenditures during the second half of the current fiscal year and thereafter as it moves toward commercial implementation of its 3G Tech and development of JVs (including costs associated with additions of personnel to carry out the business activities of the Company) and, therefore, is likely to continue to face significant cash flow management challenges due to limited capital resources and working capital constraints which have only recently begun to be alleviated. To partially mitigate these working capital constraints, the Company’s core senior management and several key employees and consultants have been deferring (and continue to defer) portions of their cash compensation and/or are accepting compensation in part in the form of securities of the Company and/or converting portions of their compensation and deferred compensation to securities of the Company (Notes 5 and 7) and members of the Company’s senior management have made loans to the Company from time to time. During the year ended June 30, 2018, senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $<span id="xdx_90E_ecustom--DeferredCompensationLiabilityAmountCancelled_c20170701__20180630_pp0p0" title="Deferred Compensation Liability, Amount Cancelled">2,404,000</span>. Additionally, the Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again during the year ended June 30, 2018. The constraint on available resources has had, and continues to have, negative effects on the pace and scope of the Company’s efforts to develop its business. At times, the Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company is able to continue its recent relative success in its efforts to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and curtailment of ongoing activities including research and development activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Projects (including the Initial Project, JV Projects (including the Dalhart and Olson Projects),and the Kreider 2 facility) and CAFO Retrofit waste remediation systems. The Company anticipates that it will seek to raise from $<span id="xdx_90F_eus-gaap--CapitalRequiredForCapitalAdequacy_c20230331__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Capital Required for Capital Adequacy">20,000,000</span> to $<span id="xdx_900_eus-gaap--CapitalRequiredForCapitalAdequacy_c20230331__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Capital Required for Capital Adequacy">80,000,000</span> or more debt and/or equity through joint ventures, strategic partnerships and/or sale of its equity securities (common, preferred and/or hybrid) and/or debt (including convertible) securities, and/or through use of ‘rights’ and/or warrants (new and/or existing) and/or through other means during the next twelve months. However, as discussed above, there is no assurance, especially in light of the difficulties the Company has experienced in many recent years and the extremely unsettled capital markets that presently exist for small companies like us, that the Company will be able to obtain the funds that it needs to stay in business, complete its technology development or to successfully develop its business and Projects.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There is no realistic likelihood that funds required during the next twelve months (or in the periods immediately thereafter) for the Company’s basic operations, the Initial Project and/or proposed JVs and/or Projects will be generated from operations. Therefore, the Company will need to raise sufficient funds from external sources such as debt or equity financings or other potential sources. The lack of sufficient additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company’s existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for small companies like Bion.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Covid-19 pandemic related matters:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 15000 300 1500 0.295 Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) (‘Kreider Renewable Energy Facility’ or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). Now that development of the Company’s Gen3Tech is being deployed, the Company has commenced discussions with KF regarding updating and amending the JV agreement and anticipates executing an amended joint venture agreement during 2023. During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA). 3451000 8291000 10235000 902000 2507305 147000 3516000 1737000 5209000 3385000 48000 2404000 20000000 80000000 <p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zVI9aCnpv1ij" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2.       <span id="xdx_826_z6PLZTDxsDVf">SIGNIFICANT ACCOUNTING POLICIES</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zfsA14mBsZMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86A_zwHzk7lz5qq5"><span id="xdx_868_zIsXPxsaLJc9">Principles of consolidation</span>:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its <span id="xdx_900_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20230331__srt--OwnershipAxis__custom--CenterpointMember_z0w1mHYtdai6" title="Noncontrolling interest, ownership percentage by parent">58.9</span>% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying condensed consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements reflect all adjustments (consisting of only normal recurring entries) that, in the opinion of management, are necessary to present fairly the financial position at March 31, 2023, the results of operations of the Company for the three and nine months ended March 31, 2023 and 2022 and the cash flows of the Company for the nine months ended March 31, 2023 and 2022. Operating results for the three and nine months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending June 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zwzgTNqEjDk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86B_zxfGVnBsQZb6"><span id="xdx_864_zI8XMY5smUX">Cash and cash equivalents</span>:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of March 31, 2023 and June 30, 2022 there are <span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20230331_zUtCWLz1aB2k" title="Cash equivalents"><span id="xdx_905_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20220630_zek0avmiDJS2" title="Cash equivalents">no</span></span> cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zfysEQKD0gJi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><span><span id="xdx_86D_zsgllN8MwB7a"><span id="xdx_862_zGg1nGHsRUyi">Property and equipment</span>:</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects such as consulting fees, internal salaries and benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zOCB7KgZZKA7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_865_zss17s5FqSb9"><span id="xdx_86B_zTkeHSNczmRc">Patents</span>:</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s condensed consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zBOo3EvprG6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_864_z0n1R7Qjnjal"><span id="xdx_866_zfFY5J77yFM4"><span id="xdx_863_zAB8M2ZDlmob">Stock-based compensation</span>:</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--DerivativesPolicyTextBlock_zSKbpR3RUdW" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_869_z95IyESAo3Gh"><span id="xdx_867_zs1YD6sMPGq8">Derivative Financial Instruments</span>:</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_846_eus-gaap--AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_zIHIbiWf8dEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_861_z9R6DoThGD7a"><span id="xdx_86F_zYU95IZQ83x8">Options</span>:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84D_ecustom--EquityIssuancesWarrantsPolicyPolicyTextBlock_zUnckNtT7I0f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86A_zqLh9fZckr3b"><span id="xdx_867_zEaYW44jkfI">Warrants</span>:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zlNiLHrytcZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86A_zf5RbMvY45d2"><span id="xdx_862_z3RIdWiJl8Ug">Concentrations of credit risk</span>:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_840_ecustom--MinorityInterestPolicyPolicyTextBlock_zaBjB6YKWnJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86A_zohcFfeVvHw7"><span id="xdx_864_zUifJdDIRjd9">Noncontrolling interests</span>:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the condensed consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the condensed consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zQ6YzJY6abG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86B_zxtRvcM3ywBe"><span id="xdx_867_zZKcL4P5b1K5">Fair value measurements</span>:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 – assets and liabilities whose significant value drivers are unobservable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--LessorLeasesPolicyTextBlock_zE8cPJMWyvfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86A_zRr7sOsQgAgc"><span id="xdx_867_zcBVhSd1n7yc">Lease Accounting</span>:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">The Company accounts for leases under ASC 842, <i>Leases</i> (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the condensed consolidated statements of operations over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s condensed consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_z6bhDZFM8C3h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86C_zVmnu8MNZYvi"><span id="xdx_866_zYrPbA0O5NQ2">Revenue Recognition</span>:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_z1KbTWWnCN79" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_864_zrWPWi1tqzMl"><span id="xdx_862_zFEzhe1uh9Q2">Income (Loss) per share</span>:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the three and nine months ended March 31, 2023 and 2022, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zFyB8oNOa6Y9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_8B8_ze7onyko45Ke" style="display: none">Schedule of warrants and options and convertible securities</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; font-weight: bold; text-align: justify"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">March 31, <br/> 2023</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">March 31, <br/> 2022</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: justify">Warrants</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 14%; text-align: right" title="Antidilutive securities">21,944,437</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 14%; text-align: right" title="Antidilutive securities">19,078,635</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Options</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_pdd" style="text-align: right" title="Antidilutive securities">11,506,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_pdd" style="text-align: right" title="Antidilutive securities">10,481,600</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Convertible debt</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities">10,052,765</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities">10,847,026</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Convertible preferred stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities"><span style="-sec-ix-hidden: xdx2ixbrl0907">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities"><span style="-sec-ix-hidden: xdx2ixbrl0909">—</span>  </td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the three and nine months ended March 31, 2023 and 2022:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z47kJ4L40OWi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 0in"><span id="xdx_8BC_zhibeRQDVZRh" style="display: none">Schedule of earnings per share, basic and diluted</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20230101__20230331_zqvHjrjFocH8" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20220101__20220331_zLPot0xWtVH2" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20220701__20230331_zQpX4yq6u2Q" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20210701__20220331_zyZjM5kIsdOg" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Three months <br/>ended <br/>March 31, <br/>2023</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Three months <br/>ended <br/>March 31, <br/>2022</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Nine months <br/>ended <br/>March 31, <br/>2023</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Nine months <br/>ended <br/>March 31, <br/>2022</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr id="xdx_40E_ecustom--SharesIssuedBeginningOfPeriod_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left; text-indent: 0in">Shares issued – beginning of period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">44,529,884</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">43,733,850</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">43,758,820</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">41,315,986</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--SharesHeldBySubsidiaries_zMNi9di2VEfb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0in">Shares held by subsidiaries (Note 7)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--SharesOutstandingBeginningOfPeriod_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in">Shares outstanding – beginning of period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,825,575</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,029,511</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,054,511</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,611,677</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--WeightedAverageSharesIssuedDuringPeriod_i_pdd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Weighted average shares issued <br/>    during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,630,842</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0929">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,110,798</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">990,713</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Diluted weighted average shares – <br/>    end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">45,456,417</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">43,029,511</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">44,165,309</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">40,904,342</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--UseOfEstimates_zgFXVN5MAn32" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_865_zT07NLJmP0U2"><span><span><span id="xdx_869_zxysJx5NwgPf"><span id="xdx_869_zmERQ4oR6bMg">Use of estimates</span>:</span></span></span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In preparing the Company’s condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zE30fmFG3M6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86E_zKdD85UwTdE4"><span id="xdx_865_zCaEKdtdfgHg"><span id="xdx_860_z4dAzySlNrqj">Recent Accounting Pronouncements</span>:</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its condensed consolidated financial statements and assures that there are proper controls in place to ascertain that the Company’s condensed consolidated financial statements properly reflect the change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zfsA14mBsZMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86A_zwHzk7lz5qq5"><span id="xdx_868_zIsXPxsaLJc9">Principles of consolidation</span>:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its <span id="xdx_900_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20230331__srt--OwnershipAxis__custom--CenterpointMember_z0w1mHYtdai6" title="Noncontrolling interest, ownership percentage by parent">58.9</span>% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying condensed consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements reflect all adjustments (consisting of only normal recurring entries) that, in the opinion of management, are necessary to present fairly the financial position at March 31, 2023, the results of operations of the Company for the three and nine months ended March 31, 2023 and 2022 and the cash flows of the Company for the nine months ended March 31, 2023 and 2022. Operating results for the three and nine months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending June 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 0.589 <p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zwzgTNqEjDk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86B_zxfGVnBsQZb6"><span id="xdx_864_zI8XMY5smUX">Cash and cash equivalents</span>:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of March 31, 2023 and June 30, 2022 there are <span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20230331_zUtCWLz1aB2k" title="Cash equivalents"><span id="xdx_905_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20220630_zek0avmiDJS2" title="Cash equivalents">no</span></span> cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 0 0 <p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zfysEQKD0gJi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><span><span id="xdx_86D_zsgllN8MwB7a"><span id="xdx_862_zGg1nGHsRUyi">Property and equipment</span>:</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects such as consulting fees, internal salaries and benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zOCB7KgZZKA7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_865_zss17s5FqSb9"><span id="xdx_86B_zTkeHSNczmRc">Patents</span>:</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s condensed consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zBOo3EvprG6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_864_z0n1R7Qjnjal"><span id="xdx_866_zfFY5J77yFM4"><span id="xdx_863_zAB8M2ZDlmob">Stock-based compensation</span>:</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--DerivativesPolicyTextBlock_zSKbpR3RUdW" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_869_z95IyESAo3Gh"><span id="xdx_867_zs1YD6sMPGq8">Derivative Financial Instruments</span>:</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_846_eus-gaap--AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_zIHIbiWf8dEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_861_z9R6DoThGD7a"><span id="xdx_86F_zYU95IZQ83x8">Options</span>:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84D_ecustom--EquityIssuancesWarrantsPolicyPolicyTextBlock_zUnckNtT7I0f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86A_zqLh9fZckr3b"><span id="xdx_867_zEaYW44jkfI">Warrants</span>:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zlNiLHrytcZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86A_zf5RbMvY45d2"><span id="xdx_862_z3RIdWiJl8Ug">Concentrations of credit risk</span>:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_840_ecustom--MinorityInterestPolicyPolicyTextBlock_zaBjB6YKWnJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86A_zohcFfeVvHw7"><span id="xdx_864_zUifJdDIRjd9">Noncontrolling interests</span>:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the condensed consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the condensed consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zQ6YzJY6abG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86B_zxtRvcM3ywBe"><span id="xdx_867_zZKcL4P5b1K5">Fair value measurements</span>:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 – assets and liabilities whose significant value drivers are unobservable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--LessorLeasesPolicyTextBlock_zE8cPJMWyvfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86A_zRr7sOsQgAgc"><span id="xdx_867_zcBVhSd1n7yc">Lease Accounting</span>:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">The Company accounts for leases under ASC 842, <i>Leases</i> (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the condensed consolidated statements of operations over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s condensed consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_z6bhDZFM8C3h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86C_zVmnu8MNZYvi"><span id="xdx_866_zYrPbA0O5NQ2">Revenue Recognition</span>:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_z1KbTWWnCN79" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_864_zrWPWi1tqzMl"><span id="xdx_862_zFEzhe1uh9Q2">Income (Loss) per share</span>:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the three and nine months ended March 31, 2023 and 2022, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zFyB8oNOa6Y9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_8B8_ze7onyko45Ke" style="display: none">Schedule of warrants and options and convertible securities</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; font-weight: bold; text-align: justify"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">March 31, <br/> 2023</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">March 31, <br/> 2022</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: justify">Warrants</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 14%; text-align: right" title="Antidilutive securities">21,944,437</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 14%; text-align: right" title="Antidilutive securities">19,078,635</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Options</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_pdd" style="text-align: right" title="Antidilutive securities">11,506,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_pdd" style="text-align: right" title="Antidilutive securities">10,481,600</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Convertible debt</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities">10,052,765</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities">10,847,026</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Convertible preferred stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities"><span style="-sec-ix-hidden: xdx2ixbrl0907">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities"><span style="-sec-ix-hidden: xdx2ixbrl0909">—</span>  </td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the three and nine months ended March 31, 2023 and 2022:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z47kJ4L40OWi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 0in"><span id="xdx_8BC_zhibeRQDVZRh" style="display: none">Schedule of earnings per share, basic and diluted</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20230101__20230331_zqvHjrjFocH8" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20220101__20220331_zLPot0xWtVH2" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20220701__20230331_zQpX4yq6u2Q" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20210701__20220331_zyZjM5kIsdOg" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Three months <br/>ended <br/>March 31, <br/>2023</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Three months <br/>ended <br/>March 31, <br/>2022</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Nine months <br/>ended <br/>March 31, <br/>2023</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Nine months <br/>ended <br/>March 31, <br/>2022</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr id="xdx_40E_ecustom--SharesIssuedBeginningOfPeriod_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left; text-indent: 0in">Shares issued – beginning of period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">44,529,884</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">43,733,850</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">43,758,820</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">41,315,986</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--SharesHeldBySubsidiaries_zMNi9di2VEfb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0in">Shares held by subsidiaries (Note 7)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--SharesOutstandingBeginningOfPeriod_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in">Shares outstanding – beginning of period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,825,575</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,029,511</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,054,511</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,611,677</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--WeightedAverageSharesIssuedDuringPeriod_i_pdd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Weighted average shares issued <br/>    during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,630,842</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0929">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,110,798</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">990,713</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Diluted weighted average shares – <br/>    end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">45,456,417</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">43,029,511</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">44,165,309</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">40,904,342</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zFyB8oNOa6Y9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_8B8_ze7onyko45Ke" style="display: none">Schedule of warrants and options and convertible securities</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; font-weight: bold; text-align: justify"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">March 31, <br/> 2023</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">March 31, <br/> 2022</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: justify">Warrants</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 14%; text-align: right" title="Antidilutive securities">21,944,437</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 14%; text-align: right" title="Antidilutive securities">19,078,635</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Options</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_pdd" style="text-align: right" title="Antidilutive securities">11,506,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_pdd" style="text-align: right" title="Antidilutive securities">10,481,600</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Convertible debt</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities">10,052,765</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities">10,847,026</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Convertible preferred stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities"><span style="-sec-ix-hidden: xdx2ixbrl0907">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities"><span style="-sec-ix-hidden: xdx2ixbrl0909">—</span>  </td><td style="text-align: left"> </td></tr> </table> 21944437 19078635 11506600 10481600 10052765 10847026 <table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z47kJ4L40OWi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 0in"><span id="xdx_8BC_zhibeRQDVZRh" style="display: none">Schedule of earnings per share, basic and diluted</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20230101__20230331_zqvHjrjFocH8" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20220101__20220331_zLPot0xWtVH2" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20220701__20230331_zQpX4yq6u2Q" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20210701__20220331_zyZjM5kIsdOg" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Three months <br/>ended <br/>March 31, <br/>2023</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Three months <br/>ended <br/>March 31, <br/>2022</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Nine months <br/>ended <br/>March 31, <br/>2023</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Nine months <br/>ended <br/>March 31, <br/>2022</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr id="xdx_40E_ecustom--SharesIssuedBeginningOfPeriod_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left; text-indent: 0in">Shares issued – beginning of period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">44,529,884</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">43,733,850</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">43,758,820</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">41,315,986</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--SharesHeldBySubsidiaries_zMNi9di2VEfb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0in">Shares held by subsidiaries (Note 7)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--SharesOutstandingBeginningOfPeriod_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in">Shares outstanding – beginning of period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,825,575</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,029,511</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,054,511</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,611,677</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--WeightedAverageSharesIssuedDuringPeriod_i_pdd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Weighted average shares issued <br/>    during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,630,842</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0929">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,110,798</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">990,713</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Diluted weighted average shares – <br/>    end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">45,456,417</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">43,029,511</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">44,165,309</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">40,904,342</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 44529884 43733850 43758820 41315986 -704309 -704309 -704309 -704309 43825575 43029511 43054511 40611677 1630842 1110798 990713 45456417 43029511 44165309 40904342 <p id="xdx_842_eus-gaap--UseOfEstimates_zgFXVN5MAn32" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_865_zT07NLJmP0U2"><span><span><span id="xdx_869_zxysJx5NwgPf"><span id="xdx_869_zmERQ4oR6bMg">Use of estimates</span>:</span></span></span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In preparing the Company’s condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zE30fmFG3M6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86E_zKdD85UwTdE4"><span id="xdx_865_zCaEKdtdfgHg"><span id="xdx_860_z4dAzySlNrqj">Recent Accounting Pronouncements</span>:</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its condensed consolidated financial statements and assures that there are proper controls in place to ascertain that the Company’s condensed consolidated financial statements properly reflect the change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_807_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z92tkBah2FOj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>3.  <span id="xdx_826_zhqx8IkKyFx4">PROPERTY AND EQUIPMENT:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment consist of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--PropertyPlantAndEquipmentTextBlock_zy8osOK1RXak" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span id="xdx_8BA_zC10w6pFh819" style="display: none">Schedule of property and equipment</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_497_20230331_zKIqGwqTRQN1" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_492_20220630_zUFC6ACXuf88" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 8pt"><b> </b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>March 31, <br/>2023</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b> </b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>June 30, <br/>2022</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr id="xdx_402_ecustom--ComputersAndOfficeEquipment_iI_pp0p0_maPPAEGzfNz_ztIQ2cC2KXc4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: left">Computers and office equipment</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 14%; font-size: 10pt; text-align: right">15,156</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 14%; font-size: 10pt; text-align: right">13,598</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConstructionInProgressGross_iI_pp0p0_maPPAEGzfNz_zJrQTMGyK3X" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Initial Project: construction in process</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,784,494</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,892,222</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pp0p0_mtPPAEGzfNz_maPPAEOzI0B_zA27ioIKwxP2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Property and equipment, gross</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">5,799,650</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">2,905,820</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAEOzI0B_zJDMYD2z94D7" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(11,447</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(10,262</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentOtherNet_iTI_pp0p0_mtPPAEOzI0B_zOtEet6Mfiae" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"> Property and equipment, net</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,788,203</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,895,558</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 3G1 project (“Initial Project”) began in July of 2021, with a lease signed on land October 1, 2021 (Note 9). Once the lease commenced the Company moved into construction phase. The balance for the Initial Project construction in process includes $<span id="xdx_90F_eus-gaap--InterestCostsCapitalized_c20220701__20230331_pp0p0" title="Capitalized interest">149,342</span> for capitalized interest and $<span id="xdx_904_ecustom--NonCashCompensation_c20220701__20230331_pp0p0" title="Non cash compensation">135,648</span> in non-cash compensation as of March 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has reviewed the remaining property and equipment for impairment as of March 31, 2023 and believes that <span id="xdx_900_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20220701__20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--PropertyPlantAndEquipmentOfPA1Member_zBEcd6lYKuHi" title="Impairment of Long-Lived Assets Held-for-use">no</span> impairment exists.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense was $<span id="xdx_90D_eus-gaap--Depreciation_c20230101__20230331_pp0p0" title="Depreciation expense">461</span> and $<span id="xdx_90F_eus-gaap--Depreciation_c20220101__20220331_pp0p0" title="Depreciation expense">252</span> for the three months ended March 31, 2023 and 2022, respectively and $<span id="xdx_906_eus-gaap--Depreciation_c20220701__20230331_pp0p0" title="Depreciation expense">1,185</span> and $<span id="xdx_908_eus-gaap--Depreciation_c20210701__20220331_pp0p0" title="Depreciation expense">832</span> for the nine months ended March 31, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--PropertyPlantAndEquipmentTextBlock_zy8osOK1RXak" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span id="xdx_8BA_zC10w6pFh819" style="display: none">Schedule of property and equipment</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_497_20230331_zKIqGwqTRQN1" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_492_20220630_zUFC6ACXuf88" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 8pt"><b> </b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>March 31, <br/>2023</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b> </b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>June 30, <br/>2022</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr id="xdx_402_ecustom--ComputersAndOfficeEquipment_iI_pp0p0_maPPAEGzfNz_ztIQ2cC2KXc4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: left">Computers and office equipment</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 14%; font-size: 10pt; text-align: right">15,156</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 14%; font-size: 10pt; text-align: right">13,598</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConstructionInProgressGross_iI_pp0p0_maPPAEGzfNz_zJrQTMGyK3X" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Initial Project: construction in process</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,784,494</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,892,222</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pp0p0_mtPPAEGzfNz_maPPAEOzI0B_zA27ioIKwxP2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Property and equipment, gross</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">5,799,650</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">2,905,820</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAEOzI0B_zJDMYD2z94D7" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(11,447</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(10,262</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentOtherNet_iTI_pp0p0_mtPPAEOzI0B_zOtEet6Mfiae" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"> Property and equipment, net</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,788,203</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,895,558</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> 15156 13598 5784494 2892222 5799650 2905820 11447 10262 5788203 2895558 149342 135648 0 461 252 1185 832 <p id="xdx_803_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zqUpu9xtgmua" style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify"><b>4.       <span id="xdx_82A_zPf5OxvxfzPc">DEFERRED COMPENSATION:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">The Company owes deferred compensation to various employees, former employees and consultants totaling $<span id="xdx_901_eus-gaap--DeferredCompensationLiabilityCurrent_c20230331_pp0p0" title="Deferred compensation liability">784,255</span> and $<span id="xdx_906_eus-gaap--DeferredCompensationLiabilityCurrent_c20220331_pp0p0" title="Deferred compensation liability">525,699</span> as of March 31, 2023 and 2022, respectively. Included in the deferred compensation balances as of March 31, 2023, are $<span id="xdx_906_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pp0p0_c20230331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zSDwd7TjhzMf" title="Deferred compensation liability">504,401</span> and $<span id="xdx_908_eus-gaap--DeferredCompensationLiabilityCurrent_c20220331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Deferred compensation liability">5,000</span> owed Dominic Bassani (“Bassani”), the Company’s Chief Operating Officer (who was Chief Executive Officer until through April 30, 2022), and Mark A. Smith (“Smith”), the Company’s President, respectively, pursuant to extension agreements effective January 1, 2015, whereby unpaid compensation earned after January 1, 2015, accrues interest at <span id="xdx_905_ecustom--InterestRateOnDeferredCompensation_iI_dp_c20230331_zkXSKCcUy1D4" title="Interest Rate on Deferred Compensation">4</span>% per annum and can be converted into shares of the Company’s common stock at the election of the employee during the first five calendar days of any month. The conversion price shall be the average closing price of the Company’s common stock for the last <span id="xdx_903_ecustom--DeferredCompensationConsecutiveTradingDays_dtD_c20220701__20230331_zAY6o6VBOIw6" title="Deferred Compensation Consecutive Trading Days (Day)">10</span> trading days of the immediately preceding month. The deferred compensation owed Bassani and Smith as of March 31, 2022 was $<span id="xdx_90B_eus-gaap--DeferredCompensationLiabilityCurrent_c20220331__srt--CounterpartyNameAxis__custom--BassaniMember_pp0p0" title="Deferred compensation liability">410,585</span> and <span id="xdx_90C_eus-gaap--DeferredCompensationLiabilityCurrent_c20220331__srt--CounterpartyNameAxis__custom--SmithMember_pp0p0" style="display: none" title="Deferred compensation liability">0</span> nil, respectively. The Company also owes various consultants and an employee, pursuant to various agreements, for deferred compensation of $<span id="xdx_90B_eus-gaap--DeferredCompensationLiabilityCurrent_c20230331__srt--TitleOfIndividualAxis__custom--ConsultantsMember_pp0p0" title="Deferred compensation liability">92,355</span> and $<span id="xdx_90A_eus-gaap--DeferredCompensationLiabilityCurrent_c20220331__srt--TitleOfIndividualAxis__custom--ConsultantsMember_pp0p0" title="Deferred compensation liability">42,614</span> as of March 31, 2023 and 2022, respectively, with similar conversion terms as those described above for Bassani and Smith, with the exception that the interest accrues at <span id="xdx_90A_ecustom--InterestRateOnDeferredCompensation_iI_dp_c20230331__srt--TitleOfIndividualAxis__custom--ConsultantsMember_z8ANFoEvWTN1" title="Interest Rate on Deferred Compensation">0</span>% to <span id="xdx_903_ecustom--InterestRateOnDeferredCompensation_iI_dp_c20220331__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zMpoF7U7GLlk" title="Interest Rate on Deferred Compensation">3</span>% per annum. The Company also owes a former employee $72,500, which is not convertible and is non-interest bearing. Bassani and Smith have each been granted the right to convert up to $<span id="xdx_909_ecustom--DeferredCompensationConvertibleToCommonStock_pp0p0_c20220701__20230331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z8zEpgr5llqg" title="Deferred Compensation, Convertible to Common Stock">300,000</span> of deferred compensation balances at a price of $<span id="xdx_906_ecustom--DeferredCompensationConvertibleToCommonStockPricePerShare_c20230331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pdd" title="Deferred Compensation, Convertible to Common Stock, Price Per Share (in dollars per share)">0.75</span> per share until June 30, 2024 into common shares (to be issued pursuant to the 2006 Plan). Smith also has the right to convert all or part of his deferred compensation balance into the Company’s securities (to be issued pursuant to the 2006 Plan) “at market” and/or on the same terms as the Company is selling or has sold its securities in its then current (or most recent if there is no current) private placement. Smith also received the right to transfer future deferred compensation to his 2020 Convertible Obligation at his election but such right is no longer in force.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bill O’Neill has a balance of $<span id="xdx_90B_eus-gaap--DeferredCompensationLiabilityCurrentAndNoncurrent_c20230331_pp0p0" title="Deferred compensation">110,000</span> and <span id="xdx_90A_eus-gaap--DeferredCompensationLiabilityCurrentAndNoncurrent_c20220331_pp0p0" style="display: none" title="Deferred compensation">0</span> nil at March 31, 2023 and 2022, respectively. There is no interest or conversions on the deferred balance. During the three and nine months ended March 31, 2023, Smith elected to convert $<span id="xdx_909_ecustom--DeferredCompensationConvertibleToCommonStock_c20230101__20230331__srt--CounterpartyNameAxis__custom--SmithMember_pp0p0" title="Deferred Compensation, Convertible to Common Stock">30,000</span> and $<span id="xdx_907_ecustom--DeferredCompensationConvertibleToCommonStock_c20220701__20230331__srt--CounterpartyNameAxis__custom--SmithMember_pp0p0" title="Deferred Compensation, Convertible to Common Stock">90,000</span>, respectively, of deferred compensation into the 2020 Convertible Note.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">The Company recorded interest expense of $<span id="xdx_90D_eus-gaap--InterestExpense_c20230101__20230331__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_pp0p0" title="Interest Expense">5,034</span> ($<span id="xdx_904_ecustom--InterestExpenseRelatedParties_pp0p0_c20230101__20230331__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_zzXiyHFO3Iyg" title="Interest Expense, Related Party">4,428</span> with related parties) and $<span id="xdx_902_eus-gaap--InterestExpense_c20220101__20220331__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_pp0p0" title="Interest Expense">3,824</span> ($<span id="xdx_901_ecustom--InterestExpenseRelatedParties_pp0p0_c20220101__20220331__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_zlsQ6YL8WgCl" title="Interest Expense, Related Party">3,570</span> with related parties) for the three months ended March 31, 2023 and 2022, respectively, and $<span id="xdx_908_eus-gaap--InterestExpense_c20220701__20230331__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_pp0p0" title="Interest Expense">14,458</span> ($<span id="xdx_909_ecustom--InterestExpenseRelatedParties_pp0p0_c20220701__20230331__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_znwJbpZrR42i" title="Interest Expense, Related Party">12,893</span> with related parties) and $<span id="xdx_90E_eus-gaap--InterestExpense_c20210701__20220331__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_pp0p0" title="Interest Expense">12,124</span> ($<span id="xdx_905_ecustom--InterestExpenseRelatedParties_pp0p0_c20210701__20220331__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_zst6dwbOueX6" title="Interest Expense, Related Party">11,615</span> with related parties) for the nine months ended March 31, 2023 and 2022, respectively.</p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b>  </b></p> 784255 525699 504401 5000 0.04 P10D 410585 0 92355 42614 0 0.03 300000 0.75 110000 0 30000 90000 5034 4428 3824 3570 14458 12893 12124 11615 <p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_zBdNfZWsQ9x1" style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b>5.       <span id="xdx_829_zGxN9pZojLk6">LOANS PAYABLE:</span></b></p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $<span id="xdx_905_eus-gaap--ConstructionLoan_c20230331__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Construction Loan">10,010,000</span> under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $<span id="xdx_906_ecustom--AccruedInterestAndLateChargesPayable_c20230331__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Accrued Interest and Late Charges Payable">2,255,802</span> as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s condensed consolidated balance sheet. At September 30, 2021, PA1’s total assets were $<span id="xdx_90C_eus-gaap--Assets_iI_pp0p0_c20210930_z4KuOGTxyzqk" title="Total assets">297</span> and its total liabilities were $<span id="xdx_90E_eus-gaap--Liabilities_iI_pp0p0_c20210930_zvKtERcOB7Pc" title="Total liabilities">10,154,334</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_909_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pp0p0_c20210930_zn7Ad1nz9esd" title="Accounts payable and accrued liabilities">9,939,148</span>, accounts payable of $<span id="xdx_903_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20210930_z8ATyhtCmekl" title="Accounts payable">214,235</span> and accrued liabilities of $<span id="xdx_903_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_c20210930_zUIKmcJtAXT1" title="Accrued Liabilities, Current">950</span>) which sums were included in the Company’s condensed consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer condensed consolidated and included in the Company’s balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $<span id="xdx_909_eus-gaap--Liabilities_c20211229_pp0p0" title="Total liabilities">10,234,501</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_904_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_c20211229_pp0p0" title="Accounts payable and accrued liabilities">10,009,802</span>, accounts payable of $<span id="xdx_903_eus-gaap--AccountsPayableCurrent_c20211229_pp0p0" title="Accounts payable">212,263</span> and accrued liabilities of $<span id="xdx_906_eus-gaap--AccruedLiabilitiesCurrent_c20211229_pp0p0" title="Accrued Liabilities, Current">12,436</span>). The net amount of $<span id="xdx_906_eus-gaap--GainOrLossOnSaleOfStockInSubsidiary_pp0p0_c20220701__20230331_z3nX53fHN989" title="Gain on legal dissolution of subsidiary">10,234,501</span> was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt; text-align: justify; background-color: white">As background, the terms of the Pennvest Loan provided for funding of up to $<span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_c20230331__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Line of Credit Facility, Maximum Borrowing Capacity">7,754,000</span> which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220701__20230331__srt--StatementScenarioAxis__custom--YearsOneThroughFiveMember__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zHDpNK4bjHP4" title="Debt Instrument, Interest Rate During Period">2.547</span>% per annum for years 1 through 5 and <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220701__20230331__srt--StatementScenarioAxis__custom--YearsSixThroughMaturityMember__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zuSXKMnO7ZCl" title="Debt Instrument, Interest Rate During Period">3.184</span>% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $<span id="xdx_90F_eus-gaap--DebtInstrumentAnnualPrincipalPayment_c20230331__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Debt Instrument, Annual Principal Payment">5,886,000</span> in fiscal years 2013 through 2021, and $<span id="xdx_901_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c20230331__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Long-Term Debt, Maturity, Year Two">846,000</span> in fiscal year 2022, $<span id="xdx_90C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c20230331__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Long-Term Debt, Maturity, Year Three">873,000</span> in fiscal year 2023 and $<span id="xdx_908_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_c20230331__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Long-Term Debt, Maturity, Year Four">149,000</span> in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $<span id="xdx_902_eus-gaap--InterestExpenseDebt_c20210701__20220630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Interest Expense, Debt">123,444</span> and $<span id="xdx_90D_eus-gaap--InterestExpenseDebt_c20200701__20210630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Interest Expense, Debt">246,887</span> for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s condensed consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $<span id="xdx_90B_eus-gaap--LinesOfCreditCurrent_c20210630_pp0p0" title="Loans as a liability">9,868,495</span> despite the fact that the obligation (if any) was solely an obligation of PA1<b>. </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $<span id="xdx_909_eus-gaap--DebtDefaultLongtermDebtAmount_c20140925__dei--LegalEntityAxis__custom--PA1Member_pp0p0" title="Debt Instrument, Debt Default, Amount">8,137,117</span> (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $<span id="xdx_90F_eus-gaap--GainLossOnSecuritizationOfFinancialAssets_c20220601__20220615__dei--LegalEntityAxis__custom--PA1Member_pp0p0" title="Realized from the asset sale">104,725</span> was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest described above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.</p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 10010000 2255802 297 10154334 9939148 214235 950 10234501 10009802 212263 12436 10234501 7754000 0.02547 0.03184 5886000 846000 873000 149000 123444 246887 9868495 8137117 104725 <p id="xdx_804_ecustom--ConvertibleDebtTextBlock_zfHAiBcdJRj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>6.       <span id="xdx_82E_zqdTE7Cz5g21">CONVERTIBLE NOTES PAYABLE - AFFILIATES:</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2020 Convertible Obligations </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2020 Convertible Obligations, which accrue interest at either <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20200101__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zeNmnZDOgmR5" title="Debt Instrument, Interest Rate, Stated Percentage">4</span>% per annum or <span id="xdx_905_ecustom--DebtInstrumentInterestRateStatedPercentageQuarterly_iI_dp_c20200101__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zmX3aq0jrU4k" title="Debt Instrument, Interest Rate, Stated Percentage, Quarterly">4</span>% compounded quarterly and effective January 1, 2020 are due and payable on July 1, 2024. The 2020 Convertible Obligations (including accrued interest, plus all future deferred compensation added subsequently), are convertible, at the sole election of the holder, into Units consisting of one share of the Company’s common stock and one half to one warrant to purchase a share of the Company’s common stock, at a price of $<span id="xdx_907_ecustom--ConversionPricePerUnit_c20200101__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pdd" title="Conversion price per unit">0.50</span> per Unit until July 1, 2024. The original conversion price of $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20230331_pdd" title="Original conversion price">0.50</span> per Unit approximated the fair value of the Units at the date of the agreements; therefore, no beneficial conversion feature exists. Management evaluated the terms and conditions of the embedded conversion features based on the guidance of ASC 815-15 “Embedded Derivatives” to determine if there was an embedded derivative requiring bifurcation. An embedded derivative instrument (such as a conversion option embedded in the deferred compensation) must be bifurcated from its host instruments and accounted for separately as a derivative instrument only if the “risks and rewards” of the embedded derivative instrument are not “clearly and closely related” to the risks and rewards of the host instrument in which it is embedded. Management concluded that the embedded conversion feature of the deferred compensation was not required to be bifurcated because the conversion feature is clearly and closely related to the host instrument, and because of the Company’s limited trading volume that indicates the feature is not readily convertible to cash in accordance with ASC 815-10, “Derivatives and Hedging”. Effective February 1, 2023, a large portion of the 2020 Convertible Obligations were adjusted as set forth below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2023, the remaining unadjusted portion of the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts (and his donees), Smith and Edward Schafer (“Schafer”), a director of the Company, were $<span id="xdx_902_eus-gaap--ConvertibleLongTermNotesPayable_c20230331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Convertible Notes Payable, Noncurrent">358,151</span>, $<span id="xdx_908_eus-gaap--ConvertibleLongTermNotesPayable_c20230331__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Convertible Notes Payable, Noncurrent">36,072</span> and <span id="xdx_901_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20230331__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zzFl2an2sGSd" style="display: none" title="Convertible Notes Payable, Noncurrent">0</span> nil, respectively. As of March 31, 2022, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts, Smith and Schafer were $<span id="xdx_90D_eus-gaap--ConvertibleLongTermNotesPayable_c20220331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Convertible Notes Payable, Noncurrent">2,573,716</span>, $<span id="xdx_909_eus-gaap--ConvertibleLongTermNotesPayable_c20220331__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Convertible Notes Payable, Noncurrent">1,315,069</span> and $<span id="xdx_90F_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20220331__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zlxtSXI0vyQk" title="Convertible Notes Payable, Noncurrent">494,736</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended March 31, 2023 (on dates prior to the adjustment on February 1, 2023), Smith elected to add $<span id="xdx_903_eus-gaap--SalariesAndWages_c20220701__20230331__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_pp0p0" title="Salary paid">90,000</span> of his salary and $<span id="xdx_90C_eus-gaap--CostsAndExpenses_pp0p0_c20220701__20230331__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_z7k1jE7ZEsbf" title="Accounts payable for reimbursable expenses">23,943</span> in accounts payable for reimbursable expenses to his 2020 Convertible Obligations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended March 31, 2023 (on dates prior to the adjustment on February 1, 2023), Smith elected to convert $<span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20220701__20230331__us-gaap--DebtInstrumentAxis__custom--PrincipalMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member_zhGXZwxPmSz8" title="Debt conversion value">30,000</span> in principal of the 2020 Convertible Obligation to <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20230331__us-gaap--DebtInstrumentAxis__custom--PrincipalMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member_zCWeuVSZUwAc" title="Debt conversion shares">60,000</span> units (<span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20230331__us-gaap--DebtInstrumentAxis__custom--PrincipalMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member__us-gaap--AwardTypeAxis__custom--CommonSharesMember_zeaUQYv8Q684" title="Debt conversion shares, common shares">60,000</span> common shares and <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20230331__us-gaap--DebtInstrumentAxis__custom--PrincipalMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember_pdd" title="Debt conversion shares, warrants">60,000</span> warrants), and $<span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220701__20230331__us-gaap--DebtInstrumentAxis__custom--AccruedInterestMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member_pp0p0" title="Debt conversion value">20,000</span> of accrued interest of the 2020 Convertible Obligation to <span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20230331__us-gaap--DebtInstrumentAxis__custom--AccruedInterestMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member_zlgwcfeWu5x2" title="Debt conversion shares">40,000</span> units (<span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20230331__us-gaap--DebtInstrumentAxis__custom--AccruedInterestMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member__us-gaap--AwardTypeAxis__custom--CommonSharesMember_pdd" title="Debt conversion shares, warrants">40,000</span> common shares and <span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20230331__us-gaap--AwardTypeAxis__custom--WarrantsMember__us-gaap--DebtInstrumentAxis__custom--AccruedInterestMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member_pdd" title="Debt conversion shares, warrants">40,000</span> warrants). The warrants are exercisable for three years from conversion date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded interest expense of $<span id="xdx_908_eus-gaap--InterestExpense_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Interest Expense">16,208</span> and $<span id="xdx_902_eus-gaap--InterestExpense_pp0p0_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zCasRmosWrbc" title="Interest Expense">6,366</span> for the three months ended March 31, 2023 and 2022, respectively. The Company recorded interest expense of $<span id="xdx_902_eus-gaap--InterestExpense_c20220701__20230331__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Interest Expense">98,948</span> and $<span id="xdx_903_eus-gaap--InterestExpense_pp0p0_c20210701__20220331__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z9BT9GbFjvj1" title="Interest Expense">17,430</span> for the nine months ended March 31, 2023 and 2022, respectively. The Company capitalized $<span id="xdx_904_eus-gaap--CostsIncurredDevelopmentCosts_c20230101__20230331_pp0p0" title="Capitalized amount">51,238</span> and nil <span id="xdx_901_eus-gaap--CostsIncurredDevelopmentCosts_pp0p0_c20220101__20220331_zWozxAJNHHH5" style="display: none" title="Capitalized amount">0</span> related to the Initial Project for the three months ended March 31, 2023 and 2022, respectively. The Company capitalized $<span id="xdx_90F_eus-gaap--CostsIncurredDevelopmentCosts_c20220701__20230331_pp0p0" title="Capitalized amount">117,342</span> and nil <span id="xdx_901_eus-gaap--CostsIncurredDevelopmentCosts_c20210701__20220331_pp0p0" style="display: none" title="Capitalized amount">0</span> related to the Initial Project for the nine months ended March 31, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long-term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes) owed to them by the Company in a manner which reduces the indebtedness of the Company by 80% (approximately $<span id="xdx_906_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn3n3_dm_c20230331_zzRoQzNrR5nh" title="Convertible note">3.47</span> million, in aggregate) while equitably maintaining existing conversion rights.  Mark A. Smith (the Company’s President) (“Smith”), Dominic Bassani (the Company’s Chief Operating Officer) (“Bassani”) and Ed Schafer (Director) (“Schafer”), adjusted/reduced the principal owed to them by $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_c20230331__srt--CounterpartyNameAxis__custom--MarkASmithMember_pp0p0" title="Principal amount">1,109,649</span>, $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_c20230331__srt--CounterpartyNameAxis__custom--DominicBassaniMember_pp0p0" title="Principal amount">1,939,670</span> and $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__srt--CounterpartyNameAxis__custom--EdSchaferMember_zDxCPofGg2d9" title="Principal amount">424,873</span>, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations (see below).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>September 2015 Convertible Notes</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2016, the Company entered into September 2015 Convertible Notes with Bassani, Schafer and a Shareholder which replaced previously issued promissory notes. The September 2015 Convertible Notes bear interest at <span id="xdx_90F_ecustom--FinancingReceivableInterestRateStatedPercentage_iI_dp_c20230331__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zd9LhOU1PcBi" title="Financing receivable interest rate stated percentage">4</span>% per annum, have maturity dates of July 1, 2024, and may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $<span id="xdx_902_ecustom--ConversionPricePerUnit_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zs0HXUAzyL84" title="Conversion price per unit">0.60</span> per share. As the conversion price of $0.60 approximated the fair value of the common shares at the date of the September 2015 Convertible Notes, no beneficial conversion feature exists.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The balances of the September 2015 Convertible Notes as of March 31, 2023, including accrued interest owed Bassani, Schafer and Shareholder, are $<span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_c20230331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--BassaniFamilyTrustsMember_pp0p0" title="Convertible Notes Payable">157,682</span>, nil <span id="xdx_90C_eus-gaap--ConvertibleNotesPayable_c20230331__srt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--SchaferMember_pp0p0" style="display: none" title="Convertible Notes Payable">0</span> and $<span id="xdx_903_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20230331__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ShareholderMember_zgbMvNt5I0o1" title="Convertible Notes Payable">457,094</span>, respectively. The balances of the September 2015 Convertible Notes as of March 31, 2022, including accrued interest, were $<span id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20220331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--BassaniFamilyTrustsMember_zQkbmBzSf3Be" title="Convertible Notes Payable">276,944</span>, $<span id="xdx_908_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20220331__srt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--SchaferMember_zbrEi1dcPRH3" title="Convertible Notes Payable">20,681</span> and $<span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20220331__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ShareholderMember_zaDFDy5la5K3" title="Convertible Notes Payable">441,977</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded interest expense of $<span id="xdx_902_eus-gaap--InterestExpense_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Interest Expense">5,507</span> and $<span id="xdx_90E_eus-gaap--InterestExpense_pp0p0_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zqsNy6upupe8" title="Interest Expense">5,366</span> for the three months ended March 31, 2023 and 2022, respectively. The Company recorded interest expense of $<span id="xdx_909_eus-gaap--InterestExpense_c20220701__20230331__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Interest Expense">18,239</span> and $<span id="xdx_905_eus-gaap--InterestExpense_pp0p0_c20210701__20220331__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z8CuJEoDwEQb" title="Interest Expense">17,430</span> for the nine months ended March 31, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including the September 2015 Convertible Notes owned by Bassani and Schafer) owed to them by the Company in a manner which reduces the indebtedness of the Company by 80% (approximately $<span id="xdx_906_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn3n3_dm_c20230331_z2TQmq45vsh" title="Convertible note">3.47</span> million, in aggregate) while equitably maintaining existing conversion rights.  Mark A. Smith (the Company’s President), Dominic Bassani (the Company’s Chief Operating Officer)(and a family Trust) and Ed Schafer (Director), adjusted/reduced the principal owed to them by $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__srt--CounterpartyNameAxis__custom--MarkASmithMember_zooKdNHmuZFi" title="Principal amount">1,109,649</span>, $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__srt--CounterpartyNameAxis__custom--DominicBassaniMember_zIRvsDUb3043" title="Principal amount">1,939,670</span> and $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_c20230331__srt--CounterpartyNameAxis__custom--EdSchaferMember_pp0p0" title="Principal amount">424,873</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes) owed to them by the Company in a manner which reduces the indebtedness of the Company by 80% (approximately $<span id="xdx_906_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn3n3_dm_c20230331_zAVTeoY8C0v2" title="Convertible note">3.47</span> million, in aggregate) while equitably maintaining existing conversion rights.  Mark A. Smith (the Company’s President)(“Smith”), Dominic Bassani (the Company’s Chief Operating Officer)(“Bassani”) and Ed Schafer (Director)(“Schafer”), adjusted/reduced the principal owed to them by $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__srt--CounterpartyNameAxis__custom--MarkASmithMember_zU42UL7cUfog" title="Principal amount">1,109,649</span>, $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__srt--CounterpartyNameAxis__custom--DominicBassaniMember_zVXCs3p6FLVl" title="Principal amount">1,939,670</span> and $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__srt--CounterpartyNameAxis__custom--EdSchaferMember_z48eh9RLvYVj" title="Principal amount">424,873</span>, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes. The Adjusted 2020 Convertible Obligations of Smith, Bassani and Schafer are convertible into Units at prices of $.<span id="xdx_90B_ecustom--ConversionPricePerUnit_iI_pp0p0_c20230331__srt--CounterpartyNameAxis__custom--MarkASmithMember_zXd1EkekYPD5" title="Conversion price per unit">0946</span>, $<span id="xdx_906_ecustom--ConversionPricePerUnit_iI_pp0p0_c20230331__srt--CounterpartyNameAxis__custom--DominicBassaniMember_zFfEZUvMY2V4" title="Conversion price per unit">0953</span>, and $.<span id="xdx_903_ecustom--ConversionPricePerUnit_iI_pp0p0_c20230331__srt--CounterpartyNameAxis__custom--EdSchaferMember_zYFAMHBxXLGk" title="Conversion price per unit">0953</span>, respectively, and the Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.115 per share. The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (July 1, 2024). Effective February 1, 2023 the Company owed Smith, Bassani (and trust) and Schafer $<span id="xdx_90E_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20230202__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--RelatedPartyTransactionAxis__custom--SmithMember_zzRmah6UASSk" title="Convertible Notes Payable">262,154</span>, $<span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20230202__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--RelatedPartyTransactionAxis__custom--BassaniFamilyTrustsMember_zF0QI57PsnVl" title="Convertible Notes Payable">434,016</span> and $<span id="xdx_900_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20230202__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--RelatedPartyTransactionAxis__custom--SchaferMember_znqLWB1ktnx4" title="Convertible Notes Payable">96,364</span> of Adjusted 2020 Convertible Obligations and Bassani and Schafer $<span id="xdx_902_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20230202__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__srt--CounterpartyNameAxis__custom--BassaniMember_zDUqjw8ZvGJ3" title="Convertible Notes Payable">24,230</span> and $<span id="xdx_908_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20230202__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__srt--CounterpartyNameAxis__custom--EdSchaferMember_zI0n6ufKKDh8" title="Convertible Notes Payable">4,012</span> of Adjusted September 2015 Convertible Notes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective March 8, 2023, Smith converted $<span id="xdx_903_eus-gaap--ConversionOfStockAmountConverted1_c20230307__20230308__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zCyDQKYuSYib" title="Conversion of shares, value">70,000</span> of his Adjusted 2020 Convertible Obligation into <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_c20230307__20230308__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zGsa45FYI0Cg" title="Conversion of shares, shares">739,958</span> Units (each Unit consisting one share and one warrant). Effective March 31, 2023, Smith converted $<span id="xdx_909_eus-gaap--ConversionOfStockAmountConverted1_c20230302__20230331__us-gaap--DebtInstrumentAxis__custom--AdjustedConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zQERbU4hkxX7" title="Conversion of shares, value">29,888</span>.64 of his Adjusted Convertible Obligation into <span id="xdx_900_eus-gaap--ConversionOfStockSharesConverted1_c20230302__20230331__us-gaap--DebtInstrumentAxis__custom--AdjustedConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zpqZKOwCQJsg" title="Conversion of shares, shares">315,948</span> Units (each Unit consisting one share of common stock and one warrant). Smith donated to charitable organizations and/or gifted to family members and others a large portion of these securities (<span id="xdx_907_eus-gaap--ConversionOfStockSharesIssued1_c20230307__20230308__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member__us-gaap--AwardTypeAxis__custom--CommonSharesMember_z000P3aS4Me2" title="Convertible stock shares issued, common shares">450,000</span> common shares and <span id="xdx_90F_eus-gaap--ConversionOfStockSharesIssued1_c20230307__20230308__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member__us-gaap--AwardTypeAxis__custom--WarrantsMember_z5A6AKwMjCCh" title="Convertible stock shares issued, warrants">705,000</span> warrants, in aggregate) while retaining direct ownership of <span id="xdx_908_eus-gaap--SharesIssued_iI_c20230308__us-gaap--AwardTypeAxis__custom--CommonSharesMember__srt--OwnershipAxis__custom--DirectOwnershipMember_zeDqIcRCB4Ij" title="Shares issued, common shares">255,906</span> common shares and <span id="xdx_903_eus-gaap--SharesIssued_iI_c20230308__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--OwnershipAxis__custom--DirectOwnershipMember_zGgM0A0hYWcj" title="Shares issued, warrants">79,958</span> warrants and indirect ownership of <span id="xdx_903_eus-gaap--SharesIssued_iI_c20230308__us-gaap--AwardTypeAxis__custom--CommonSharesMember__srt--OwnershipAxis__custom--IndirectOwnershipMember_zIs3BMn2WzW8" title="Shares issued, common shares">350,000</span> common shares and <span id="xdx_908_eus-gaap--SharesIssued_iI_c20230308__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--OwnershipAxis__custom--IndirectOwnershipMember_zL2SVZijOC3c" title="Shares issued, warrants">270,948</span> warrants (owned by his wife). The warrants are exercisable for three years from conversion date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2023, the Adjusted 2020 Convertible Obligation balances, including accrued interest, owed Bassani (and his donees), Smith and Edward Schafer were $<span id="xdx_90B_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20230331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_zIT9tLG8NXub" title="Convertible Notes Payable, Noncurrent">436,988</span>, $<span id="xdx_905_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20230331__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_z3Y24BtZ9Nqd" title="Convertible Notes Payable, Noncurrent">164,060</span> and $<span id="xdx_905_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20230331__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_zkEXS2SorZH6" title="Convertible Notes Payable, Noncurrent">97,024</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2023 the Adjusted September 2015 Convertible Notes balances, including accrued interest, owed Bassani Family Trusts and Schafer were $<span id="xdx_900_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20230331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember_zKJcFhixmJUe" title="Convertible Notes Payable, Noncurrent">24,396</span> and $<span id="xdx_90D_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20230331__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember_zPRD2SkH0vga" title="Convertible Notes Payable, Noncurrent">4,039</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 0.04 0.04 0.50 0.50 358151 36072 0 2573716 1315069 494736 90000 23943 30000 60000 60000 60000 20000 40000 40000 40000 16208 6366 98948 17430 51238 0 117342 0 3470000 1109649 1939670 424873 0.04 0.60 157682 0 457094 276944 20681 441977 5507 5366 18239 17430 3470000 1109649 1939670 424873 3470000 1109649 1939670 424873 946 953 953 262154 434016 96364 24230 4012 70000 739958 29888 315948 450000 705000 255906 79958 350000 270948 436988 164060 97024 24396 4039 <p id="xdx_802_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z8NiyENZCCyh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>7.       <span id="xdx_82F_zwqKfHAw6WPb">STOCKHOLDERS' EQUITY:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Debt Modification to Additional Paid in Capital </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes) owed to them by the Company in a manner which reduces the indebtedness of the Company by 80% (approximately $<span id="xdx_906_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn3n3_dm_c20230331_zIhl5Ue0fqT7" title="Convertible note">3.47</span> million, in aggregate) while equitably maintaining existing conversion rights.  Mark A. Smith (the Company’s President)(“Smith”), Dominic Bassani (the Company’s Chief Operating Officer)(“Bassani”) and Ed Schafer (Director)(“Schafer”), adjusted/reduced the principal owed to them by $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__srt--CounterpartyNameAxis__custom--MarkASmithMember_zdd2o1wEWS54" title="Principal amount">1,109,649</span>, $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__srt--CounterpartyNameAxis__custom--DominicBassaniMember_zAYIRRY1SEs6" title="Principal amount">1,939,670</span> and $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__srt--CounterpartyNameAxis__custom--EdSchaferMember_zxiROUHoLTyh" title="Principal amount">424,873</span>, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes. The Adjusted 2020 Convertible Obligations of Smith, Bassani and Schafer are convertible into units at prices of $.<span id="xdx_90B_ecustom--ConversionPricePerUnit_iI_pp0p0_c20230331__srt--CounterpartyNameAxis__custom--MarkASmithMember_zmALz0c4WIp" title="Conversion price per unit">0946</span>, $<span id="xdx_906_ecustom--ConversionPricePerUnit_iI_pp0p0_c20230331__srt--CounterpartyNameAxis__custom--DominicBassaniMember_zEQ29eHpCHCe" title="Conversion price per unit">0953</span>, and $.<span id="xdx_903_ecustom--ConversionPricePerUnit_iI_pp0p0_c20230331__srt--CounterpartyNameAxis__custom--EdSchaferMember_zn1223gSqy9d" title="Conversion price per unit">0953</span>, respectively, and the Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $<span id="xdx_900_ecustom--ConversionPricePerUnit_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--AwardTypeAxis__custom--RestrictedCommonSharesMember_zxkY0ZP89Fr5" title="Conversion price per unit">0.115</span> per share. The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (<span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20220701__20230331__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zdVBP0GybAra" title="Convertible debt maturity date">July 1, 2024</span>). The Company treated this as an equity transaction and recorded the reduction of debt through addiotnal paid in capital at the net present value of the modified debt agreements. This resulted in an increase to Additional Paid in Capital of $<span id="xdx_902_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20230101__20230331_zVDdlrHTkNb6" title="Increase to additional paid in capital">3,521,000</span> at the modification date and a reduction of additional paid in capital of $<span id="xdx_90F_ecustom--ReductionOfAdditionalPaidInCapital_c20230101__20230331_zTNYoINTYA1j" title="Reduction of additional paid in capital">5,620</span> for the three months ended March 31, 2023 for the adjustment to the net present value of the modified debt agreements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Series B Preferred stock:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since July 1, 2014, the Company had <span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_c20140702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred Stock, Shares Outstanding, Ending Balance (in shares)">200</span> shares of Series B redeemable convertible Preferred stock outstanding with a par value of $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_c20140702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Par value">0.01</span> per share, convertible at the option of the holder at $<span id="xdx_906_ecustom--PreferredStockConvertibleOptionPerShare_iI_c20140703__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zc3kWan2AC73" title="Preferred Stock, Convertible Option Per Share">2.00</span> per share, with dividends accrued and payable at <span id="xdx_907_eus-gaap--PreferredStockDividendRatePercentage_dp_c20140625__20140701__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zaGC3NvIpRf5" title="Preferred stock dividend rate percentage">2.5</span>% per quarter. The Series B Preferred stock is mandatorily redeemable at $<span id="xdx_90F_eus-gaap--PreferredStockRedemptionPricePerShare_iI_c20140702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zT15AOkwPxwb" title="Preferred Stock, Redemption Price Per Share">100</span> per share by the Company three years after issuance and accordingly was classified as a liability. The 200 shares had reached their redemption date and the Company approved the redemption of the Series B preferred stock during the year ended June 30, 2022. The 200 shares of Series B redeemable convertible Preferred stock were redeemed for $<span id="xdx_90E_ecustom--RedemptionOfConvertiblePreferredStock_c20220701__20230331_pp0p0" title="Redemption of convertible Preferred stock">41,000</span>, which included the $<span id="xdx_90E_eus-gaap--DividendsPayableCurrentAndNoncurrent_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pp0p0" title="Dividends Payable">21,000</span> in accrued dividend payable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended June 30, 2022, and 2021, the Company declared dividends of $<span id="xdx_90A_eus-gaap--DividendsPreferredStock_pp0p0_c20220701__20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsGqsJUN0vbc" title="Dividends, Preferred Stock">1,000</span> and $<span id="xdx_90E_eus-gaap--DividendsPreferredStock_pp0p0_c20210701__20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zTXic50N51di" title="Dividends, Preferred Stock">2,000</span> respectively. The dividends are classified as a component of operations as the Series B Preferred stock is presented as a liability in these financial statements. There is <span id="xdx_90E_eus-gaap--LiabilitiesCurrent_iI_pp0p0_do_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zWC1WcxCzW4g" title="Liability">no</span> liability at March 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common stock:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Holders of common stock are entitled to one vote per share on all matters to be voted on by common stockholders. In the event of liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to share in all assets remaining after liabilities have been paid in full or set aside and the rights of any outstanding preferred stock have been satisfied. Common stock has no preemptive, redemption or conversion rights. The rights of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of any outstanding series of preferred stock or any series of preferred stock the Company may designate in the future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Centerpoint holds <span id="xdx_903_ecustom--SharesHeldBySubsidiaries_iN_di_c20220701__20230331_zxw0cqAfCwCj" title="Shares Held by Subsidiaries">704,309</span> shares of the Company’s common stock. These shares of the Company’s common stock held by Centerpoint are for the benefit of its shareholders without any beneficial interest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended December 31, 2022, the Company entered into a subscription agreement to sell <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220701__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zRTS02UmyAzj" title="Sale of stock, shares">2,000,000</span> shares of restricted and legended common stock of which <span id="xdx_907_eus-gaap--StockRepurchasedDuringPeriodShares_c20230102__20230110__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember_z1slKObg4nQd" title="Shares purchased, shares">1,800,000</span> shares were purchased on January 10, 2023 (the other <span id="xdx_908_eus-gaap--StockRepurchasedDuringPeriodShares_c20221202__20221231__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember_zO9tNBaBM005" title="Shares purchased, shares">200,000</span> shares were purchased on December 31, 2022) for total proceeds during the nine month period ending March 31, 2023 of $<span id="xdx_90C_eus-gaap--StockRepurchasedDuringPeriodValue_c20220701__20230331__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember_zH0ejPIqQkbe" title="Shares purchased, value">2,000,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended March 31, 2023, the Company entered into subscription agreements to sell <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zNj6xprRiew1" title="Sale of stock, shares">575,000</span> units at a price of $<span id="xdx_906_ecustom--SaleOfUnitPricePerUnit_iI_c20230331__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zsdNeDr5zZg" title="Sale of units">1.60</span>, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_900_eus-gaap--SharePrice_iI_c20230331__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zY8VMcSJ4Wsl" title="Sell units">2.40</span> per share with an expiry date of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zJBeA09AUDUe" title="Expiry date">June 30, 2024</span>, and pursuant thereto, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_z6XJlHS7wi2h" title="Number of shares issued">575,000</span> units for total proceeds of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zsCBB2Smhofh" title="Number of shares issued, value">920,000</span>, in aggregate. The Company paid commissions of $<span id="xdx_90C_eus-gaap--PaymentsForCommissions_pp0p0_c20230101__20230331_zTGZ7LnZOdXb" title="Commissions paid">48,000</span> on the sale of units.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">During the three months ended March 31, 2023, <span id="xdx_909_ecustom--ClassOfWarrantOrRightExercisedDuringPeriod_c20230101__20230331_zLvhaIbcWUIk" title="Class of Warrant or Right, Exercised During Period">84,000</span> warrants were exercised to purchase <span id="xdx_905_ecustom--CommonStockSharesIssuedUponExerciseOfWarrants_c20230101__20230331_zYnXfpvdhZxc" title="Common Stock Shares Issued upon Exercise of Warrants">84,000</span> shares of the Company’s common stock at $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4Ig7bsMz0t3" title="Warrants exercisable per share">0.75</span> per share for total proceeds of $<span id="xdx_90D_ecustom--WarrantsExercisedForCommonStock_pp0p0_c20230101__20230331_zivuit7RYfgg" title="Warrant Exercised for Common Stock">63,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended March 31, 2023, Smith elected to convert $<span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20220701__20230331__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__srt--TitleOfIndividualAxis__custom--PrincipalMember_zsdek9Ud7cua" title="Debt conversion value">99,889</span> in principal of his Adjusted 2020 Convertible Obligation into <span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNLEId4OhTO4" title="Debt conversion value">1,055,906</span> units at $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_zkkwbK4B5b8f" title="Conversion price per share">0.0946</span> per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__srt--TitleOfIndividualAxis__srt--PresidentMember_zojeM4glBVYd" title="Warrants exercisable per share">0.75</span> per share until March 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended March 31, 2023, the Company entered into subscription agreements to sell units for $<span id="xdx_904_ecustom--SaleOfUnitPricePerUnit_iI_c20230331_zkFHJG2g5Dti" title="Sale of unit, price per unit">1.00</span> per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_90E_eus-gaap--SharePrice_iI_c20230331_zbAqNyzSFKBj" title="Share price">0.75</span> per share with an expiry date of December 31, 2024, and pursuant thereto, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220701__20230331_z8I4VTWJEoo2" title="Number of shares issued">346,230</span> units for total proceeds of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220701__20230331_zvvopmHUn514" title="Number of shares issued, value">346,230</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended March 31, 2023, the Company entered into a subscription agreement to sell <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220701__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVmH7DWjmclj" title="Sale of stock, shares">2,000,000</span> shares of restricted and legended common stock of which <span id="xdx_90E_eus-gaap--StockRepurchasedDuringPeriodShares_c20230102__20230110__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember_zI57JJFbxZla" title="Shares purchased, shares">1,800,000</span> shares were purchased on January 10, 2023 (the other <span id="xdx_907_eus-gaap--StockRepurchasedDuringPeriodShares_c20221202__20221231__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember_zE0cL15aHefj" title="Shares purchased, shares">200,000</span> shares were purchased on December 31, 2022) for total proceeds during the nine-month period ending March 31, 2023 of $<span id="xdx_90B_eus-gaap--StockRepurchasedDuringPeriodValue_c20220701__20230331__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember_zz7AaGfy64N3" title="Shares purchased, value">2,000,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended March 31, 2023, the Company entered into subscription agreements to sell <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220701__20230331__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_z0s7QcIkIWu" title="Sale of stock, shares">575,000</span> units at a price of $<span id="xdx_90C_ecustom--SaleOfUnitPricePerUnit_iI_c20230331__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zfosH9asi10a" title="Sale of units">1.60</span>, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_902_eus-gaap--SharePrice_iI_c20230331__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zKRRYq64sqvg" title="Sell units">2.40</span> per share with an expiry date of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zNECucoclCk2" title="Expiry date">June 30, 2024</span>, and pursuant thereto, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220701__20230331__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zqO1ShW0g19k" title="Number of shares issued">575,000</span> units for total proceeds of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20220701__20230331__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_z7O8xr8jKRLf" title="Number of shares issued, value">920,000</span>, in aggregate. The Company paid commissions of $<span id="xdx_909_eus-gaap--PaymentsForCommissions_pp0p0_c20220701__20230331_zziCXci2gOB1" title="Commissions paid">48,000</span> on the sale of units.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">During the nine months ended March 31, 2023, <span id="xdx_904_ecustom--ClassOfWarrantOrRightExercisedDuringPeriod_c20220701__20230331_zdk7CuaG8Cwd" title="Class of Warrant or Right, Exercised During Period">158,834</span> warrants were exercised to purchase <span id="xdx_900_ecustom--CommonStockSharesIssuedUponExerciseOfWarrants_c20220701__20230331_zygyIN0SGXy" title="Common Stock Shares Issued upon Exercise of Warrants">158,834</span> shares of the Company’s common stock at $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEHHYA7bn2z6" title="Warrants exercisable per share">0.75</span> per share for total proceeds of $<span id="xdx_905_ecustom--WarrantsExercisedForCommonStock_pp0p0_c20220701__20230331_zUhnvBttUaj9" title="Warrant Exercised for Common Stock">119,125</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">During the nine months ended March 31, 2023, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220701__20230331__srt--TitleOfIndividualAxis__custom--ConsultantServiceMember_zAHfQiOZVRZb" title="Shares issued for consultant services">50,000</span> shares of the Company’s common stock to a consultant for services. The shares were issued at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20230331__srt--TitleOfIndividualAxis__custom--ConsultantServiceMember_zNWKU9Rso3ee" title="Share price">1.60</span> per share for a total value of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220701__20230331__srt--TitleOfIndividualAxis__custom--ConsultantServiceMember_z2cZzqNZzyq4" title="Total value of consultant services">80,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended March 31, 2023, Smith elected to convert $<span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220701__20230331__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__srt--TitleOfIndividualAxis__custom--PrincipalMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4GPl5UN8Si4" title="Debt conversion value">30,000</span> in principal and $<span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220701__20230331__srt--TitleOfIndividualAxis__custom--AccruedInterestMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_z6LeTUOJ6qgb" title="Debt conversion value">20,000</span> in accrued interest from the 2020 Convertible Obligation to <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20230331__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zixQ1pwnCc2h" title="Debt conversion shares">100,000</span> units at $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGryG7Ykv5d9" title="Conversion price per share">.50</span> per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdAoQ8dX1VOg" title="Warrants exercisable per share">0.75</span> per share until December 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> <b>Warrants:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2023, the Company had approximately <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pn3n3_dm_c20230331_zlsuXXGkbDBg" title="Warrant outstanding">21.9</span> million warrants outstanding, with exercise prices from $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__srt--RangeAxis__srt--MinimumMember_zqaOszq6oMeh" title="Warrants exercise price per share">0.60</span> to $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__srt--RangeAxis__srt--MaximumMember_z5p6z4QCSLP2" title="Warrants exercise price per share">2.40</span> and expiring on various dates through November 9, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted-average exercise price for the outstanding warrants is $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20230331__us-gaap--AwardTypeAxis__custom--WarrantsMember_zjcHqldYSw3d" title="Weighted average exercise price">0.78</span>, and the weighted-average remaining contractual life as of March 31, 2023 is <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220701__20230331__us-gaap--AwardTypeAxis__custom--WarrantsMember_zthdmHaIWJib" title="Remaining contractual life">1.8</span> years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended March 31, 2023, Smith elected to convert $<span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220701__20230331__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__srt--TitleOfIndividualAxis__custom--PrincipalMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuZlXGYuhlwi" title="Debt conversion value">30,000</span> in principal and $<span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220701__20230331__srt--TitleOfIndividualAxis__custom--AccruedInterestMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_zituYPvBgR4d" title="Debt conversion value">20,000</span> in accrued interest from the 2020 Convertible Obligation to <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20230331__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFmNmm4VZJZa" title="Debt conversion shares">100,000</span> units at $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgn6FnomTBs2" title="Conversion price per share">.50</span> per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztd73h9UEq9g" title="Warrants exercisable per share">0.75</span> per share until three years after the date of conversion.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended March 31, 2023, Smith converted $<span id="xdx_902_eus-gaap--ConversionOfStockAmountConverted1_c20220701__20230331__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zcUqtboCzfm7" title="Conversion of shares, value">70,000</span> of his Adjusted 2020 Convertible Obligation into <span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_c20220701__20230331__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zF1do3QBb4C4" title="Conversion of shares, shares">739,958</span> Units (each Unit consisting one share and one warrant) and converted $<span id="xdx_900_eus-gaap--ConversionOfStockAmountConverted1_c20220701__20230331__us-gaap--DebtInstrumentAxis__custom--AdjustedConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zWIFjJ0hAj6j" title="Conversion of shares, value">29,889</span> of his Adjusted Convertible Obligation into <span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_c20220701__20230331__us-gaap--DebtInstrumentAxis__custom--AdjustedConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zLhwsGk5Ot5b" title="Conversion of shares, shares">315,948</span> Units (each Unit consisting one share of common stock and one warrant). Smith donated to charitable organizations and/or gifted to family members and others a large portion of these securities (<span id="xdx_906_eus-gaap--ConversionOfStockSharesIssued1_c20220701__20230331__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member__us-gaap--AwardTypeAxis__custom--CommonSharesMember_zdWfqMnswD9h" title="Convertible stock shares issued, common shares">450,000</span> common shares and <span id="xdx_90E_eus-gaap--ConversionOfStockSharesIssued1_c20220701__20230331__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member__us-gaap--AwardTypeAxis__custom--WarrantsMember_zk08Gz9anTnf" title="Convertible stock shares issued, warrants">705,000</span> warrants, in aggregate) while retaining direct ownership of <span id="xdx_907_eus-gaap--SharesIssued_iI_c20230331__us-gaap--AwardTypeAxis__custom--CommonSharesMember__srt--OwnershipAxis__custom--DirectOwnershipMember_z2nr8NSu46U7" title="Shares issued, common shares">255,906</span> common shares and <span id="xdx_902_eus-gaap--SharesIssued_iI_c20230331__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--OwnershipAxis__custom--DirectOwnershipMember_zDvjKOJ92Vx2" title="Shares issued, warrants">79,958</span> warrants and indirect ownership of <span id="xdx_904_eus-gaap--SharesIssued_iI_c20230331__us-gaap--AwardTypeAxis__custom--CommonSharesMember__srt--OwnershipAxis__custom--IndirectOwnershipMember_zWpIstRSkJC2" title="Shares issued, common shares">350,000</span> common shares and <span id="xdx_90A_eus-gaap--SharesIssued_iI_c20230331__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--OwnershipAxis__custom--IndirectOwnershipMember_zOubA4kuoula" title="Shares issued, warrants">270,948</span> warrants (owned by his wife). The warrants are exercisable for three years from conversion date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the nine months ended March 31, 2023, the Company approved the issuance of <span id="xdx_90C_ecustom--ClassOfWarrantOrRightExercisedDuringPeriod_c20220701__20230331__srt--TitleOfIndividualAxis__custom--ThreeConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEuxx2yqQvZ7" title="Class of Warrant or Right, Exercised During Period (in shares)">210,000</span> warrants, in aggregate, to three new members of its Advisory Group for advisory and/or consulting services of $<span id="xdx_905_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c20220701__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmLQrBwQVzbe" title="Issuance of warrants">21,000</span>, in aggregate. The warrants are exercisable at $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__srt--TitleOfIndividualAxis__custom--ThreeConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zYeZyndKK2Q5" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">1.50</span> to $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__srt--TitleOfIndividualAxis__custom--ThreeConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zbezrmbQL3g3" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">1.60</span> and expire in August 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">During the nine months ended March 31, 2023, the Company approved the modification of existing warrants held by one former consultant and investors, which extended certain expiration dates. The modifications resulted in incremental non-cash compensation of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20220701__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaUrGSsUxZx4" title="Share-based Payment Arrangement, Plan Modification, Incremental Cost">154,932</span> and interest expenses of $<span id="xdx_90D_ecustom--InterestExpenses_pp0p0_c20220701__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGLE5jG2Xir2" title="Interest expenses">72,589</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the nine months ended March 31, 2023, <span id="xdx_908_ecustom--ClassOfWarrantOrRightExercisedDuringPeriod_c20220701__20230331_zbi2f10umpWh" title="Class of Warrant or Right, Exercised During Period">158,834</span> warrants were exercised to purchase <span id="xdx_908_ecustom--CommonStockSharesIssuedUponExerciseOfWarrants_c20220701__20230331_zPql0Zxxb3Ih" title="Common Stock Shares Issued upon Exercise of Warrants">158,834</span> shares of the Company’s common stock at $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlK5Sx4caof5" title="Warrants exercisable per share">0.75</span> per share for total proceeds of $<span id="xdx_901_ecustom--WarrantsExercisedForCommonStock_pp0p0_c20220701__20230331_zoSgQawQRQK5" title="Warrant Exercised for Common Stock">119,125</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective May 1, 2022, an entity affiliated with William O’Neill (“O’Neill”) was issued <span id="xdx_900_eus-gaap--SharesIssued_iI_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zlTwvtw4tIEa" title="Number of shares issued">1,000,000</span> Incentive Warrants exercisable at $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pdd" title="Warrants exercisable per share">1.00</span> per share until April 30, 2026 of which up to <span id="xdx_90C_ecustom--CancellationOfWarrants_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pdd" title="Cancellation of warrants">700,000</span> Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a <span id="xdx_904_ecustom--ExerciseBonus_iI_dp_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zuS3rVTIkMQ8" title="Exercise bonus">75</span>% exercise bonus if the terms set forth therein are met.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The <span id="xdx_901_eus-gaap--SharesIssued_iI_c20230331__srt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zx80fwsdW9S3" title="Number of shares issued">700,000</span> of the warrants are vesting through <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220701__20230331__srt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zK3HjFt8cTa4" title="Vesting period">May 1, 2023</span> and 2024. The vesting resulted in non-cash compensation of $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230331__srt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYSuiy7N7VI9" title="Non cash compensation">9,844</span> and $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20230331__srt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z84mmKrFqc05" title="Non cash compensation">36,094</span> during the three and nine months ended March 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Stock options: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 7, 2022 the Company’s shareholders approved the Bion Environmental Technologies, Inc. 2021 Equity Incentive Award Plan (the “<span style="text-decoration: underline">Equity Plan</span>”). The Equity Plan provides for the issuance of options (and/or other securities) to purchase up to <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zqOqRRQxM6oj" title="Stock options, authorized (in shares)">30,000,000</span> shares of the Company’s common stock. The Equity Plan was adopted and ratified by Board of Directors on April 8, 2022. Terms of exercise and expiration of options/securities granted under the Equity Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. No grants have been made pursuant to the Equity Plan as of the date of this report.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s 2006 Consolidated Incentive Plan, as amended during the year ended June 30, 2021 (the “2006 Plan”), provides for the issuance of options (and/or other securities) to purchase up to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ziPMoEFVEurh" title="Stock options, authorized (in shares)">36,000,000</span> shares of the Company’s common stock. Terms of exercise and expiration of options/securities granted under the 2006 Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. The 2006 Plan will be maintained to service grants already made thereunder (together with new grants, if any, to employees and consultants who already has received grants pursuant to its terms,</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 11, 2022, the Company granted <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220201__20220211__us-gaap--PlanNameAxis__custom--Plan2006Member_z2mblUcsZIm2" title="Number of shares granted">10,000</span> options under the 2006 Plan to one consultant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 29, 2022, the Company granted an aggregate of <span id="xdx_903_ecustom--SharebasedCompensationGranted_c20220401__20220429_zLG35enSIss4" title="Share-based Compensation, Granted">720,000</span> options under the 2006 Plan to seven employees/consultants/directors including: i) <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20220429__srt--CounterpartyNameAxis__custom--NorthropMember_zJweeL21Sfq6" title="Share-based Compensation, Granted">50,000</span> options each to Schafer and Northrop for service as directors, ii) <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20220429__srt--CounterpartyNameAxis__custom--BassaniMember_zDIhjfhr4DV5" title="Share-based Compensation, Granted">200,000</span> options to Bassani (now COO of the Company and formerly CEO) and iii) <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20220429__srt--CounterpartyNameAxis__custom--SmithMember_pdd" title="Share-based Compensation, Granted">200,000</span> options to Smith, the Company’s President, which new option grants are included in the presentation below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded compensation expense related to employee stock options of $<span id="xdx_90E_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" title="Share-based Payment Arrangement, Expense"><span id="xdx_90B_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20220701__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" title="Share-based Payment Arrangement, Expense">220,510</span></span> and $<span id="xdx_90C_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pp0p0_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOeNdGFfwflg" title="Share-based Payment Arrangement, Expense"><span id="xdx_90D_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20210701__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" title="Share-based Payment Arrangement, Expense">4,650</span></span> for both the three and nine months ended March 31, 2023 and 2022, respectively. The Company granted <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230331__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_pdd" title="Share-based Compensation, Granted"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220701__20230331__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_pdd" title="Share-based Compensation, Granted">305,000</span></span> and <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20220331__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_pdd" title="Share-based Compensation, Granted"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20220331__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_pdd" title="Share-based Compensation, Granted">10,000</span></span> options for both the three and nine months ended March 31, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">A summary of option activity under the 2006 Plan for nine months ended March 31, 2023 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"/> <table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zzdjJLvTvUL5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY - Stock Option Activity (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left"><span id="xdx_8B4_z08oic3BkYp3" style="display: none">Schedule of option activity</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: left; font-size: 12pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt; font-size: 12pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Options</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Weighted- <br/> Average <br/> Exercise <br/> Price</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Weighted- <br/> Average <br/> Remaining <br/> Contractual <br/> Life</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Aggregate <br/> Intrinsic <br/> Value</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td style="width: 38%; text-align: left"><span style="font-size: 10pt">Outstanding at July 1, 2022</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220701__20230331_zGtle97EUJF1" style="width: 12%; text-align: right" title="Options outstanding, beginning (in shares)">11,201,600</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220701__20230331_zeVvZaO4MrMi" style="width: 12%; text-align: right" title="Options outstanding, beginning weighted-average exercise price">0.80</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210701__20220630_z71e0qpuNnr5" title="Outstanding, weighted-average remaining contractual life (Year)">2.7</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220701__20230331_z5wXm49919Pa" style="width: 12%; text-align: right" title="Outstanding, aggregate intrinsic value beginning">4,429,263</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left"><span style="font-size: 10pt">  Granted</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230331_pdd" style="text-align: right" title="Granted, options (in shares)">305,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220701__20230331_pdd" style="text-align: right" title="Granted, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1504">—</span>  </td><td style="text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: left"><span style="font-size: 10pt">  Exercised</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220701__20230331_pdd" style="text-align: right" title="Exercised, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1506">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220701__20230331_pdd" style="text-align: right" title="Exercised, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1508">—</span>  </td><td style="text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left"><span style="font-size: 10pt">  Forfeited</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220701__20230331_pdd" style="text-align: right" title="Forfeited, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1510">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220701__20230331_pdd" style="text-align: right" title="Forfeited, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1512">—</span>  </td><td style="text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: left"><span style="font-size: 10pt">  Expired</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220701__20230331_pdd" style="text-align: right" title="Expired, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1514">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220701__20230331_pdd" style="text-align: right" title="Expired, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1516">—</span>  </td><td style="text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">Outstanding at March 31, 2023</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220701__20230331_z8Bf9XoZETIj" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending (in shares)">11,506,600</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220701__20230331_z4NLgEP5ku8j" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending weighted-average exercise price">0.82</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20230331_z20b2gPUNcz7" title="Outstanding, weighted-average remaining contractual life (Year)">2.02</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20220701__20230331_zbAACRoEb4v7" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding, aggregate intrinsic value ending">10,238,395</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The total fair value of stock options that vested during both the three and nine months ended March 31, 2023 and 2022 was $<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20230101__20230331_zkwSBWsMW1U7" title="Fair value of stock options"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20220701__20230331_zTyOU3wWuNfe" title="Fair value of stock options">220,510</span></span> and $<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20220101__20220331_zWkW7Kowjdw8" title="Fair value of stock options"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20210701__20220331_zRHaocTlQSDa" title="Fair value of stock options">4,650</span></span>, respectively. As of March 31, 2023, the Company had no unrecognized compensation cost related to stock options.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> 3470000 1109649 1939670 424873 946 953 953 0.115 2024-07-01 3521000 5620 200 0.01 2.00 0.025 100 41000 21000 1000 2000 0 -704309 2000000 1800000 200000 2000000 575000 1.60 2.40 2024-06-30 575000 920000 48000 84000 84000 0.75 63000 99889 1055906 0.0946 0.75 1.00 0.75 346230 346230 2000000 1800000 200000 2000000 575000 1.60 2.40 2024-06-30 575000 920000 48000 158834 158834 0.75 119125 50000 1.60 80000 30000 20000 100000 0.50 0.75 21900000 0.60 2.40 0.78 P1Y9M18D 30000 20000 100000 0.50 0.75 70000 739958 29889 315948 450000 705000 255906 79958 350000 270948 210000 21000 1.50 1.60 154932 72589 158834 158834 0.75 119125 1000000 1.00 700000 0.75 700000 2023-05-01 9844 36094 30000000 36000000 10000 720000 50000 200000 200000 220510 220510 4650 4650 305000 305000 10000 10000 <table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zzdjJLvTvUL5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY - Stock Option Activity (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left"><span id="xdx_8B4_z08oic3BkYp3" style="display: none">Schedule of option activity</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: left; font-size: 12pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt; font-size: 12pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Options</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Weighted- <br/> Average <br/> Exercise <br/> Price</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Weighted- <br/> Average <br/> Remaining <br/> Contractual <br/> Life</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Aggregate <br/> Intrinsic <br/> Value</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td style="width: 38%; text-align: left"><span style="font-size: 10pt">Outstanding at July 1, 2022</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220701__20230331_zGtle97EUJF1" style="width: 12%; text-align: right" title="Options outstanding, beginning (in shares)">11,201,600</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220701__20230331_zeVvZaO4MrMi" style="width: 12%; text-align: right" title="Options outstanding, beginning weighted-average exercise price">0.80</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210701__20220630_z71e0qpuNnr5" title="Outstanding, weighted-average remaining contractual life (Year)">2.7</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220701__20230331_z5wXm49919Pa" style="width: 12%; text-align: right" title="Outstanding, aggregate intrinsic value beginning">4,429,263</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left"><span style="font-size: 10pt">  Granted</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230331_pdd" style="text-align: right" title="Granted, options (in shares)">305,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220701__20230331_pdd" style="text-align: right" title="Granted, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1504">—</span>  </td><td style="text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: left"><span style="font-size: 10pt">  Exercised</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220701__20230331_pdd" style="text-align: right" title="Exercised, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1506">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220701__20230331_pdd" style="text-align: right" title="Exercised, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1508">—</span>  </td><td style="text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left"><span style="font-size: 10pt">  Forfeited</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220701__20230331_pdd" style="text-align: right" title="Forfeited, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1510">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220701__20230331_pdd" style="text-align: right" title="Forfeited, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1512">—</span>  </td><td style="text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: left"><span style="font-size: 10pt">  Expired</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220701__20230331_pdd" style="text-align: right" title="Expired, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1514">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220701__20230331_pdd" style="text-align: right" title="Expired, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1516">—</span>  </td><td style="text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">Outstanding at March 31, 2023</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220701__20230331_z8Bf9XoZETIj" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending (in shares)">11,506,600</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220701__20230331_z4NLgEP5ku8j" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending weighted-average exercise price">0.82</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20230331_z20b2gPUNcz7" title="Outstanding, weighted-average remaining contractual life (Year)">2.02</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20220701__20230331_zbAACRoEb4v7" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding, aggregate intrinsic value ending">10,238,395</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 11201600 0.80 P2Y8M12D 4429263 305000 11506600 0.82 P2Y7D 10238395 220510 220510 4650 4650 <p id="xdx_80F_ecustom--SubscriptionReceivableTextBlock_zJ8ie6JaVV6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>8.       <span id="xdx_82E_zjiMgvKGdDsc">SUBSCRIPTION RECEIVABLE - AFFILIATES:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2023, the Company has three interest bearing, secured promissory notes with an aggregate principal amount of $<span id="xdx_903_eus-gaap--NotesReceivableNet_c20230331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_pp0p0" title="Financing Receivable, after Allowance for Credit Loss, Total">428,250</span> ($<span id="xdx_90D_ecustom--NotesReceivableInterest_c20230331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_pp0p0" title="Notes receivable interest">513,282</span>, including interest) from Bassani which were received as consideration for purchases of warrants to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20230331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_pdd" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">5,565,000</span> shares, in aggregate, of the Company’s restricted common stock, which warrants have an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230331__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_pdd" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.75</span> and have expiry dates ranging from December 31, 2024 to December 31, 2025. The promissory notes bear interest at 4% per annum and are secured by portions of Bassani Family Trust’s 2020 Convertible Obligation and Bassani Family Trust’s September 2015 Convertible Notes. The secured promissory notes are payable July 1, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2023, the Company has an interest bearing, secured promissory note for $<span id="xdx_902_ecustom--FinancingReceivablePrincipalAmount_c20230331__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_pp0p0" title="Financing Receivable, Principal Amount">30,000</span> ($<span id="xdx_907_eus-gaap--NotesReceivableNet_c20230331__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_pp0p0" title="Financing Receivable, after Allowance for Credit Loss, Total">35,586</span> including interest) from Smith as consideration to purchase warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20220331__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_pdd" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">300,000</span> shares of the Company’s restricted common stock, which warrants are exercisable at $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230331__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_pdd" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.60</span> and have expiry dates of December 31, 2024. The warrants have a 75% exercise bonus and the promissory note bears interest at <span id="xdx_903_ecustom--FinancingReceivableInterestRateStatedPercentage_iI_dp_c20230331__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zjNdqrrRZYfl" title="Financing receivable interest rate stated percentage">4</span>% per annum, and is secured by $<span id="xdx_906_ecustom--FinancingReceivablePrincipalAmount_iI_c20230331__srt--CounterpartyNameAxis__custom--SmithsMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zWeURojpUK9i" title="Financing Receivable, Principal Amount">30,000</span> ($<span id="xdx_909_eus-gaap--NotesReceivableNet_iI_c20230331__srt--CounterpartyNameAxis__custom--SmithsMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_z6t9PTE7IZAc" title="Financing Receivable, after Allowance for Credit Loss, Total">35,714</span>, including interest) of Smith’s 2020 Convertible Obligations. The secured promissory note is payable on July 1, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">As of March 31, 2023 the Company has two interest bearing, secured promissory notes with an aggregate principal amount of $<span id="xdx_90A_ecustom--FinancingReceivablePrincipalAmount_c20230331__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_pp0p0" title="Financing Receivable, Principal Amount">46,400</span> ($<span id="xdx_906_eus-gaap--NotesReceivableNet_c20230331__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_pp0p0" title="Financing Receivable, after Allowance for Credit Loss, Total">56,396</span> including interest) from two former employees as consideration to purchase warrants to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20230331__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_pdd" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">928,000</span> shares of the Company’s restricted common stock, which warrants are exercisable at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_zTzpcDprMdOd" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.75</span> and have expiry dates of December 31, 2024. These warrants have a 90% exercise bonus. The promissory notes bear interest at <span id="xdx_901_ecustom--FinancingReceivableInterestRateStatedPercentage_iI_dp_c20230331__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zBz6DkBpYXZ3" title="Financing Receivable, Interest Rate, Stated Percentage">4</span>% per annum, are secured by a perfected security interest in the warrants, and are payable on July 1, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">These secured promissory notes are recorded as “Subscription receivable—affiliates” on the Company’s balance sheet pending payment.</p> 428250 513282 5565000 0.75 30000 35586 300000 0.60 0.04 30000 35714 46400 56396 928000 0.75 0.04 <p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zOp9EZEQQdV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>9.       <span id="xdx_82D_zcJno9Z2xmok">COMMITMENTS AND CONTINGENCIES:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Employment and consulting agreements:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Smith has held the positions of Director, Executive Chairman, President and General Counsel of Company and its subsidiaries under various agreements (and extensions) and terms since March 2003. On October 10, 2016, the Company approved a month to month contract extension with Smith which includes provisions for i) a monthly salary of $<span id="xdx_902_ecustom--MonthlyOfficersCashCompensation_c20161001__20161010__srt--TitleOfIndividualAxis__srt--PresidentMember_pp0p0" title="Monthly Officers Cash Compensation">18,000</span> until the Board of Directors re-instates cash payments to all employees and consultants who are deferring compensation, ii) the right to convert up to $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230331__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_z2byspFyfyaj" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">300,000</span> of his deferred compensation, at his sole election, at $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember_zRpRDY8m0gWj" title="Warrants exercisable per share">0.75</span> per share, until December 31, 2024, and iii) the right to convert his deferred compensation in whole or in part, at his sole election, at any time in any amount at “market” or into securities sold in the Company’s current/most recent private offering at the price of such offering to third parties. Smith agreed effective July 29, 2018 to continue to serve the Company under the same basic terms on a month-to-month basis. On May 1, 2022 Smith’s compensation was increased to $<span id="xdx_904_ecustom--CompensationIncreased_c20220427__20220502_zf9feQHCLjVa" title="Compensation increased">25,000</span> per month of which $5,000 per month is deferred. For the three months ended March 31, 2023 and 2022, Smith was paid $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230331__srt--CounterpartyNameAxis__custom--SmithMember_zNhj8U8ADpWd" title="Cash compensation paid">40,000</span> and $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220331__srt--CounterpartyNameAxis__custom--SmithMember_zoeGNaD3LHGi" title="Cash compensation paid">18,000</span>, respectively, of cash compensation. For the nine months ended March 31, 2023 and 2022, Smith was paid $<span id="xdx_906_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20230331__srt--CounterpartyNameAxis__custom--SmithMember_zhgpwZoqN0Ie" title="Cash compensation paid">140,000</span> and $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20210701__20220331__srt--CounterpartyNameAxis__custom--SmithMember_zqnjfoMfoft" title="Cash compensation paid">72,000</span>, respectively, of cash compensation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Since March 31, 2005, the Company has had various agreements with Bassani (and/or Brightcap which provided his services during some of the initial years), now the Company’s Chief Operating Officer (‘COO’) and formerly the Company’s Chief Executive Officer (‘CEO’), (any reference to Brightcap or Bassani for all purposes are the same individual). The Board appointed Bassani as the Company's CEO effective May 13, 2011. On February 10, 2015, the Company executed an Extension Agreement with Bassani pursuant to which Bassani extended the term of his service to the Company to December 31, 2017, (with the Company having an option to extend the term an additional six months.) Pursuant to the Extension Agreement, Bassani continued to defer his cash compensation ($<span id="xdx_909_ecustom--MonthlyOfficersCashCompensation_pp0p0_c20150203__20150210__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zDcaeso8YvR9" title="Monthly Officers Cash Compensation">31,000</span> per month) until the Board of Directors re-instates cash payments to all employees and consultants who are deferring their compensation. During October 2016 Bassani was granted the right to convert up to $<span id="xdx_90B_ecustom--DeferredCompensationMaximumConvertibleAmount_iI_pp0p0_c20161031__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_zZs8GvrCIc0e" title="Deferred Compensation, Maximum Convertible Amount">125,000</span> of his deferred compensation, at his sole election, at $<span id="xdx_90C_ecustom--DeferredCompensationStockConversionPricePerShare_c20161031__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_pdd" title="Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share)">0.75</span> per share, until March 15, 2018 (which was expanded on April 27, 2017 to the right to convert up to $<span id="xdx_902_ecustom--DeferredCompensationMaximumConvertibleAmount_c20170427__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_pp0p0" title="Deferred Compensation, Maximum Convertible Amount">300,000</span> of his deferred compensation, at his sole election, at $<span id="xdx_906_ecustom--DeferredCompensationStockConversionPricePerShare_c20170427__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_pdd" title="Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share)">0.75</span> per share, until June 30, 2024 (including extensions). During February 2018, the Company agreed to the material terms for a binding two-year extension agreement for Bassani’s services as CEO. Bassani’s salary remained $<span id="xdx_90C_eus-gaap--AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent_c20180228__srt--TitleOfIndividualAxis__custom--BassaniMember_pp0p0" title="Salaries and wages">31,000</span> per month, which will continue to be accrued in part until there is adequate cash available. Additionally, the Company has agreed to pay him $<span id="xdx_90D_eus-gaap--OtherAdditionalCapital_c20180228__srt--TitleOfIndividualAxis__custom--BassaniMember_pp0p0" title="Additional paid amount">2,000</span> per month to be applied to life insurance premiums (which sums have been accrued as liabilities). On August 1, 2018, in the context of extending his agreement to provide services to the Company on a full-time basis through December 31, 2022) plus 2 years after that on a part-time basis, the Company received an interest bearing secured promissory note for $<span id="xdx_90E_ecustom--InterestBearingSecuredPromissoryNote_pp0p0_c20180728__20180801__srt--TitleOfIndividualAxis__custom--BassaniMember_zs6PSq1l9L4f" title="Interest bearing secured promissory note">300,000</span> from Bassani as consideration to purchase warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20180801__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsExpiringOnDecember312025Member_z6gzLVW6QQl2" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">3,000,000</span> shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of June 30, 2025. The promissory note is secured by a portion of Bassani’s 2020 Convertible Obligations and as of March 31, 2023, the principal and accrued interest was $<span id="xdx_908_eus-gaap--NotesReceivableNet_iI_pp0p0_c20230331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member_zucWN9WM0vc4" title="Financing Receivable, after Allowance for Credit Loss, Total">358,151</span>. For the three months ended March 31, 2023 and 2022, Brightcap was paid $<span id="xdx_909_eus-gaap--RepaymentsOfLongTermDebt_pp0p0_c20230101__20230331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member_zgctPCo4P7f" title="Repayments of Long-term Debt, Total">75,000</span> and $<span id="xdx_90B_eus-gaap--RepaymentsOfLongTermDebt_pp0p0_c20220101__20220331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member_zHdETXSUOYcj" title="Repayments of Long-term Debt, Total">60,000</span>, respectively, of cash compensation. For the nine months ended March 31, 2023 and 2022, Brightcap was paid $<span id="xdx_907_eus-gaap--RepaymentsOfLongTermDebt_pp0p0_c20220701__20230331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member_zgdY4cQpA7ki" title="Repayments of Long-term Debt, Total">225,000</span> and $<span id="xdx_90F_eus-gaap--RepaymentsOfLongTermDebt_pp0p0_c20210701__20220331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member_z63UiFmvWRRf" title="Repayments of Long-term Debt, Total">184,764</span>, respectively, of cash compensation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">William O’Neill (“O’Neill”) was hired as the Company’s Chief Executive Officer (“CEO”) effective May 1, 2022.  O’Neill had previously been working with the Company as a consultant and had been employed by the Company as its CEO during 2010-2011. Bassani, CEO of the Company since 2011, has assumed the position of COO while retaining existing operational management responsibilities and working with O’Neill on ‘commercialization’ of the Company’s technology and work related to JVs (and other transactions) based on the Company’s Gen3 Technology and related matters. Bassani’s compensation arrangements with the Company have not been altered in the context of the change of positions. The Company and O’Neill have entered into a thirty-seven (37) month employment agreement (subject to Board renewal for the final two (2) years during the 13<sup>th</sup> month ) with compensation of $<span id="xdx_900_ecustom--MonthlyOfficersCashCompensation_pp0p0_c20220701__20230331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zyvjwJDhhDR2" title="Monthly Officers Cash Compensation">25,000</span> cash and $<span id="xdx_90D_ecustom--DeferredCompensationMaximumConvertibleAmount_iI_pp0p0_c20230331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zNDt7LWYEPPb" title="Deferred Compensation, Maximum Convertible Amount">10,000</span> deferred compensation per month. The cash payment is paid $<span id="xdx_90D_eus-gaap--PaymentsForFees_c20220425__20220502__srt--CounterpartyNameAxis__custom--WilliamONeillMember_z6FKiDB7OTXd" title="Payment for cash">12,500</span> to O’Neill and $12,500 to an entity affiliated with O’Neill. An entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise bonus if the terms set forth therein are met.  For the three months ended March 31, 2023 and 2022, O’Neill and the entity affiliated with O’Neill was paid $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zzSa9mvoz0L8" title="Cash compensation paid">75,500</span> and nil <span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zp4WyHz4gFQb" style="display: none" title="Cash compensation paid">0</span> , respectively, of cash compensation. For the nine months ended March 31, 2023 and 2022, O’Neill was paid $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20230331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zpAPsoqF4lZ2" title="Cash compensation paid">150,000</span> and nil <span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20210701__20220331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zIkJY5thNO8l" style="display: none" title="Cash compensation paid">0</span> , respectively, of cash compensation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Execution/exercise bonuses:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of agreements the Company entered into with Bassani and Smith effective May 15, 2013, they were each granted the following: a) a 50% execution/exercise bonus which shall be applied upon the effective date of the notice of intent to exercise (for options and warrants) or issuance event, as applicable, of any currently outstanding and/or subsequently acquired options, warrants and/or contingent stock bonuses owned by each (and/or their donees) as follows: i) in the case of exercise by payment of cash, the bonus shall take the form of reduction of the exercise price; ii) in the case of cashless exercise, the bonus shall be applied to reduce the exercise price prior to the cashless exercise calculations; and iii) with regard to contingent stock bonuses, issuance shall be triggered upon the Company’s common stock reaching a closing price equal to 50% of currently specified price; and b) the right to extend the exercise period of all or part of the applicable options and warrants for up to five years (one year at a time) by annual payments of $.05 per option or warrant to the Company on or before a date during the three months prior to expiration of the exercise period at least three business days before the end of the expiration period. Effective January 1, 2016 such annual payments to extend warrant exercise periods have been reduced to $.01 per option or warrant. These exercise bonuses were subsequently increased to 75%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2021, the Company added a <span id="xdx_902_ecustom--ExerciseBonus_iI_dp_c20220331_znSfYJqiJTni" title="Exercise bonus">75</span>% execution/exercise bonus to the terms of <span id="xdx_907_ecustom--WarrantsHeldByTrustOwned_pp0p0_c20220701__20230331_zck2x8iqe653" title="Warrants held by trust owned">3,000,000</span> warrants held by a trust owned by Bassani.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2023, the execution/exercise bonuses ranging from <span id="xdx_904_ecustom--ExerciseBonus_iI_dp_c20230331__srt--RangeAxis__srt--MinimumMember_zLMHplR1pW06" title="Exercise bonus">50</span>-<span id="xdx_908_ecustom--ExerciseBonus_iI_dp_c20230331__srt--RangeAxis__srt--MaximumMember_zxJ7NXlqVMA1" title="Exercise bonus">90</span>% were applicable to 11,114,600 of the Company’s outstanding options and <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20230331_zCSmLHYdgUQl" title="Warrants and Rights Outstanding">18,438,339</span> of the Company’s outstanding warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective May 1, 2022, an entity affiliated with O’Neill was issued <span id="xdx_906_eus-gaap--SharesIssued_iI_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z0O08yzW6BU9" title="Number of shares issued">1,000,000</span> Incentive Warrants exercisable at $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zncXNT5cjT74" title="Warrants exercisable per share">1.00</span> per share until April 30, 2026 of which up to <span id="xdx_904_ecustom--CancellationOfWarrants_iI_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zuoVZhaMwwWb" title="Cancellation of warrants">700,000</span> Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a <span id="xdx_905_ecustom--ExerciseBonus_iI_dp_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zWdIbj6riKx2" title="Exercise bonus">75</span>% exercise bonus if the terms set forth therein are met.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Purchase Order Agreement and Initial Project:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #222222; background-color: white">On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $<span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20220101__20220128_z0Z1KPbxyZSb" title="Debt instrument paid amount">2,665,500</span> (and made the initial <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220101__20220128_zR9DGsYBAqu9" title="Debt Instrument, Interest Rate During Period">25</span>% payment ($<span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPayment_c20220101__20220128_pp0p0" title="Principal, interest">666,375</span>) for the core of the ‘Bion System’ portion (without the crystallization  modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. The Company received progress billing in March 2022 and June 2022 for the second and third <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220302__20220331_z9LF4OPXJpH5" title="Debt Instrument, Interest Rate During Period"><span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220601__20220630_zz4T2hx09bof" title="Debt Instrument, Interest Rate During Period">25</span></span>% installments, both of which have been paid as of the filing date. On January 17, 2023 the Company received an invoice from Buflovak for $</span><span style="background-color: white"><span id="xdx_900_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20230102__20230117_zDfcrFg6zRw2" title="Principal, interest">533,100</span> which was paid on March 1, 2023 bringing the aggregate payments to $<span id="xdx_90C_ecustom--AggregatePayment_pp0p0_c20230209__20230301_zxJVA7GJhkHk" title="Aggregate payment">2,532,225</span> as of the date of this filing. There remains $<span id="xdx_90E_ecustom--PurchaseOrder_c20220401__20220430_zJp5QUgN3ZTl" title="Purchase order">133,275</span> open on the Purchase Order of which $<span id="xdx_905_ecustom--PurchaseOrderBilled_c20220401__20220430_zAK0Oqdj48wk" title="Purchase order billed">86,275</span> has been billed in April and the remaining $<span id="xdx_902_ecustom--PurchaseOrderInvoiced_c20220401__20220430_zzSWcfRNKGZ4" title="Purchase order Invoiced">50,000</span> will be invoiced at the completion of the project. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"><span style="background-color: white">Buflovak has worked with the Company on design and testing of its 3G Tech over several years. The basic design for the Initial Project’s Bion System is complete, fabrication and delivery of equipment from Bufflovak from the Purchase Order Agreement has been largely completed and assembly/construction is in process.  3G1 is working in concert with Integrated Engineering Services, the primary site engineering firm for the facility, on the integration of all project components/modules at the Initial Project site. Additional agreements have been entered into various professional services providers (engineers, surveyors, utilities, etc.) for work related to the Initial Project. The Company has incurred costs of $<span id="xdx_907_eus-gaap--InterestCostsIncurredCapitalized_c20220701__20230331_zK4OH4bmGclb" title="Capitalized labor and interest costs">5,164,256</span> on the Initial Project, not including capitalized labor and interest. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Litigation:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><span style="text-decoration: underline">A: Website: Domain Sale/Resolved Litigation/Hacking/Theft</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> On March 23, 2022 <span id="xdx_908_ecustom--SaleOfDomainDescription_c20220302__20220323_zlN4ozpSPeBa" title="Sale of domain, description">the Company entered into an agreement to sell domain name &lt;biontech.com&gt; and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490.</span> The Company has been using www.bionenviro.com as its primary website (and domain) since July 2021 due to the events described below. The Company has not been using biontech.com as its primary website since July 2021 so domain name &lt;biontech.com&gt; no longer represented a core asset of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the &lt;biontech.com&gt; domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and &lt;biontech.com&gt;, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name &lt;biontech.com&gt; ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and &lt;biontech.com&gt;, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name &lt;biontech.com&gt; to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">No shareholder, sensitive or confidential information was available to be breached which has limited damages from the hack/theft to date. However, the Company’s email operations were subjected to disruption and expenses were incurred related to the matter including legal fees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company created ‘work-arounds’ as a result. These issues have been resolved and the Company has moved our website (and email) to a new domain: bionenviro.com. Website access is now www.bionenviro.com. To send emails to Bion personnel, one uses the same name identifier previously used, but in the address, substitute ‘bionenviro.com’ for “biontech.com’: For example cscott@biontech.com (no longer functional) is cscott@bionenviro.com and mas@biontech.com (no longer functional) is now mas@bionenviro.com.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><span style="text-decoration: underline">B: Pennvest Loan and Dissolution of Bion PA1, LLC (“PA1”)</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $<span id="xdx_90A_eus-gaap--LongTermConstructionLoanCurrent_c20211229_pp0p0" title="Loan related to construction">10,010,000</span> under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $<span id="xdx_904_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pp0p0_c20211229_zCnxw91AuXUk" title="Accrued interest">2,255,802</span> as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s condensed consolidated balance sheet. At September 30, 2021, PA1’s total assets were $<span id="xdx_90C_eus-gaap--Assets_iI_pp0p0_c20210930_zjJeBXtNrpn5" title="Total assets">297</span> and its total liabilities were $<span id="xdx_900_eus-gaap--Liabilities_iI_pp0p0_c20210930_zYx484Vk522h" title="Total liabilities">10,154,334</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_90B_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pp0p0_c20210930_zCUv7a2yS4lb" title="Accounts payable and accrued liabilities">9,939,148</span>, accounts payable of $<span id="xdx_906_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20210930_zFWL4yh4ifX3" title="Accounts payable">214,235</span> and accrued liabilities of $<span id="xdx_90F_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_c20210930_zK1jCklCsOzg" title="Accrued Liabilities, Current">950</span>) which sums were included in the Company’s condensed consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s condensed consolidated balance sheet. As of December 29, 2021, PA1’s total assets were nil <span id="xdx_902_eus-gaap--Assets_iI_pp0p0_c20211229_zDfrNPbxHEq6" style="display: none" title="Total assets">0</span> and its total liabilities were $<span id="xdx_90B_eus-gaap--Liabilities_iI_pp0p0_c20211229_zNW0sSzam8Sl" title="Total liabilities">10,234,501</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_908_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pp0p0_c20211229_zdQ3Y22pgY5j" title="Accounts payable and accrued liabilities">10,009,802</span>, accounts payable of $<span id="xdx_90D_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20211229_zCZNwqsMo6W1" title="Accounts payable">212,263</span> and accrued liabilities of $<span id="xdx_90F_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_c20211229_z2uxwBa6Xea2" title="Accrued Liabilities, Current">12,436</span>. The net amount of $<span id="xdx_90C_eus-gaap--ExtinguishmentOfDebtGainLossNetOfTax_pp0p0_c20220701__20230331_zSdY7dfkEzz6" title="Gain on legal dissolution of subsidiary">10,234,501</span> was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As background, the terms of the Pennvest Loan provided for funding of up to $<span id="xdx_902_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20230331__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zACjHiwHSurf" title="Line of Credit Facility, Maximum Borrowing Capacity">7,754,000</span> which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220701__20230331__srt--StatementScenarioAxis__custom--YearsOneThroughFiveMember__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zNu6CgNwJbZh" title="Debt Instrument, Interest Rate During Period">2.547</span>% per annum for years 1 through 5 and <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220701__20230331__srt--StatementScenarioAxis__custom--YearsSixThroughMaturityMember__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_z0uVpJo9QOi4" title="Debt Instrument, Interest Rate During Period">3.184</span>% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $<span id="xdx_908_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pp0p0_c20230331__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zoifSwsjePHc" title="Debt Instrument, Annual Principal Payment">5,886,000</span> in fiscal years 2013 through 2021, and $<span id="xdx_908_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_c20230331__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zfJCkUQ84gV6" title="Long-Term Debt, Maturity, Year Two">846,000</span> in fiscal year 2022, $<span id="xdx_904_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_c20230331__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zRaBNeWdIEM1" title="Long-Term Debt, Maturity, Year Three">873,000</span> in fiscal year 2023 and $<span id="xdx_90D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_c20230331__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zByjEkzQIIaj" title="Long-Term Debt, Maturity, Year Four">149,000</span> in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $<span id="xdx_90E_eus-gaap--InterestExpenseDebt_pp0p0_c20210701__20220630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zXi3ZC2mup31" title="Interest Expense, Debt">123,444</span> and $<span id="xdx_90F_eus-gaap--InterestExpenseDebt_pp0p0_c20200701__20210630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_z4VPodI7BgZh" title="Interest Expense, Debt">246,887</span> for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s condensed consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $<span id="xdx_90C_eus-gaap--LinesOfCreditCurrent_iI_pp0p0_c20210630_zwDCwFVjTh02" title="Loans as a liability">9,868,495</span> despite the fact that the obligation (if any) was solely an obligation of PA1<b>. </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $<span id="xdx_907_eus-gaap--DebtDefaultLongtermDebtAmount_iI_pp0p0_c20140925__dei--LegalEntityAxis__custom--PA1Member_zPwgdVnF0658" title="Debt Instrument, Debt Default, Amount">8,137,117</span> (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $<span id="xdx_903_eus-gaap--GainLossOnSecuritizationOfFinancialAssets_pp0p0_c20220601__20220615__dei--LegalEntityAxis__custom--PA1Member_zukyGwgMZLm6" title="Realized from the asset sale">104,725</span> was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest set forth above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception, and no payment will be made to the Company or any affiliate in connection with the dissolution.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>C: OMRI Litigation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 23, 2023 the Company filed ‘Complaint for Declaratory Judgment and Injunctive Relief’ against the Organic Materials Review Institute (“OMRI”) in the Circuit Court for the State of Oregon for the County of Lane to contest OMRI’s negative determination with regard to the Company’s application for listing of its solid ammonium bicarbonate product. The Company alleges that OMRI failed to properly follow its own procedures and reached a result without scientific support. The Company has elected to proceed with “Judicial Dispute Resolution” as set forth in the OMRI Policy Manual and has initiated litigation contesting the determination. The Company has requested declaratory relief from the court. OMRI filed its Answer to the Complaint during the first week of May 2023 and the discovery process has now commenced. See Note 1 “<b>Fertilizer: Organic and ‘Climate Smart’” </b>above.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company currently is not involved in any other material litigation or similar events.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Lease:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The requirement for payment of Lease obligations commenced January 1, 2023 and the Company is awaiting a rent invoice. The sum of $<span id="xdx_902_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_c20230331_zNlELZngjX9e" title="Accrued current liability">18,750</span> has been accrued as a current liability for the period for the quarter ended March 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The future minimum lease payment under noncancelable operating lease with terms greater than one year as of March 31, 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_zcuKZqSqbUCl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8BF_zi7n2jGcrla5" style="display: none">Schedule of future minimum lease payments</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20230331_zO8PJeeqmYlc" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 84%">From April 2023 to December 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">56,250</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">From January 2024 to December 2024 </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">75,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--UndiscountedCashFlow_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Undiscounted cash flow</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">131,250</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--LessImputedInterest_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(11,299</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--CapitalLeasesContingentRentalPaymentsDue_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">119,951</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> <span style="text-underline-style: double"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of March 31, 2023 were <span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230331_z4WrxVXXsbxl" title="Weighted average remaining lease term">1.83</span> years and <span id="xdx_902_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_c20230331_z8MboKx14PV7" title="Discounted rate">10</span>%, respectively. The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> 18000 300000 0.75 25000 40000 18000 140000 72000 31000 125000 0.75 300000 0.75 31000 2000 300000 3000000 358151 75000 60000 225000 184764 25000 10000 12500 75500 0 150000 0 0.75 3000000 0.50 0.90 18438339 1000000 1.00 700000 0.75 2665500 0.25 666375 0.25 0.25 533100 2532225 133275 86275 50000 5164256 the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490. 10010000 2255802 297 10154334 9939148 214235 950 0 10234501 10009802 212263 12436 10234501 7754000 0.02547 0.03184 5886000 846000 873000 149000 123444 246887 9868495 8137117 104725 18750 <table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_zcuKZqSqbUCl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8BF_zi7n2jGcrla5" style="display: none">Schedule of future minimum lease payments</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20230331_zO8PJeeqmYlc" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 84%">From April 2023 to December 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">56,250</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">From January 2024 to December 2024 </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">75,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--UndiscountedCashFlow_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Undiscounted cash flow</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">131,250</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--LessImputedInterest_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(11,299</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--CapitalLeasesContingentRentalPaymentsDue_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">119,951</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 56250 75000 131250 -11299 119951 P1Y9M29D 0.10 <p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_z4M0m3orRPsb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>10.        <span id="xdx_820_zncdhIqasDWd">SUBSEQUENT EVENTS:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The Company has evaluated events that occurred subsequent to March 31, 2023 for recognition and disclosure in the financial statements and notes to the financial statements.<br/> <br/> From April 1, 2023 through May 9, 2023, the Company has paid $<span id="xdx_906_eus-gaap--PaymentsForPurchaseOfOtherAssets1_c20230401__20230509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zyx4v5uxz7E8" title="Cash paid">395,000</span> and accrued $<span id="xdx_903_ecustom--AccruedPaid_c20230401__20230509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztrnvRqxFtpa" title="Accrued paid">65,000</span> for an aggregate of $<span id="xdx_900_ecustom--AggregateAmount_c20230401__20230509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLXzuT6sPj7i" title="Aggregate amount">6,245,000</span> for the Initial Project. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The requirement for payment of Lease obligations commenced January 1, 2023 and the Company was awaiting rent invoices as of March 31, 2023.  The sum of $<span id="xdx_902_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_c20230331_zj8kJqujq5Gd" title="Accrued current liability">18,750</span> has been accrued as a current liability for the quarter ended March 31, 2023.  On May 10, 2023 the invoices were received and $<span id="xdx_905_eus-gaap--PaymentsForRent_c20230101__20230510__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcofwESElf81" title="Rent">31,250</span> was paid for rent covering January through May 2023. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">From April 1, 2023, through May 9, 2023, <span id="xdx_90E_ecustom--Warrants_c20230401__20230509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJ01TX5Y0rqd" title="Warrants">1,280</span> warrants have been exercised at $<span id="xdx_901_ecustom--WarrantsExercised_uUSDPShares_c20230401__20230509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMsT4kAHew8" title="Warrants exercised">0.75</span> for a total of $ 960.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On May 1, 2023, <span id="xdx_908_ecustom--ConsultingServicesDescription_c20230429__20230501__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zqcRf3mUb7hc" title="Consulting services description">a contract for consulting services was signed and 32,259 shares with a valuation of $50,000 were issued.  Additional shares valued at $50,000 will vest in 3 months.</span>   </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On May 9, 2023, the Board of Directors confirmed the final two years of the Personal Services Agreement of O’Neill, the Company’s CEO, and granted O’Neill <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230401__20230509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsjZ09uq6PQl" title="Options granted">500,000</span> Incentive Options (“Options”), which Options: i) are exercisable at a price of $1.60 per share, ii) expire June 30, 2026, iii) vest one-half on June 1, 2024 and one-half on June 1, 2025, and iv) include a 50% exercise bonus.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> 395000 65000 6245000 18750 31250 1280 0.75 a contract for consulting services was signed and 32,259 shares with a valuation of $50,000 were issued.  Additional shares valued at $50,000 will vest in 3 months. 500000 EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ,R+JE8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #,BZI6URWDZ^X K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)VG50^CVHGA2$%Q0O(5D=C?8_"$9:??M3>MN%]$'\)B97[[Y M!J;34>J0\#F%B(DLYJO)#3Y+'3?L0!0E0-8'="K7)>%+24U2>:0]1Z0^U M1V@XOP6'I(PB!3.PBBN1]9W14B=4%-();_2*CY]I6&!& P[HT%,&40M@_3PQ M'J>A@PM@AA$FE[\+:%;B4OT3NW2 G9)3MFMJ',=Z;)=621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M ,R+JE:JQY H+P8 %DG 8 >&PO=V]R:W-H965T&UL MM9IK<^(V%(;_BH;.=-J99?&%6[:$F6"2;::[23;0=K:=?A"V $]LB\H"DG_? M(V-LG)%/\%3YDN#+^V(]ENSS"HWV7#RE:\8D>8ZC)+ULK:7;>B*S9C\??,@8*M3N 1AS)(TY D1;'G9 MNK(_3=U,D)WQ1\CVZ>R'5*KI. !1J]A^L=&S'H0&.*%CG' M%DTF BY(%Z M]Q%X?6L?4[A3\;JJ?=VA^J;0#)E5H%T4T"[.@W83ICZ-CNQN8+>V<,'=OFEA MH9JFL R956#95EG868UP?6=4U,-ZPZRN<^&RIL!,N56)G93"-MI(;RO$:V#8 MR'S#KMVV^FW7TF)#E8VQ&7*K8G-*; [:SNM$AO(%J$6,W&WC!1-:6+B)95EM M^\)U];T,U3;&9F2K4-7TT-_N:*SO7[C11+UCKY-=*'BB M!CITV3GSUPF/^"IDZ0=RF_A:FD9+?%-N59IED6_C97I.TX/V"P!P"R'RF?S& M7K0\<2OH@M9PT!LX%UIJ1@M_4VY5:F7I;^.U>TYM3I_);0#HPF7HTZQF0P8P M;CGLMFU[T.\/'"T]HZ' E%N57AD+;+R8S^G!\.("*MP,W X.< KX( W.%!E7\@7^ \&6 M%^2:IE!/4_&D;H V=GBX1V.([Y$@[#)"V'CE_QJBI[:@^\WY/M$"Q.WNHX!, MF%RKV5XM.Z,YPI1;E5V9)&R\^'_-KAB[#X+OPL37]T#<\^Z[%IO11&'*K3JQ M6D8*!T\!K[$]\%15'7^%F]J'W1N.MCVTNMI)6J/!PI1;E5L9+)PW@D5&33!: MCPDWZ-E]+22C,<*46Q52&2,!Q#X3>3W'_28C,:%TRY M5;&5<<'!:_RYH$&8K,CL)5[P2$L+-YC<7<^UE(S& U-N54IE/'#.B@?'^9## M/&Z&#=Z3^OFC-QR_:W];]'!58VKO$0N<,A8X9\8"R<3AYVPUP31"3-O5]!C9@$AP,M?2,A@!3 M;E5Z90APS@H!LYA&$9EL4SBT$3?YW##VA^J<%UC;.]1];MEU>^>5?7/U@SZ& (+MVF\#@&_ MJ#KT4U-74855EOHN7JD?7YTG117$RVQQ#;G?2LA+B2I M/Q,5O.>4;=I[M;+ MW-1:LMVX.W"[CM6W1YW=*;'.R5HD-="R-5TI\=6DV&%94K&W6#=VE:V6ZI2G M'Q:=?:5JG*8D8DN06A\'\/7BL([KL"'Y)EO9M.!2\CC[N&8T8$*= ,>7G,OC MAOJ"8C7=^#]02P,$% @ S(NJ5H\Z;/]Y!@ V1X !@ !X;"]W;W)K M3//4LG9JE2*HSDQ#'L>LS"9 M^,?EM2OI'XM<16'"KR3*\CAF\OZ,1^+N9((G#Q<^AS<;55R8^\5:B&_%R?O5R<0H M/.(1#U1A@L'/+5_P*"HL@1_?*Z.3W3,+Q?WC!^M_E. !S#7+^$)$?X(*"O_H[M*UIB@(,^4B"ME\" .D^TO^U$%8D\! M6ST*I%(@CU4P*X4R(&,34J"^&U?_,$U W2G725)\#U!U> MLL-+2GNFWEY1%4=9R@)^,H&TS[B\Y1/_Q6_8-MXN"62IRQ<(?X#FEO&,YWW6^-TWWML8@.WG->(48=20^\[W?E. MQ_I^SE.1A2I#+%DAH39<5OFG T$[WMF&8;0@=(7POE #@+T#8(\%\$4H%D&G MVJ\=G>]VURW')(;CMMSORIDF=CVO)WV<'0)G+()/*9=,AK*$=>CE+IZ1-X.D?>\#.O/+*_CD6,3Q[+: MGG?E;-,V3+-G+;!1CU#CN3,E"MEU&(4JY/K!4CWA0)/E4-::\=BC%'BL_=,@ M$'D"[2YE]^PZXF66LB"0.1_NW]4C]U?/-0ROT\ U/9#/ M^9K#.J]0(.(" BL9ZK;:+#UG(MVD=2U":1M.5XYZEN/U5!NNYS\>30":'7TO M<[5 3,W$="FF=AN)1A#Z1B\OP#4QP*.90;NU/X"YUT+1<03/HYT4T\@1U[7[ M,JQF"7@T35B(Y!:Z>EB43 )I51?0#+'U&C"QXN(VY6Q]RFF(@6,"MVD3.(T@ MQ8YAXQX2@6L6@9])(WZ6;!IR8%G@F=6&T!5T"+4\;/= J&D$=H9ZO7\&E?TR M0[ O"[YM1+3B,GM9CEF8N*]@^Q@&H7JM;_&C"8JVQ1_(6C,,-?_ @P3$7X@X MAA97A@&XA8!TE.B613F'G1HUIL XBS^4;1@\'K%<;80,_^.K*;+<*>P&IHYG ME,W?,J<.=:? -!Z$PRS+"T$X3GFYRX_NWR++F9J6,;7/1I28-C$,JZ=\2$V5R"#U\)?Y=1;(,%7;MT !#V_[NIBK M[6*5_7WG9A0D,&Z8T/'":/\PA<7:&JXK6>=IG(#!,;1IY+ MV]14+VL9E@/2/?[NO?$8)"[^MK5J&M>+WUR"G;>=]J5%TR4B%K8\TIGS&L&9 M9Q),>^8\J2D+&:0L_J5( I$H*:*HF.AAHCB4E#[V7;)A.M3IA/UG8DU/:T9" M!AE)%?%'A;7+)2SLVBYI%Z5&<.9ZL)7T>IRM60<99!U^9_*6_74HL;O\0+_A MT@@.[KA(323(()'PEUP6CIZB*_E O9=%8J-_/O+XFLM_M7Z/)B?:MW<'LM:, M0,U#R*_B(>2@/.10UIIAJ'D(&>8A]?J7D=#B/=2H/X"A)LIZU)/A4?^$?C+B M+8L>[/,--5],UQ3!_ E%V-;VXDFU/6SSJ4E]*&O-"-0$P\2_J+;-T2]FM&$X MD+5F&&K>8@[SED?4]K"%)Z3[ 0PU4>Y]B!EF-8^O[6%#3P'[?$-;L/.][X[% M1]^/3-Z$288BO@;+QAL'1K_W%= , -P- 8 >&PO=V]R M:W-H965T&ULK9=MDYHZ%,>_2H;;N=/.M OA0=V]ZHSKVNEV M]L$I;>^+._=%5HZ262 T"=KVTS<$%D58U'9]H0F<_\GO!/X>&&X8?Q0A@$3? MXR@1(R.4,KTP3;$((2;BC*60J#-+QF,BU92O3)%R(($6Q9%I6U;/C E-C/%0 M'YOS\9!E,J()S#D261P3_N,2(K89&=AX.O")KD*9'S#'PY2LP ?Y)9US-3.K M+ &-(1&4)8C#[E 1WREL!$[8Y27\L#88SZY#D:&E1-!! N9IR#J M9PU3B*(\D^+X5B8UJC5SX>[X*?M[7;PJYH$(F++H7QK(<&0,#!3 DF21_,0V M'Z L2 ,N6"3T-]H4L;V^@1:9D"PNQ8H@IDGQ2[Z7&[$CP.XS KL4V,<*G%+@ MZ$(+,EW6%9%D/.1L@W@>K;+E [TW6JVJH4E^&7W)U5FJ='(\O;^[FMWYLRND M1O[]S?75Y+.:7$YN)G?3&?(_S&:???1Z3C@D,@1)%R1Z@]ZA5\A$(E1'Q="4 MBB//9B[*-2^+->UGUKPE_ PY^"VR+=MID4^[Y1^S1,DM+;?K$.+-?MG^\#MP0Z?6\PL)_A]2I>[W3>^TP*29* )JLV:*_)TG=< M2Y'O0;<$.I;G>ABW0_."Y&2!8P,U1H$\#48X[__PCWKGS:WOE"R6O7]JOI^9_7;HO?MJ_T1L"@B M7* 4>.&55JL42_1W/7MFX;WK=R"H1C^HZ >GT1]O[T'C=O):K'THJD9]7E&? MGT9-M:4/$9\W6/9INR)JI-C:=C?K-%:VM?,AX#)U%W%G2!UYIR'C8PP]/]6R[ MHHE $2R5QCKK*S$O7B6*B62I?AI_8%(]V^MAJ%Z_@.Z M\2]02P,$% @ S(NJ5EPR.!@R!@ 7!T !@ !X;"]W;W)K>?ZU6#,FT+33 M"=^*),[80XZ*;9K2_-\KEO#7BQ$>[1X\QJNUD _&T\F&KMB,B>?-0PYWXX8E MBE.6%3'/4,Z6%Z-+?!X2(@U*Q)\Q>RWVKI$,9<[Y5WES$UV,#/E&+&$+(2DH M?+RP:Y8DD@G>XY^:=-3XE(;[USOVCV7P$,R<%NR:)U_B2*PO1MX(16Q)MXEX MY*]_L#H@6_(M>%*4_]%KC35&:+$M!$]K8WB#-,ZJ3_JM3L2> ?#H#4AM0+H& MUA$#LS8PW^K!J@VLMWJP:X,R]'$5>YFX@ HZG>3\%>42#6SRHLQ^:0WYBC/9 M*#.1P[S^\TUP^00WLR?XN WOGF;H_B.Z?P@?+Y]N M (!.GN\NGX,;P'Q I^AY%J"3GS],Q@)>11*.%[7;J\HM.>+61+<\$^L"A5G$ M(HU]T&_O]]B/(05-'L@N#U>DE_"6YF?(Q+\A8A!3\S[7;S1,=UYLZ()= MC& J*UC^PD;37W["CO&[+L]#D@5#DH4#D1U4Q&HJ8O6Q3Q_9"\NV3)?]7D/] M:R%=X@?B"0;B"7^US$-8H,*(:3N& MY1[B0A6';3';?+C]N8G8)#T15Q&JPO65=Q:3C=2%4-LT@E3Q6#L MV9T859!G$GU\7A.?]YTYKV T7ZS+!HA@ DSXIER-WEM]3PW6@K].2C0HW^JV M2*"B'-[0<5AQS:);^L#QT:K5HW>T#_SHD#+G*>[\'FF#;NFV7^# M4VW@.J V=!U0'[P.V1_^GEC'_8N36+.\['_09Q]VA=X_E*Q"J,>-C?&\J'(;?B M&_>K[T\TSA#/4$$3AO@215S^!*,-?"@U7A,=9- WB.4;W=P,I;??X/$P?:VB MQKTRL4E?Q.:R:^2:M8V+M5S+M3E\A^C4YW @HF HHK F.ASAL.6W[*/CLE7+ MN%\NUZJ@7"'ZAJ:J1D^)[9E&=VAJ<)Y-+,?M-J!&5!-B&=W!J>'#!LAO[!T; MGZT0QOU*^([M9E]TDH!"T/\@I4I4",CU/$42:(2S7.>564E#"#C7-!1%H")] M8MB>?ZSHK43&_1I91BXC1E2(/)YO!9W#%"4X@C9 &8><9"+G22)E8EQ/W-KD M]+KY/V-.E;RVY78U;?8W[!;;23XAN-DF\V"7W"F3GKX7< M<*1R59![D#5/(I;KM6CES/E^XZE :#P'*U.^AO!(XZE(:#S8R1Y1HJ05XJ1? MB+\_10B$N_QM/UY4&[LXV8IJ]U8BUS37SEOU^[C[01MG1E=#:6" Z@[=(V0= MS1]JRTGP59P5*V!)<&6'>55-X)ORK.J.1>" MI^7EFE&8-B0 OE]R+G8WTD%SH#K]#U!+ P04 " #,BZI6>OB!Q0,- "S MB@ & 'AL+W=O M^;PP>?P"[S,#YR]Y\:U\D+*R?E\MU^7%Y*&J'G^>3LOY@UREY;O\4:[K3^[R M8I56]=OB?EH^%C)=;#JMEE-JV^YTE6;KR>7YYG>?BLOS_*E:9FOYJ;#*I]4J M+?[X12[SEXL)F7S_Q>?L_J%J?C&]/'],[^6-K+X^?BKJ=],=99&MY+K,\K55 MR+N+R7ORLW"BQ'=BV ^MUH/1 ![[MP/L1W ,=G&T'Y]A-0-L.7C\".]#! MWW;P>QW(H0[!MD.PD?;P.H^N;*+3J5S#ZMZBUMXDWGVZWZY76KZ(&MNI%%)DOKO?6IEKXL"KFP;JI\ M_LWZSP>YNI7%?S7(JZ.05V.0H1EYE:]6]?=U$!.9,>\7BZSYXJ=+ZU.:+U2FI"Q&?E95G7RK,L!ZW:;UM^%W1>"[KX0 M=,/A!SB_R/MLW>Q>G4.7Z7HN?[*>T^63M-+*^OO3^IW%[)\L:E.B4[41W1RW M?BX?T[F\F-0'IE(6SW)R:>FD#.*$($[TRG$WG.;P^7Q)*&%!8+O>^?1Y7Y5J MRS/'YJYC=]O%FG:$4<8"WV/=IHG:E 6$] (+'9!PVZV1NY8=0;"=(-A8090/ M:3U>1RG"R!ZA"! G?.4X>\/$"2-.X+O=\8Q."/B7/Q'7_ILN5R%A,1*6(&$" M!.O(E.]DRHTR_5=:%.FZ*BWYNRSF65GGZ?I4V)J_'J->%:L3J)$Z0J @3@CB M1%P1.O&8Z[JTE[! \6(0)P%QQ/#^=V3F[&3FO%EFUD\&O1GQ([]P5TA8Z"@C M1NO,Z/0/71$RZ P)BY&P! D3(%A'LNY.LJY1LLUI>E:6FQ/A6J,OKPK>"5BK M4B-Q1%8$<4(0)W(5C9\1W[5)+RF"PL4@3@+BB,'=[PC,VPG,>Y/ C/G0B!Z; M#Y&PT%,&RW7KP>IE0V3(&1(6(V$)$B9 L(Y8_9U8?:-815D^-5!,KF>I$:D2/2(8@3@CB1KTC<<^R>PF>@8#&(DX X8F#G.^H*=NH*!E+A M^ED6FTIXK:^%O*VL=+VPEEEZFRVS*M/+R\@<(2\0)P1QHD!S#NZ1_L$6%"T& M<1(01PSM?4=@Q&X+UO8;)68ZW)KA8X^W4%JXI>V/&',XY;TC+C3H#$J+H;0$ M2A,H6E>W>T8+,>KV-UE6316Q%FV^+ESF?\BFG%BKV'00-O-'I$D4 M*$2!HBVH4Y94:L8S5+@8!4I0(#$T %W-M5X&,9L9'_)%=I?-TVJ;+;^?\&GE MA3(O4* 0!8JVH/W1]1GK6Q>H<#$*E*! 8F@ NO)JG1%BMD:N964M\U(O)Y3S M@0*%*%"$ LU0H)BHMDY ;8\SI^>E:1J>$8?W3C&$GN?XP:&SM]:E(&:;(EHO M]-[JA[1X9S&R<=*H5E HIP(%"E&@B&B*]9O:,Z-N/TFI3?4&JZYA V64,[^O M"K4M\YR^$2MT2,XY\0\XK*0U%8C95>BKHC58AV5Q0FE9+PL0*"2JD<"9QYA/ M^[6S4T(:SN2A7@*4ED!I D7KJK7U$XC94#!-$0GE?*=7[80 ,WN,7E'> @H4 M$;6\ODECMNLI:4Q3B=>G,5W)GC+'\6VNI#&U+?,)I?TTID'Z'@L.U;Y(ZP,0 MLQ%@G"HRK(P3RL)Z98! (5$M@$.9#&H#0&DQE)9 :0)%ZPJV]0*(V0PX4),P M5B%07@ *%*) $5$KXKHJ!,H/0($2%$@,#4!79:TG0,RF@/$R$57[1X%"%"A" M@68H4$S4DCRGCDOL_H%4;7?F\*!_'-72;/? -2)M*_S47.$__1K1#!XS 1<$ M"E&@B*KFP*%K1$W3 Y-P-0T/72-JVNJN$75(TS4B;>OGU%P_?\,UHID\1A:H MRCG5U'OU9U:GA#Q\9@6EQ5!: J4)%*VKUK;R3C'+"/1ZA:TC@"TD@*TD4"O1 M=<9QJ5WGIWX:4YL>2&.:AH1RFWN.N2UG_HA 5,4:!$A1('#$&766U57]JKOIWE&6:M&/F MC)VT Z6%5+-L(*!$D4@$#3N#TF(H+8'2!(K6%6E;[*?F8O^IZZK,V#%9$57G M1X$BJJGSDX!0IY\44*K#_#$1IU!J7%4%H"I0D4K:O=UDV@QR\MV!S3!\T$,W!,DD29"2A01-5: MNF_;RN("5+P8!4I0(#$X EV9M78"-=L)9ID9<^,)A71#;D320JI6TQU5+Q$T MZ Q*BZ&T!$H3*%KW%A*MI<',EL9)JZ[,S!'9$04*4:"(J3:!X]E![T1@AHH7 MHT )"B0&1Z"KM-8F86:;Y+056&;H&*FA'!(4*&*JU4)XX/M!7VNHU04H4((" MB>$AZ(JM=3F8V>5XVUHL,WSLX1A*"YG&IR".$]C*?7*086=06@RE)5":0-&Z MRMV[J9/9AGGS:BPS?TS&A-W:";6^@:F6#J6VTY\F,D,%C%&@! 42PT/0U5WK MIC"SF]*[5T0Y9*Z8<6-DAC)74*"(J<;"&??52V14P!@%2E @,3P$79FUU@HS M6RN'%OY99]8Z7Y_-T_*AJ2D^:B6'6E&! H4H4,14LX8X 6>L+SE0P!@%2E @ M,3P$7BJJ_4QF-G',,U7-W<=(RJ48X$"12C0# 6*F>H@G%'']IC=7]>,"BF."=F5 M5>M;,+-O<=2T=J85'6J1! H4HD 1T]PEB!%J^YZC%.ATJQ)T\T%U#0EU'8?[ M3O_FTIJVNOF@FF:<^*Y/#Y30>.L,\'&+'?33VK6R,)-'R (%"KE:U*XO9SCW M@KZ/=4K(PV4S*"V&TA(H3:!H7;6V[@(WNPO'+GW63EXVL\?H%64RH$ 1UU38 M*7>I1SSEAM-J4WT:TS4DU'&#YE\OC6G:ZM*8%NDPU_<.^$Z\M0+XZ 4/^K7/ M>FF@5CR@0"%7#0#.'1KX?G^VTBDA#:D,Z@! :0F4)E"TKF!;!X";'8#!>>WF M_F,TB:KPHT 1UY2W/:J9GH2*&*- "0HDCAB#KK+VGL1@KO$?/:_=S!EK@$)I M(5=+TY0U-XA5SN2086=06@RE)5":0-&Z(FT= O[V!SEH-8MR!U"@$ 6*N%H: M=YDF)Z+, 10H08'$X ATQ=9Z _SMBRB,L]K-_-&9$DD+N5KD]KDF3R*#SJ"T M&$I+H#2!HG6EVUH-W&PUG#1ST\P3=I9 M3M"P,9260&GBB"'I:J^U0YS3G^5@[CHFG:&<$!0H0H%F*%#L:![1X#N>XCLF MJ(CBB(A=4;5.B&-V0DZ?\F0&CY$<"!2B0-$6M/^H^D-3GC1-]7,%= T/37G2 MM-7-%= T,TYY(8UXVH->%BCW 04*'UY.ZS^K1^*>]JO/W.JZ,5V?W#[DV5/UY,ZC.^ MV[RJ\M7FY8-,%[)H&M2?W^5Y]?W-M.:_Y,6W38S+_P-02P,$% @ S(NJ M5C")]TL1" >20 !@ !X;"]W;W)KLBA69_V^#)<\8?)SMN(I M_++(\H05<)D_]^4JYRPJ!R5QGSB.UT^82'NC\_+>?3XZS]9%+%)^GR.Y3A*6 MOUWR.'N]Z.'>YL:#>%X6ZD9_=+YBSWS.BR^K^QRN^ELMD4AX*D66HIPO+GIC M?#9QRP&EQ%?!7^7.=Z2@/&79=W4QC2YZCK*(QSPLE H&'R]\PN-8:0([_JJ5 M]K9SJH&[WS?:;TKP .:)23[)XF\B*I87O6$/17S!UG'QD+W^SFM Z4OS&)9 M_D>OE:SO]5"XED66U(/!@D2DU2?[43MB9P#H,0\@]0#2'N!V#*#U %H"K2PK M85VQ@HW.\^P5Y4H:M*DOI6_*T8!&I&H9YT4.OPH85XPF=[.KZ]G\^@K!M_G= M'].K\2-\S\3Y",IVW. NW6 :],^ MFD$&$FF8)1R=Q)F4QCU2J?!*%2K?O(Q.R<#QJ3,X[[_L(M$% ^(,A@'>RNT9 M.=@:.;"NTCCZ$R(,DE(A49%!5@JS-!0Q1RE8KZQ6=]7WD,DE6DL> 28$*31G MA4B?JQPD"L'EF0G>X)B+>21E>W[RMG[RK(OY&U.P4Q3S9Q:C2$B9Q>LR"V<+ M* !/4D0":H#)!U;%9K.1"7ZE9["[53!$NCMP.O: O\7F6[%=<9@Y%*R$PW] M>93\[9D3!%E%@130O MLO#[:5E\]TTV&1KH)D#D8Z=EJ2Z&?=]WS89BIRF.S@&FZI8BX$](;5<1)7EN<,\J 1#-:].W"#G9U= MH[%.^9,Y"I,&$K%"^E9#0)"?5,2H-?K8HA$-Y\!W K<-TVK&S\)LF 6VUFU( M6"'P=DZBV M_),R/>*K3 JU6FF5IA"3DG=L0%?/_@-#-!G$W#VY?0@-3<#6ZCHZV6#XU%@+ M18.+%Y6 T2+/$@0WD61P!<$490E+4-V &IH ;;S@NT2 ME;%D( !&HPT5W3-%DD&.N-3S.ZQN2C^VU_[9(63::+E>X4^).\38]]JV&R0Q MADU$.\*"-'2 .!]ZJIO.OE[/#WBJ(S]1YKN?!(ZE;=\)#7,@=N9PO\[#I=IX MD.A6N5J_XJT,&/[76JS4PY31!3J'@/5SJ)X"3)(8>[[K=<0,:1@"L3,$;?>) M] 4H]?N[C^C,H,MZ@Z3=^J;PDX_U%&ZFL_%L19R'LFJZ&X*[CH59N9 =$I B><1VLYX]FD_SL1)0RZ(G5SL(^(_>!Z**KIL MG)SHM1_C )/V$ZE)SJ<>N*!C.S8<@=@YPB1+$F#:4&DD*A^=#S3\6!T!8FH) M#+VN?@!IJ *Q4X46L/?WF*'$NT.]J-JG_8DMUG %8N<*#SSBR6KSJ'>?;^C" MG.>0\- EDDL&4Y99?--G,"*U3O.1M=/YQ:F+.YDZ:?@%.9!?0&5Z$1%@?'I# M"Y&R-#P@R^O,@5+JTX$65(9V@^?[CM>Q]VC#,*B]X5"W34WD6\$RMHSU5L,I M/)Y#Q6F;;9+TL$NZ6E2TX034S@DFRN6L0$_\6:2I\C3LLS?.C+TGJA=X"O7! M==O!YOMM2W5!ZCG$&08=ENZ< M(]B+_GR]6L5@Y.0*:S9%.= M.V W& Z'[;@VR/D^[LH_#<6@[U&,PW"D6<&WW18C$$,7@@8N;>,X,O6@#?6@ M=NK11FHZJ3@(J,X8 D-#W2"&]^7V<33$@MJ)Q82M!*1@\??N44S9@3WT"9@: M2 -0<;WJ60WY^%JY#?EPWSGMJ%C@3ON\)O(-N0\;;FP\T/WWYQGU@:].508. M=@?F970;HN+^V^9%B;O=Z#1BQ=JA-/7)4.L(&.3@\8OZ;2S]G9&PO=V]R:W-H965T&UL MM7U;6EJKH!^GAB]SQ8EDB@NBHKKU]>^KO[IKWMMM[W^9==57??GVW[ M?O_L\K);;?W.=1?-WM?TFW73[EQ/_VPWE]V^]:[@+^VJRZM'CYY>[EQ9G_WP M'?_L0_O#=\W05V7M/[1Y-^QVKCV\\%5S__W9XS/[P<=RL^WQ@\L?OMN[C;_Q M_>?]AY;^=1E6*_WLH[-\-71]L],OTPYV M92W_=U^4#G_D"U?ZA2O>MSR(=_G*]>Z'[]KF/F_Q:5H-?^&C\K=I/'=_GUNU?Y3]?OKM_\^-./[S[]^3^^N7K\E^?;=94];PL*7*WW\"WG\U0./_S;_J:G[;9?_6!>^&'__DHX2SG-EYWEQ];L+ M_N3:B_S)XWE^]>CJR>^L]R30YPFO]^0A^K0;5Y?_?ZRJ;NF*@LG'%47 M^8?6=[[NY0?-.G]=UJY>E:[*;^B'GMBW[_+_?;WL^I88\/^V=/_OAS__Q^.FCY[]SO*_"\;[ZO=7_^Z__=Q]_^G"/+_+1 MMK+_QVWEZ1WRI=6N'UJ/ZUH.'6VIZY[E+_#+'^N[LFUJW!K=X">_VM9-U6Q* MW\WSM_7JXG]T^?D9/CD_R\Y>-KN]JP_SL_SL%X\_/W?T9]/F9^^']FR6W[LN M+^M5T^Z;EEBAH'_DC[_]YB_X?[_UPB#8!&D4^D317/ F=/==MBL[5GUEE_<- MR?RMSRO28*025K?YOFV*013;KJ&S=*0J2 6[9>7G.?%:361MZ1A\7OKPNNSQ MNXO\%T_/[SW]E!9UJQ4=HBJ[+>V(GK,\D$;;5\VAK#=Y,[3Y&U\_ 1FR?>5Z MF(!+HQ@]MO!5?EZ4':FICHZWA(:?X71W]& B<)>O&_H=_:J1$_/1GCY?>U_X M5L^9\_V##/C$J0->WKEJ\/EJ2^?+:-/TF[NR\/SY%0GDL/,M:'B='=WOZM:.3KER=K\B^T=WX+T3)IBUHG?:0 MRS:("$R9;DOTW385G:1C(OL=".=IO7-753C0_;;9YK9^U1 Y#KS?RK4;O^A6KGJ A=9N55:R0=I\U^2W-?9-#(Q;NGKTG!3?BIXA M?'Q=ESL2C]=TC<0GV?N];UFV.O[PX^>0 ?O>]>OWW1D=\Q^G'HL=EZ0?^21S M(D/;EZN!=DL7N&Z)>/SU>;ZEC2R])U$H:!-TQ2!51UQE?)-M^,*Z/N^:LIKG MKFSGO/H]_;3-?QL+F@L2@<(>+_'I/AQ73'S1%HN- MK_5\Z75@<1.%R_CS("?YN5+ )$AI,\O!7WPA=,@=T7P#3J/==,1O(_5CNYT3 M(Y5T!5LY E_8DJNR M4*EJ%B860G+F3I#=Y%/8K .?[2[R3[Q1^9F*LR/I[\/'^?_$ _70$Q>3]6_5#!(WGAWG=N%9^^; MJAJ()O'Y])Q>[C1?#Z2@2$QWZZ'*7+5Q/E]630.*DM[H';E3H'TWM&NHH$W; MT$.98X1Y_!?Z<;O$9U85L7S/2JC>^+&BSB4^&7_8QM'AV)3\;$)W7/CR(ZDT1!&W0#>6CXC*NRJJDW M"V*"7:+Q<=\7Y *8T>G)-&!?W4 GH#N@PW@S*,J"],%@CT;V.5^2>2Y$<(T% M6//2NKA^%@B6FH8=EQ7;U!TQCNUZ+TZGW LM!+6..R;]Y^LM6P?Z%*TUR&;; MZGGLX?B%'KA M4.?AGMDH+WD/T##TX'Y+0K;9)G2CG>4NAW"U\)IMJ1W);UG?-=6=UPW!U A1 M\H8>W@:+[;N)/ :&@P=&)K/U6IMZ*$0)'-IZ(,K$(/^V;H2QTC\E"SEBR"A M9(T@"+W?RX;H(YOH.S@QO[:8F+FQ*V#/9'Y9>K5DV-5!'^Z+N;(#Z(IE2=[+ MCIG=%::6C8OHE%',5JY=BO&^I ]/B;0PV2-55Y1"T7GN6:]!S\/,'WB3_"@Z M!BE4$(?,4W>@8^PRD>/Q0\V>;5]>+%>X9"V1'V,7^:N!+3:66Y_7.'I+?B7Y$BW1%E9 5:;/R8LW+2$L9_O/@W%(?292A*+X28O# M_2)]1':"I"AX:FMW1S$-1QQZA+\-9.2QZ[F7HW>;43A#T0#'WT367_VJSQ?TD<=? MSQ\]>K38>E<@R'3[;SD=3L%AR:OW(5.1G] MG.+%+W3\Y"4B?C"]5N$$W,EIWQ4]")38V[,RE> TRAYQ/YG MT(S^MP%'ME_,@OK4DXH.-1L9KY!H"(#)'CP''U#5KJWI:>)ZX9PEP%U6 M@!F"#%C*VFBQ'[E93HP_.]D[IA'[RQK]ZJ*(<.A3H.7E/2.S M^88VEX>@Z# 3:I*OU^ +.Y*PU@MR0E8^.P^>"K-D 0^5="-?N:N=I]BL7)': MA/\#^I]?OYJE+@;Y="U=6QV#*GV"!%)$H35@FZKI.O/"R'8WW9ZVS0Y*\*RS M:&$9MR*6VD#-?'SW9L:FI@/#28@($A5DULQDC +*2S7I*S7,Z)#D,VZ9OR!4D]EI1@$]REC&J#W/;2XB3.&;G&AI:R-:15>PM.AQY MU1$/&@<([(>W1L2.38]LOL#)2N01R'G-W*;UBO"R#PCW"U\*QI3U2OP04_?6 M'Z(5EKT_:(B+:/QK!!Q=^651@[0[!LT%/ K>-@6:#!8FH)O_XE<#[PG004F! M4[(?]J9%U76)KC/_#8P>'<$CZ?[;SZ;9Z,M$KKA+"D+AME3%W@E00N]Z[ MMHAVX2VH2=&.:IO\G.(. Q+YK@#QB&(W?UHUV"4KM,NQ#E,UC?NR'YJN/E=_ M56*'&)-.SC)CJNR'MAM8"?.GQW&:.D(12 LNDF?ZL+[ZG%;$,)71 M#9DU6&FBP9:(Y[I=+L?HFMW)4^H>62&.M5[RJ,O6&YIWA^Z2P5FR 1DXI/4(P0'"#V)P9C#'=F380)&D_X2Q< WQN33(W1^ M(SANSV'1OB0^="L_B@%$P+8DPBI?\Q':(\A^!Y2<@7TOVHR63Q!7BA?*.KH7 M+/M[?'@IW@ M]AR3B88KB*C=$ M@ZA<-_=!,9+G1S:AI(MIZF=Y.3//!M2_3,EU&8B4Z9H3PLQYAZ7^\&AOR=:) M :I*LXAE.>-P+7DL*^^:-$+&"R+0+0(O4:.( M#E@>L)ZZ"BJM+\64WB26-,6G3L$B*2Y7D4VC_W>7&E:O(M\%LU25OPVEX+R< M80T+S4*6()6BW\'*'HBW!:A%)COJ$TG'9LJ+.@ MTQ.UJ:H&["'V^9SH J2PK-GL05IA GU\T-@&)DZ"H,ODTG"2,3H%YXSQ.9'L MO[>>1+_-]@U=>'L(01&QZ@3%D?N^(YXUU_SCG]UN__R5%' H+/+7MS>?WG_\ MYSQ_?\NN7G][^_/;3VQ]O\AMB1)]JR># MXA=[$4D&4K8I7)@P ?ZE2;!+_[%/ :YF@/!#2/F22^T)$S?2J% M=(]08%ER!GH%'TR>-4\46.+K180,B&]#;L9[N&5/'JE*(?UNF^6%)=&+L_44 M;]_G_VS:6]+-9'BFA:.OV%R9!R"MFB:>3.8/3H"(CRB C!;.2"2Y>M M&D+/GMR^Z?PS#W+&.>ZBXV\1>Q1L44ZH1X&][^G97I,,6*YN@-]SU,DHI:"+CH1! MI'GL16;7'MV&MS=D]P7P0.PY%T"! ?TUR(A MTNB1&TW2NPS.A*M.:WCV;BJOMJQ]Q(! M ;^$\5CJT\RV:?2E0\EL"7JG.183$^::^QW\"C)[Q*&YP@4,5P2_9_(.S^0 MQIAGT9@L\(F9S)+!B)C/+ MN:0!" 3T=-W)CEPZ!,81+;-,P>A30-DC% $E]Y^/__(U':.J<&,,N)^(>(BX MG"//6-=!NZ^0+Z\/P9$;EQ-(7+LDWP]X:47W9$"0)>5+^_O3Y^.OANU"]9O] M7"Q4W7+*)>M+DD.22-H6_.?-IF)= 7XH_(K^(;TW@X[U$=$WH?3R9ZL8@ A=TM?]/T@'@>BAGXA#B1=*3V=0ULQ##!< M+_R!MIG]!![#@][NR!IV)?CNQ4#FH!6G= *GDO8@"-WB-IU-^T*$K6%EX_G5W&)9F*X22+05&Q (PS_@,%:.4TY(\P M*%P[*;F8.K"A+"J74"VI2H**G#T@TW-) I*N/JJC$GXL'_RJ:9Z%KG! -,>JT\RV@JHDK)2H^SC..2+$)?FY">T1MI'$)D( Y$$J#J@[B<_D7K.D@##)BTZ*;J2N8VS0<&@N M@C.M?>ZZU%[-X).3U9D+%CV&IU-@&FR[EW(^X/@,HD ]BEXLDBC< M0GVU7.=6-U-S4MM*I#3^&S.R?8=<,:A:.G(V<+$#HX!, K-I]M'(EN<,M@5N M!$AVXH'3J"I%'V:V]Z!---=A^%Z*/3P,-DPI$"EV*KL\2I:"TDFJ#\EJ8RC/ ML&0AR/XQ#LZF:YKPS<_'V=Z9 326VCP_G;:<&>_&?&?DW/&)L%V+8Z*-FJ>BS0UPC?2;Y-#:6$E^=)[H]Y-PD:WG9^M6!'2^CRHX2?4X[JQ#4U:=9_!9-BP-#8M&C1SCP#/B>8;-"W%,T.0*"2;:F*D4OE M+=&*M)48*>!@R7%3>B7J]%#ZJIB%>IRQ:MQKFG;J\?]Q-72.A:%. :?KSU:D M[I,'T:54 X)GBHY1O6D?8XRSFY:.L6'(BMG$_":)]B.G@@'?8#98]E#!E(<* MIE!M*.[6I-(DU/J,BB7FV5CSC'B%JR^X%",@E(=\V">U+5A3*S/.0U6&U&A8 ME8/X=)L-\%>H/$LPN/[2<1GN):.1FZ$9.)N!+9:3I$1:)O5I4E"KWH#DXB:5 M.\@.@LXAY29>O&'WQGA3NQ88-BW]UI+?'170 MH=N6:ZZJ'B1B$'T,S"&!%20,N/59FM%XG-37B)S*^E).3VJH:QIN$["H@FZB MP3,4<4T3L>8O)-6S$Q)GXU0V1R:\9W;QE3I U:L&B UR&^M3&6)^PFXOB@A& M;929:\:7@K@5.@U>&3-\-H'^8^E=*]-#<%$79+$ ^[ / M%41)X6="$ M"&9/EV'B=])(0.&NB?6KQ.((_I8A$MCY/A15N&5KD4[!Y18AB<*I-J))RMS) MMM)>F&B>L:4G.9<(TS(I7Y/4O38#(V!S)W$NYW:3"QI=\%R,1B'XD%NM*' ( M]RJ46Y$BZ4JY)_E^PA1F(D]X3.2:5"CARH*UQ/4N#XE*C7Y$.$@_F H'_0UQV;J!FZ(%&#&_K:5B9X!]>$=J MLF56M(H+=4$ ?7.D(%W0'#1^"M\82RYK!L_178] VO6LI_C.8T%--DFD&(S+ MW^[1ZR=:E"$VIQEX>V[2W6&*+. FLD)T_I-''L2X4SR?XG:4Q,!2%\5 M,S:?W_@]F86E9S7\>)Y)S4(:!*+RDUU(E>?TF,RR_UX50#ZI MC;Q\6]FY9( M6)VE^4*-P@=?V!'E9!\]YOPK;;P+\E]$\%( M;]%68+#(<81@:6!FRB26;+VDRR8E\)*6N:6;0>X./AM\AJYOV ^7K]_ MG=3?2KY$(:U1$00:^*,*R?3RKH<-L9'D4#B;.K1W_L#)#[X4#YS8^X!X2;(; MOUK B07B=?093=KP ^DPEAJSHIF"='HT(%FPK$B['N*%0B_(SLTY,LZ9%M!$ MO5@<571?3;0O;RH4TA]M31!0CX17>)QKV_(.H'+-:;*@2 />BE_H%O5GX1 2 M%HI>F6Y;6IA+#;W-< +S\QFR/&F0=RHPF90TJ\X#%@[*A811!UA@T:P7M+$% MHI-M,X3>EE&:_,F;A8B29:F2NJ(_U ^KI4JQ*TCB0JM1PH.]5I1"6$;R]X2\ MA#9<;41'BJ=Y"PRB'P2V\A*)QIT@S @>@)'I"*8UK;,,\=ZCW^.+FDN=9!L*TS:#L)/ M:C'VJG.I")=/)V5-+">I"8J5*$QBP)):RW>1WZA>D(:D4P)[#I-=J>?6H4\G M"WZXIP@=S?*3FTY848&"I+W^>+U\M![[)NR^T*+D5R-*:!IV4J+]L,*0Y(ZR M1?Z*(KFD%B6!II3N*1*S),=FK6U96J\J'O7H?DA7)'5:J6ON@>&SOH\]9J'Z M=.RSVW8O:(\_GM[$"%A@Y+ 9^B23-SMJ+TNYZCP%Q&+#.[S>ZU=62D9&T3!Y M^15P V*80?@<59;&..ZS-FPQ7BUH_2\6B%WP..SB.:'R#Q8S#[ M.4KJMXQ'D7XR>_!15CKSB\U4S["LS\EP0!(41_BY MUGJF.2%XO">J,1BP(:D*1:.@+6.JLYDY]E:,#&<%D%7Q0)$V5WDS*H8'IN[H MJ%[3G(2U#/BI-S.I7R5%IZ8GB>AB!< 4!?LOXK>T-E6<>HGC^ =EKV[A9B#E M-^X*2T*W<:(;RV;&-;&1X,'X:Y;<3^1JH&CJJN'[&]1A&&NK\E_;Y*-YDD(, M_2UI3XP-'"C]*-\T2<>;[6:9O/P>E>:)0X%KE MJDK:V=4L)0M,N\9PRTLZF4=5/X.XDH/JRV5)++SB' C:KE=P%S%C(8:41AGQ MRB7FNI=&N)@_GS3Y8[3L=]A+L9&A^C].0Y@]TPDM8F1!\24'XK4P<6BP6 M*IMD/N%.)SI-XYO$)Y$R)LXG+&W,BW9L M<:^D1C3I?)>Y5;UK91=3PU=K.O361:^[5GG0Q DBX5<;YC= X% *P WUP?.! AF[((HN]QQDG<^A8 M*(FK(_:IMCP$I86T2E4L]@6KB-2X,OZ>6-2H;SY'EXN.934:BW]@6EO%CV$O MKCIDL18BC1O8.34P(_9OG!Y":ME%;3<2T%F M0V'\Z[=92\Z2,H*D+(/K'\#:#Y553#/Q,1[0@2TAE$+@>1'>$# KKK-_M+-9Z M]WG6^WYU,4NQ2YF==3#A2YB9D>^8&E& 8MR&%A;GD2V=4),)0,%D#&53B']TN*3E1C9[ M,C(3=SX[X>\'\)/EYKT^[B<=&D3. !D-?T^DH("L'VBI, /BIX]Q6D-J;\0H M\K=2("-/XCZQ+^IR_N08JWTT&A27Q"A,.^E<.WFV-'*1)V%K05Y>PJB0]U2Z M_!6H&VJ 7\-YY@:H['K38CH>QY5VOI>O7E^'\T7%.]2)T8*+SCLC#\N1IPKE+#A/TLC7/7>4?M'TNR<-C MM>DX2^"R<: 9<0,98H"\C%\,+3QA-"QA YT5_R1+O]G$V^8]-.NU.D)Q$-JE;',\$TWL:"@A)C+ZVWG&+5)FLGL&]R53 M^H5%@-69)9V]SH7A")T!0%JHE!)9O]8BPO9VGG2A:2OB1?X.#T52O.O)AOIN M!(<#V. .C+"[J/ ]'<]S%?0Z#?7X-%(40.H7B@O3B!]_F[_[Y^?\!O7R01VJ MBB[Q"* MH.M,0D6P=]TP'SUY]#QMP$^?IK_F5#X3GE;Y]A$HOX^>6'-YAX2<:FD3[!,9468?_A1+SS\7[1T#?J]Z48#'2#GNPN;-JZTP M.E6F>ZD0N3C1('3Y)U3K./38-DTG'_ [S/2;- ] EBR!P^D#UDC030PS-1BK MQH.2I$M >H#("!^X.IEO(YRL<+URNGWMP'.]#C^YL Z2(^GC+B([5@VX[:MO+[Y&U4(<81N&*28#&]G 6!%^ MGXZY!? ?(8]3\VU5 C8V@ ME1ER;R0#836J.A&"G&QY"D5UW!R5%O/ +SMUL ?F.X:8>P0HC290VJ11KLD1 M-F"6DB-S\X1ZM. M8X$NA-[O9<2C#/F22JZ[HUMQ1<%I"I$W4=KJ.TTUBC7'2ZRL&CK,:]X/@BHO M'8!P= UT.IDX<#(''VO6Z?S)*00H"FD,4D_(QWHL:.2BSAYOX5?N0(A MZEL,K7_R-6K?I*)@X8I?AXX+43PW^/-C42GR],F?Q"[ $:,@]HXYC8NMC"0H M;6$FWI:K6U];*91C/^0^&6R KB3I,1H/CB-2\2PRD749 ) ET6PJFCR5EU9^ M?/4G?NA3^O]JZ]T>D&=:X/Z;GE+C#2Q0SJCOI#RM9+L:4K[BA< M7QD+SD\UPLVY/@-AJHAP63,#M]H6AA2$U)O,U?6!.Q%LX%PR-Z'7=#(ZC;^: MR91J17=SF9'-M2"C?E2+/4_VG+(.IMOB&!NB?$:553]EH-+0\-TC6R M/EP\'1I^[[V[A8%0$(:HO*F:)7=)'TDDW_S6%8I16E1%+"Q>D@Q^"$U(7B:=#.^ (WR27HPOBE)Z@9D)<@R"L*C@FTHBC'H9X.AQ/F$+@^ M.);J29T879(IW8YN+W@+]='T=6EG'OGT+,VQ3,T<_[%1QEZJ\M;GB3<_:8LV MAQX:20I\2&'<8;^TQ*Z)'26[#E/NTF&Y1:G%ELSTOOZ5IZL(5J\=4V)Q2: 0 M$'Z3ORN!X=9O_V?^5U(L'?/TM:RD7QF?/QH(L)GTB"-Z># M:DC/WWAVT34N^WS#.HAXW3R3$^\E2(HH@K9+FHO3<.(E)AH@^WK]ZJ=Y_L&W MJ-LSAJ)-<# VEX=PF!,THY4ABTN@<4E)F$7A*$U//TAG0[2XS337F M^[)?;;D%J."NKK1J1'<5S*F-C [O;6@$F0R%KV30*;"S/+EY"J75CPCFX6P. M-7D!T_?@!(],3L$MT+S>N=746L&9W^W+ENL./M8IGSB!IN$N0XK()K29[47=-R)SW/D!AX6.U)6H^*!1*5 M*G,A6X8:&E$VTW1R9B/-H*8B-ERY 9,@68\%,9C.(N"^Y,C8S+A!,S,\J,I# MK_5%Z_[EZR3Z0"YDQF..LC+4QAY\'_-!7/EAY:7W6ZEE"0T4G'=58WLGBB5Y MFT(K0X"98I8;J */<="7MN 65D6=:1-9,-+V%13%U^3#PF%/QG\ S%%,I&XD MSR411>=/*(6=A(F,]T=1.2*Q M)9CW\0B)0]1B,,3$C;*I&Z\%O)\KO+UUW<1#0^#"08 DAH[/JL,J6#-RL["A M=#J0*YPBTS=ML6-;J])1TV!%H/.TG/72(M#@GI:HD+.F!"U9"54JB\4B"9[5 MF,@\2<'BHK^&=RU(XL^@$]*)%/93*%.S4BT M'F--+B #*5.\S(@?^.35@G>,*4]>!O]C;N8O'!8A X"T4ZS3<]5ZGPEYTN%B3[KE08>0R1ZGP\2_Z$,3]'6:!,LAD/V47QBR[&R160 M;'31J 74M^PM+0W.;]QCEI5&QC#\1M)C)RKP'KR)-(.9%"=+.6$B0K6^P\L> M+*"3Y-%'A6:\5.9&+PM1LREZ:JSW, $-+#71G?.\(!OM>NF""!5BH> ]*15+ MJL1PV16[\'V#J#J4!MY**3_?U_B58:F]"1%XITTN.AQ.I%%/.6F[786 P8?3 M)J]2=6M%*3F8\(/CCBSMBGO%-2OT=W13'R.L)#*9#5IITR,JYT_:1 MY XX@].%%MC19 D%ZZ5U M?IF^E>ZX(I%GG#&J-!G HN @WX]47Y3M)4_1#-B5B($T)6:10)7FVP7[0)%@ M01IEA=L_\:*&1%XX<7$\9>.!82M2+;+@221A$ FK8OPZ3%A1OV>&AK[Q;45R MVPLL$GA##%D*I$5O/ MHOG*B4'CYAA[-QZY*\E[E&P"%$:0;3Q\_?V6PZ)B.S$QJ M>LW][LE-7J]M%W%B2]K))AT'TS=!I&. ;*Y.3*V,WA-AB\8NQ(2-R4/G?*.- MIRJ+2!TF19<,!I-7FJW+#1?I)F_]0(BIRI*9*Y0+9\&6C8J44QUT//9RQ#=] M;%0,MT5A3,FX"S RJ>O0]=G]X,DHO_RAMX3:U:I-+S)]0US,5-@ Y!/>@LC1 M.,_#L;>8?;86K,O\5M,"80C^:&RRZJR88))7]C!:R$FGZ<1TKG:/'3,O;*IFH & 4/N6>$U?/W*' M">KB0:1OF2S()='WH/ 5\6AVS7:[A[8KO?Q-'Q*LB3N!$>/=H::MHKI^@("B M.J_>'@K.IZM>GPLE=\L=TI_LHB"ZG^L]CW MHX5I?0SK6,]Z>+#B[826D/$KFK"?$2AR^BPS?:]=/?"H >A05$D^\/9=QED, MC@IIV1'@I-4S>%?PIR:+P%K+K9A\35]ZC?XY0V!'*6.S,)>W,_<7)1Q0O/5R MA+\(>XS>OW!Q7"&G%,L4)6 H9?RZ$AXM$5&G9&P$GV52"!%.?OH]T2N>W%NM M3=U-H=OV5+L-<F51=GRH*3B,'LDD4K MQWW4$Q,+53P:'BU:<>=]'X$$"2)CZ=)>2\0GDLBLPWEAM!:$-VG$IG[V4# V MO@V]71*,AT++20Q^JBC3T)!1"X9U )2/? M17G0SII4WK [&&UWC2&>K*V (' <#10GL[F& J3P0'&.24<<8(G .)'Z@7*? ME*O5QQM%XE#12.;(_)Y!,V\!=LJ2M+EV1]B*Z0-Y3E,RZ'_4D#7J>AS1ZM0P M6@BR)#BLZH>4=98,/>342E+X!$M%-S(?"[ 6T4S,DF2LS6%51SF:0 E<#"B- M#Q2X',#@WL!R*)R0=973YD?9F+BR@(N*$W-BY"B9,\]T=_%.939Y>+-5UPU6 M%WB$3;$NDFPHQ;P%O[ @ON\#+A+\$>2R*O;VV7CKKCJ$)>)()!HY,P&R&I H M12(\UY;E"GIJTIG!T%PR\.9!F=(9?@P5ZO01_%+>JYA]=]G_\-UEV=$?*_J/ MA(7^I ?Z_I7KW0_?$6TV_B6= 54(0]U_?_;X+/DIWA#X_=GUXV?75V>7],WX M\1^^VY.1^DDGPU=^35]]=/&7K\]RKBZS?_3-'DL"I^R;'?\5[6B^Q0?H]P"Y M[!]X # 'WMX/_Q=02P,$% @ S(NJ5NDT/#5:$P ,S4 !@ !X;"]W M;W)KO0'FK]B15M"S)EB^32Y7C MFZ I?%G6SSEK\;)8G=M/HK.!) MZ_)D.AZ?GZPS4QV]?O-]E2W^OVR^:NP:^30*4P:UU94U>JT8LW1]>3G]Z=T7@>\"^C'VWT MK&@G\[K^2C]NBS='8V)(ESIOB4*&_Q[TC2Y+(@0V_G0TC\*2-#%^]M1_Y;UC M+_/,ZINZ_-T4[>K-T>61*O0BZ\KV4_WX#^WV,R-Z>5U:_E<]RMC3Z9'*.]O6 M:S<9'*Q-)?]GWYP_NZJ1]50Z-!C1YXJSP; MS)F*E'+?-OAJ,*]]>W_[_N/MK[*7^65?MRJI?JD(7P_DG8"YP./4N0U/]E-ENLW1W +JYL'??3V[W^;G(]?/#V[#GJ_XU^GB6XG]WI M2$4+)7L64G>-J7*S*2&M>J'RNK(07I&Q:WU>:7I3P%=U$7W#CX6I,LS+2F5; MO( [MU:!4MD56K4KG62B#J:*W^JF7F^R:JNRJE &KQ]7=5ENC^O'"M1L-[>F M,%D#I:7J':U]6[5ZV?!:=TW]!YS=JO=-W6U2?,I';M1GG:^JNJR7/+'_<%^; MTOU.>. ]!&+R0/WN>JH^?+AA;OC%Z?OC";]Y\?>_74ZGXU>G[R?\-'GU\E5@ M>G8YNO($9/AC9E5A+ 3S $[QX6>=Z_5<-VIZQ:8]42_NM4X^UJU6LY^%AH8H%-E1%N\+>EZNGY$>L)9(VRY>(_H#*DE7VH-5< MZTK!:C;@HT"@:E<(\RKK"M.J3=?8+JM:U=;,5M.1J9! &KWL2N8N*/E>YUUC M6N-&_/(M7V75DI6_AI!H(UZ^][_<>/F.DA\U-$1X"O\J*TN5%7\@G,K[%S35 M6!8M6*JKNL0MXBBFE"FJD@ MML@J+"YG Y'PO(<@ M(_-OJ%QKEF,%7T_6$GXUA=\=XCP(#U-^8./)[$HMD)D/4B>:ZGMHCM1OP5P= M_\E^%I\G1X*LVR!, ^&9JC!Y1NG;<^D%1*J!'K8P3:6_;:!K,@6WZE9G#2T" MCI+_[;#NZ5@6&:D;VC?QPP+0?W;F(2O9-#Y',F K*71CV8!62/!@IC083=[W MH+TYP?9AP-;Y!.BJNC%+:+M,@!O(TK?".$G!;1X\PD$LFJ+-ZT940 MYH.VO5)+^I9DB'4M(O!25S"HDKV')$>1Y1$,;UFS=C345;8Q;5::_VC15F$: M\GS:C009>DF&Q*\11!OV7"8/'0,0+$PV+[6;X7EQT:S0UBPKT1",HFTZ 97@ MG.+]OB1D.R@,49_&PU9)0 M-B06BTTU%@2HK.9,QV3DVNS".5QX"80VVF#3Z M@4 IK[C9KTHR?8/1IN&?I#%-PL<_G&,;)9&6V4.9< ZS@D85%P7V93+7 M>09W&T3WN2Z-)M=C*^V=A'EGE+$F*3:4K%[T0*/5W]J=1!&X:6LXDY ZI>S$!HS:UOG78[$=PC%8HP>@?>(J.9\1 M)7C)@[$^>4;(_QY&7V1-89.;NH#GYT+'@X[K^P ZU,7D,G6&V0>DAEP.6A1G ML2N(;!]?"(9XS"5]SP5^@0/2- ,CK^'$B3A EYW,+Z2[C3@,[!K!!H-(WY&= M0T(_0V4/DBE_#6CCE@.6I*J["*9AE^HS\$RN+B4Q"+^(M_4Q_0\_ZA$?Y36=@2*P:]VP!4"X!JD)\ # A98O-.P=%39E MND$A0LC;LJJ!Z 9[($P?Q)64R!^( (1J)6Y'+(ME[TQ'1!(6)4YXL-H.IS[' M>NH!QU8R&LPD@5P++<\^<$34^MC2N!IB/]:D^%C%$@2#P_WT.[<$_63:;LP$ MF.\HT+O/%#K7F[+>:F==+CEF5&)TB&9B$]114G>(8@RD';@BSP)V$F?;A:L] M!Q2\F,>07B)?Z7'*.\"8K\?W.:I+(L:3CS>-R^P?T6' MB]V.!/ ?L>S@6@+SC/UZO"! YV$.+[ C;T]]2'E'+,X3B FSUGLX8=UKP;(] M:8;<*%T)^E!U$,?7OJ@+PO:8 @+Z'; DVP<.G*$_^N]/#3K>C[;@@0^VCFA)4E_0?P7'L%IF2N.D2F8B0"4LR8Z_H M+7^!O%8WOIG#!"K@S##\@.6[H&83]YT9<,_$$D&7-%1>SY(JS=J0/EU%!N'6 M$+G'T[0I*K" 2PIWDI8=[E!'+5>[/4NL2'$1D*4:R :KD&E@0RUSDND/I]C M7"$=Q8 @ F'$F\&NYL-JWF9&R>]48#W&]N#,RK!3S\$#RX.#?J'G+0%ZRH\( M-#:T5-+8!@9FQ=DR0!!RZ$$<$V"&3';0HJPDC-*A&\%N OR\7JE.$A^3NND MD\Q+H"J;TTC%-S7T7[51RP.IC/I+%#5BK_L?>P!8,")S_EY;*>'R9ZFZ9A"_ M1BP=[2S#\=7PU@N])KY1%5,#1X7>I2N*62\+73B0"*ZZ)FY-)<2G:;O>.*PO M*N9-_173E@'=$-PE;/YD+7)C!#O+Z$A*GSUKLF_LE,@4IU"S)10(47=6.9O$ MUC<7*65PS1H8^ BQ ?0W0-12JTBXIGJ71S4%%QJ\;0*3EY-QZG'D3=R6=" Q MC;T->]]D%/C!=5Z2X2S(+JI#:](J#L_TUA2'A^\JAYS4_UB'6.P+I7V,1'W) =8:L3B+@CN"(J(#*S GINJT;QMY3K6T MG3G#$'&G4:KZE5DXEW!CY31-,!\8SN@,"UBBW5DT"8LZ 8[4KWU86#,\<+N) MWG/&64BZ\248!5KF(&X$:,09=DUX0,E0DTM?A(I-9B1\4.VT 'A!G>Z0]989 MINX:S)W:0GUY!;+M([6G?7S/&D%(WF56 Z8E[8B^DHT<;2".8/DUM[^*!TR$ M-]:==12'KM1Q-SY.O2L#?2+2;V6O*]X^@9P26BA9Y:;:=)2&YC7\I9Y3]XQ- MC&RJJ_H7:<(>136[,VT4M*0)1 )K: ;3#"2'$*OG::0^\+@)^^1D\DK]V=5D M*ZP3JUYTE:\_7K)D.<$ELE^IT*0S1EDMM%Y45.>\B7A(,&PSY MJ9\DJTC!BO'/, M94Z_T..JMF%K[&W]AK&L?*8*P$ M,+/VI<:7/81\K1]OLL?CZH^N6$ISI/&8'+0X?-IZS4UTCWX/X@S M?5"A1+J0]C!YDED@ZG#W,G@N18E]OLYKM\XD7",UW07E<=@Q89.^# FIKXBJ M4^?ONVX.2TU (38OA[/V+Q<@A,2&S,5^U[J*R>R1\KX>1CBFZ)%/MI48M@'. M_B9E4B(]JIWV,3)#IQV_^&I7R+O'7.6Y,Y+#?1/( YKS2S$4"WOBQ4DV>,U% M8+]*4G$W*32/"6RZ34K;1%*RPLZK?!N@/!4V$A5,&W ?7_,XQ!ZTJ8$,B164 MI[">AM,]%1$#N5".WFEL]]R&$MZ2=)NH@;%+4YICY'6N9239EE)>S-&Z+^#T M+N>A^O*4!VU+UYE!6&DYW2 RZE[5QRI;4*N;MA0"YX9N3\"6'&3R)7.\/]^E M(SZW2G3C^>#>3\ERB7NFE,&H@HXZMW$6#E:XX-,T+K*DB\1H]&R:RGQ E'Z M4SU;GL!G(CN9NH.Y-,ED9(PZ;-\Q.Q#BO@=\DIT*:>H($/YF6W1*]+[O#XZ] MA;'5+,PWJOY-9=;=FC0A<1"5Z-+7-+[/(RO0]D;J&BM!O7932Y^CX:.Y>G%, MV,*WE'-S1#3XZ6X\#Z6[E>W@#WF@%XW-_T'B #Y%Q;N,)M*],ZG[9JO$G MG+ :E%X<1+B+0/[(AYDP@'IM=_M9Q&BTQ&ZA/5.%#:)SE+ M>7(:Q'9540.GJ+FZ;-TI#N]!YM+9G5E(1X(Z,,.#LJ61QO63:?&P1\,G@5#% M5JQVS^D30M+Y^-S7QYYQ!EPW5'Y,8RAO9=0#YO+NFR#!W_ M&3YCYI.&SW?5^"XJZYE"(ER$T+ZAP V^6/@$. M4;_/#79?:;"KD_V],N1BN=?&'B%W ,1D7>R?[[=UZ:O_E-SG*^BS9+/9Q^XS MS"6];L)3$OKRTTEZ=7:6GIU>J,E5.KZX3,]/9XD_;YI,TMGX/#T?C]5DG)Y= M3N@QN8G6X1XHOHUGT_3B?$:/EV<7Z7AZ/ABVB_(86DQ?A?^'6J(PRJFWRAF* M17TPX)":T7[=A"Z[R.Y[[(N"6-=&F>Z_M.NA0I[Z3?J4I^1S?$%J\.-CM&ST MG-R+4;LVN:^@.6A7[G*?.R."!F?3J_3R\DR=G:87IZ?IY6S,C[/+]'**QTEZ M.IFE5Y?GGNJ*#N* +>);I^H%W]"\>*E>7(S/TM/QE?KK1T\P#I[/\@KFIK-T M=C&CQS'8GDTF_#@[D\=Q>@[#.[^X2'[?#>%V(!(,.B5[FP8[FJ036.#%U:6Z MNL+_D]/$!^TGV<"1\JR>S=*SV7EZ-KD8L'663LYGO%&P=45[QFI?I'D5CLZH M4):;HSY6?B>"[IOG@PO$-(C0$B%10?1]B;#IKRKW-S;P76_:_C+-EXK/CNY; MYH[R,Q(N\%$:U\([Y?HZ^ZJ3?DM<"/<]#==)D@PC!0_UEDF>ZW#%^4!SQ]>> MA;$Y/-)5K=+N73)ZWCLO<9W-^!!M[T583W\?2P[/R"!_WPG#L.!Z!-VMRB-W_]@CY4^C&^ M_;$9DM@]:4:QB_*[I*J42Y:1X@,VLWLP*GK;(:X&Q)U:[3[+37J)!TGM5 14 MD[8P'LL]AZ[8/CT5)Z.'J6F^B^=/-.16-,9RY^ 'KFM[TPQ7E-IP/51N#OI# M#?8E/KZB93*;$Z/L(LZT?M1-8ZN3I?BZ%%<+2;^ID=KWQQ$GT1^RP!V7_.CB]F1E+_^1UMO^,]BYG4+ ML,V/*]1$NJ$!^+ZH$>C=#UH@_)W4V_\'4$L#!!0 ( ,R+JE9"53.UO@, M /@' 8 >&PO=V]R:W-H965T&ULE55M;]LV$/ZN7W%0 MAR(!!$NB)$=V; -YVY9B2=PDW3 ,^T!+M,55(E62BI-_WR/EN$YA!]@7FZ3X M//?<'>]NLI;JJZX8,_#Z:AJJ7#>[ZJC#T( M9Y.6KM@#,U_:N<)=N&4I><.$YE* 8LNI?Q:/SU-[WUWXD[.UWEF#]60AY5>[ MN2ZG?F0%L9H5QC)0_'MB%ZRN+1'*^+;A]+[E^G>V\2>S?(6LM?N%=7\W18M%IXUL-F#<-UST__1Y$X<= M0!X= ) -@#C=O2&G\I(:.ILHN09E;R.;73A7'1K%<6&3\F 4?N6(,[/Y_=W\ MZO[Q;SB[O82KSU^NYS=7MX_C26B0W%X)BPW1>4]$#A"-X$8*4VFX$B4KW^)# M%+551EZ5G9-W"6^H&D 2!T BDKS#EVP]31Q?I; MQUM\8@;^.5MHH_"-_+O/]9XYW<]LZV:L6UJPJ8^%H9EZ8O[LXX=X&)V^HSO= MZD[?8_\_&7J7:+_,9 '#,!KP%RDV#92A<2*U ;D$DS%8"EK+&PN5F/O 3M& MV=7,?FKW@CU,:E%Y-JN?.L&\) J\"]FTG6%*NZMRN>0%VS$79T&<#2%.@FR4 M>]>"&TYKJ^T_K.NQ4V-4UYWTC 8 M'0_@3F"X;2)[7"$;%%P@U)[9W%#Q HU\PA,NC'P;\+9"S,"S#BPH&BKL>U . M^I/X@XGBHJB[DFF,2)R.@B0EF.LL&*8YW%"!<\&] K2#(^ )>_)&F6)VXN"S M>_/2O!_OQNK@J)XKMT4\!LH]OVU3<3E:L)JS)[1O*FI 2+C<33%[QNF'85E3 M*S =QD R%!C$>09Y0F!??8<[W;AA:N5FCL8 =,+TC7E[NAUK9WTW_W&]GXFH M=\6%QMPL$1H-3C(?5#]G^HV1K>OM"VEP4KAEA:.9*7L!OR\EYGFSL0:VPW[V M'5!+ P04 " #,BZI6L=?C_N@" E!@ &0 'AL+W=O[ E5U((^?==R8D),R$SO4C:U;ZGM[)VW5])]:(+1 -O=27TP"N,:JJR!B[#2H>2F\8=_YIFK8ETM3E0*G"O2R MKKE:C[&2JX$7>EO'0[DHC'4$PW[#%_B(YD68/-Y%G*%VOLX*PPMQ8!D[3*UYB55DBDO%WP^EU1UK@ M[GK+?NURIUR>N<9+6?TJ9Z88>)D',YSS964>Y.H[;O))+5\N*^U&6+6Q2>Q! MOM1&UALP*:A+T<[\;7,/.X",?0*(-H#(Z6X/K0 M)*X4]J,\&D6[)>',\&IR/7EXF%S!Y?WM='+W.'JZN;\[[P>&N&U$D&]XQBU/ M] E/#VZE,(6&B9CA[",^($V=L&@K;!P=)+SEZ@3BT(>(1?$!OKA+-'9\\2=\ MCP57^&U,'W &4[ZF=V5@I!07"W3KWZ-G;10]DC_[DF^YD_W9G,"6_\L'?G@J$"YEW7"Q!KE" M;=\Z*D77EY.7RI*[LC+RRRM7I5QJP+JIY!I1^V"[!:IW#W!A<4)3L7!A-,$, M)X$+^ IG6>)':0IIE/JGO1ZD+/$3%D+J,\8@@9"&D/EIE@*#7N3'%)M$_FF8 MD!U#S)@+9"=G*8S+JH+[XZ,L"L\N[M!:!:?3J7(K+G($.:<3PW #(;!;]-II M-V6%N53TE*$4!NFZ#.";S7I#0>+B!$AHE$'L9U%"8WK&("17FD$8^5DOME-( M6V%(:E/8]Q:"G=*E&UNX!J7IJI;"M%7<>;L>.&I+_SV\;:!4,8M2:*AP3E![ M'1ZHMBFUAI&-:P3/TE!;<Z=95JY+TA MV]:U,$\WLM*'JU$ZZF_\IK:EXQN3Z\N=V,H'Z7[?W1M<308KA:IE8Y5NR,C- MU6B5OKV9\7J_X%]*'NS1=V)/UEH_\L7'XFJ4,"!9R=RQ!8&/O7PGJXH- <8? MG6__@?85 M]?_I$-9FBQ'EK76Z[C8#0:V:\"F^='$XVK!,OK$AZS9D'G%?];H!3#2?EP1D\5=CGKN\^KWY]H/O5?U8W=^_?7DX<;/*32=[M MOPG[LV_L/Z=/NG&EI?=-(8N7^R? ,@#*>D WV7<-?A)F3-,TIBS)IM^Q-QT< MG'I[TV_8NY5K1[?*YI6VK9'TW]7:.@,R_.^4L\'6[+0M+I"W=B=R>35"!5AI M]G)T_=,/Z5ER\1VDLP'I['O6_T8JOKO_-+KYF%[:I7O9-'MI'=UI@:IH"KKA M\KA?I71W]XY>_?3#,LN2"US[;^G%ZPCAL[IJ7;J?KG6B>>%&ZN+#1 MH=15]?1&'QI9H,;75A4*91[305@JO(4]GL#$K-'*HM3SQZW1 M;5,$=YTTM8WTQE^\C"%0[A783]!(VF"':K:$E>V.G ;N1;P .@][/)\M:#I. MES,"_.69O[N<=9^+J?],9^?A,YO&L]F,,CQ?+A=TVQJVO&JWT 4$#KB/,Q$- M. 9XKSB]'O#J]OW]:VB+\S$6$*Y:-UP(CDVZ4CB_[A9E\#:J M$4W.YQE\J)=:J4NZ)"?0C2+H\6\:S\SF-Z7-##W+GNH*8LT$0 MEPU%;,@^57O1*$$?FXT12%B;.Y:QC_X(CAGXX$IM8/RY=CL$?0&3_")-KM@Q M!9"&.Q53LY!Y)6 L,"0=XO#"@PAIZ]H<,I/G:*@AG2=\!=M +,&M('"*,[$3 M7+S+.)TNXC1=L,=?*4!PN,M'*'P6"S8(['G+YXF>A.^0'':\*\8'L( ^!7NX MU:D9]>[0JYZ_B$R_%E%&D3@D(-2H( UGPL#6& 8L:<@?;H!@L<& MS8(LTFNXY/!/.6V&6-YKZ]X^[5AJ?(%;R:6L!TA>EG ,)QV0(UZY;J$PTMKQ M5QZ2X!#Q,5$I]J&Z^.B=CQJ\\0P0N*],@>K@[(C6#ZD2@40?)6$@K=NNH_!^ M*RJ?8#YY2&DHMPI3K6<,(:W\,,?AEEZQ*[@)^M:((8S;B#>$F9(YEB.^7LO8 M^&OVM_=@3,RP#A,>Z$?:51@LJ @=B!$!@M(%;_^$^DZG;]*E9V<6-O]56K'< MZJ:1%8<7,9=%=%0#R@;@UK)>(@PL()"/1GN4'AM3@BVS7WB%(*^D:3*+%]F< M?M_IYF6U#HF%"U$7G"ZS@6 83$J)+8:S@4;8V T+B FQ[@I\,,&;^.0AOL(^ M]WVQAEK%75'CG-9Z(#6+KJ\UO"[!>[&N9"0WR&E'+\$+/6IX/G0OCW2@+3>N M%TAZ_,^5$+SJJZ 6A63K1PV.O6+FB T$2*%L[3@*23JEAG0D@)C&'VDUI@=4 M5GFZ:=ZC42,*K!_=L,%M&3 :O-29(=C/_FI&V?$6-/!#$V!UO/J6?GH+6^P! M*9S*9:_^QP(1$,!U\<@9A-\^OP@FQV57N5>5C4/&CZ< MX"&ZF)]0(NS?RZ9@56"Q\B<\"P6:9^ILF;7P9=?9("2=L874.[DB7NX81M&:8ZA*)J M!RP\/]H^EA_"Z"JJ9[[:;GT8&S!'P\53;X63HY=U*,36_R3!LR=Z;WAO'^X. MOWJLPLO^\_+PDPFJ^5?_M780??^UE,B?X05X MOM%PJKO@ X;?@J[_!%!+ P04 " #,BZI6#)PXJ+P% #$0 &0 'AL M+W=O%V10JHL=Z/-#'@ MI F6H8^@R3KL(VW1%E=)]$@Y3O[]#B79M5L_V@7%!@,22?%>GOLXEZ1/%U)] MUCGG-3V41:7/>GE=ST[Z?3W.>XX3 M]4LFJM[@M!F[48-3.:\+4?$;17I>EDP]GO-"+LYZ;F\Y\%%,\]H,] >G,S;E MM[S^?7:CT.NOM&2BY)46LB+%)V>]H7MR'ICYS81/@B_T6IN,)2,I/YO.=7;6 M[4(/R#:O9X%3)!2DS&]I,HS&UD08X49F@W-8*7P7DZL'%A_>? M+C_>79^_O:3W'^XN;^EF^.?0]%[1\.KJ^NWU$(,GI_T:BQF1_KA3?-XJ]G8H M3NF=K.I$NFYMU?A.Z:.R7=M\AS/WZ//7UGN-_K\79;+ MZIZK6HP*3N]ES37=L$=F>K!\,A&%8!C<9GBK-]BNU[#H1,_8F)_U0!/-U3WO M#5X\9 )*IQ,<^,IA95MH)EDUR@ M>\ZT9I6@*U:*XI'N%!;3=,2JC'*A*9,5Y_JE3;S)4QP^B!9SB5+3&Y(>973J0C^" SB6_- ME,#ZM6SD6E>B&->$"5=\I.8HX=1)+8VDIMA"*:18E@%GZMB. W2^G0;^?P-D MW ;:.*T%$VU[>>TKV/:Z^Q( Y-=8JFPM&8@_8(/4W$3J.;F1[3D)1;8?190F ML#HA-[8#WZ'0M3T_0:A<#/B!"=KE9,*;7>D;0TPR*\ZM(__E*A=T7Z(LC;G2 M7V4%L2GF=EXW[FD^SI2\%[JA'Z87LIJ^ N)RZ8\F\>4:1X^^)'PIH4-.K -D MT622^I;/:EZ.D,^>XX;T35E]V;*EC5])H\<-Z (;,_:SJH)\6P,4S^8@H)EE M"63&"'&LN/[&:"A*G%_ MQDL?1#8H#E8B"@?!S'H&= MQ/Y!P.MI^LB9ZO+SMSDR%BEDI")[ PIO"PVYD/5Y?E3.N@ _ZOT>N*Z:&3A[9^ M:B=)0N9\8S;6(.P^.V&[AX<8=R**V]E^]]F# M%C-]]Z%Q9SI:3SL9[C@+TI:S8'>N"W"@2V&B&\%7J,DIJIX7;(6^B?Q@H7[R MP7:MGBS1(JQ^&IFPHHANN]STURZF)5?3YOJM$>)Y5;=WU-7HZH8_;"^V7Z:W M?P_ ^*D LPH^@:AS'(<]4NV5N^W4RQJ6Y:>:<83,Q$_!](N&'KF,6 M6/WO,?@'4$L#!!0 ( ,R+JE8SZR(JK @ $X7 9 >&PO=V]R:W-H M965T;,R]&)T>KSF-^): MF-_65PV>1ELIA:Q$K:6J62.6)X.S^.@\H_5VP=^EV.C>F)$F"Z4^T\.[XF00 M$2!1BMR0!(Z?6_%*E"4) HP_O,S!]DC:V!]WTM]8W:'+@FOQ2I6?9&%6)X/9 M@!5BR=O2?%";M\+K,R9YN2JU_<\V;FV2#%C>:J,JOQD(*EF[7W[G[=#;,(N^ ML"'Q&Q*+VQUD4;[FAI\>-VK#&EH-:32PJMK= "=K&0@FA:,SN M'P'2%E?2X3I/#@I\SYLA2^.0)5&2'I"7;O5,K;ST"_(N_FBEN6?_/%MHTR 4 M_K5/1R!*]/ PVP+,#DG_=D<<%C,= MLAU)@9?$7HN%@9,*N90YMPEA%#LK"DEC7K(K+@LF:_:*KZ7A97"Q7 J;,>R- M6#0M$I9Y;X3,K!HAV//T!2MD@U6JT2.UA:*:6F!?LE:K6O+X/^ W6%G08 M+WY'/-O)=:-N)>6U75ZJ^H89T50L5_6M:(Q.=I;\J(_0+IC8.',15;''?AT[6 MX,BUNA8-VZQDO@(+%6TNM%TE$>D+(XI:Z,=*DZ!9]"?VG*^AZ9T$>8CRGCUC MZ3";PHQQ- \GV1RC>8K1-&)9DH6S:3;!OW'J_PUCP/YK6W;&SU@:CI,X MC**(C<,)U+\6C02BT;0G5&(O.2$ MJ9"WLL!&:ZIGS!]@_]>*(%6(2 _\K2H+'TEY;X)!$,XVTI3.9PH ;N%&MH:# M]8JFB>?+$DXSAB1@T<*M*6@*;ND+7+ESANQ=;;43MY!N U*"+0H;1R&0:ZW* MUJ:,0B# [V2.=OW(Z4[QU3=B=W"E@\NU%D8CNN@6)>%\"?B P1>R1(+"ORN. M3%P(4;.U3]1EBYT A*T0 .-:%Q"@AFXB'0 "N0 WL3;<@5[OQDA/JH:V>BE% M,=QQ!E9HK)?JRJ=GF!F:W2@3L8H&GQG@4>63])"%$A MM+RID<-D=II#P+9VG&NE]K M^SB>AW'R_?[?JHF;I,62"*-P1+9C&7>M=/( MA6#BV6/J5J=^.H$46OYD(K%^N17NNJ>HXBCUZ,)/XJA?NL6DMHVS)\?LSE%5 MOW_ <>).:D-RMSY=B9(N:UN;T2<#82L$C1X9T_:.ES"FII8A]$6UN#,.!MH' M@P((+]:RL6<$*,*$KRCZ9U.M1#(M9> O;RQ'H(VI5?U3SO6*:HVUJ/46*DAT MG*'>3M@T"<>S^?=9Y" ?/+1*[WE7J-N*V%5\MHI!'<<)[@8!Q3[)$H]5 %>TY/2?1RYZU]%[]\ 0OKCC_B!S(>VF#S03>V=NH>@27P^!FB M-$/K, EQB;%K5P59?@437-;L#,E:LJD#W@\TCT2[JK$,5U/K2= ?,].%Z076"N,X1-P:Y*6.HYR?(&Z!;:"9?. M5J./>X#1QR?JZU"B4\4.4 _B:7\8P&Z\MT!&4ZAX5E^Y'ETL\F#(\X(+CW43]U5 MUAN=;XV?).7 MP86_+8ONS7;FC6J60IH],Q?$CGO>/T+XR"# .(XF#Q@3ZO@38L4(=>0L3.>. M/8RB#%YRV;!;7K;68KLN-2M()PJ'XWU"+1#HO:*;6/YKE-I]+T@LL3V*D7V? MTT:];YRX56[LEUR-N&QKXSYW;M]N/Q:?N6^D#\O=EV8@N9'0I!1+;"4J'[B^ MLGLP:FV_F$(OHRH[7 F.4*0%F%\J9;H'.F#["?WTWU!+ P04 " #,BZI6 MMMMO/0@# [!P &0 'AL+W=O]7$.ZP)R]V;"=-FPN09"D68)*="[JF+J:8:EW(^]KO>\L>)Y M8>Q&,!G5+,/V,?NMBIU@V3.-/"7LK:*#KE9&>P&-7D=U5;0C:Y9BF./2D2C>D!O\O:R MVP^'9S@G+>?D'/J_W]5YV$$'CI$O3B'#5(/< MU$6K17X8,I$.:RJIEX@H)I MDA4B<&&0,F N-L@4%[D/&M.=P@QJ)2NNM51/("1EF1Z\*8!1@>:YPIP23RI< MI+QF);!*[H2Q;M] $@W\J!="KQO[T2""GM_K]_PP#"'L7/7^DAWY^6MJ0#V/ M_,:AY?!G@O;ROZ2G[R?$I-?WX^L^7%.RVM0D M<%_0:SSM@RFD#IM*1<4*3%^\O1Q$43A\422J+1)[VHV&K"T4I]X= FD=!>O4 MKH::NF;)1$KNW92A<9)1Q%"S)VKNIO-:801'#:U"E;NVK2&UT3:]K=UM)\.T M:8B_U9NQ0I>124G00 MK(-V7DY^ 5!+ P04 " #,BZI6ID<@*7"87[T] G@E2NTII6D/BS4EFF9&_Y?K.W8\>! I(VIRX6;# H6 MNK!_Y7REN_>5.5:5#0:J]$'9I5G@SA=D%(> MZPIO->;5[Z[NOWRY_?;EYN[;H[B\NQ97]W??;N\^WMQ=W=X\7KPYKK$'C3Q. MW7KO[7J#%]8[%U_*HIX;<5-D*MN>?PS: H$#3^#[P0\7_"*KGA@FL1CT!\,? MK#<,# ]YO>%+#)>+A:YA5K41LLC$%W?A#SIPBQEJMX>P%6,JE;JX-W/?TM.^J]_P,(HL##ZT>K_@%$ZP5-(G.TQ.8N8C[+U<5N5*94**!1F_ MJ$OW 3)A$VKW@GOCN17*>JZQ"?;+FPS4TB*:Z8D0;(4^\NOE&V%DCI!)#/\D MDK.XW^^+8;_/?_N]T[$8C/GSR#YR(Q+W]73 ?QX[G%F'ZH^9D<@SPEJ2V3Z) M,=GOI3&RT"R^8Y#XOJ*8E\JE8X4Y@-N+N88@84#Y/2U@2%H-17W2VB=#>M^.L62E3CD$2>OK^[O MW=@CM@!*4JJ"O#KJV5FLM;)GB]V$Q>+HD.2!!*$J15*#1EMFB7,G"5*4S'.Q M;"I8-9B5B!RTN9$+8C/3$$@C\Z.>^(:G[TM9960OI2YJR,DO [EW*/X':+VY M%VHZ59RSHB]R(Y(AFU["]OA!3:J&#,(9Y'C;(!7S2 99@%]O>9=>F]O*!.FF MD7@*'JT:_1LV6E(GK4W>0?[:42W-Z&Z+K]',&1VWX/AW'@(>7PWA 3)65K MD$89D;,-CROR'];S^-S^)DG(A3.__$ M/AVXY9*S47QZ,A*_ZSS7&^WLRZ%S!CVO 4]I"?=>&(DE4VIC"UH5, _S)GH%TLP0?>J)SK*,L1-CB M>UM,V,E%#Q@30D^*J*;_XH7=N!WJO<:B6J7SHLS+V2;L@=US65M3_?2;RU(E M)E<"602&RD#6'#$,S6CO?:: )#D4W[97]PL#Q<*[3"]R\@V3MEQ!5MAMU@W\ M.]ZK$+!KJUV98T&LK"TQY&YP9<]T.J>%Z%O(^1P(HV[:WC4\+(^=W:H0A<12 MNJHWKXQ:8F12Z^J@T!"<#L$!/@#!LXQF^,M0KA:0\\4K(FJJ8;6HWI= MBL/!DMQV4RCQM<@X*YK6%V$0/AX1*S!=5E],E2#N7#HT$YF38))5B+6:I43XEU)T*B>W+$ M>S&$VX$;K4@4I)&Q^5%DKX+OTJC60/?:-<>69DE+3\E3.*A$A[ @_BAD36%, M+]01V8DL"J+>F8MA6-_KCXD"#XFPG%M[%V79EQ.%'4&6][C+>:\,SND&5L/N!48\V8+1K22O9+B].+Z;#G/9T#93=L1( 1 M,"]C5SP=_[TGKELQLM8L^OW40(M#!MJ#9*?RRS @DH*P88"!EZS0;ITUL-'Z MQ1"L3$09E_:>5N4"-BW.N8H;#<_BX?"\(U8+V6C-04P@&:SH&H0 [P%54OQ_ MCE(B@H_DBWB;!#*3'B4T]P4, %8C78.D^XJJYK9:(#N_=07;0U52;KU $1)Y M#0_.+#WB/:GBIECIJBQH)L8''*(I'MP6:2^46^];C(0*$#,G"E%B2K+CA88? M$_'Y\U48C^_M<(FLA9B\><4!/ I5_R;>Q0XOLF6+H&::EROYQ$S^HB8JQQ@P MF9+I/Y9Y8UW],,5F5@/(-YX!-]=3%;DX+1=E8Y/ 3R@53DXL9AB,Q%L&T, M1KB%BPX^L!%&NP!DAJ,K7W;8D!9;4J9_O$=*.N@-H9<4\;DRM%D);U)BK M&@EH*B<(M@X^@HA,Y9"5[5C X?221<[ :BCHAK]OU<5C,2O=\Q MXXX-H!*JS7QS3+5'7;E,"L*@B:558H_M2)L XO$*HU$;.0NXA;D .I'GW) + M*L4QX-%U+ZSC(HY2RQJE1TT1, R+IAIY/.!*F5+9L(D]--=N;1=VN5%@)]^R)R[88[D#)$!RC+:OW_1ML-H4,7 WM^S&N2P/0 M>^A9 9NFJ59J4])'&+VM?N!,=8J*FQC<+5#VD-J+OFW5":0'SLO4'#0NSXEQ MG)R,XL'X1'S&[!E+!U#Y0ORN)L3KA;@NZ31!/,I<'7]5ILQ7T'<[^/@7F9(J MC[';M*9VB.O6#6TI^S+ IJ9"L"U\-PH:R>QN!35L?L[KUQ---4PZ[T%%/\]J MBQ]L%>;9)[NSV0L.<5S M9%;6FQC*,3SDOBN&=0.^6 2VOL-2I'CG0@ MU+/BUOM4S@NX@7(K1DAVX(]8XAF.;.E>1JK9/J_R4PB,5##I'4>CJ-Q)\,X^A:30'1"'][T1]> M41JY*WLBN1@DK]+5JW[2'XZ &(Q2'/^=9C8>Q';=?\O3J:$FJ=?)(K$IMU*Z M8'NYPQK67,X[N##Z3P4K?BQ8A]VH8MZUUEZ.?\?$5N8=R1N;1L#;C!MM&W6RVX$.>7:/9Z]X,/0NUIC*9U$PE(/?A^!2: MHYAN+6*W-]A0"V4IN:<1"EL;U G2N4<<816+B&.L ]?J$"W "G9R"2 JY7K"19W(A M9[#R@.(H0!W;T$J]=DF1Z)=R39 SWLNF302A$]O6: 0F7,=>FZI9!E@9LB6/ M#.AB)W?:+J<[6".;RM6,VG]*F6VE4OU'\YS-$<1Y)2N@]RQ8![>V*T6=;5]: MLC=N%Z86HX1H_MQH*&7Z/'D8DN!1:R?6HBYV=-KSH"B2*9KWN[ M([\1GO$K>W#"E;DIBT+EE-N1:$AZX8"*#=@:PU1#9!U(@(& Y.F=DDC0JT+ M1ADI3E!AU U8<8+;)L7'8K)N%YRV_,.^OA ?\!ZQCD",2$U:UO469H@.BU+D M93$#7=.F2"WZ/>*ZHQW=L7\2ZX(*AB[PV+](Y.3HAW?E^/Y"/*BB6*&,$I]+ M:0T/L=JX:C#R!>K#):)^J%#!)1Z$0Q9^N>](LUNWBF[=2NZ7\38K"^G"6=K MY1AZ:/V0FSX((/"NS!X_?T>!4E.%]!.WK%W;&J7E>!R?]0=8XY1>).-1/!R. MQ'E\/CR/D]&9&"0 X\.Q # 5W.X>#$-(=!!@Y M@=O/V&GB<'S')_M(^\0_D, MHR+;( QR3TLA.!AI?8X+6+&;,R^*ZFBG_\@MDD@N^K>X9G:A3'\7L(99YR;7DH[=-Q+4BS._D# 7+6.R@]($]!1E9'Z.% MS"9?22 H (-I)6TW@*[QW/(67/%=-O4<-0MJA>"QCH+V;-3UY>QEDM NSE2: M^Y-]Y^4LART.J/_C[H-!,XC7N:JD/Y%Y'E)@6-*=KD/TI(FE)/<]BY/A:9PD MI\3QLQBP?6&CO7G"R=&?^GLCO()RW'D$T? (*Q!?['IM$!-) ,_>?NG V$VE M,_TV]@4Y$J'V\TE(CK(!D+B ML^_<7D\)P,MW^#KG4@QDN63\X.):V\6RSN'O$ VXCD[Z]B" #LGK-?DH<4K? MO:58SRL+4&!K0P/U,B+$?[HNJR#+A]+4KSI"CJ.NC3+BM(?9:VU/83R$H[Q? M46 @&-(.JY0[3\-C*Q8,R;A:F32<>) ]V<%]&\23Y Y%-"D=)$=5XOKE6U@T@.* UTB\D#EEJ=8'M/&-38J7$ ,%$(0/H!RBDFDCDZ"5 MB2_?=D+.'L6G@['XU1^[!6\-BG78AH3C-&L-#-!DKK@JIALB6S1T"$NR M=@X>EJ!)M'.0KS1MWI<31*O8,81]J-!I+TYP(TJ">RI (C6ELMN:EZ2!3#4X MW^JGMF;+94^7$D]_ZPF6*^\%"YD]N\)$I].47/UQBO$]S7W14'0"X!=9/8G+ MGCVRWY\TM^\RLK%20+:W3ZH@[)9?KL"L MW2%,06G/HYEOUB_=5"P4R[CBH,">#'1&PWT<51SEMKV:"QT2)^S0'^[1L>,* M!0E%!0I6O$,;*&P?OG"7LT.(W\H5]NK+7%J+]:?K'?_K=&?8M)[;0,3GN.TY M*S'[I/E^THHO(%06(>TQAKBCHY T V(BQ*:6K31;SO<96-0Q,$[:I1Z:9[ M,-BD_^J?(;#::S)<[ _Z_3,Z)BZ;V=S"NE!J,RT$((T7Y@>+75%_!X,U_LYK MUO;4KB[$_9>OMYTS 3IB#/<%KWS#?3T0'5"1 MP^U7NDJI.;S=]G,P98K5U:PL.LT?8 E.2Y]EP?;"EZA BE^;E5$H$LM*19FB M"@M2;0TFW,78&W?3IOF>NN D.$[( W*'(UL,<'0:H(87-.Q5TG74[:; M)HBZ:J:,K1A89U/)BNBB!7MAAM?G#CTE ^1$=Z'.-Y5\[<)< $T)DVK;BTB1 MN99T)O&\"\<_Z C;48Z)6 A.(="V9G-#2%R2IO@$J8M>M[NZ3F?,R -$D6Z@ M=KZE8&\Q&G=9F;;L]-2=CGPPWE+*\W,P0E2*=D:OOU MD-]E8=:JZBK7FGD'8DQU!7,!BGSR,(-\)?)I!K'$];P]=B":J/_!N1=Q+$/B M4M9Q4=$Z28H/ $^(4G^IZB*X!'=6G#'3EI4.LN@[8<_=H ME EVP-J>A;>)B7V?Z6FK<]/J9OLJ34>OGG^(5:ZEMC^]$%RAD(B1^^VV+0@\ MBT_'?7XV;;@ZALGJ!5Y;<7AZ;%>^*(N4ROG,VJLO4 M[96G/==@+J)'[( MD;N0'?U:L"WXNCJ)O)9U" M),EY?#Y.6(AK_LT7!3*Z5C$C!2_<16/+C+O*GHG.QM03Z'2LHWTAV\X.S9"] MLK1]HZ1W-D2B%OM^5G3<^5D8(/:,?_Q&A@5"["_$PM/P^[I+^[.R=KC]<1ZV MGB$]@K IIM)E^ /;'?%?ZG+)/S*;E#6J)OY()SJJH@%X/RT16]P7VB#\ZO#= M_P)02P,$% @ S(NJ5AX$&%F6 P Q0< !D !X;"]W;W)K&ULC551D]HX#'[G5VC2FSXQ) 38A2TP ULZUYMK=Z]TVX>; M>S")2#Q-;&H[4/[]24X([,PNTY?$MJ1/GR1+GAZT^6%S1 >_RD+969 [M[L+ M0YOD6 K;TSM4)-EJ4PI'6Y.%=F=0I-ZH+,(XBF["4D@5S*?^[-',I[IRA53X M:,!692G,<8F%/LR"?G Z^"*SW/%!.)_N1(9K=$^[1T.[L$5)98G*2JW X'86 M+/IWRR'K>X5O$@_V8@T0XE94A?NB#W]B$\^(\1)=6/^%0ZT; M3P)(*NMTV1@3@U*J^B]^-7FX,!A'KQC$C4'L>=>./,OWPHGYU.@#&-8F-%[X M4+TUD9.*B[)VAJ22[-Q\_;1P4BFFS^U#XM.2BD^DEO%5P$_"]�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 50 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 265 311 1 false 73 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://biontech.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://biontech.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://biontech.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://biontech.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) Sheet http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 6 false false R7.htm 00000007 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS: Sheet http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS: Notes 7 false false R8.htm 00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://biontech.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - PROPERTY AND EQUIPMENT: Sheet http://biontech.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT: Notes 9 false false R10.htm 00000010 - Disclosure - DEFERRED COMPENSATION: Sheet http://biontech.com/role/DeferredCompensation DEFERRED COMPENSATION: Notes 10 false false R11.htm 00000011 - Disclosure - LOANS PAYABLE: Sheet http://biontech.com/role/LoansPayable LOANS PAYABLE: Notes 11 false false R12.htm 00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES: Notes http://biontech.com/role/ConvertibleNotesPayable-Affiliates CONVERTIBLE NOTES PAYABLE - AFFILIATES: Notes 12 false false R13.htm 00000013 - Disclosure - STOCKHOLDERS' EQUITY: Sheet http://biontech.com/role/StockholdersEquity STOCKHOLDERS' EQUITY: Notes 13 false false R14.htm 00000014 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES: Sheet http://biontech.com/role/SubscriptionReceivable-Affiliates SUBSCRIPTION RECEIVABLE - AFFILIATES: Notes 14 false false R15.htm 00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES: Sheet http://biontech.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES: Notes 15 false false R16.htm 00000016 - Disclosure - SUBSEQUENT EVENTS: Sheet http://biontech.com/role/SubsequentEvents SUBSEQUENT EVENTS: Notes 16 false false R17.htm 00000017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://biontech.com/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 17 false false R18.htm 00000018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://biontech.com/role/SignificantAccountingPoliciesTables SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://biontech.com/role/SignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - PROPERTY AND EQUIPMENT: (Tables) Sheet http://biontech.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT: (Tables) Tables http://biontech.com/role/PropertyAndEquipment 19 false false R20.htm 00000020 - Disclosure - STOCKHOLDERS' EQUITY: (Tables) Sheet http://biontech.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY: (Tables) Tables http://biontech.com/role/StockholdersEquity 20 false false R21.htm 00000021 - Disclosure - COMMITMENTS AND CONTINGENCIES: (Tables) Sheet http://biontech.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES: (Tables) Tables http://biontech.com/role/CommitmentsAndContingencies 21 false false R22.htm 00000022 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS: (Details Narrative) Sheet http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS: (Details Narrative) Details http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans 22 false false R23.htm 00000023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) Sheet http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) Details 23 false false R24.htm 00000024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) Sheet http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) Details 24 false false R25.htm 00000025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://biontech.com/role/SignificantAccountingPoliciesTables 25 false false R26.htm 00000026 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details) Sheet http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails PROPERTY AND EQUIPMENT - Property and Equipment (Details) Details 26 false false R27.htm 00000027 - Disclosure - PROPERTY AND EQUIPMENT: (Details Narrative) Sheet http://biontech.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT: (Details Narrative) Details http://biontech.com/role/PropertyAndEquipmentTables 27 false false R28.htm 00000028 - Disclosure - DEFERRED COMPENSATION: (Details Narrative) Sheet http://biontech.com/role/DeferredCompensationDetailsNarrative DEFERRED COMPENSATION: (Details Narrative) Details http://biontech.com/role/DeferredCompensation 28 false false R29.htm 00000029 - Disclosure - LOANS PAYABLE: (Details Narrative) Sheet http://biontech.com/role/LoansPayableDetailsNarrative LOANS PAYABLE: (Details Narrative) Details http://biontech.com/role/LoansPayable 29 false false R30.htm 00000030 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES: (Details Narrative) Notes http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative CONVERTIBLE NOTES PAYABLE - AFFILIATES: (Details Narrative) Details http://biontech.com/role/ConvertibleNotesPayable-Affiliates 30 false false R31.htm 00000031 - Disclosure - STOCKHOLDERS' EQUITY - Stock Option Activity (Details) Sheet http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails STOCKHOLDERS' EQUITY - Stock Option Activity (Details) Details 31 false false R32.htm 00000032 - Disclosure - STOCKHOLDERS' EQUITY: (Details Narrative) Sheet http://biontech.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS' EQUITY: (Details Narrative) Details http://biontech.com/role/StockholdersEquityTables 32 false false R33.htm 00000033 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES: (Details Narrative) Sheet http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative SUBSCRIPTION RECEIVABLE - AFFILIATES: (Details Narrative) Details http://biontech.com/role/SubscriptionReceivable-Affiliates 33 false false R34.htm 00000034 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://biontech.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://biontech.com/role/CommitmentsAndContingenciesTables 34 false false R35.htm 00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES: (Details Narrative) Sheet http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES: (Details Narrative) Details http://biontech.com/role/CommitmentsAndContingenciesTables 35 false false R36.htm 00000036 - Disclosure - SUBSEQUENT EVENTS: (Details Narrative) Sheet http://biontech.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS: (Details Narrative) Details http://biontech.com/role/SubsequentEvents 36 false false All Reports Book All Reports [dq-0540-EntityShellCompany-Missing] Submission type 10-Q should have a non-empty value for EntityShellCompany in the Required Context. bion_10q-q3.htm bion_10q-q3.htm bnet-20230331.xsd bnet-20230331_cal.xml bnet-20230331_def.xml bnet-20230331_lab.xml bnet-20230331_pre.xml ex31x1.htm ex31x2.htm ex32x1.htm ex32x2.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 54 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bion_10q-q3.htm": { "axisCustom": 0, "axisStandard": 20, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 690, "http://xbrl.sec.gov/dei/2022": 28 }, "contextCount": 265, "dts": { "calculationLink": { "local": [ "bnet-20230331_cal.xml" ] }, "definitionLink": { "local": [ "bnet-20230331_def.xml" ] }, "inline": { "local": [ "bion_10q-q3.htm" ] }, "labelLink": { "local": [ "bnet-20230331_lab.xml" ] }, "presentationLink": { "local": [ "bnet-20230331_pre.xml" ] }, "schema": { "local": [ "bnet-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 494, "entityCount": 1, "hidden": { "http://biontech.com/20230331": 118, "http://fasb.org/us-gaap/2022": 121, "http://xbrl.sec.gov/dei/2022": 5, "total": 244 }, "keyCustom": 85, "keyStandard": 226, "memberCustom": 47, "memberStandard": 18, "nsprefix": "bnet", "nsuri": "http://biontech.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://biontech.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - DEFERRED COMPENSATION:", "menuCat": "Notes", "order": "10", "role": "http://biontech.com/role/DeferredCompensation", "shortName": "DEFERRED COMPENSATION:", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - LOANS PAYABLE:", "menuCat": "Notes", "order": "11", "role": "http://biontech.com/role/LoansPayable", "shortName": "LOANS PAYABLE:", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "bnet:ConvertibleDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES:", "menuCat": "Notes", "order": "12", "role": "http://biontech.com/role/ConvertibleNotesPayable-Affiliates", "shortName": "CONVERTIBLE NOTES PAYABLE - AFFILIATES:", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "bnet:ConvertibleDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - STOCKHOLDERS' EQUITY:", "menuCat": "Notes", "order": "13", "role": "http://biontech.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS' EQUITY:", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "bnet:SubscriptionReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES:", "menuCat": "Notes", "order": "14", "role": "http://biontech.com/role/SubscriptionReceivable-Affiliates", "shortName": "SUBSCRIPTION RECEIVABLE - AFFILIATES:", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "bnet:SubscriptionReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES:", "menuCat": "Notes", "order": "15", "role": "http://biontech.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES:", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - SUBSEQUENT EVENTS:", "menuCat": "Notes", "order": "16", "role": "http://biontech.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS:", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "17", "role": "http://biontech.com/role/SignificantAccountingPoliciesPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)", "menuCat": "Tables", "order": "18", "role": "http://biontech.com/role/SignificantAccountingPoliciesTables", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - PROPERTY AND EQUIPMENT: (Tables)", "menuCat": "Tables", "order": "19", "role": "http://biontech.com/role/PropertyAndEquipmentTables", "shortName": "PROPERTY AND EQUIPMENT: (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - STOCKHOLDERS' EQUITY: (Tables)", "menuCat": "Tables", "order": "20", "role": "http://biontech.com/role/StockholdersEquityTables", "shortName": "STOCKHOLDERS' EQUITY: (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - COMMITMENTS AND CONTINGENCIES: (Tables)", "menuCat": "Tables", "order": "21", "role": "http://biontech.com/role/CommitmentsAndContingenciesTables", "shortName": "COMMITMENTS AND CONTINGENCIES: (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "bnet:Techwastage", "reportCount": 1, "unique": true, "unitRef": "Decimal", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS: (Details Narrative)", "menuCat": "Details", "order": "22", "role": "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "shortName": "ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS: (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "bnet:Techwastage", "reportCount": 1, "unique": true, "unitRef": "Decimal", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-012023-03-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)", "menuCat": "Details", "order": "23", "role": "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-012023-03-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2023-01-012023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "bnet:SharesIssuedBeginningOfPeriod", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)", "menuCat": "Details", "order": "24", "role": "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2023-01-012023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "bnet:SharesIssuedBeginningOfPeriod", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "menuCat": "Details", "order": "25", "role": "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "bnet:ComputersAndOfficeEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details)", "menuCat": "Details", "order": "26", "role": "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails", "shortName": "PROPERTY AND EQUIPMENT - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "bnet:ComputersAndOfficeEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestCostsCapitalized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - PROPERTY AND EQUIPMENT: (Details Narrative)", "menuCat": "Details", "order": "27", "role": "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative", "shortName": "PROPERTY AND EQUIPMENT: (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestCostsCapitalized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationLiabilityCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - DEFERRED COMPENSATION: (Details Narrative)", "menuCat": "Details", "order": "28", "role": "http://biontech.com/role/DeferredCompensationDetailsNarrative", "shortName": "DEFERRED COMPENSATION: (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "lang": "en-US", "name": "bnet:DeferredCompensationConsecutiveTradingDays", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - LOANS PAYABLE: (Details Narrative)", "menuCat": "Details", "order": "29", "role": "http://biontech.com/role/LoansPayableDetailsNarrative", "shortName": "LOANS PAYABLE: (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:GainOrLossOnSaleOfStockInSubsidiary", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://biontech.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "p", "bnet:ConvertibleDebtTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES: (Details Narrative)", "menuCat": "Details", "order": "30", "role": "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "shortName": "CONVERTIBLE NOTES PAYABLE - AFFILIATES: (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "bnet:ConvertibleDebtTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2023-01-012023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:CostsIncurredDevelopmentCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "AsOf2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - STOCKHOLDERS' EQUITY - Stock Option Activity (Details)", "menuCat": "Details", "order": "31", "role": "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails", "shortName": "STOCKHOLDERS' EQUITY - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "bnet:ConvertibleDebtTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "AsOf2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ConvertibleNotesPayableCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - STOCKHOLDERS' EQUITY: (Details Narrative)", "menuCat": "Details", "order": "32", "role": "http://biontech.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS' EQUITY: (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2023-01-012023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalOther", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "bnet:SubscriptionReceivableTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "AsOf2023-03-31_custom_SmithsMember_custom_SecuredPromissoryNoteMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesReceivableNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES: (Details Narrative)", "menuCat": "Details", "order": "33", "role": "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative", "shortName": "SUBSCRIPTION RECEIVABLE - AFFILIATES: (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "bnet:SubscriptionReceivableTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "AsOf2023-03-31_custom_SmithsMember_custom_SecuredPromissoryNoteMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesReceivableNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "menuCat": "Details", "order": "34", "role": "http://biontech.com/role/CommitmentsAndContingenciesDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-04-272022-05-02", "decimals": "0", "first": true, "lang": null, "name": "bnet:CompensationIncreased", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES: (Details Narrative)", "menuCat": "Details", "order": "35", "role": "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES: (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-04-272022-05-02", "decimals": "0", "first": true, "lang": null, "name": "bnet:CompensationIncreased", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherAccruedLiabilitiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - SUBSEQUENT EVENTS: (Details Narrative)", "menuCat": "Details", "order": "36", "role": "http://biontech.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS: (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2023-04-012023-05-09_us-gaap_SubsequentEventMember", "decimals": "0", "lang": null, "name": "us-gaap:PaymentsForPurchaseOfOtherAssets1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2023-01-012023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "menuCat": "Statements", "order": "4", "role": "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2023-01-012023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)", "menuCat": "Statements", "order": "5", "role": "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "menuCat": "Statements", "order": "6", "role": "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2021-07-012022-03-31", "decimals": "0", "lang": null, "name": "bnet:GainOnLegalDissolutionsOfSubsidiary", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS:", "menuCat": "Notes", "order": "7", "role": "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans", "shortName": "ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS:", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "8", "role": "http://biontech.com/role/SignificantAccountingPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - PROPERTY AND EQUIPMENT:", "menuCat": "Notes", "order": "9", "role": "http://biontech.com/role/PropertyAndEquipment", "shortName": "PROPERTY AND EQUIPMENT:", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-q3.htm", "contextRef": "From2022-07-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 73, "tag": { "bnet_AccruedInterestAndLateChargesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued Interest and Late Charges Payable" } } }, "localname": "AccruedInterestAndLateChargesPayable", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_AccruedInterestMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Interest [Member]" } } }, "localname": "AccruedInterestMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_AccruedPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued paid" } } }, "localname": "AccruedPaid", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_AdjustedConvertibleObligationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjusted Convertible Obligations [Member]" } } }, "localname": "AdjustedConvertibleObligationsMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_AdjustmentToAdditionalPaidInCapitalModificationOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Modification of warrants" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalModificationOfWarrants", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_AggregateAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Aggregate amount" } } }, "localname": "AggregateAmount", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_AggregatePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Aggregate payment" } } }, "localname": "AggregatePayment", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_BassaniFamilyTrustsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bassani Family Trusts [Member]" } } }, "localname": "BassaniFamilyTrustsMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_BassaniMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bassani [Member]" } } }, "localname": "BassaniMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_CancellationOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cancellation of warrants" } } }, "localname": "CancellationOfWarrants", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_CapitalizedInterestInPropertyAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Capitalized interest in property and equipment" } } }, "localname": "CapitalizedInterestInPropertyAndEquipment", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_CattlePerHead": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cattle per head" } } }, "localname": "CattlePerHead", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "decimalItemType" }, "bnet_CenterpointMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Centerpoint [Member]" } } }, "localname": "CenterpointMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_ClassOfWarrantOrRightExercisedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercised During Period" } } }, "localname": "ClassOfWarrantOrRightExercisedDuringPeriod", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_CommissionsOnSaleOfUnits": { "auth_ref": [], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "CommissionsOnSaleOfUnits", "negatedLabel": "Commissions on sale of units" } } }, "localname": "CommissionsOnSaleOfUnits", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_CommissionsOnWarrantExercises": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Commissions on warrant exercises" } } }, "localname": "CommissionsOnWarrantExercises", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_CommissionsOnWarrantExercisesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commissions on warrant exercises , shares" } } }, "localname": "CommissionsOnWarrantExercisesShares", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "bnet_CommonSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Shares [Member]" } } }, "localname": "CommonSharesMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_CommonStockSharesIssuedUponExerciseOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Shares Issued upon Exercise of Warrants" } } }, "localname": "CommonStockSharesIssuedUponExerciseOfWarrants", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_CompensationIncreased": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Compensation increased" } } }, "localname": "CompensationIncreased", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_ComputersAndOfficeEquipment": { "auth_ref": [], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Computers and office equipment" } } }, "localname": "ComputersAndOfficeEquipment", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "bnet_ConsultantServiceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consultant Service [Member]" } } }, "localname": "ConsultantServiceMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_ConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consultants [Member]" } } }, "localname": "ConsultantsMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_ConsultingServicesDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consulting services description" } } }, "localname": "ConsultingServicesDescription", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "bnet_ConversionOfDebtAndLiabilitiesIntoCommonUnits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of debt and liabilities into common units" } } }, "localname": "ConversionOfDebtAndLiabilitiesIntoCommonUnits", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_ConversionOfDebtAndLiabilitiesIntoNotesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of debt and liabilities into notes payable" } } }, "localname": "ConversionOfDebtAndLiabilitiesIntoNotesPayable", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_ConversionOfDeferredCompensationToNotesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of deferred compensation to notes payable" } } }, "localname": "ConversionOfDeferredCompensationToNotesPayable", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_ConversionPricePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Conversion price per unit" } } }, "localname": "ConversionPricePerUnit", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bnet_ConvertibleDebtTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONVERTIBLE NOTES PAYABLE - AFFILIATES:" } } }, "localname": "ConvertibleDebtTextBlock", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-Affiliates" ], "xbrltype": "textBlockItemType" }, "bnet_ConvertibleObligations2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Obligations 2020 [Member]" } } }, "localname": "ConvertibleObligations2020Member", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_ConvertiblePreferredStockAntidilutiveSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock Antidilutive Securities [Member]" } } }, "localname": "ConvertiblePreferredStockAntidilutiveSecuritiesMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "bnet_DebtInstrumentInterestRateStatedPercentageQuarterly": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage, Quarterly" } } }, "localname": "DebtInstrumentInterestRateStatedPercentageQuarterly", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "percentItemType" }, "bnet_DebtModification": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Debt modification" } } }, "localname": "DebtModification", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_DeferredCompensationConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Compensation Consecutive Trading Days (Day)" } } }, "localname": "DeferredCompensationConsecutiveTradingDays", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "bnet_DeferredCompensationConvertibleToCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Deferred Compensation, Convertible to Common Stock" } } }, "localname": "DeferredCompensationConvertibleToCommonStock", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_DeferredCompensationConvertibleToCommonStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Compensation, Convertible to Common Stock, Price Per Share (in dollars per share)" } } }, "localname": "DeferredCompensationConvertibleToCommonStockPricePerShare", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bnet_DeferredCompensationLiabilityAmountCancelled": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deferred Compensation Liability, Amount Cancelled" } } }, "localname": "DeferredCompensationLiabilityAmountCancelled", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_DeferredCompensationMaximumConvertibleAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Deferred Compensation, Maximum Convertible Amount" } } }, "localname": "DeferredCompensationMaximumConvertibleAmount", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_DeferredCompensationStockConversionPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share)" } } }, "localname": "DeferredCompensationStockConversionPricePerShare", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bnet_DeficitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity (deficit):" } } }, "localname": "DeficitAbstract", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "bnet_DescriptionOfKreider2PoultryProject": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of kreider 2 poultry project" } } }, "localname": "DescriptionOfKreider2PoultryProject", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "stringItemType" }, "bnet_DirectOwnershipMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Direct Ownership [Member]" } } }, "localname": "DirectOwnershipMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_DisclosureConvertibleNotesPayableAffiliatesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable - Affiliates" } } }, "localname": "DisclosureConvertibleNotesPayableAffiliatesAbstract", "nsuri": "http://biontech.com/20230331", "xbrltype": "stringItemType" }, "bnet_DisclosureSubscriptionReceivableAffiliatesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subscription Receivable - Affiliates" } } }, "localname": "DisclosureSubscriptionReceivableAffiliatesAbstract", "nsuri": "http://biontech.com/20230331", "xbrltype": "stringItemType" }, "bnet_DominicBassaniMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dominic Bassani [Member]" } } }, "localname": "DominicBassaniMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_EdSchaferMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ed Schafer [Member]" } } }, "localname": "EdSchaferMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Incentive Plan [Member]" } } }, "localname": "EquityIncentivePlanMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_EquityIssuancesWarrantsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants" } } }, "localname": "EquityIssuancesWarrantsPolicyPolicyTextBlock", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "bnet_ExecutiveViceChairmanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Executive Vice Chairman [Member]" } } }, "localname": "ExecutiveViceChairmanMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_ExerciseBonus": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise bonus" } } }, "localname": "ExerciseBonus", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "bnet_ExtensionBonusMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Extension Bonus [Member]" } } }, "localname": "ExtensionBonusMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_FinancingReceivableInterestRateStatedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financing receivable interest rate stated percentage", "verboseLabel": "Financing Receivable, Interest Rate, Stated Percentage" } } }, "localname": "FinancingReceivableInterestRateStatedPercentage", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "percentItemType" }, "bnet_FinancingReceivablePrincipalAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Financing Receivable, Principal Amount" } } }, "localname": "FinancingReceivablePrincipalAmount", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_FormerEmployeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Former Employee [Member]" } } }, "localname": "FormerEmployeeMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_Fy2016ExtensionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fy 2016 Extension Agreement [Member]" } } }, "localname": "Fy2016ExtensionAgreementMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_GainOnLegalDissolutionsOfSubsidiary": { "auth_ref": [], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "GainOnLegalDissolutionsOfSubsidiary", "negatedLabel": "Gain on legal dissolution of subsidiary" } } }, "localname": "GainOnLegalDissolutionsOfSubsidiary", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_GainOnSaleOfDomainAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Gain on sale of domain [Default Label]", "verboseLabel": "Gain on sale of domain" } } }, "localname": "GainOnSaleOfDomainAmount", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_GainOnSaleOfDomains": { "auth_ref": [], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Gain on sale of domain" } } }, "localname": "GainOnSaleOfDomains", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "bnet_IndirectOwnershipMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Indirect Ownership [Member]" } } }, "localname": "IndirectOwnershipMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_InterestBearingSecuredPromissoryNote": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Interest bearing secured promissory note" } } }, "localname": "InterestBearingSecuredPromissoryNote", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_InterestExpenseOnDeferredCompensationObligationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest Expense On Deferred Compensation Obligation [Member]" } } }, "localname": "InterestExpenseOnDeferredCompensationObligationMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_InterestExpenseRelatedParties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Interest Expense, Related Party" } } }, "localname": "InterestExpenseRelatedParties", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_InterestExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Interest expenses" } } }, "localname": "InterestExpenses", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_InterestRateOnDeferredCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest Rate on Deferred Compensation" } } }, "localname": "InterestRateOnDeferredCompensation", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "percentItemType" }, "bnet_InterestsExpense": { "auth_ref": [], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Interest expense" } } }, "localname": "InterestsExpense", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "bnet_IssuanceOfWarrantsForServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Issuance of warrants for services" } } }, "localname": "IssuanceOfWarrantsForServices", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_LessImputedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Less imputed interest" } } }, "localname": "LessImputedInterest", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "bnet_MarkASmithMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mark A Smith [Member]" } } }, "localname": "MarkASmithMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_MinorityInterestPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncontrolling interests" } } }, "localname": "MinorityInterestPolicyPolicyTextBlock", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "bnet_ModificationOfWarrants": { "auth_ref": [], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "ModificationOfWarrants", "verboseLabel": "Modification of warrants" } } }, "localname": "ModificationOfWarrants", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_ModificationOfWarrantsInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Modification of warrants - interest" } } }, "localname": "ModificationOfWarrantsInterest", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_ModificationOfWarrantsNoncashComp": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Modification of warrants - non-cash comp" } } }, "localname": "ModificationOfWarrantsNoncashComp", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_MonthlyOfficersCashCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Monthly Officers Cash Compensation" } } }, "localname": "MonthlyOfficersCashCompensation", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_NetIncomeLossApplicableToBionsCommonStockholdersPerBasicAndDilutedCommonShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net income (loss) applicable to Bion's common stockholders per basic and diluted common share" } } }, "localname": "NetIncomeLossApplicableToBionsCommonStockholdersPerBasicAndDilutedCommonShare", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "bnet_NonCashCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Non cash compensation" } } }, "localname": "NonCashCompensation", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_NorthropMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Northrop [Member]" } } }, "localname": "NorthropMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_NotesReceivableInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Notes receivable interest" } } }, "localname": "NotesReceivableInterest", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_PA1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "P A 1 [Member]" } } }, "localname": "PA1Member", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_PennvestLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Pennvest Loan [Member]" } } }, "localname": "PennvestLoanMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_PercentageOfSustainable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Percentage of sustainable" } } }, "localname": "PercentageOfSustainable", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "percentItemType" }, "bnet_Plan2006Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Plan 2006 [Member]" } } }, "localname": "Plan2006Member", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_PreferredStockConvertibleOptionPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock, Convertible Option Per Share" } } }, "localname": "PreferredStockConvertibleOptionPerShare", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bnet_PrincipalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Principal [Member]" } } }, "localname": "PrincipalMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_ProceedsFromSaleOfUnits": { "auth_ref": [], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from sale of units" } } }, "localname": "ProceedsFromSaleOfUnits", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_PropertyPlantAndEquipmentOfPA1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment Of P A 1 [Member]" } } }, "localname": "PropertyPlantAndEquipmentOfPA1Member", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_PurchaseOfPropertyAndEquipmentForAccountsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Purchase of property and equipment for accounts payable" } } }, "localname": "PurchaseOfPropertyAndEquipmentForAccountsPayable", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_PurchaseOrder": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Purchase order" } } }, "localname": "PurchaseOrder", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_PurchaseOrderBilled": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Purchase order billed" } } }, "localname": "PurchaseOrderBilled", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_PurchaseOrderInvoiced": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Purchase order Invoiced" } } }, "localname": "PurchaseOrderInvoiced", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_RedemptionOfConvertiblePreferredStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Redemption of convertible Preferred stock" } } }, "localname": "RedemptionOfConvertiblePreferredStock", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_RedemptionOfPreferredSeriesBSharesAndInterest": { "auth_ref": [], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Redemption of Preferred Series B shares and interest" } } }, "localname": "RedemptionOfPreferredSeriesBSharesAndInterest", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_ReductionOfAdditionalPaidInCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Reduction of additional paid in capital" } } }, "localname": "ReductionOfAdditionalPaidInCapital", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_ReductionOfDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Reduction of debt" } } }, "localname": "ReductionOfDebt", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_RestrictedCommonSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted Common Shares [Member]" } } }, "localname": "RestrictedCommonSharesMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_RestrictedCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted Common Stock [Member]" } } }, "localname": "RestrictedCommonStockMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_RibbonwireMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ribbonwire [Member]" } } }, "localname": "RibbonwireMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_SaleOfDomainDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sale of domain, description" } } }, "localname": "SaleOfDomainDescription", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "bnet_SaleOfUnitPricePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SaleOfUnitPricePerUnit", "verboseLabel": "Sale of units" } } }, "localname": "SaleOfUnitPricePerUnit", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bnet_SaleOfUnitsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sale of units, shares" } } }, "localname": "SaleOfUnitsShares", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "bnet_SaleOfUnitsValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Sale of units" } } }, "localname": "SaleOfUnitsValue", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_SchaferMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schafer [Member]" } } }, "localname": "SchaferMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Secured Promissory Note Consideration For Warrants Expiring On December 312025 [Member]" } } }, "localname": "SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_SecuredPromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Secured Promissory Note [Member]" } } }, "localname": "SecuredPromissoryNoteMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_September2015ConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "September 2015 Convertible Notes [Member]" } } }, "localname": "September2015ConvertibleNotesMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_SharebasedCompensationGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Granted" } } }, "localname": "SharebasedCompensationGranted", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_ShareholderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder [Member]" } } }, "localname": "ShareholderMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_SharesHeldBySubsidiaries": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares held by subsidiaries (Note 7)", "negatedLabel": "Shares Held by Subsidiaries" } } }, "localname": "SharesHeldBySubsidiaries", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_SharesIssuedBeginningOfPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued \u2013 beginning of period" } } }, "localname": "SharesIssuedBeginningOfPeriod", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "bnet_SharesIssuedForWarrantExerciseCommissions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued for warrant exercise commissions" } } }, "localname": "SharesIssuedForWarrantExerciseCommissions", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_SharesOutstandingBeginningOfPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares outstanding \u2013 beginning of period" } } }, "localname": "SharesOutstandingBeginningOfPeriod", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "bnet_SmithMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Smith [Member]" } } }, "localname": "SmithMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_SmithsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Smiths [Member]" } } }, "localname": "SmithsMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_StockIssuedDuringPeriodValueCommissionsOnSaleOfUnits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Commissions on sale of units" } } }, "localname": "StockIssuedDuringPeriodValueCommissionsOnSaleOfUnits", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_SubscriptionReceivableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSCRIPTION RECEIVABLE - AFFILIATES:" } } }, "localname": "SubscriptionReceivableTextBlock", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-Affiliates" ], "xbrltype": "textBlockItemType" }, "bnet_SubscriptionsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subscriptions Receivable [Member]" } } }, "localname": "SubscriptionsReceivableMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "bnet_Techwastage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tech wastage" } } }, "localname": "Techwastage", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "decimalItemType" }, "bnet_The2020ConvertibleObligationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "The 2020 Convertible Obligations [Member]" } } }, "localname": "The2020ConvertibleObligationsMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_ThreeConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Three Consultants [Member]" } } }, "localname": "ThreeConsultantsMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_UndiscountedCashFlow": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Undiscounted cash flow" } } }, "localname": "UndiscountedCashFlow", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "bnet_VestingOfOptionsForEmployeesAndServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Vesting of options for employees and services" } } }, "localname": "VestingOfOptionsForEmployeesAndServices", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_Warrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants [Default Label]", "verboseLabel": "Warrants" } } }, "localname": "Warrants", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_WarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants exercised" } } }, "localname": "WarrantsExercised", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bnet_WarrantsExercisedForCommonShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Warrants exercised for common shares" } } }, "localname": "WarrantsExercisedForCommonShares", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_WarrantsExercisedForCommonSharesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants exercised for common shares , shares" } } }, "localname": "WarrantsExercisedForCommonSharesShares", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "bnet_WarrantsExercisedForCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Warrant Exercised for Common Stock" } } }, "localname": "WarrantsExercisedForCommonStock", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_WarrantsExpiringOnDecember312025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Expiring On December 312025 [Member]" } } }, "localname": "WarrantsExpiringOnDecember312025Member", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_WarrantsHeldByTrustOwned": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Warrants held by trust owned" } } }, "localname": "WarrantsHeldByTrustOwned", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Issued In Connection With Sale Of Units In Exchange For Salary [Member]" } } }, "localname": "WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_WarrantsIssusedSubscriptionReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Issused Subscription Receivable [Member]" } } }, "localname": "WarrantsIssusedSubscriptionReceivableMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_WeightedAverageSharesIssuedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average shares issued \u00a0\u00a0\u00a0\u00a0during the period" } } }, "localname": "WeightedAverageSharesIssuedDuringPeriod", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "bnet_WilliamONeillMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "William O Neill [Member]" } } }, "localname": "WilliamONeillMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_WorkingCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Working Capital" } } }, "localname": "WorkingCapital", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_YearsOneThroughFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Years One Through Five [Member]" } } }, "localname": "YearsOneThroughFiveMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_YearsSixThroughMaturityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Years Six Through Maturity [Member]" } } }, "localname": "YearsSixThroughMaturityMember", "nsuri": "http://biontech.com/20230331", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r486", "r488", "r489" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r487" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r490" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r185", "r186", "r274", "r301", "r451", "r453" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r258", "r259", "r260", "r261", "r320", "r429", "r435", "r447", "r448", "r465", "r466", "r474", "r529", "r567", "r568", "r569", "r570", "r571", "r572" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r258", "r259", "r260", "r261", "r320", "r429", "r435", "r447", "r448", "r465", "r466", "r474", "r529", "r567", "r568", "r569", "r570", "r571", "r572" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_PresidentMember": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "label": "President [Member]" } } }, "localname": "PresidentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r258", "r259", "r260", "r261", "r319", "r320", "r349", "r350", "r351", "r405", "r429", "r435", "r447", "r448", "r465", "r466", "r474", "r523", "r529", "r568", "r569", "r570", "r571", "r572" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r258", "r259", "r260", "r261", "r319", "r320", "r349", "r350", "r351", "r405", "r429", "r435", "r447", "r448", "r465", "r466", "r474", "r523", "r529", "r568", "r569", "r570", "r571", "r572" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r185", "r186", "r274", "r301", "r452", "r453" ], "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r201", "r321", "r496", "r515" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r201", "r321", "r496", "r497", "r515" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r518", "r563" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Information by type of receivable.", "label": "Receivable Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r12", "r473" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent": { "auth_ref": [ "r12" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to underwriters, promoters, and employees excluding salaries, wages and amount to related party, classified as current.", "label": "Salaries and wages" } } }, "localname": "AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r133", "r147" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.", "label": "Accrued interest" } } }, "localname": "AccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r63", "r162" ], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentOtherNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r7", "r473" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r358", "r359", "r360", "r512", "r513", "r514", "r559" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentOfWarrantsGrantedForServices": { "auth_ref": [ "r43" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustment for noncash service expenses paid for by granting of warrants.", "label": "Warrants issued for compensation for services" } } }, "localname": "AdjustmentOfWarrantsGrantedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Increase to additional paid in capital" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r103", "r104", "r322" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Vesting of options for services" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r73", "r82", "r90" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Issuance of warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r353" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "verboseLabel": "Non cash compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r127", "r140", "r163", "r184", "r227", "r230", "r234", "r242", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r366", "r370", "r376", "r473", "r527", "r528", "r565" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r159", "r168", "r184", "r242", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r366", "r370", "r376", "r473", "r527", "r528", "r565" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for premium paid to acquire option for investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Options" } } }, "localname": "AvailableForSaleSecuritiesPurchasedOptionsPricePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r324", "r325", "r326", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r348", "r349", "r350", "r351", "r352" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalLeasesContingentRentalPaymentsDue": { "auth_ref": [ "r155" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount due based upon the occurrence of an event specified in the contractual terms.", "label": "Total" } } }, "localname": "CapitalLeasesContingentRentalPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalRequiredForCapitalAdequacy": { "auth_ref": [ "r433", "r434" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of minimum total risk-based capital required for capital adequacy as defined by regulatory framework.", "label": "Capital Required for Capital Adequacy" } } }, "localname": "CapitalRequiredForCapitalAdequacy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r441", "r442", "r473", "r498" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r39", "r45", "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash at end of year", "periodStartLabel": "Cash at beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r39", "r121" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r498" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r164", "r165", "r166", "r184", "r205", "r206", "r213", "r214", "r217", "r218", "r242", "r262", "r264", "r265", "r266", "r269", "r270", "r299", "r300", "r303", "r307", "r314", "r376", "r449", "r495", "r509", "r516" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "http://biontech.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r91", "r97" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrants exercisable per share", "verboseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Warrant outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r67", "r255", "r256", "r443", "r526" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES:" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r512", "r513", "r559" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable": { "auth_ref": [ "r6" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of subscription receivable from investors who have been allocated common stock.", "label": "Common Stock, Share Subscribed but Unissued, Subscriptions Receivable", "negatedLabel": "Subscription receivable - affiliates (Note 8)" } } }, "localname": "CommonStockShareSubscribedButUnissuedSubscriptionsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r6", "r82" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r6", "r473" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, no par value, 250,000,000 shares authorized, 48,044,790 and 43,758,820 shares issued, respectively; 47,340,480 and 43,054,511 shares outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r138", "r221" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentrations of credit risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r109", "r454" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r62" ], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Initial Project: construction in process" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConstructionLoan": { "auth_ref": [ "r1" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the carrying value of a short-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project, usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property. Note that there are separate concepts for the current and noncurrent portions of long-term construction loans.", "label": "Construction Loan" } } }, "localname": "ConstructionLoan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r47", "r48", "r49" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of shares, value" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r47", "r48", "r49" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of shares, shares" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r47", "r48", "r49" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Convertible stock shares issued, warrants" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r72", "r271", "r272", "r283", "r284", "r285", "r289", "r290", "r291", "r292", "r293", "r460", "r461", "r462", "r463", "r464" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible Debt Securities [Member]" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r20" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible notes payable - affiliates (Note 6)", "verboseLabel": "Convertible Notes Payable, Noncurrent" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r3", "r130", "r142", "r149" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible note" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r27" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Accounts payable for reimbursable expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsIncurredDevelopmentCosts": { "auth_ref": [ "r126" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Development costs incurred, including capitalized costs and costs charged to expense, in oil and gas activities.", "label": "Capitalized amount" } } }, "localname": "CostsIncurredDevelopmentCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r47", "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt conversion value", "verboseLabel": "Debt instrument paid amount" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r47", "r49" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt conversion shares, warrants", "verboseLabel": "Debt conversion shares" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDefaultLongtermDebtAmount": { "auth_ref": [ "r182" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.", "label": "Debt Instrument, Debt Default, Amount" } } }, "localname": "DebtDefaultLongtermDebtAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r77", "r182", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r287", "r294", "r295", "r297" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "LOANS PAYABLE:" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/LoansPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAnnualPrincipalPayment": { "auth_ref": [ "r3" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the total principal payments made during the annual reporting period.", "label": "Debt Instrument, Annual Principal Payment" } } }, "localname": "DebtInstrumentAnnualPrincipalPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r1", "r2", "r3", "r128", "r130", "r139", "r188", "r271", "r272", "r273", "r274", "r275", "r277", "r283", "r284", "r285", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r385", "r460", "r461", "r462", "r463", "r464", "r510" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r74", "r273" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Original conversion price", "verboseLabel": "Conversion price per share" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r123", "r125", "r271", "r385", "r461", "r462" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r19", "r123", "r290" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r19", "r272" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r169", "r460", "r560" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Convertible debt maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r20", "r188", "r271", "r272", "r273", "r274", "r275", "r277", "r283", "r284", "r285", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r385", "r460", "r461", "r462", "r463", "r464", "r510" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r20", "r137" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Principal, interest" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationLiabilityCurrent": { "auth_ref": [ "r94", "r96" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.", "label": "Deferred compensation (Note 4)", "verboseLabel": "Deferred compensation liability" } } }, "localname": "DeferredCompensationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.", "label": "Deferred compensation" } } }, "localname": "DeferredCompensationLiabilityCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsCurrent": { "auth_ref": [ "r501" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.", "label": "Deposits and other assets" } } }, "localname": "DepositsAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r43", "r61" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations", "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r43", "r61" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r115", "r116", "r117", "r118", "r119", "r187" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivative Financial Instruments" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r323", "r354", "r355", "r357", "r362", "r467" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "DEFERRED COMPENSATION:" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/DeferredCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r2", "r4", "r129", "r141" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "Dividends Payable" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPreferredStock": { "auth_ref": [ "r90", "r136" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Preferred Stock" } } }, "localname": "DividendsPreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r52", "r53" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Income (Loss) per share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for employee benefit and equity-based compensation.", "label": "Share-based Payment Arrangement, Expense" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r82", "r156", "r172", "r173", "r174", "r189", "r190", "r191", "r193", "r198", "r200", "r216", "r243", "r316", "r358", "r359", "r360", "r363", "r364", "r374", "r377", "r378", "r379", "r380", "r381", "r382", "r393", "r436", "r437", "r438" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtGainLossNetOfTax": { "auth_ref": [ "r75" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the reacquisition price and the net carrying amount of the extinguished debt recognized currently as a component of income in the period of extinguishment, net of tax.", "label": "Extinguishment of Debt, Gain (Loss), Net of Tax", "verboseLabel": "Gain on legal dissolution of subsidiary" } } }, "localname": "ExtinguishmentOfDebtGainLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair value measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r240", "r241", "r244", "r245", "r246", "r247", "r249", "r250", "r251", "r252", "r296", "r312", "r372", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r459", "r519", "r520", "r521", "r577", "r578", "r579", "r580", "r581", "r582", "r583" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_GainLossOnSecuritizationOfFinancialAssets": { "auth_ref": [ "r401", "r504", "r505", "r508", "r575", "r576" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "A gain (loss) realized on a transfer, accounted for as a sale, of all or a portion of financial assets in which the transferor surrenders control and receives consideration other than a beneficial interest in the assets transferred. Reflects the amount of sales proceeds in excess of, or deficient from, the sum of the carrying amounts of transferred financial assets plus transaction costs.", "label": "Realized from the asset sale" } } }, "localname": "GainLossOnSecuritizationOfFinancialAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainOrLossOnSaleOfStockInSubsidiary": { "auth_ref": [ "r504", "r505", "r508", "r574", "r576" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries.", "label": "Gain on legal dissolution of subsidiary" } } }, "localname": "GainOrLossOnSaleOfStockInSubsidiary", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r43", "r75", "r76" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Gain on debt extinguishment" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r30" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative (including stock-based compensation)" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Patents" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r43", "r60", "r65" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment of Long-Lived Assets Held-for-use" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r29", "r44", "r108", "r194", "r195", "r196", "r197", "r211", "r214" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Net income" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "auth_ref": [ "r42" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.", "label": "Increase (Decrease) in Accounts and Other Receivables", "negatedLabel": "(Increase) in other receivable from the sale of doman name" } } }, "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r42" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (decrease) in accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r42" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase in deferred compensation" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r507", "r562" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Decrease (increase) in operating lease assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r42" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Increase (decrease) in deposits in other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r42" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Decrease in prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestCostsCapitalized": { "auth_ref": [ "r122" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest capitalized during the period.", "label": "Capitalized interest" } } }, "localname": "InterestCostsCapitalized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestCostsIncurredCapitalized": { "auth_ref": [ "r150" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest capitalized, including amount of allowance for funds used during construction.", "label": "Capitalized labor and interest costs" } } }, "localname": "InterestCostsIncurredCapitalized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r124", "r135", "r175", "r226", "r384" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r31", "r291", "r298", "r463", "r464" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOperating": { "auth_ref": [ "r28" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.", "label": "Interest Income, Operating", "negatedLabel": "Interest income" } } }, "localname": "InterestIncomeOperating", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r176", "r179", "r180" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterimPeriodCostsNotAllocableDomain": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred." } } }, "localname": "InterimPeriodCostsNotAllocableDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r43" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Stock-based compensation for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Discounted rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_LessorLeasesPolicyTextBlock": { "auth_ref": [ "r389", "r390", "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor.", "label": "Lease Accounting" } } }, "localname": "LessorLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r16", "r184", "r242", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r367", "r370", "r371", "r376", "r457", "r527", "r565", "r566" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Total liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r11", "r132", "r145", "r473", "r511", "r522", "r561" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r18", "r160", "r184", "r242", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r367", "r370", "r371", "r376", "r473", "r527", "r565", "r566" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liability", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r13" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LinesOfCreditCurrent": { "auth_ref": [ "r1", "r128" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Loans as a liability" } } }, "localname": "LinesOfCreditCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermConstructionLoanCurrent": { "auth_ref": [ "r15" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the current portion of a long-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project (generally one to seven years), usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property.", "label": "Loan related to construction" } } }, "localname": "LongTermConstructionLoanCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r70", "r188", "r289" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r70", "r188", "r289" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r70", "r188", "r289" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r20", "r71" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r68", "r69", "r257", "r258", "r259", "r524", "r525" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r25", "r131", "r144", "r184", "r242", "r262", "r264", "r265", "r266", "r269", "r270", "r376" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Noncontrolling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling interest, ownership percentage by parent" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_NatureOfExpenseAxis": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cost or expense.", "label": "Nature of Expense [Axis]" } } }, "localname": "NatureOfExpenseAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r178" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r178" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r39", "r41", "r44" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r26", "r44", "r134", "r148", "r158", "r170", "r171", "r174", "r184", "r192", "r194", "r195", "r196", "r197", "r199", "r200", "r211", "r227", "r229", "r233", "r235", "r242", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r375", "r376", "r458", "r527" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r110", "r112", "r170", "r171", "r199", "r200", "r502" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Net loss attributable to the noncontrolling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r194", "r195", "r196", "r197", "r202", "r203", "r212", "r214", "r227", "r229", "r233", "r235", "r458" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net income (loss) applicable to Bion's common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r204", "r207", "r208", "r209", "r210", "r212", "r214" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (loss)" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing transactions:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r106", "r316", "r512", "r513", "r514" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_NotesReceivableNet": { "auth_ref": [ "r239", "r248" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.", "label": "Financing Receivable, after Allowance for Credit Loss, Total" } } }, "localname": "NotesReceivableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r227", "r229", "r233", "r235", "r458" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r387" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r386" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r388", "r472" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears": { "auth_ref": [ "r153" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Future rental payments receivable within the third year from the balance sheet date under an operating lease.", "label": "From January 2024 to December 2024" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears": { "auth_ref": [ "r153" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Future rental payments receivable within the second year from the balance sheet date under an operating lease.", "label": "From April 2023 to December 2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionMember": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).", "label": "Options Held [Member]" } } }, "localname": "OptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r113" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS:" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Accrued current liability" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAdditionalCapital": { "auth_ref": [ "r24", "r33" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of additional paid-in capital (APIC) classified as other.", "label": "Additional paid amount" } } }, "localname": "OtherAdditionalCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashExpense": { "auth_ref": [ "r44" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.", "label": "Accrued interest on loans payable, deferred compensation and other" } } }, "localname": "OtherNoncashExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r32" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedTotalLabel": "Total other expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other (income) expense:" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsForCommissions": { "auth_ref": [ "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for commissions during the current period.", "label": "Commissions paid" } } }, "localname": "PaymentsForCommissions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForFees": { "auth_ref": [ "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for fees classified as other.", "label": "Payment for cash" } } }, "localname": "PaymentsForFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForPurchaseOfOtherAssets1": { "auth_ref": [ "r38", "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid to purchase other assets as part of operating activities.", "label": "Cash paid" } } }, "localname": "PaymentsForPurchaseOfOtherAssets1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Rent" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfWarrants": { "auth_ref": [ "r36" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.", "label": "Payments for Repurchase of Warrants", "negatedLabel": "Commissions on exercise of warrants" } } }, "localname": "PaymentsForRepurchaseOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r34" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Preferred stock dividend rate percentage" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r5", "r299" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)", "verboseLabel": "Par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockRedemptionPricePerShare": { "auth_ref": [ "r81", "r83", "r85" ], "lang": { "en-us": { "role": { "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.", "label": "Preferred Stock, Redemption Price Per Share" } } }, "localname": "PreferredStockRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r5", "r299" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, outstanding (in shares)", "verboseLabel": "Preferred Stock, Shares Outstanding, Ending Balance (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r5", "r473" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r167", "r253", "r254", "r450" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r35" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r506" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r158", "r170", "r171", "r177", "r184", "r192", "r199", "r200", "r227", "r229", "r233", "r235", "r242", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r365", "r368", "r369", "r375", "r376", "r431", "r458", "r469", "r470", "r502", "r527" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r66", "r444", "r445", "r446" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY AND EQUIPMENT:" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r62", "r161" ], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentOtherNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r64", "r146", "r432", "r473" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net (Note 3)" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOtherNet": { "auth_ref": [], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Property, Plant and Equipment, Other, Net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentOtherNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r64", "r444", "r445" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivableTypeDomain": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "localname": "ReceivableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r152", "r394", "r395", "r564" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt, Total" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r105", "r151", "r573" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development (including stock-based compensation)" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r8", "r90", "r143", "r439", "r440", "r473" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r156", "r189", "r190", "r191", "r193", "r198", "r200", "r243", "r358", "r359", "r360", "r363", "r364", "r374", "r436", "r438" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r224", "r225", "r228", "r231", "r232", "r236", "r237", "r238", "r317", "r318", "r430" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r455", "r456" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r503" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary paid" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of stock, shares" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of warrants and options and convertible securities" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r93", "r95" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of earnings per share, basic and diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.", "label": "Schedule of future minimum lease payments" } } }, "localname": "ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r98", "r99", "r100" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r78", "r79", "r80", "r83", "r84", "r86", "r87", "r88", "r89", "r90", "r164", "r165", "r166", "r217", "r299", "r300", "r301", "r303", "r307", "r312", "r314", "r465", "r495", "r509" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r499", "r500", "r530" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "http://biontech.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r499", "r500", "r530" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [ "r499", "r500", "r530" ], "lang": { "en-us": { "role": { "documentation": "Series C preferred stock.", "label": "Series C Preferred Stock [Member]" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "http://biontech.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r42" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock- based compensation", "verboseLabel": "Cash compensation paid" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Remaining contractual life" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Date the equity-based award expires, in YYYY-MM-DD format.", "label": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Stock options, authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Expired, options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Forfeited, options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Granted, options (in shares)", "terseLabel": "Options granted", "verboseLabel": "Number of shares granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Share-based Compensation, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Outstanding, aggregate intrinsic value ending", "periodStartLabel": "Outstanding, aggregate intrinsic value beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r328", "r329" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options outstanding, ending (in shares)", "periodStartLabel": "Options outstanding, beginning (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r328", "r329" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Weighted average exercise price", "periodEndLabel": "Options outstanding, ending weighted-average exercise price", "periodStartLabel": "Options outstanding, beginning weighted-average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "auth_ref": [ "r356" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.", "label": "Share-based Payment Arrangement, Plan Modification, Incremental Cost" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r324", "r325", "r326", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r348", "r349", "r350", "r351", "r352" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised, weighted-average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Expired, weighted-average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Forfeited, weighted-average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Granted, weighted-average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r327", "r346", "r347", "r348", "r349", "r352", "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-based compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Sell units" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding, weighted-average remaining contractual life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r343" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Fair value of stock options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares issued, warrants", "verboseLabel": "Number of shares issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Share price" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r51", "r181" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r164", "r165", "r166", "r184", "r205", "r206", "r213", "r214", "r217", "r218", "r242", "r262", "r264", "r265", "r266", "r269", "r270", "r299", "r300", "r303", "r307", "r314", "r376", "r449", "r495", "r509", "r516" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "http://biontech.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r22", "r82", "r156", "r172", "r173", "r174", "r189", "r190", "r191", "r193", "r198", "r200", "r216", "r243", "r316", "r358", "r359", "r360", "r363", "r364", "r374", "r377", "r378", "r379", "r380", "r381", "r382", "r393", "r436", "r437", "r438" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "http://biontech.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r189", "r190", "r191", "r216", "r430" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "http://biontech.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r21", "r82", "r83", "r90", "r288" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Conversion of debt and liabilities, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Issuance of units for services, shares", "verboseLabel": "Shares issued for consultant services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r5", "r6", "r82", "r90" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Number of shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r5", "r6", "r82", "r90", "r333" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Exercised, options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r22", "r82", "r90" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Conversion of debt and liabilities" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Issuance of units for services", "verboseLabel": "Total value of consultant services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r5", "r6", "r82", "r90" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Number of shares issued, value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r5", "r6", "r82", "r90" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Shares purchased, shares" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r5", "r6", "r82", "r90" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Shares purchased, value" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r6", "r9", "r10", "r58", "r473", "r511", "r522", "r561" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Bion's stockholders\u2019 equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bion's stockholders' equity (deficit):" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r106", "r107", "r111", "r156", "r157", "r173", "r189", "r190", "r191", "r193", "r198", "r243", "r316", "r358", "r359", "r360", "r363", "r364", "r374", "r377", "r378", "r382", "r393", "r437", "r438", "r511", "r522", "r561" ], "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total equity (deficit)" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r92", "r183", "r300", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r313", "r316", "r373" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS' EQUITY:" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r383", "r397" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r383", "r397" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r383", "r397" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r383", "r397" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r396", "r398" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS:" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r240", "r241", "r296", "r312", "r372", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r519", "r520", "r521", "r577", "r578", "r579", "r580", "r581", "r582", "r583" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r55", "r56", "r57", "r219", "r220", "r222", "r223" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r204", "r214" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Diluted weighted average shares \u2013 \u00a0\u00a0\u00a0\u00a0end of period" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfLimitedPartnershipAndGeneralPartnershipUnitOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The average number of limited partnership and general partnership units issued and outstanding that are used in calculating basic and diluted earnings per limited partnership and general partnership unit.", "label": "Basic and diluted" } } }, "localname": "WeightedAverageNumberOfLimitedPartnershipAndGeneralPartnershipUnitOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted-average number of common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "83", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126929950&loc=d3e34841-113949", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=6435544&loc=d3e41834-113960", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62014-109447", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "835", "Topic": "980", "URI": "https://asc.fasb.org/extlink&oid=6501662&loc=d3e56162-110433", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.T)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868742-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919352-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL119206284-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)(1)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=117337116&loc=SL5958568-112826", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=117337116&loc=SL5958570-112826", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r475": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r476": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r477": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r478": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r479": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r481": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r482": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r483": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r484": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r485": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r486": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r487": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r488": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r489": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r491": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r492": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r493": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r494": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e639-108305", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(g))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r577": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r578": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r579": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r581": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r582": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r583": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21564-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20028-108363", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 55 0001079973-23-000655-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001079973-23-000655-xbrl.zip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�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end

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